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HIV remains the major global health threat, and neither vaccine nor cure is available. 
Increasing our knowledge on HIV infection will help overcome the challenge of HIV/
AIDS. This book covers several aspects of HIV-host interactions in vitro and in vivo. 
The first section covers the interaction between cellular components and HIV proteins, 
Integrase, Tat, and Nef. It also discusses the clinical relevance of HIV superinfection. 
The next two chapters focus on the role of innate immunity including dendritic cells 
and defensins in HIV infection followed by the section on the impact of host factors 
on HIV pathogenesis. The section of co-infection includes the impact of Human 
herpesvirus 6 and Trichomonas vaginalis on HIV infection. The final section focuses 
on generation of HIV molecular clones that can be used in macaques and the potential 
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It has been 30 years since the first case of acquired immunodeficiency syndrome 
(AIDS) was reported. Worldwide, there are approximately 33 million people currently 
living with HIV, and 2.6 million became newly infected in 2009 (UNAIDS 2010). In the 
United States, an estimated 56,000 people become newly infected with HIV every year, 
and this number has remained stable. Importantly, more than 21% of the 1.1 million 
infected individuals in the United States are unaware of their infection. While 
significant scientific progress in HIV infection has been made, especially the 
development of antiretroviral therapy that prolongs the lives of HIV-infected 
individuals and appears to be a promising strategy for HIV prevention, HIV remains 
one of the major global health threats. Currently, there is no vaccine to prevent HIV 
infection nor is there a cure for HIV/AIDS. Louis Pasteur said, “In the fields of 
observation, chance favors only the prepared mind.” We may overcome the challenges 
of HIV/AIDS in the future if we continue to increase our knowledge of HIV infection. 
The chapters comprising this book focus on various aspects of HIV and host 
interactions. Suzuki and colleagues review the molecular interaction between HIV 
integrase and cellular factors, and highlight potential drug designs. The chapter from 
Dr. Bahraoui’s group focuses on the mechanism of HIV Tat protein-mediated IL-10 
induction and the impact of Tat on HIV pathogenesis. Percario and colleagues provide 
a clear view of HIV Nef functions in vitro. Hoogmoed et al. review HIV superinfection 
and its clinical outcome. Posch and colleagues focus on the interplay between HIV and 
innate immune responses including complement and immune cells, especially 
dendritic cells. Shah and Chang summarize the Janus-like role of innate effectors such 
as defensins in HIV infection. A comprehensive review of host factors that contribute 
to HIV pathogenesis is provided by Uittenbogaart’s team. Guzzo and colleagues 
review the interplay between T cell subsets and HIV infection. Nuñez and Martinez-
Quiles discuss the role of the MHC in HIV infection. The chapter from Beck and 
Alving focuses on the role of erythrocytes in HIV pathogenesis. Two chapters examine 
the role of co-infection: Ongrádi’s team discusses the impact of human herpesvirus 6 
on HIV in vitro and in vivo, and Garber’s team addresses the effect of Trichomonas 
vaginalis on HIV transmission. As the limited number of suitable animal models 
continues to impede progress toward understanding HIV transmission and 
pathogenesis, two chapters discuss strategies for studying HIV in animal models. 
Nomaguchi’s team focuses on generation of HIV molecular clones that can be used in 
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macaques. Blanco and colleagues summarize the potential use of cotton rats for 
studying HIV infection.  
This book is one of the HIV infection series published by InTech-Open Access 
Publisher. Other aspects in HIV infection absent in this book may be covered in other 
books. It was my pleasure to serve as the Ad Hoc Editor of this book and to read the 
manuscripts of these chapters. I thank all contributors for their efforts and hope that 
this book will provide insights into development of new strategies of HIV prevention 
and treatment.  
September 2011 
 
Dr. Theresa L. Chang 
Public Health Research Institute and  
Department of Microbiology and Molecular Genetics, 
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The human immunodeficiency virus (HIV) is the causative agent of acquired 
immunodeficiency syndrome (AIDS), which is one of the leading causes of infectious 
disease-related mortality worldwide (UNAIDS, 2010). An HIV infection is a chronic disease. 
While there is no regimen to eradicate the HIV from an infected person, there are more than 
20 drugs approved for the treatment of HIV infection, the majority of which target viral 
reverse transcriptase (RT) and protease (PR). In addition to the development of 
chemotherapeutic agents such as RT and PR inhibitors (RTI and PI), the advent of the 
combination therapy of different classes of antiviral drugs, the highly active antiretroviral 
therapy (HAART), has brought a significant decrease in the morbidity and mortality 
associated with HIV infections for over a decade. Nowadays, HAART is a standard 
treatment for HIV infection and AIDS (Palella et al., 1998). However, despite the successful 
suppression of HIV RNA detected in plasma over prolonged periods of time and a dramatic 
decrease in patient mortality, HAART is still facing problems, including the emergence of 
drug resistant viruses and serious side effects in treated individuals. In addition, current 
treatments only suppress the HIV replication, and eradication of virus from the body cannot 
be achieved. Therefore, considerable efforts have been made to develop novel anti-HIV 
drugs that exhibit entirely distinct mechanisms of action. To date, three additional classes of 
inhibitors have been approved by the US Food and Drug Administration (FDA) as oral anti-
HIV agents: a fusion inhibitor blocking the fusion step of the viral and cellular membranes, 
an entry inhibitor targeting coreceptor binding by the virus, and an integrase (IN) inhibitor 
blocking the integration step of viral DNA. 
Although many promising inhibitors against HIV replication have arisen over recent years, 
the current approach in anti-HIV chemotherapy is mostly based on competitive agents 
targeting the active sites of viral enzymes or the binding pockets of cellular receptors. One of 
the drawbacks of existing drugs, particularly the antivirals exhibiting allosteric effects, is the 
rapid emergence of mutant HIV strains resistant to the drugs due to the innately high 
mutational rate in of viral enzymes. On the other hand, it is becoming increasingly clear that 
protein-protein interactions (PPIs) could also serve as attractive targets of drugs for human 
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therapeutics (Cochran, 2001; Arkin & Wells, 2004; Pagliaro et al., 2004; Ryan & Matthews, 
2005). PPIs are central to most biological processes including virus infection and many 
human diseases are attributed to aberrant PPIs in cells. Not surprisingly, there are a number 
of interactions between viral and cellular proteins involved in all stages of HIV replication 
(Goff, 2007; Arhel & Kirchhoff, 2010) and recent evidence demonstrates that these PPIs can 
be potential targets for the development of a novel class of anti-HIV drugs termed small 
molecule protein-protein interaction inhibitors (SMPPIIs) (Busschots et al., 2009; Christ et al., 
2010). Although a challenging approach, an advantage of SMPPIIs in HIV chemotherapy is 
that the mutation rate in the PPI interface is considerably low compared to the mutation rate 
in the active sites of viral enzymes, particularly for the host proteins. Therefore, SMPPIIs 
targeting HIV and cellular proteins hold great promise with regards to preventing the 
emergence of drug resistant viruses in administrated persons. Thus, understanding the 
molecular basis of virus-host interactions should provide new insights into alternative 
strategies for the treatment of HIV infection and AIDS. In this chapter, we focus our 
attention on integration, an essential step in the HIV replication cycle catalyzed by IN, and 
review the current knowledge of molecular interactions between IN and cellular cofactors. 
2. HIV infection - from cell entry to integration 
HIV belongs to lentivirus, a separate genus of the Retroviridae family, and it can be further 
divided into antigenically distinct members, HIV-1 and HIV-2 (Levy, 2009). In the case of 
HIV-1, the enveloped viral particle contains two copies of positive sense RNA of 9.7-kb in 
length which encode two regulatory (tat and rev) and four accessory (vpr, vif, vpu, and nef) 
genes in addition to the characteristic retroviral gag, pol, and env genes. These protein-coding 
regions are flanked by the 5’ and 3’ long terminal repeat (LTR) sequences that are required 
for reverse transcription, integration, and gene expression steps. 
HIV-1 infection begins with the specific binding of the viral envelope (Env) glycoprotein 
gp120 to the CD4 receptor molecule on the surface of target cells. This interaction triggers a 
conformational change in the gp120 that facilitates subsequent binding to a coreceptor. As 
for the coreceptor, most of HIV-1 strains use either the -chemokine receptor CXCR4 or the 
-chemokine receptor CCR5. The formation of the gp120, CD4, and coreceptor complex then 
induces refolding of the gp41 subunit of Env, allowing the fusion of the HIV-1 and cell 
membranes. 
After penetrating the cell membrane, the HIV-1 core particle, which contains genomic RNA 
and the proteins needed to establish an infection, is first released into the cytoplasm where it 
then undergoes the uncoating process. Although this uncoating is defined as the loss of 
HIV-1 capsid (CA) protein after the entry step, the nature and timing of the uncoating 
process is poorly understood (Arhel, 2010). The formation of the reverse transcription 
complex (RTC), in which reverse transcription from viral RNA to DNA takes place, 
accompanies the uncoating of infecting virion core (Warrilow et al., 2009; Arhel, 2010). 
Currently, little is known about the components of the RTC, although several studies have 
shown that matrix (MA), Vpr, RT, and IN are contained in the HIV-1 RTC (Fassati & Goff, 
2001; McDonald et al., 2002; Iordanskiy et al., 2006). CA is only found in the HIV-1 RTC very 
early after cell entry but it becomes barely detectable at later times (Fassati & Goff, 2001). 
Interestingly, in the case of the Moloney murine leukemia virus (MoMLV), CA has shown to 
be stably associated with the RTC even at the later stages (Fassati & Goff, 1999). These pieces 
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5 
of evidence suggest that dissociation of CA from the HIV-1 core proceeds rapidly as 
compared to other retroviruses. 
The newly synthesized full-length viral DNA remains associated with viral and cellular 
proteins in a high molecular weight nucleoprotein complex. This integration-competent 
nucleoprotein complex is called the preintegration complex (PIC) (Goff, 2001; Suzuki & 
Craigie, 2007). Although the structure of the PIC is also poorly understood, a number of 
studies using immunoprecipitation assays have revealed that HIV-1 PICs retain many 
components of the RTC (Farnet & Haseltine, 1990, 1991; Bukrinsky et al., 1993; Gallay et al., 
1995; Farnet & Bushman, 1997; Miller et al., 1997; Iordanskiy et al., 2006). Additionally, 
several cellular proteins have been shown to associate with the HIV-1 PIC (Farnet & 
Bushman, 1997; Li et al., 2001; Lin & Engelman, 2003; Llano et al., 2004). A defining 
characteristic of the PIC is its full fidelity to the authentic integration reaction. When 
purified IN alone is used for an in vitro integration reaction, most of the products are the 
result of the integration of only a single viral DNA end into one strand of target DNA 
(Bushman & Craigie, 1991; Turlure et al., 2004). In contrast, a PIC isolated from virus-
infected cells is able to efficiently insert both viral DNA ends into the target DNA in a 
pairwise manner in vitro, and this is a hallmark of the integration reaction in vivo (Farnet & 
Haseltine, 1990; Chen & Engelman, 2001). Another striking feature of PICs is that suicidal 
intramolecular integration into its own viral DNA, a reaction termed autointegration, is 
precluded and it has been reported that cellular proteins are implicated in this barrier to 
autointegration in HIV-1 PICs (Yan et al., 2009). 
The PIC formed in the cytoplasm also serves as the vehicle for the translocation of its genetic 
cargo (i.e. viral DNA) into the nucleus. Once the PIC reaches the nuclear periphery it must 
gain entry into the nucleus for integration. In non-dividing cells such as macrophages, the 
PIC must permeate the barrier of an intact nuclear envelope. This is particularly important 
as macrophages are a major target of HIV-1 infection. How is the PIC to cross the nuclear 
envelope? Passive diffusion cannot explain the translocation because the size of the HIV-1 
PIC exceeds the allowances of a nuclear pore. Molecules up to 9 nm in diameter can pass 
through the nuclear pore complex by diffusion (Mattaj & Englmeier, 1998), but the HIV-1 
PIC is estimated to be more than 50 nm in diameter (Miller et al., 1997; McDonald et al., 
2002; Nermut & Fassati, 2003). Thus, active transport mechanisms are necessary for this task; 
one widely accepted model is that the HIV-1 PIC possesses karyophilic signals and many 
viral and cellular proteins have been proposed as the karyophilic proteins that cause the 
nucleoprotein complex to be imported into the nucleus (Fouchier & Malim, 1999; Fassati, 
2006; Luban, 2008). Although the actual participation of these proteins in the nuclear import 
of HIV-1 PICs is a matter of debate (Fassati, 2006; Suzuki & Craigie, 2007), this property is 
important in the pathogenesis of HIV-1 (Blankson et al., 2002). Additionally, the ability of 
HIV-1 to infect non-dividing cells makes the virus an attractive candidate for a gene transfer 
vector (Verma & Somia, 1997). 
In the nucleus, chromosomal DNA serves as the target for integration. Integration is 
essential in the replication of all retroviruses including HIV-1, and this step as well as 
reverse transcription are hallmarks of retroviral infection. The integration process occurs in 
three well-characterized reactions referred to as 3’-end processing, DNA strand transfer and 
gap repair (described below). IN catalyzes the first two reactions whereas the last reaction is 
likely carried out by yet-to-be identified cellular enzymes (Turlure et al., 2004). Once 
integrated, the viral DNA, called the provirus, is acted upon by cellular transcription factors 
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Fig. 1. Early stages of HIV-1 replication. HIV-1 infection begins with the binding of Env to 
the CD4 receptor and a coreceptor (CCR5 or CXCR4), allowing fusion between the cellular 
and viral membranes. After entry, the viral nucleoprotein core containing the genomic RNA 
is released into cytoplasm and reverse transcription takes place in a nucleoprotein complex 
called the RTC. The resulting full-length viral DNA remains associated with viral and 
cellular proteins in an integration-competent nucleoprotein complex termed the PIC. This 
PIC mediates integration of viral DNA into chromatin. Integrated viral DNA, called the 
provirus, then acts as a transcription template for the synthesis of viral RNAs. 
3. HIV-1 IN and the mechanism of integration 
3.1 IN structure 
During HIV-1 replication, IN is expressed from the provirus as the C-terminal part of a 160-
kDa Gag-Pol polyprotein and it is incorporated into nascent virions. Following the budding 
and release of viral particles from infected cells, viral PR cleaves the Gag-Pol precursor 
protein to generate the mature form of IN (Swanstrom & Wills, 1997). In the HIV-1 genome, 
Gag (a precursor for structural proteins such as MA, CA and nucleocapsid [NC]) and Pol (a 
precursor for enzymes such as PR, RT and IN) are encoded by overlapping open reading 
frames (ORFs), and the Gag-Pol precursor is generated by ribosomal frameshifting during 
translation of the gag gene. This translation mechanism results in the synthesis of Gag-Pol at 
a 20-fold lower level than Gag’s in HIV-1 infected cells (Jacks et al., 1988). Consequently, 
only 50 to 100 molecules of IN are contained in a viral particle. Although the production of 
Gag protein has been reported to suffice for generation of virus-like particles (VLP) 
(Mergener et al., 1992), incorporation and processing of the Gag-Pol protein is required for 
the formation of infectious HIV-1 virions (Swanstrom & Wills, 1997; Wu et al., 1997).  
HIV-1 IN is a 32-kDa protein that consists of three structurally and functionally distinct 
domains called the N-terminal domain (NTD), the catalytic core domain (CCD), and the  C-
terminal domain (CTD) (Fig. 2A) (Lewinski & Bushman, 2005). The structures of these 
individual domains have been determined by X-ray crystallography or NMR (Craigie, 2001; 
Vandegraaff & Engelman, 2007). The CCD is highly conserved amongst retroviral INs and 
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contains a triad of conserved amino acids comprising of Asp64, Asp116, and Glu152 and this 
is termed the D,D-35-E motif. By coordinating divalent metal ions such as Mg2+ to this motif, 
the CCD domain plays a key role during the integration reaction (Lewinski & Bushman, 
2005). This domain is dimeric in solution and the crystal structure of the dimer shows that 
the CCD domain consists of a five-stranded -sheet and six -helices. This structure is also 
found in many nucleotidyl transferases including RNase H, bacterial Mu, and the 
Argonaute protein of the RNA-induced silencing complex (RISC). Hence, IN belongs to the 
superfamily of polynucleotidyltransferases (Vandegraaff & Engelman, 2007). 
A well-conserved motif is also found in the NTD, which comprises two His and two Cys 
residues (HHCC motif). This domain contains a bundle of three -helices, and the HHCC 
motif stabilizes the helices by coordinating Zn2+. Mutation studies of the NTD have 
indicated that the HHCC motif contributes to the multimerization and catalytic function of 
HIV-1 IN (Lewinski & Bushman, 2005). 
In contrast to the NTD and CCD, the CTD is the least conserved domain of retroviral INs. 
Although the functional role of the CTD for catalysis is less clear, this domain exhibits 
strong and non-specific DNA-binding activity in vitro. The isolated CTD forms dimers in 
solution, and its monomer has an all -strand SH3-type fold (Lewinski & Bushman, 2005). 
3.2 Integration reaction 
The chemical mechanism of the integration catalyzed by HIV-1 IN has been elucidated by in 
vitro biochemical studies using recombinant IN protein and oligonucleotide DNA substrates 
(Craigie, 2001; Lewinski & Bushman, 2005; Vandegraaff & Engelman, 2007). This reaction 
proceeds with well-defined 3’ processing and strand transfer steps (Fig. 2B). In the 3’ 
processing step, IN specifically recognizes the viral attachment (att) sites on the 5’ and 3’ 
LTRs where it removes two nucleotides from each of the 3’ ends of the viral DNA to expose 
a recessed hydroxyl immediately following a CA dinucleotide that is conserved among 
retroviruses and many transposons. Water serves as the nucleophile this cleavage of viral 
DNA. Next, in the strand transfer step, the exposed hydroxyl groups attack a pair of 
phosphodiester bonds on opposite strands of the target DNA, causing the viral DNA 
termini to be covalently linked to the protruding 5’ phosphoryl ends of the target DNA. 
Since the cleavage sites on the opposite strands of target DNA are separated by 5 bp, HIV-1 
integration generates a five-base duplication flanking the provirus. Stereochemical analysis 
has revealed that these reactions occur by single-step transesterification mechanism 
(Engelman et al., 1991).  
The 3’ processing and strand transfer steps are reproducible in vitro using recombinant IN 
and DNA substrates, indicating that IN alone is sufficient to carry out the DNA breakage 
and joining reactions. However, these events yield short staggered DNA breaks at the points 
of joining, and so in virus-infected cells the mispaired 5’ viral DNA ends must be excised 
and the resulting nicks filled in order to produce the provirus (gap repair step). However, 
this final step is likely carried out by yet-to-be identified cellular enzymes and the molecular 
mechanisms involved in this reaction have not yet been elucidated (Smith & Daniel, 2006; 
Yoder et al., 2006; Turlure et al., 2004). 
4. Cellular proteins interacting with HIV-1 IN 
Although the enzymatic activities of HIV-1 IN in the integration reaction have been clearly 
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demonstrated that mutations in the IN gene, including deletion mutants, influence many 
other stages of viral replication in addition to integration. This pleiotropic effect of IN is 
characterized by defects in uncoating, reverse transcription, nuclear import, viral gene 
expression, virion precursor protein processing, and virion morphology (Shin et al., 1994; 
Engelman et al., 1995; Masuda et al., 1995; Bukovsky & Gottlinger, 1996; Leavitt et al., 1996; 
Nakamura et al., 1997; Engelman, 1999; Tsurutani et al., 2000; Lu et al., 2004; Dar et al., 2009; 
Briones et al., 2010). However, the mechanisms for these pleiotropic effects of the IN gene 
are still poorly understood. 
 
 
Fig. 2. HIV-1 integration reaction. (A) Domain organization of HIV-1 IN. Retroviral IN , 
including HIV-1 IN, consists of the N-terminal domain (NTD), catalytic core domain (CCD), 
and C-terminal domain (CTD). Highly concerved aspartic (D) and glutamic acid (E) residues  
are found in the CCD, forming the catalytic centre in IN (D,D-35-E motif). Likewise, the 
NTD contains a well-conserved motif that is formed from two histidine and two cystein 
residues (HHCC motif) while the CTD is the least conserved of the retroviral INs domains. 
(B) Mechanism of DNA integration. IN recognizes both ends of the viral DNA and removes 
two nucleotides from each of the ends (3’ processing). This reaction takes place in the 
cytoplasm. After entering the nucleus and binding to chromosomal DNA, IN cleaves the 
target DNA in a staggered fashion via the exposed hydroxyl groups (OH) on the viral DNA 
ends, the viral DNA termini are then joined to the cuts (strand transfer step). Finally, the 
resulting nicks at the viral-target DNA junction are repaired by cellular enzymes to 
complete the integration process (gap repair step). 
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Meanwhile, a number of cellular proteins have been identified as binding partners for HIV-1 
IN (Turlure et al., 2004; Al-Mawsawi & Neamati, 2007; Ao et al., 2007; Christ et al., 2008; 
Woodward et al., 2009; Ao et al., 2010). Some of these cellular interactors have been reported 
to assist in HIV-1 integration in infected cells (Turlure et al., 2004). However, other cellular 
partners for HIV-1 IN appear to have functional roles in steps other than the integration 
process including reverse transcription, nuclear import, and infectious particle production 
(Yung et al., 2001; Hamamoto et al., 2006; Al-Mawsawi & Ao et al., 2007; Mousnier et al., 
2007; Neamati, 2007; Christ et al., 2008; Ao et al., 2010). These pieces of evidence suggests 
that PPIs between IN and its cellular partner could be the molecular basis for the pleiotropic 
effects that have been observed in genetic studies using HIV-1 with mutant IN. 
Below, we summarize the current knowledge of the HIV-1 IN-binding cellular proteins and 
their possible roles in virus replication. 
4.1 Cellular interactors affecting on integration step 
So far, identification of HIV-1 IN cofactors has mostly been conducted by using yeast two-
hybrid screenings or co-immunoprecipitation assays (Turlure et al., 2004). Integrase 
interactor 1 (INI1) was the first IN-binding protein identified by the yeast two-hybrid 
screening (Kalpana et al., 1994). INI1 is the human homologue of yeast SNF5, a core subunit 
of the ATP-dependent SWI/SNF chromatin-remodeling complex (Wang et al., 1996). Thus, 
INI1 is also known as hSNF5. By exposing transcriptionally active regions of chromatin, 
SNF5 regulates the expression of numerous genes in eukaryotic cells (Carlson & Laurent, 
1994). INI1/hSNF5 is a 385 amino acid protein that is composed of three conserved domains 
including two direct imperfect repeat (Rpt) regions (Rpt1 and Rpt2) and a C-terminal coiled-
coil domain referred to as the homology region III (HRIII) (Morozov et al., 1998). A yeast 
two-hybrid assay has revealed that the Rpt1 is necessary for binding to HIV-1 IN (Morozov 
et al., 1998). 
In an early study using recombinant HIV-1 IN, INI1/hSNF5 was found to stimulate the 
integration reaction in vitro (Kalpana et al., 1994). However, when the minimal IN-binding 
domain of INI1/hSNF5, including the Rpt1 region (residues 183-294) termed S6, was co-
transfected with HIV-1 proviral DNA in HEK293 cells, a 10,000-fold reduction in virus 
production from the transfected cells was observed (Yung et al., 2001). Moreover, expression 
of the S6 fragment in Jurkat T cells protected the cells against HIV-1 replication (Yung et al., 
2001). Although this inhibitory effect was not detected in full-length INI1/hSNF5, the WT 
INI1/hSNF5 has been shown to be incorporated into virions during virus production (Yung 
et al., 2001; Yung et al., 2004). Given the recent report that depletion of endogenous 
INI1/hSNF5 did not affect the transduction efficiency of an HIV-1-based vector, this 
suggests that INI1/hSNF5 is likely implicated in post-integration steps, rather than the 
integration step as we shall see below, particularly in HIV-1 production (Ariumi et al., 2006). 
In terms of integration cofactors, lens epithelium-derived growth factor (LEDGF) is the first 
host protein whose role has been most clearly elucidated (Engelman & Cherepanov, 2008). 
LEDGF, a transcriptional regulator that belongs to the hepatoma-derived growth factor 
(HDGF) related protein (HRP) family, was identified as an IN-binding protein as a result of 
co-immunoprecipitation analysis using FLAG-tagged HIV-1 IN (Cherepanov et al., 2003). 
LEDGF is a 530 amino acid protein that consists of several functional domains (Fig. 3A) 
(Engelman & Cherepanov, 2008). The N-terminal 92 amino acid region is termed the PWWP 
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proteins and is thought to function as a protein-protein interaction domain and/or DNA-
binding domain (Stec et al., 2000; Qiu et al., 2002). LEDGF also includes three segments of 
polar amino acids called CR (charged region) domains, and a putative nuclear localization 
signal (NLS) and dual copies of the AT-hook DNA-binding motif can be identified in the N-
terminal half of the protein. In addition, a limited proteolysis analysis of recombinant 
LEGFP has revealed an evolutionarily conserved domain at the C terminus, which mediates 
the interaction with HIV-1 IN (integrase-binding domain: IBD) (Cherepanov et al., 2004). 
The IBD is a compact right-handed bundle composed of five  helices (Cherepanov et al., 
2005b). As for HIV-1 IN, CCD has been identified as the main determinant for interactions 




Fig. 3. Function of LEDGF in HIV-1 integration. (A) Domain structure of LEDGF. LEDGF is 
a 530 amino acid protein containing the PWWP domain, CR domains, a putative NLS, and 
dual copies of the AT-hook DNA-binding motif. Interaction of HIV-1 IN and LEDGF occurs 
between the CCD of IN and the C-terminal IBD of LEDGF, and this has been demonstrated 
to be critical for enhancement of the intgration reaction in vitro and in vivo. (B) LEDGF-
mediated tethering of the HIV-1 PIC to chromain. The most widely accepted model of 
LEDGF function in HIV-1 infection is that LEDGF serves as an adaptor molecule to anchor 
the PIC to chromain via i) protein-protein interaction between IN and LEDGF and ii) 
subsequent protein-DNA interaction between LEDGF and chromatin. This thethering 
function may also regulate integraton-site selection of the HIV-1 PICs in virus-infected cells. 
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Early works using recombinant proteins have shown that LEDGF is able to stimulate the 
integration activity of the HIV-1 IN in vitro (Cherepanov et al., 2003, 2004). Furthermore, 
LEDGF associates with HIV-1 PICs (Llano et al., 2004). While these studies have raised the 
possibility that LEDGF might be implicated in the integration reaction of HIV-1 infection, 
subsequent in vivo studies using RNA interference reported that depletion of endogenous 
LEDGF resulted in only a modest effect or none at all on the replication efficiency of HIV-1 
(Llano et al., 2004; Vandegraaff et al., 2006; Zielske & Stevenson, 2006). However, if residual 
expression of LEDGF is sufficient to complement the activity of HIV-1 IN in virus-infected 
cells, the results obtained by experiments using RNA interference-based knockdown assays 
might downplay the contribution of LEDGF to HIV-1 replication. Indeed, a significant 
reduction of HIV-1 infection was observed in human CD4+ T cells in which there was a more 
complete knockdown of endogenous LEDGF (Llano et al., 2006a), and in mouse embryo 
fibroblasts (MEFs) derived from LEDGF knockout mice (Marshall et al., 2007; Shun et al., 
2007), indicating a crucial role of LEDGF in virus replication. These genetic knockdown and 
knockout studies have revealed that the defect in HIV-1 replication in the absence of LEDGF 
clearly occurred at the DNA integration step (Llano et al., 2006a; Marshall et al., 2007; Shun 
et al., 2007). How is LEDGF involved in the integration process of HIV-1? Several lines of 
evidence have demonstrated that although in vitro integration by recombinant IN or PIC 
derived from HIV-1-infected cells occurs almost randomly, in vivo integration sites of HIV-1 
are enriched with active transcription units (TUs) (Bushman et al., 2005). Considering the 
fact that the N-terminal PWWP domain/AT-hook motifs mediate chromatin-binding of 
LEDGF (Llano et al., 2006b; Turlure et al., 2006) and are also required for HIV-1 infection as 
much as the IBD (Llano et al., 2006a; Shun et al., 2007), the simplest model would be that 
LEDGF functions as a molecular adaptor for tethering HIV-1 IN within the PIC to 
chromatin, thereby promoting the integration process (Fig. 3B). Since LEDGF is a 
transcriptional coactivator, it would be plausible that the distribution of LEDGF on certain 
regions of chromatin is a primary determinant for the integration site specificity of HIV-1 
(De Rijck et al., 2010). Indeed, genome-wide studies analyzing integration sites in HIV-1-
infected cells have shown that a significant reduction in the frequency of integration into 
TUs was observed in LEDGF knockdown and knockout cells (Ciuffi et al., 2005; Marshall et 
al., 2007; Shun et al., 2007). 
Posttranslational modifications of HIV-1 IN by cellular enzymes have also been reported to 
be implicated in integration. p300, a histone acetyltransferase (HAT), was first identified as a 
cellular protein that directly binds to HIV-1 IN in vitro and in human cells (Cereseto et al., 
2005). HATs are known as enzymes that catalyze the transfer of acetyl groups from acetyl 
coenzyme A (acetyl-CoA) to specific lysine residues within the N-terminal tails of 
nucleosomal histones. This histone acetylation leads to chromatin decondensation and 
transcriptional activation (Roth et al., 2001). In addition to histones, HATs are able to 
acetylate other proteins including transcription factors. In vitro analysis using recombinant 
proteins showed that p300 can also acetylate three specific lysines (Lys264, Lys266, and 
Lys273) in the C-terminus of HIV-1 IN (Cereseto et al., 2005). Interestingly, the acetylation 
increased IN binding to LTR DNA its catalysis of the strand transfer reaction in vitro 
(Cereseto et al., 2005). Because HIV-1 harbouring mutations in the Lys264, Lys266, and 
Lys273 of IN exhibited replication defect at the integration step, these results suggest that 
acetylation of IN is important for efficient integration during HIV-1 infection (Cereseto et al., 
2005). A recent study from the same group showed that another HAT, GCN5, was also able 
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Fig. 3. Function of LEDGF in HIV-1 integration. (A) Domain structure of LEDGF. LEDGF is 
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Early works using recombinant proteins have shown that LEDGF is able to stimulate the 
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(Cereseto et al., 2005). Because HIV-1 harbouring mutations in the Lys264, Lys266, and 
Lys273 of IN exhibited replication defect at the integration step, these results suggest that 
acetylation of IN is important for efficient integration during HIV-1 infection (Cereseto et al., 
2005). A recent study from the same group showed that another HAT, GCN5, was also able 





depleted cells (Terreni et al., 2010). However, it should be noted that the role of acetylation 
of IN in HIV-1 replication remains controversial (Topper et al., 2007; Vandegraaff & 
Engelman, 2007). 
Another type of posttranslational modification of IN that regulates HIV-1 infection has also 
been demonstrated. The c-Jun NH2-terminal kinase (JNK), a member of mitogen-activated 
protein kinase (MAPK) family, is reported to phosphorylate a highly conserved serine 
residue (Ser57) in the CCD of HIV-1 IN. This phosphorylated IN is, in turn, recognized by 
the cellular peptidyl-prolyl cis-trans isomerase Pin1, and this association with Pin1 induces a 
conformational change in HIV-1 IN, eventually resulting in an increase in IN stability 
(Manganaro et al., 2010). Intriguingly, expression of JNK is very low in resting CD4+ T cells, 
which are resistant to the establishment of productive infection by HIV-1, but not in 
activated cells permissive to HIV-1 infection. Hence, JNK and Pin1 may collaborate to 
increase the permissivity of T lymphocytes to HIV-1 via the phosphorylation and 
subsequent stabilization of IN (Manganaro et al., 2010). 
Several other cellular proteins including uracil DNA glycosylase (UDG), heat-shock protein 
(HSP) 60, Rad18, and Polycomb group protein EED (embryonic ectoderm development) have 
also been found to interact with HIV-1 IN (Willetts et al., 1999; Parissi et al., 2001; Mulder et 
al., 2002; Violot et al., 2003), and some of them have been shown to stimulate in vitro 
integration activity of recombinant IN (Parissi et al., 2001; Violot et al., 2003). Yet, the 
contributions of these cellular interactors in HIV-1 integration and infection remain unclear 
(Turlure et al., 2004). 
4.2 Cellular interactor affecting on reverse transcription step 
It has been demonstrated that a specific interaction occurs between the HIV-1 IN and RT (Wu 
et al., 1999; Zhu et al., 2004), and that IN stimulates RT-catalyzed early synthesis of viral DNA 
in vitro (Dobard et al., 2007). This suggests that interaction between IN and RT has a functional 
consequence during the reverse transcription step of HIV-1 infection. Supporting the role of IN 
in viral DNA synthesis, a cellular binding protein for IN has been implicated in the reverse 
transcription of HIV-1. Gemin2 is a component of the survival of motor neurons (SMN) 
complex that is essential for the biogenesis of spliceosomal small nuclear ribonucleoproteins 
(snRNPs). The SMN complex, which is composed of an SMN protein and 7 additional proteins 
(Gemin2-8), recognizes specific sequences and structures of small nuclear RNAs and serves as 
an assembly complex for snRNP formation (Paushkin et al., 2002). A yeast two-hybrid 
screening identified Gemin2 as a novel interactor of HIV-1 IN (Hamamoto et al., 2006). This 
interaction involves the CTD alongside partial contribution from the CCD of HIV-1 IN 
(Hamamoto et al., 2006). Although Gemin2 was found in the HIV-1 PIC, knockdown 
experiments using small interfering RNA (siRNA) revealed that depletion of endogenous 
Gemin2 significantly reduced HIV-1 infectivity in human primary monocyte-derived 
macrophage (MDM), and importantly, the replication defect was observed at the early reverse 
transcription step during virus replication (Hamamoto et al., 2006). Moreover, a recent study 
shows that viral DNA synthesis by RT is augmented by IN in a Gemin2-dependent manner in 
vitro (Nishitsuji et al., 2009). These results suggest that the concerted action of IN and Gemin2 
enhances the RT-catalyzed reverse transcription step in HIV-1 infection. 
4.3 Cellular interactors affecting on nuclear import step 
As mentioned above, a striking feature of HIV-1 is its ability to infect non-dividing cells. The 
nuclear envelope is intact in the non-dividing cells, and the HIV-1 PIC must cross this 
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nuclear envelope to integrate viral DNA into chromosomal DNA. Therefore, it is believed 
that the HIV-1 PIC carries karyophilic signals that cause it to be transported into the nucleus 
through nuclear pore complexes (NPCs) (Suzuki & Craigie, 2007). HIV-1 IN has been 
implicated as a karyophilic protein that facilitates the nuclear import of the PICs (Ikeda et 
al., 2004). Although many studies using reporter proteins have shown that HIV-1 IN 
accumulates in the nucleus ( Petit et al., 1999; Pluymers et al., 1999; Ikeda et al., 2004), recent 
evidences suggest that IN may lack a transferable NLS and that the accumulation of HIV-1 
IN may be attributed to its interactions with the cellular karyophilic protein(s) (Devroe et al., 
2003; Llano et al., 2004). 
Shortly after its identification as an interactor of HIV-1 IN, LEDGF was proposed as the 
karyophilic factor (Maertens et al., 2003). A siRNA-mediated knockdown experiment 
showed that depletion of endogenous LEDGF abolished nuclear accumulation of HIV-1 IN 
in HeLa cells (Maertens et al., 2003). Because the LEDGF is the cellular component of HIV-1 
PICs (Llano et al., 2004), this suggests that LEDGF is the nuclear import factor directing IN 
and viral DNA into the nucleus (Maertens et al., 2003). However, this overplays the role of 
LEDGF in HIV-1 replication; replication defect of HIV-1 in LEDGF knockdown and 
knockout cells was not observed at the step of nuclear import of the PIC, as measured by the 
formation of a circular ligation product of viral DNA in the nucleus (Llano et al., 2006a; 
Shun et al., 2007). Thus, LEDGF should contribute to the stable tethering of IN and viral 
DNA (i.e. the PIC) to chromatin, thereby regulating integration efficiency and integration-
site selection of HIV-1 (Fig. 3B) (Engelman & Cherepanov, 2008). 
Translocation of proteins (cargo molecule) across the NPC requires specific transport 
receptors. Importin is one of the best-studied receptors for nuclear translocation. Importin 
contains two subunits, importin  and importin . The NLS of a cargo molecule is first 
recognized by importin , and after binding to importin , the cargo-receptor complex is 
targeted to the NPC via direct association of importin  with components of the NPC called 
nucleoporin (NUP) (Mattaj & Englmeier, 1998). To date, several importins have been 
reported to interact with HIV-1 IN (Krishnan et al., 2010). By employing the in vitro nuclear 
import assay, importin 7, a member of importin  family acting as an import receptor for 
ribosomal proteins and histone H1, was shown to mediate nuclear import of the HIV-1 PICs 
(Fassati et al., 2003). Although HIV-1 IN was found to interact with importin 7 through the 
CTD (Ao et al., 2007), the functional role of this cellular protein in the nuclear entry of the 
PIC remains a matter of debate (Zielske & Stevenson, 2005). 
Another member of the importin  family, transportin 3 (TNPO3/transportin-SR2), has also 
been identified by yeast two-hybrid screening as an HIV-1 IN-binding protein that directs 
the PICs to the nucleus (Christ et al., 2008). The requirement of TNPO3 in HIV-1 replication 
was confirmed by studies using siRNA-mediated knockdown (Brass et al., 2008; Konig et al., 
2008; Krishnan et al., 2010). However, a recent study reveals that CA, but not IN, determines 
the TNPO3 dependency during HIV-1 replication (Krishnan et al., 2010). Additionally, later 
studies disclosed that the different cellular proteins regulating nucleocytoplasmic 
trafficking, importin 3 and NUP153, also interact with HIV-1 IN (Woodward et al., 2009; 
Ao et al., 2010). Understanding how the HIV-1 PIC crosses the intact nuclear envelope in 
non-dividing cells is one of the most fascinating areas in retroviral research. Further 
experiments will be therefore required to unveil the role of IN and its cellular cofactors in 
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4.4 Cellular interactors affecting on postintegration steps 
Following integration, the provirus serves as a template for viral gene expression. During 
this postintegration process, disassembly of IN from the integrated viral DNA is a 
prerequisite for efficient transcription (Yoder & Bushman, 2000). It is well known that when 
HIV-1 IN is solely expressed in mammalian cells it undergoes proteasome-mediated 
degradation via ubiquitination (Mulder & Muesing, 2000). Although the function of this 
ubiquitin-mediated degradation of IN in HIV-1 replication remains unclear, one 
ubiquitination pathway has been suggested to participate in the gene expression step of 
HIV-1 replication through the degradation of IN (Mousnier et al., 2007). von Hippel-Lindau-
binding protein 1 (VBP1) was identified as a cellular partner for HIV-1 IN by yeast two-
hybrid screening. VBP1, also known as a subunit of the prefoldin chaperone, associates with 
the substrate recognition component of the cullin2-based von Hippel-Lindau (Cul2/VHL) 
ubiquitin ligase complex. Co-immunoprecipitation assays showed that HIV-1 IN bound 
both VBP1 and pVHL, and this IN-pVHL interaction was reduced by siRNA-mediated 
knockdown of endogenous VBP1 expression (Mousnier et al., 2007). Intriguingly, the 
depletion of VBP1 by siRNA had a negative impact on the transcriptional activity of 
integrated HIV-1 DNA without affecting provirus formation. Additionally, the specific 
knockdown of components of the Cul2/VHL ubiquitin ligase complex, including VBP1, 
resulted in a slower degradation and a decreased ubiquitination of HIV-1 IN as observed in 
pVHL deficient cells, indicating that Cul2/VHL ubiquitin ligase is responsible for the 
proteasomal degradation of IN (Mousnier et al., 2007). This study suggests that the 
recruitment of Cul2/VHL ubiquitin ligation complex by VBP1-IN interaction may play a 
pivotal role in degradation of IN, leading to efficient transition from integration to viral gene 
expression during HIV-1 infection. 
Recently, a different class of ubiquitin ligase was found to interact with HIV-1 IN 
(Yamamoto et al., 2011). By employing a tandem affinity purification (TAP) procedure 
combined with mass spectrometry (MS) analysis, we have identified Huwe1 (HECT, UBA, 
and WWE domain containing 1), a HECT (homologous to E6-AP carboxyl terminus)-type E3 
ubiquitin ligase, as a novel cellular interactor of MoMLV IN. Interestingly, Huwe1 also 
interacts with HIV-1 IN, and the binding was mediated through the CCD of IN and a wide-
segment of Huwe1 (Fig. 4A). Because Huwe1 was associated with the PICs in 
immunoprecipitation assays, this ubiquitin ligase was expected to have a role in the 
integration process. However, when endogenous Huwe1 was depleted from a human T cell 
line by RNA interference technique, comparable levels of reverse transcription, integration, 
and gene expression were observed in HIV-1-infected knockdown and control cells. On the 
other hand, the knockdown experiment revealed that the infectivity of HIV-1 virions 
released from Huwe1-depleted T cells was significantly augmented compared to the virions 
produced from control cells, suggesting that Huwe1 has a negative impact on the 
production of infectious virions during HIV-1 replication (Yamamoto et al., 2011). 
One question to be pondered is how the IN-binding protein Huwe1 modulates HIV-1 
infectivity. IN is expressed as the C-terminal part of the Gag-Pol protein that is required for 
the formation of infectious virions during retroviral replication (Swanstrom & Wills, 1997). 
Further analysis showed that Huwe1 also associates with the HIV-1 Gag-Pol polyprotein in 
a C-terminal IN domain dependent manner (Yamamoto et al., 2011). Given that 
incorporation of Huwe1 into HIV-1 virions was not detected, one possibility would be that 
Huwe1 blocks the proper intracellular localization of the Gag-Pol precursor. It has been well 
demonstrated that during HIV-1 particle assembly, viral structural proteins, including Gag-
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Pol, are taken up by the detergent-resistant membrane (DRM) fraction, the so called lipid 
raft, which is characterized by its insolubility against non-ionic detergents such as NP-40 
(Halwani et al., 2003; Ono, 2010). In contrast, Huwe1 was distributed in a NP-40-soluble 
(non-DRM) fraction (Yamamoto et al., 2011). Thus, Gag-Pol precursor protein may be 
sequestered by Huwe1 present in the non-DRM domains of the cytoplasm through the IN 
region, resulting in interference of proper localization of Gag-Pol to the lipid raft where 
assembly of infectious virions is meant to take place (Fig. 4B, left). 
 
 
Fig. 4. A novel HIV-1 IN-binding protein, Huwe1. (A) Interacting domains between Huwe1 
and HIV-1 IN. Huwe1 is a HECT-type E3 ubiquitin ligase which possesses several 
recognizable domains; ARLD (Armadillo [ARM] repeat like domain) 1 and 2 in the N-
terminus, UBA (ubiquitin-associated), WWE, and the well-conserved BH3 domain in the 
middle, and a HECT domain in the C-terminus. Our study shows that Huwe1 interacts with 
the CCD of HIV-1 IN through a broad region spanning 3,500 amino acids (Yamamoto et al., 
2011). (B) Possible mechanisms by which Huwe1 hampers the formation of infectious HIV-1. 
In virus producing cells, Huwe1 may act as a scaffolding modulator that reduces infectivity 
of virions by interfering with the proper localization (left) or function (right) of HIV-1 Gag-
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Pol, are taken up by the detergent-resistant membrane (DRM) fraction, the so called lipid 
raft, which is characterized by its insolubility against non-ionic detergents such as NP-40 
(Halwani et al., 2003; Ono, 2010). In contrast, Huwe1 was distributed in a NP-40-soluble 
(non-DRM) fraction (Yamamoto et al., 2011). Thus, Gag-Pol precursor protein may be 
sequestered by Huwe1 present in the non-DRM domains of the cytoplasm through the IN 
region, resulting in interference of proper localization of Gag-Pol to the lipid raft where 
assembly of infectious virions is meant to take place (Fig. 4B, left). 
 
 
Fig. 4. A novel HIV-1 IN-binding protein, Huwe1. (A) Interacting domains between Huwe1 
and HIV-1 IN. Huwe1 is a HECT-type E3 ubiquitin ligase which possesses several 
recognizable domains; ARLD (Armadillo [ARM] repeat like domain) 1 and 2 in the N-
terminus, UBA (ubiquitin-associated), WWE, and the well-conserved BH3 domain in the 
middle, and a HECT domain in the C-terminus. Our study shows that Huwe1 interacts with 
the CCD of HIV-1 IN through a broad region spanning 3,500 amino acids (Yamamoto et al., 
2011). (B) Possible mechanisms by which Huwe1 hampers the formation of infectious HIV-1. 
In virus producing cells, Huwe1 may act as a scaffolding modulator that reduces infectivity 
of virions by interfering with the proper localization (left) or function (right) of HIV-1 Gag-





Another possible mechanism for the Huwe1-mediated negative modulation of HIV-1 
infectivity is that Huwe1 could mask the IN region of Gag-Pol, thereby blocking the 
incorporation of INI1/hSNF5 and its associated cellular factors into HIV-1 virions (Fig. 4B, 
right). As described above, INI1/hSNF5 has been shown to be specifically encapsidated into 
HIV-1 virions, probably through the IN region of Gag-Pol (Yung et al., 2001, 2004). In 
addition, a recent study demonstrates that the IN-INI1/hSNF1 interaction selectively 
recruits SAP18 and HDAC1, components of the Sin3a-HDAC complex, into the HIV-1 
virion, increasing the infectivity of the virions (Sorin et al., 2009). Although Huwe1 is an E3 
ubiquitin ligase, our study suggests that enzymatic activity of Huwe1 is not involved in the 
ubiquitination and subsequent proteasomal-degradation of IN and Gag-Pol (Yamamoto et 
al., 2011). Therefore, in HIV-1 producer cells, Huwe1 may function as a scaffolding 
modulator that hampers proper localization or function of the Gag-Pol precursor protein via 
interaction with IN region (Fig. 4B). 
5. Conclusion and implications for future treatment of HIV infection 
This chapter highlights the functional role of PPIs between HIV-1 IN and its cellular 
cofactors for virus replication. Although the indispensability of these IN interactors in the 
HIV-1 infection cycle requires further validation, research into intracellular binding proteins 
of IN provide an important insight for the development of novel classes of anti-HIV drugs: 
inhibitors blocking IN-cellular protein interactions that can act synergistically with existing 
drugs. The design of this class of inhibitors (i.e. SMPPIIs) is an emerging field in retroviral 
research, but the rationale for their availability in blocking HIV-1 replication has been 
demonstrated in SMPPIIs against IN-LEDGF interaction (Christ et al., 2010). One impact on 
the pharmacological aspect is that, because cellular interactors for IN appear to be 
implicated in steps other than the integration process, SMPPIIs targeting IN could block 
HIV-1 replication at multiple steps. Therefore, further analysis of the mechanism by which 
the IN interactors regulate virus infection can be the basis of a promising new strategy for 
the treatment of HIV-1 infection and AIDS. 
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1. Introduction  
Human Immunodeficiency Virus (HIV) is the causative agent of AIDS (Acquired Immune 
Deficiency Syndrome). Currently, the infection by HIV is considered as one of the major 
problem of public health and social stability. The scale of HIV/AIDS epidemic has exceeded 
all expectations since its identification 30 years ago. Currently, according to the report on 
HIV/AIDS by UNAIDS and World Health Organization (WHO) in 2009, we estimated 
approximately 33 million people are currently living with HIV-1 and about 25 millions have 
already died (Piot, Feachem et al. 2004). HIV infection leads to a decline in the number of T 
helper CD4 cells leading to a progressive dysfunction of the immune system. This 
weakening of the immune system results in the development of opportunistic infections 
leading to death of the patient. Despite prevention policies and anti-retroviral therapies, 
AIDS still remains one of the most serious humanitarian crises that we have never known. 
1.1 HIV taxonomy, structure and genome organization 
Identified in 1983, HIV belongs to lentivirus genus of Retroviridaea (Barre-Sinoussi, Chermann 
et al. 1983). Lentiviruses are host-specific viruses which cause slowly progressive diseases in 
their hosts and are characterized by selective T CD4 depletion (Fauci 1988) associated with a 
severe immunological and neurological disorders. These disorders are amplified by the fact 
that the virus infects the key cells of the immune system. As consequences, immunological 
disorders in HIV infected patients are observed since the asymptomatic stage. Two major 
subtypes of HIV have been identified: HIV-1 and HIV-2 (Clavel, Guetard et al. 1986). The first, 
HIV-1, is world wide, virulent and responsible of HIV infection globally. However, the second, 
HIV-2, is less pathogenic and is largely confined to West Africa. These two types of virus share 
a 40% homology in their sequences. HIV-1 strain is subdivided into three genetically groups: 
M (Major), N (New or non M non O) and O (Outlier) (Clavel, Guetard et al. 1986). The M strain 
is the most spread worldwide, it represents more than 95% of the global virus isolates. The 
variability within the sequence of env gene of HIV-1, allowed it to be subdivided into 10 clades 
A to L (McCutchan 2000). At least 15 additional circulating recombinant forms (CRF) has been 
identified in HIV-1 patients living in different geographic regions of the world (Peeters and 
Sharp 2000). However, the presence of these CRF seems to be more present in Africa, Asia and 
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existence of co-infection in vivo with the two viruses, no recombination between HIV-1 and -2 
have been reported. About the question of the origin of HIV-1 and HIV-2 transmission to 
human, it is admitted that it comes respectively from a cross-species of SIVcpz (Simian 
Immunodeficiency Virus which infects chimpanzees) in Central Africa and SIVsm (Simian 
Immunodeficiency Virus which infects sooty mangabey) in West Africa (Hirsch, Olmsted et al. 
1989; Gao, Gorelick et al. 2003). 
HIV-1 is an enveloped virus. The viral particles are produced as immature virions by 
budding from infected cells. After maturation by the viral protease, mature particles adopt 
spherical forms with a diameter of 90-100 nm (figure 1). 
 
 
This spatial representation takes into account and summarizes the results from more than 100 latest 
scientific publications in the fields of virology, X-ray analysis and NMR spectroscopy. The depicted 
spatial configurations of 17 different viral and cellular proteins found in HIV particle are in strict 
accordance with known 3D-structures. This model of HIV virion is put on the cover of the special issue 
of Nature Medicine (September 8, 2010) prepared by the Global HIV Vaccine Enterprise. 
Fig. 1. Model reconstitution of spatial structure of HIV-1. 
Those mature particles have a cone shaped core composed of the p24 viral protein. It was 
estimated that each viral particle contains 1500-2000 Gag and 100-200 Pol molecules. The 
envelope glycoproteins are present as trimers of gp120/gp41 and were estimated to ten 
trimers per particle. The HIV capsid contains the viral genome composed of two identical 
single stranded RNA molecules allowing the establishment of frequent genetic changes by 
recombination. The RNA viral genome is capped at its 5’-end and polyadenylated at its 3’-
end. The viral reverse transcriptase, integrase and nucleoproteins were found associated 
with the viral genome. The HIV genome of approximately 10kb encodes for 16 distinct 
proteins (Sodroski, Rosen et al. 1985). A schematic representation of HIV genome and 
proteins is illustrated in figure 2. As in all retroviruses, those proteins are derived from three 
essential genes gag, pol and env. The first gene gag encodes for Gag precursor p55, which is 
cleaved by viral protease to give capside, matrice and nucleocapside proteins : p24, p17, p7 
and p6. Enzymatic proteins are encoded by pol gene and give three viral enzymes : protease 
p11, transcriptase reverse p65/51 and integrase p32. The env gene encodes for the precursor 
gp160 which is later proteotically cleaved by a cellular protease into the two envelope 
proteins gp120 and gp41. These steps of maturation by the viral or the cellular proteases are 
crucial for the production of infectious viral particles. In addition to these structural and 
enzymatic gene products, HIV genome encodes for two regulatory proteins Tat 
(transcriptional transactivator) and Rev (regulator of virion gene expression) and also for 
four accessory proteins : Vif (viral infectivity factor), Vpr (viral protein r), Vpu (viral protein  
HIV Infection «HIV Tat Protein, a Key Factor 





Gag (group specific antigen) and Gag-Pol (polymerase) are polyprotein precursors that are processed 
by viral protease. The 9 mature subunits are protease (PR), reverse transcriptase (RT), integrase (IN), 
matrix (MA), capsid (CA), p2, nucleocapside (NC), p1 and p6. Envelope is also cleaved, however by a 
host cellular protease into surface (SU) gp120 and transmembrane gp41 moieties. HIV genome encodes 
also for accessory and regulatory proteins: transcriptional transactivator (Tat), regulator of virion gene 
expression (Said, Dupuy et al.), viral infectivity factor (Vif), viral proteins u (Vpu), viral proteins r (Vpr) 
and negative factor (Nef). Tev contains Tat, Env and Rev sequences and functions like Tat and Rev. 
Fig. 2. HIV genome organization and proteins.  
u) and Nef (negatif factor) (Emerman and Malim 1998). The gene products of rev and tat are 
produced early in the viral cycle and their expression is essential for the viral replication. 
Deletion of one of them leads to an abortive viral cycle. The Tat protein is implicated in the 
initiation and elongation/stabilisation of transcribed viral mRNA. Tat binds to a specific site 
called TAR (Tat responsive region) located in the LTR. Tat is the major protein involved in 
the upregulation of HIV-1 replication. In parallel, the Rev protein interacts with a structure 
called RRE (Rev responsive element) located in the env gene (Emerman and Malim 1998). 
This interaction permits mono and unspliced mRNA to cross the nuclear membrane in order 
to enter in the cytoplasm, where, they will be translated to proteins or encapsidated in the 
nascent viral particles. As Tat and Rev, Nef is also an early produced protein. This protein 
has at least three distinct activities including down regulation of cell surface CD4 and MHC 
class I molecules and enhancement of virion infectivity. It has been reported that this protein 
is essential for proviral DNA synthesis. It is also important for cell-cell transmission of the 
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u) and Nef (negatif factor) (Emerman and Malim 1998). The gene products of rev and tat are 
produced early in the viral cycle and their expression is essential for the viral replication. 
Deletion of one of them leads to an abortive viral cycle. The Tat protein is implicated in the 
initiation and elongation/stabilisation of transcribed viral mRNA. Tat binds to a specific site 
called TAR (Tat responsive region) located in the LTR. Tat is the major protein involved in 
the upregulation of HIV-1 replication. In parallel, the Rev protein interacts with a structure 
called RRE (Rev responsive element) located in the env gene (Emerman and Malim 1998). 
This interaction permits mono and unspliced mRNA to cross the nuclear membrane in order 
to enter in the cytoplasm, where, they will be translated to proteins or encapsidated in the 
nascent viral particles. As Tat and Rev, Nef is also an early produced protein. This protein 
has at least three distinct activities including down regulation of cell surface CD4 and MHC 
class I molecules and enhancement of virion infectivity. It has been reported that this protein 
is essential for proviral DNA synthesis. It is also important for cell-cell transmission of the 





core packaging (Peterlin and Trono 2003). The Vpr protein affects the nuclear localization of 
viral nucleic acids in non dividing cells and induces cell differentiation (Peterlin and Trono 
2003), while the Vpu protein enhances virion release and degrades CD4 in the endoplasmic 
reticulum (Hoglund, Ohagen et al. 1994). Many studies have put forward that Vpr, Vif, Nef 
and perhaps Tat are found associated in the viral particles.  
1.2 HIV-1 tropism and replication cycle 
At least 11 distinct steps can be identified in HIV-1 viral cycle including: viral attachment, 
entry by fusion and uncoating, reverse transcription of the RNA genome by reverse 
transcriptase to double stranded DNA (dsDNA), nuclear translocation of the pre-integration 
complex, integration of the proviral dsDNA, transcription of the proviral genome after 
cellular activation, splicing and nuclear transport of mono and unspliced RNA, translation 
of the viral RNA, assembly and packaging of the genomic RNA, budding to give immature 
viral particles and maturation to give infectious viral particles. Since the infection are 
mediated through the bodily fluids, HIV infects specially CD4 positive cells and essentially 
T-CD4 helper cells, monocyte/macrophage and dendritic cells (DC) (Dalgleish, Beverley et 
al. 1984). The virus enters cells by fusion and endocytosis (Chambers, Pringle et al. 1990; 
Bernstein, Tucker et al. 1995). Productive infection of target cells is initiated by the binding 
of the external envelope glycoprotein gp120 to CD4 receptor on the cell surface membrane 
(Bour, Geleziunas et al. 1995). At the surface of the virus the trimer of gp120 is associated 
with three molecules of the transmembrane gp41 by non-covalent interactions. CD4-gp120 
interaction is mediated by conserved domains of gp120 and the first domain of CD4 
receptor. Different reports have shown that gp120 interacts with CD4 with high affinity with 
dissociation constant of nanomolar level (Fenouillet, Clerget-Raslain et al. 1989). It is 
interesting to note that the conserved domains of gp120 appear to be few or non-
immunogenic in HIV-1 infected patients. Generation antibodies against the conserved 
domains of gp120 are of great interest. In fact, despite the great variability observed in HIV-
1 sequence, all viruses recognize the same receptor CD4. Thus, the production of such 
antibodies will probably exhibit a large spectrum of HIV neutralization by blocking gp120-
CD4 interaction with all HIV-1 subtypes despite their variability. A great number of studies 
are working to design potential vaccine candidates based on these conserved domains of 
HIV-1 envelope glycoproteins. Entry of HIV requires also an interaction of gp120 with a 
coreceptor: CCR5 (R5 tropic virus) and/or CXCR4 (X4 tropic virus) (Maddon, Dalgleish et 
al. 1986; Kozak, Platt et al. 1997; Platt, Wehrly et al. 1998). At the time of primo-infection, 
HIV recognizes and infects principally cells that express CCR5 proteins 
(monocytes/macrophages) (Dragic, Litwin et al. 1996). With time the virus switch from R5 
to X4 tropic to infects T cells (Grivel and Margolis 1999; Shankarappa, Margolick et al. 1999). 
This tropic evolution correlates with late stage of HIV infection : AIDS stage. Thus, 
interaction of gp120 to CD4 receptor and coreceptors induces HIV entry by allowing viral 
and host cell membranes fusion. This mechanism continues to be largely investigated at a 
molecular level, by different groups. We will briefly summarize here the key steps.  
Subsequently to gp120-CD4 interaction, conformational changes occurs firstly in the viral 
gp120 and then, in the transmembrane gp41. Modifications in gp120 structure contribute to 
the exposure of V3 region, which contains the binding site of the viral chemokine receptors 
CCR5 or CXCR4. This latter interaction mediates further modifications in the gp41 structure 
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leading to the exposition of the hydrophobic N-terminal gp41 fusion domain. Then the 
insertion of this fusion domain into the membrane of the host cell allows its fusion with the 
viral membrane (Chan, Fass et al. 1997) (figure 3). 
 
 
The mechanism of HIV-1 entry can be summarized in the following model. After binding of gp120 to 
receptor and coreceptor (step 1-2), gp41 undergoes conformational changes leading to the exposure of 
the fusion peptide and the accessibility of trimeric HR1 and the hydrophobic N-terminal domain, which 
contains the fusogenic region, and the trimeric HR2 domains (step 3). Then, HR1 and HR2 interacts 
together forming a 6-helix bundle leading to the membrane fusion and virus entry (step 4-5). The triple 
stranded coiled-coil structure (step 3), which probably explains its low immunogenicity in human 
patients infected with HIV-1. 
Fig. 3. Representation of the different steps from the viral-host interaction and the viral 
entry after membranes fusion.  
The chemokine coreceptors CCR5 and CXCR4 of HIV are preferentially found in lipid rafts 
(Kozak, Heard et al. 2002). These cholesterol and sphingolipid-enriched microdomains in 
the plasma membrane mirror the optimal lipid bilayer of the virus and provide likely a 
better environment for membrane fusion (Chambers, Pringle et al. 1990; Chazal and Gerlier 
2003). Several inhibitors including T20 (enfuvirtide) have been developed. T20 is a synthetic 
peptide of 36 amino acids which blocks HIV-1 entry by interfering with the formation of the 
six helix bundle formed following the interaction between the trimeric HR1 and HR2 
domains of the transmembrane envelope glycoprotein gp41 (Kilby, Hopkins et al. 1998). 
More recently a selective CCR5 antagonist, named maraviroc or vicriviroc has been 
developed. By blocking gp120-CCR5 interaction this antagonist present a potent anti-HIV-1 
activity (Kromdijk, Huitema et al.; Perry). As T20, maraviroc is also active at nanomolar 
concentrations. It is postulated that CCR5 antagonists may be of great interest, if we 
consider that HIV-1 infection is essentially mediated by CCR5 tropic viruses (Kromdijk, 
Huitema et al.). The use of these type of entry inhibitors has been found to effectively inhibit 
infection of cells in vitro and in vivo by R5 strains tropic HIV-1 that have developed 
resistance to the other major classes of anti-retroviral drugs (anti reverse transcriptase and 
anti protease inhibitors). It is interesting to note that this is the first anti-HIV drug that 
targets the host cells rather than the virus directly. However, one potential limitation of such 
inhibitors is the possible selection and rapid emergence of CXCR4 tropic viruses. In fact, the 
isolation of HIV-1 from patients, who have never received an anti-retroviral therapy, naïve 
for HAART, showed the presence, of R5 tropic viruses in 85% of the cases. These results are 
in agreement with the natural resistance of persons harbouring CCR5delta32 deletion (Dean, 
Carrington et al. 1996; Huang, Paxton et al. 1996; Liu, Paxton et al. 1996; Samson, Libert et al. 
1996). While the early stage of infection was characterized by the predominance of R5 tropic 
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infection (Scarlatti, Tresoldi et al. 1997). The molecular basis of this R5 to CXCR4 switch 
remains to be clarified. CXCR4 strains seem to emerge only in 50% patients who develop 
AIDS (Connor, Sheridan et al. 1997; Scarlatti, Tresoldi et al. 1997). In addition to these two 
selective HIV-1 strains, an intermediate strain named dual tropic HIV-1 strain which use 
indifferently R5 and CXCR4 was also reported in some HIV-1 infected patients.  
The external envelope gp120 is a highly glycosylated protein. Carbohydrates represent 
about 50% of its molecular weight (Fenouillet, Clerget-Raslain et al. 1989). The majority of 
these carbohydrates are of N-type glycosylation. O-glycosylation seems to be rarely present 
in HIV-1 envelope glycoproteins. Viruses use glycosylation as tool to escape immune 
responses, resist to protease degradation, and adopt structural native conformation or to 
bind cellular receptors. By its carbohydrate parts, envelope glycoprotein gp120 recognizes 
and interacts with high affinity (Kd of nM level) with DC-SIGN (Dendritic Cell-Specific 
Intercellular adhesion molecule–3-Grabbing Non integrin) receptor. DC-SIGN is a C-type 
lectin present on the surface of membranes of dendritic and monocyte/macrophage cells 
(Geijtenbeek, Kwon et al. 2000; Geijtenbeek, Torensma et al. 2000).  
Submucosal DC, which normally process and present antigens to immune cells, bind HIV-1 
using C-type lectin essentially at the vaginal mucosa. However this interaction does not 
trigger the conformational changes necessary for the fusion of the virus and DC membranes. 
But virus bound on DC, or internalized by endocytosis, can migrate to regional lymph 
nodes where its target T-helper cells are found. Thus, dendritic cells expressing DC-SIGN 
appear to act as a “Trojan horse” facilitating the spread of the infection from mucosal 
surfaces to lymphatic organs (Geijtenbeek, Kwon et al. 2000; Geijtenbeek, Torensma et al. 
2000; Kwon, Gregorio et al. 2002). 
After entry and uncoating, the viral genome is released into the cytoplasm. This step is 
concomitant with the start of reverse transcription. The resulted dsDNA migrates into the 
nucleus where it is integrated by the viral integrase into host genome. The integration site is 
preferentially located into active genes locus because HIV like many other viruses cannot 
replicate into quiescent/latent cells. This DNA is flanked by two repeated sequence named 
LTRs (Long Terminal Repeats). Following cell activation, the viral DNA is transcribed by 
cellular RNA polymerase II (RNA pol II). Viral transcription is initiated when cellular RNA pol 
II is recruited at the 5’end of LTR provirus. For efficient transcription elongation a 5’end TAR-
hairpin structure named TAR (Tat associated region) element have to be present and bind HIV 
Tat protein. When Tat protein is absent, the initiation can begin but elongation is abrogated 
and/or inefficient. After translation, of viral protein and assembly in cholesterol rich lipid 
rafts, immature virions are released by budding from plasma membrane infected cells. 
1.3 HIV-1 genome transactivation: an essential role of HIV-1 Tat protein  
Once integrated, HIV genome behaves like the host genes and can be transcribed using the 
cellular RNA pol II and host cell machineries in addition to the viral Tat protein. The HIV 
LTR contains proximal core sequence and a distal promoter. The core element is composed 
by the initiator (Inr) and TATA box (TATA). The distal promoter carries enhancer sequences 
that contain two NF-B and three SP1 binding sites that position RNA pol II at the correct 
site for transcription initiation (Peterlin and Trono 2003; Peterlin and Price 2006). 
Downstream the core element, HIV LTR contains a short nascent stem bulged loop leader 
RNA named TAR (Transcription associated Region) (Berkhout, Silverman et al. 1989; Jeang, 
Xiao et al. 1999). HIV Tat protein is known to be the transcriptional activator that binds to 
this TAR RNA structure and HIV transcription mediated by Tat is illustrated in figure 4.  
HIV Infection «HIV Tat Protein, a Key Factor 





The first step of HIV transcription consists of the formation of the pre-initiation complex by RNA pol II 
recruitment to the promoter. The second step consists to clear the promoter by phosphorylation of the 
RNA pol II at serine position 5 of the CTD by cyclin dependent kinase : CDK7 of the TFIIH protein. This 
phosphorylation increases the binding and affinity of human enzyme capping (Brenchley, Price et al. 
2006) that leads to the 5’end capping of nascent RNA transcripts. At this step a pausing of RNA pol II 
occurs by the recruitment of two negatives elongation factors named: DSIF (DRB sensitivity inducing 
factor) and NELF. Finally, productive elongation occurs by the recruitment of P-TEFb. P-TEFb activity is 
tightly regulated by its association with a complex composed by 7SK snRNA and heterodimer 
HEXIM1/2. Tat recruitment of P-TEFb leads to efficient elongation and the obtaining of totally RNA 
transcripts production. 
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For summary, after PIC formation and clearance of the promoter a pause of RNA pol II 
occurs. Without recruitment of P-TEFb (positive transcription elongation factor b), only 
short RNA transcripts are formed and subsequently aborted. In fact, in absence of Tat, 
transcription is initiated but elongation do not occurs and only short RNA abortive 
transcripts are produced (Peterlin and Price 2006). At a molecular level, P-TEFb can be 
recruited by several mechanisms (figure 4) and notably by HIV Tat protein. Indeed, 
transcription from the HIV-1 LTR is several hundred folds higher in presence of Tat than in 
its absence. So, the question that follows is how can HIV initiate the synthesis of the first 
viral proteins, including Tat protein, in the absence of the latter viral factor essential for an 
efficient elongation ? Or how the first Tat molecules are synthetized ? 
Several studies have demonstrated that, in HIV, LTR transcription can be separated in two 
steps, the first is Tat independent whereas the second is Tat dependent. Recent studies from 
Greijtenbeek et al. and Gringhuis, van der Vlist et al.(Greijtenbeek et al. 2000; Gringhuis, 
Van der vlist et al. 2010) have shown that HIV can activate initiation and elongation by two 
separate mechanisms. The first, transcription initiation, is activated in endosomal structure 
following the HIV RNA-Toll Like Receptor 8 (TLR8) interaction. More precisely, HIV 
ssRNA-TLR8 interaction induces activation of NF-B p65 and RNA pol II phosphorylation 
at serine 5 residue leading to the recruitment of CDK7 to the transcription units. In parallel, 
they have also shown that elongation depends upon gp120-DC-SIGN interaction. This 
membrane interaction activates elongation by phosphorylation of serine 276 and serine 5 of 
NF-B p65 and RNA pol II respectively and their recruitments with CDK9 to the HIV LTR. 
This mechanism can explain how the HIV initiates the production of the first HIV-Tat protein. 
Then, Tat proteins take over and amplify viral transcription by its capacity to bind the 7SK 
small nuclear RNA (7SK nRNA) complex and recruits P-TEFb to the paused RNA pol II, by 
interacting cooperatively with TAR element. This interaction is mediated by Tat arginine rich 
motif. Once recruited to the transcription units, P-TEFb phosphorylates NELF (negative 
elongation factor) and the CTD of RNA pol II at serine 2 residue. Tat has also been reported to 
interact with many factor/co-factor implicated in transcription as: Sp1, TATA box binding 
protein, CDK2, CBP/p300, TFIIH and RNA pol II. Overall, Tat permits an efficient elongation 
and co-transcriptional processing by splicing and polyadenylation machineries. When levels of 
the regulatory Tat protein fall to below threshold levels, HIV becomes latent. 
1.4 HIV-1 infection and its effects on immune and the central nervous system 
1.4.1 Natural history of HIV-1 infection 
The course of HIV infection could be divided into three distinct clinical phases: acute 
infection, asymptomatic stage or chronic infection and symptomatic stage characterized by 
AIDS development (Furrer, Opravil et al. 2001) (figure 5).  
The first step called acute phase corresponds to the contamination, the primary viral 
replication and the beginning of immune sensitization. The most common routes of HIV 
infection are mediated by sexual transmission of the virus, transfusion by contaminated 
blood products, the use of unsafe needles by drug users, and perinatal transmission from 
infected mother to infant. This latter case of HIV transmission can occur either in utero or 
during breast-feeding (Coovadia, Rollins et al. 2007). Cases of contamination during 
delivery are also reported. Early after exposure, the virus reaches some strategic organs 
such as the secondary lymphoid organs (mucosa-associated lymphoid tissue and gut-
associated lymphoid tissues), which content most of the cells targeted by HIV. At this stage, 
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the virus replicates actively during a period of 6 to 12 weeks called the acute phase. Viral 
load reaches several millions copies of viral RNA per millilitre (ml) of plasma. T cells are 
depleted in blood and the gastro-intestinal tract, but the pool of T cells present in the blood 
compartment was restored by the central lymphoid organs. In general this step remains 
asymptomatic, but some patients could develop signs of of routine infection including, 
fever, lymphadenopathy and rash (Quinn 1997). These symptoms may last in general two to 
three weeks. At this stage of infection, the innate and adaptive immune 
systems react strongly to control HIV replication to lower the viral load to a set point often 
below 20000 RNA copies per ml of plasma (figure 5).  
 
 
A generalized graph that represent the relationship between T cells number by blood microliter (blue 
line) and HIV viral RNA copies by blood ml (red line) over the time course of untreated HIV infection. 
Two major mechanisms involved in T cells dysfunction and progression toward AIDS are represented 
(arbitrary units) such as increase in pro-inflammatory factors TNF-α, IL-6, IFN-α (pink line), and 
upregulation of immunosuppressive factors including IL-10, PD-1, PD-L1 and IDO (green line).  
Fig. 5. Evolution of T cell count and viral load over the different stages of untreated HIV 
infection.  
The second stage is an asymptomatic phase where the virus persists and the infection 
becomes chronic. During this period, that varies from 6 months to several decades 
depending on the patients, the virus replicates continuously mainly in the reservoir cell  
such as macrophages, the nervous system and regulatory T cells (Treg) (Tran, de Goer de 
Herve et al. 2008). During this phase, most of the patients maintain a normal CD4 T cell 
count with apparent normal health. The immune system is still continuously activated 
against viral replication but HIV will escape to this immune pressure by different 
mechanisms including the emergence of new variants. One of the most dramatic viral 
emergence is the appearance of X4 and dual tropic R5/X4 viruses, which replicate more 
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associated lymphoid tissues), which content most of the cells targeted by HIV. At this stage, 
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the virus replicates actively during a period of 6 to 12 weeks called the acute phase. Viral 
load reaches several millions copies of viral RNA per millilitre (ml) of plasma. T cells are 
depleted in blood and the gastro-intestinal tract, but the pool of T cells present in the blood 
compartment was restored by the central lymphoid organs. In general this step remains 
asymptomatic, but some patients could develop signs of of routine infection including, 
fever, lymphadenopathy and rash (Quinn 1997). These symptoms may last in general two to 
three weeks. At this stage of infection, the innate and adaptive immune 
systems react strongly to control HIV replication to lower the viral load to a set point often 
below 20000 RNA copies per ml of plasma (figure 5).  
 
 
A generalized graph that represent the relationship between T cells number by blood microliter (blue 
line) and HIV viral RNA copies by blood ml (red line) over the time course of untreated HIV infection. 
Two major mechanisms involved in T cells dysfunction and progression toward AIDS are represented 
(arbitrary units) such as increase in pro-inflammatory factors TNF-α, IL-6, IFN-α (pink line), and 
upregulation of immunosuppressive factors including IL-10, PD-1, PD-L1 and IDO (green line).  
Fig. 5. Evolution of T cell count and viral load over the different stages of untreated HIV 
infection.  
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depending on the patients, the virus replicates continuously mainly in the reservoir cell  
such as macrophages, the nervous system and regulatory T cells (Treg) (Tran, de Goer de 
Herve et al. 2008). During this phase, most of the patients maintain a normal CD4 T cell 
count with apparent normal health. The immune system is still continuously activated 
against viral replication but HIV will escape to this immune pressure by different 
mechanisms including the emergence of new variants. One of the most dramatic viral 
emergence is the appearance of X4 and dual tropic R5/X4 viruses, which replicate more 





Koot et al. 1992; Connor, Sheridan et al. 1997; Singh and Collman 2000). In fact, a loss of 
CD4+ cells of about 30 to 60 cells per microlitre and per year was observed in HIV-1 infected 
patients (figure 5). This asymptomatic phase has duration of 6 to 10 years and may be 
greatly modulated by highly anti-retroviral therapy (HAART). However in less than 1% of 
HIV-1 infected patients this asymptomatic phase is highly reduced (1 to 2 years), and can 
last longer, more than 25 years, in patients under HAART (Markowitz, Mohri et al. 2005). In 
addition to the direct lyses of infected cells this phase is accompanied with several immune 
disorders leading to immune exhaustion.  
One hallmark of this immune disorder is chronic immune activation characterized by 
increase production of pro-inflammatory cytokines such as TNF- and IL-6. TNF-α, thus, 
lead to the activation of HIV replication, loss of CD4 and CD8 through apoptosis (Said, 
Dupuy et al. 2010) and to neuronal disorders including HIV associated dementia (Nixon and 
Landay 2010). Increase of IL-6 production has been associated with immunological 
disorders including B cell lymphoma and hypergammaglobulinemie. It is interesting to note 
that Tat protein is able to induce TNF-α and IL-6. Production of these two cytokines has also 
been correlated with a systemic increase of bacterial products such as LPS. Indeed Brencley 
et al., (Brenchley, Price et al. 2006) have shown that chronic phase of HIV infection is 
characterized by an increase in circulating bacterial products related to the damage of the 
intestinal epithelium by the HIV-1 cytopathic effect. Released viral antigens and bacterial 
products contribute to the constant persistence of a chronic immune activation and T cells 
death. Other mechanism involved in immune activation is mediated by IFN-α produced by 
plasmacytoïd DC (pDC), a particular DC population specialized in antiviral immunity. It 
was reported that HIV induce IFN-α production by pDC through the activation of TLR7 by 
viral ssRNA. This cytokine acts on CD4+ and CD8+ lymphocytes to induce an activated 
phenotype (CD69+, CD38+) and will in turn lead to T cell apoptosis (Martinson, Montoya et 
al. 2010). This great and continual immune activation fails, however, to contain HIV 
infection. This phenomenon could be explained by the upregulation of several 
immunosuppressive factors that impaired T cell responses. Among those, it has been 
reported an a) increase in the production of the immunosuppressive cytokine IL-10, 
principally by monocytes cells; b) increase expression of programmed death 1 (PD-1) on 
monocytes (Said, Dupuy et al. 2010), LT CD4+ and LT CD8+, and its ligand PD-L1 on 
monocytes, macrophages, mDC and pDC. Subsequently, PD-1/PD-L1 interaction stimulates 
IL-10 production, induces negative signals for TCR activation and leads to T cell death; c) 
enhancement in the activation of the immunosuppressive enzyme indoleamine 2,3-
dioxygenase (IDO) in mDC and pDC which acts by depleting the essential amino acid 
tryptophan and inhibits T cell proliferation and d) increase in the generation and activation 
of T reg, a subset of T lymphocytes with immunosuppressive activity. All of these 
immunosuppressive factors will contribute to immune inactivation and have been 
associated with disease progression to AIDS. As the CD4+ cell count drops below 200 
cells/mm3 the risk of developing opportunistic infections including pneumocystis carini, 
CMV, JC or malignancies increases Kaposi’s sarcoma (Clifford and Demierre 2005; Bonnet, 
Balestre et al. 2006). Advanced HIV-disease is characterized by a strong T CD4 depletion to 
less than 50 cell/mm3, high viral load and multiple opportunistic infections and 
malignancies. 
AIDS represents the final stage of HIV-1 infection and is characterized by a profound 
depletion of CD4 positive T cells. In fact, after several years of unresolved chronic infection, 
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the rate of CD4+ T cells drops dramatically in the blood to a critical rate of 200 T CD4 cells 
microliter. This phase is characterized by the occurrence of several rare opportunistic 
infections. The first opportunists that are taking advantage of immunocompromised patients 
are oral candidiasis, pneumococcal infections, mycobacterial infections and reactivation of 
herpes simplex and varicella virus. AIDS is also associated with tumor proliferations such as 
Kaposi's sarcoma, due to Human Herpes Virus 8 (HHV8), lymphoma associated with Epstein-
Barr virus and cervical and anal carcinoma associated with human papilloma virus. In fact, 
this stage results in an extreme immunosuppression with diverse clinical features including 
opportunistic infections, malignancies and neurological disorders (So, Holtzman et al. 1988; 
Coopman, Johnson et al. 1993; Simpson and Tagliati 1994) and without treatment will 
irremediably lead to death of the patient within a few months. 
1.4.2 Neuropathogenesis of HIV-1 infection 
In addition to its tropism for the cells of the immune system, HIV is also known for its 
neurotropism. The virus is early found in the CNS carried by infected cells essentially 
macrophages. The virus can be directly isolated and cultured from the cerebrospinal fluids 
(CSF) from HIV-1 infected patients. In the CNS the virus replicates strongly in macrophages 
and microglia and moderately in astrocytes. Although HIV-1 is qualified as a neurotropic 
virus, it does not infect neurons. Consequently to CNS infection, about 60% of HIV-1 
infected patients showed HIV associated neurological, which includes dementia and 
neuropsychiatric and cognitive motor impairments (Ozdener 2005; Giunta, Obregon et al. 
2006). Infiltration of the virus in the brain is concomitant with the development of 
astrocytosis and microgliosis. While HIV-1 productively replicates in macrophages and 
microglia, infection of astrocytes allow only, the expression of early proteins Rev, Tat and 
Nef (Tornatore, Nath et al. 1991; Lipton and Gendelman 1995; Kutsch, Oh et al. 2000). It is 
interesting to note that astrocytes function also as an reservoir for HIV-1. Neuronal injury 
observed in the CNS of HIV-1 infected patients results from the activation direct by the 
virus or indirectly by inflammatory neurotoxins. For example it has been shown that the 
infection of astrocytes allowed to the impairment of the uptake and secretion of glutamate 
and to the modulation of glutamate receptor expression (Bezzi, Carmignoto et al. 1998). It 
was also demonstrated that, by its Tat protein, HIV stimulates the production of various 
chemokines including MCP-1, IL-8 and IP-10 which participate in the recruitment of 
macrophages and various type of leukocytes (Conant, Garzino-Demo et al. 1998; Kutsch, Oh 
et al. 2000). Production by HIV-1 infected macrophages of neurotoxins including quinolate, 
glutamate and L-cysteine, and inflammatory mediators including, IFN-, IFN- IL-6, IL-1, 
IL-1, TNF-, and TNF- play an essential role in HAND. The loss of neurons in HAND by 
apoptosis and other mechanisms is directly related to these release of toxic mediators by 
activated and infected cells (Zink, Zheng et al. 1999). Tat, Nef, Vpr, gp120 and gp41 have 
been described as directly implicated as neuropathogenic factors. By acting with CXCR4, 
gp120 induces apoptosis of neurons. Also by acting on voltage gated calcium channels and 
N-methyl-D-aspartate receptor (NMDAR) gp120 induces calcium mobilization which 
mediates the production of reactive oxygen species (ROS), apoptosis and various neurotoxin 
mediators (Medina, Ghose et al. 1999). As gp120, HIV-1 Tat protein has been reported to be 
implicated in neuron injury directly via apoptosis (Sabatier, Clerget-Raslain et al. 1989; Shi, 
Raina et al. 1998; Nath, Haughey et al. 2000) and indirectly via the induction of 
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infection. This phenomenon could be explained by the upregulation of several 
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IL-10 production, induces negative signals for TCR activation and leads to T cell death; c) 
enhancement in the activation of the immunosuppressive enzyme indoleamine 2,3-
dioxygenase (IDO) in mDC and pDC which acts by depleting the essential amino acid 
tryptophan and inhibits T cell proliferation and d) increase in the generation and activation 
of T reg, a subset of T lymphocytes with immunosuppressive activity. All of these 
immunosuppressive factors will contribute to immune inactivation and have been 
associated with disease progression to AIDS. As the CD4+ cell count drops below 200 
cells/mm3 the risk of developing opportunistic infections including pneumocystis carini, 
CMV, JC or malignancies increases Kaposi’s sarcoma (Clifford and Demierre 2005; Bonnet, 
Balestre et al. 2006). Advanced HIV-disease is characterized by a strong T CD4 depletion to 
less than 50 cell/mm3, high viral load and multiple opportunistic infections and 
malignancies. 
AIDS represents the final stage of HIV-1 infection and is characterized by a profound 
depletion of CD4 positive T cells. In fact, after several years of unresolved chronic infection, 
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been described as directly implicated as neuropathogenic factors. By acting with CXCR4, 
gp120 induces apoptosis of neurons. Also by acting on voltage gated calcium channels and 
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implicated in neuron injury directly via apoptosis (Sabatier, Clerget-Raslain et al. 1989; Shi, 
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1.4.3 HIV and Kaposi’s sarcoma: Effect of Tat protein  
The high incidence of Kaposi’s sarcoma (KS) in patients with HIV-1 infection has been 
related to the co-infection with HHV-8 also named KSHV (Kaposi sarcoma-associated 
herpes virus) (Schulz, Arbusow et al. 1998; Sirianni, Vincenzi et al. 1998; Aoki and Tosato 
2004). It was shown that the presence of KSHV alone is not sufficient for KS development. 
The presence of HIV-1 seems to be essential for the development of KS lesions. This 
observation is in agreement with the drastic decrease of KS in patients under HAART. The 
analysis of the HIV-1 viral factor implicated underlined the essential role of Tat protein 
which acts as a transactivator factor for KSHV lytic cycle and activates proliferation, MAP-
kinase activation, angiogenesis and tumoregenesis. It was shown that Tat promotes the 
tumorogenesis of endothelial cells both by acting at different ways by: stimulating the 
production of -FGF, recruiting VEGF-2 receptor, both on KS and on endothelial cells, 
whose stimulation is essential for VEGF angiogenic effects (Albini, Benelli et al. 1996; Albini, 
Soldi et al. 1996; Ganju, Munshi et al. 1998), blocking apoptosis, and stimulating KSHV 
replication (Pyakurel, Pak et al. 2007). In addition Tat is able to stimulate the production of 
inflammatory cytokines following its interaction with chemokine receptors.  
1.4.4 HIV and immunological disorders  
From the asymptomatic stage and before T CD4 lymphocyte depletion, a generalized immune 
depression is observed in HIV-1 infected patients including disorders of both in the 
specific/acquired and innate immunities. This immunodepression in HIV-1 infected patients is 
associated with a profound alteration of the cytokine production (McMichael, Borrow et al. 
2010; Clerici and Shearer 1993; Fauci 1996). These alterations have effects on target cells and 
influence also the virus replication. Increased production of pro-inflammatory cytokines 
stimulates HIV-1 replication via the activation of NF-B pathway. In fact the LTR promoter of 
HIV-1 contains NF-B binding sites. HIV-1 infection is associated, since the asymptomatic 
stage with a chronic immune activation and dysfunctional cytokine production. The acute host 
response to primary HIV-1 infection is characterized by Th0 cytokine profile, including the 
pro-inflammatory cytokines IL-1, IL-2, IL-6, TNF-, IFNand IFN- as well as the anti-
inflammatory cytokines IL-4, IL-10 and IL-13 (Harrich, Garcia et al. 1989; Hatada, Saito et al. 
1999). At later stages of infection with disease progression, the pattern of cytokine production 
shifts toward a strongly based Th2 response mediated by IL-4, IL-6 and IL-10 (Rinaldo, 
Armstrong et al. 1990; Graziosi, Gantt et al. 1996; Takizawa, Ohashi et al. 1996). This profile 
was revealed inefficient to eradicate the virus. The mechanism of HIV induced cytokine 
production has been largely studied. There are many HIV-1 proteins that are capable of 
inducing the production of several cytokines. These proteins include HIV-1 glycoprotein 
gp120 that induce the secretion of many pro-inflammatory cytokines including IL-1, IL-6, IL-8, 
TNF-, and IFN- (Francis and Meltzer 1993; Ameglio, Capobianchi et al. 1994; Ankel, 
Capobianchi et al. 1994; Capobianchi, Barresi et al. 1997). Interestingly, gp120 is also able to 
induce the secretion of IL-4 and IL-13 in basophils and IL-10 in mononuclear cells. Nef protein 
is able to induce the production of IL-1, IL-6, IL-10, IL-15, TNF- and IFN- in various human 
leukocyte populations (Schols and De Clercq 1996; Patella, Florio et al. 2000). There is also 
evidence that Vpr induces the expression of IL-6, IL-8, IL-10, TNF- and IFN- in a variety of 
cell types (Brigino, Haraguchi et al. 1997). 
Another HIV-1 protein, Tat, is known to stimulate the production of many cytokines and 
chemokines including IL-1, IL-2, IL-6, IL-8, IL-10, TNF- and MCP-1 (Clerici and Shearer 
1993; Moore, O'Garra et al. 1993; Badou, Bennasser et al. 2000; Nath, Haughey et al. 2000; 
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Bennasser, Badou et al. 2002; Bennasser and Bahraoui 2002; Contreras, Bennasser et al. 2005). 
Our laboratory has shown that HIV-1 Tat protein induces the production of IL-10, a highly 
immunosuppressive cytokine by human peripheral blood monocytes. Since IL-10 levels 
have been shown to progressively increase as the disease progresses toward AIDS, one can 
hypothesize that this event can play a crucial role in the immune deregulation observed 
during HIV-1 infection. In line with this hypothesis, Shearer’s group in a study including 
more than 1000 patients identified four patient classes depending on the capacity of their 
CD4 T lymphocytes to respond to different stimuli (mitogen, alloantigen, influenza virus, 
and HIV antigens). The progressive loss of the response of the immune system to these 
stimuli was found to be associated with a course leading to AIDS. Considerable production 
of IL-10 by peripheral blood mononuclear cells was observed in these patients and 
paralleled the alteration in CD4 T cell proliferative function. In addition, the 
immunosuppressive effect of IL-10 also correlated with the restoration of the capacity of 
isolated mononuclear cells of patients infected by HIV and immunodepressed to proliferate 
in vitro after stimulation by peptide antigens of HIV-1 envelope glycoprotein in the presence 
of a neutralizing anti-IL-10 antibody (Clerici, Wynn et al. 1994). In another study, Stylianou 
et al. evaluated the level of IL-10 in the sera of HIV-1 infected patients at different stages of 
infection. In agreement with Shearer’s conclusion, they showed an increase in IL-10 level 
with disease progression. They also showed a decrease in IL-10 level in patients under 
highly active retroviral therapy (HAART). Inversely, it was reported an increase of IL-10 
levels in patients with failure in tri-therapy treatment. Similarly low level of IL-10 was 
observed in HIV-1 long term non progressors or elite controllers (Clerici, Wynn et al. 1994). 
Inversely, it was showed that the persistence of a great level of IL-10 in the sera correlates 
with the failure in HAART (Stylianou, Aukrust et al. 1999). 
HIV-1 infection affects cellular signaling. The two most important signaling pathways 
involved in cytokine production include the PKC and calcium pathway (figure 6). These 
pathways are activated after ligand-receptor interaction. Subsequently, this interaction 
activates phospholipase C which then cleaves its substrate PIP2 (phosphoinositol 
biphosphate) in IP3 (inositol 1,4,5-triphospate), responsible of the mobilization of 
intracellular calcium and to DAG (diacylglycerol), which initiates PKC activation. These two 
pathways lead to the phosphorylation and activation of cellular proteins mitogen-activated 
protein (MAP) kinase and of transcriptional factors including NF-AT, NF-B, CREB and AP-
1 responsible for the induction of cytokine genes (Spitaler et Cantrell 2004). In our 
laboratory we have accumulated several data showing the mechanism recruited by Tat 
protein to stimulate the production of the highly immunosuppressive cytokine IL-10. In the 
following part we will describe the role of Tat protein at different levels including its 
structure, secretion and uptake, mode of action for the transactivation of HIV-1 
transcription, activation of signaling pathways and in the conclusion we will discuss Tat as 
potential target for drug or vaccine development. 
2. HIV Tat protein  
2.1 Background 
HIV Tat protein is one of HIV conserved protein. It is early produced after HIV infection. 
Tat is a 9-14 kDa protein encoded by two exons separated by a non coding region. The first 
exon encodes the 72 first amino acids (figure 7). The length of HIV-1 Tat protein ranges from 
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Bennasser, Badou et al. 2002; Bennasser and Bahraoui 2002; Contreras, Bennasser et al. 2005). 
Our laboratory has shown that HIV-1 Tat protein induces the production of IL-10, a highly 
immunosuppressive cytokine by human peripheral blood monocytes. Since IL-10 levels 
have been shown to progressively increase as the disease progresses toward AIDS, one can 
hypothesize that this event can play a crucial role in the immune deregulation observed 
during HIV-1 infection. In line with this hypothesis, Shearer’s group in a study including 
more than 1000 patients identified four patient classes depending on the capacity of their 
CD4 T lymphocytes to respond to different stimuli (mitogen, alloantigen, influenza virus, 
and HIV antigens). The progressive loss of the response of the immune system to these 
stimuli was found to be associated with a course leading to AIDS. Considerable production 
of IL-10 by peripheral blood mononuclear cells was observed in these patients and 
paralleled the alteration in CD4 T cell proliferative function. In addition, the 
immunosuppressive effect of IL-10 also correlated with the restoration of the capacity of 
isolated mononuclear cells of patients infected by HIV and immunodepressed to proliferate 
in vitro after stimulation by peptide antigens of HIV-1 envelope glycoprotein in the presence 
of a neutralizing anti-IL-10 antibody (Clerici, Wynn et al. 1994). In another study, Stylianou 
et al. evaluated the level of IL-10 in the sera of HIV-1 infected patients at different stages of 
infection. In agreement with Shearer’s conclusion, they showed an increase in IL-10 level 
with disease progression. They also showed a decrease in IL-10 level in patients under 
highly active retroviral therapy (HAART). Inversely, it was reported an increase of IL-10 
levels in patients with failure in tri-therapy treatment. Similarly low level of IL-10 was 
observed in HIV-1 long term non progressors or elite controllers (Clerici, Wynn et al. 1994). 
Inversely, it was showed that the persistence of a great level of IL-10 in the sera correlates 
with the failure in HAART (Stylianou, Aukrust et al. 1999). 
HIV-1 infection affects cellular signaling. The two most important signaling pathways 
involved in cytokine production include the PKC and calcium pathway (figure 6). These 
pathways are activated after ligand-receptor interaction. Subsequently, this interaction 
activates phospholipase C which then cleaves its substrate PIP2 (phosphoinositol 
biphosphate) in IP3 (inositol 1,4,5-triphospate), responsible of the mobilization of 
intracellular calcium and to DAG (diacylglycerol), which initiates PKC activation. These two 
pathways lead to the phosphorylation and activation of cellular proteins mitogen-activated 
protein (MAP) kinase and of transcriptional factors including NF-AT, NF-B, CREB and AP-
1 responsible for the induction of cytokine genes (Spitaler et Cantrell 2004). In our 
laboratory we have accumulated several data showing the mechanism recruited by Tat 
protein to stimulate the production of the highly immunosuppressive cytokine IL-10. In the 
following part we will describe the role of Tat protein at different levels including its 
structure, secretion and uptake, mode of action for the transactivation of HIV-1 
transcription, activation of signaling pathways and in the conclusion we will discuss Tat as 
potential target for drug or vaccine development. 
2. HIV Tat protein  
2.1 Background 
HIV Tat protein is one of HIV conserved protein. It is early produced after HIV infection. 
Tat is a 9-14 kDa protein encoded by two exons separated by a non coding region. The first 
exon encodes the 72 first amino acids (figure 7). The length of HIV-1 Tat protein ranges from 





The 101 amino acids form of Tat is predominant in clinical isolates. Another form that 
comprises 86 amino acids is also found in some subtype B isolates and in the laboratory 
strain HXB2. The Tat sequence can be subdivided into six functional domains including N-
terminal a proline and cysteine rich region, an hydrophobic core, a basic region followed by 
a glutamine rich region and a C terminal domain that contain a tripeptide RGD (Arginine, 
glycine, aspartatic acid) (figure 7). In addition, a domain containing the basic region is also 
called protein transduction domain (PTD), which renders Tat to have the ability to cross cell 
membranes and to be used as vector for gene transfer. Thus, viral Tat protein can be either 
intracellular or extracellular. The main function of HIV Tat protein is to transactivate the 
HIV long term repeat for retroviral transcription. 
 
 
External stimulus activates a G protein coupled receptor, which activates a stimulating G protein. This 
G protein activates phospholipase C (PLC), which cleaves phosphoinositol-4,5-biphosphate (PIP2) into 
1,2 diacylglycerol (DAG) and inositol-1, 4, 5-triphosphate (IP3). The IP3 interacts with calcium channel 
in the endoplasmic reticulum (ER), releasing calcium (Ca2+) into the cytoplasm. Intracytosolic calcium 
can interact with calmoduline proteins. This, leads to the activation of CAM kinases and calcineurine. 
Activation of CAMK and calcineurine induce activation and nuclear translocation of CREB and NF-AT 
respectively. In other hand, the increase in calcium levels activates PKC, which translocates to the 
membrane, anchoring to DAG and phosphatidylserine. Active catalytic PKC then, phosphorylate 
targets such as Rac, Raf that lead to downstream activation of MAP kinases and NF-�B and AP-1 
transcription factor. 
Fig. 6. The Protein Kinase C and calcium pathways. 
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Tat is encoded by 2 exons in the HIV genome and it is composed by several regions. N-ter region 1-21 is 
a rich proline region. A region implicated in HIV transactivation is the 21-37 amino acids cysteine rich 
region and the core region 38-48 implicated in the Tat binding of HIV RNA. The basic rich region 49-59 
is involved in Tat internalization whereas the glutamine rich region 60-72 in HIV replication. Finally the 
last region with the RGD sequence is encoded by the second exon. 
Fig. 7. Organization of HIV-1 Tat protein: primary amino acids sequence and different 
domain of Tat.  
2.1.1 HIV-1 Tat structure 
Few studies have been devoted to studying secondary and tertiary structure of Tat protein. 
It seems clear that Tat belongs to the family of intrinsically unstructured proteins (Foucault, 
Mayol et al. 2010; Bayer, Kraft et al. 1995). Circular dichroïsme studies of Tat (analyze of 
secondary structure) showed a majority of -turns structure and the absence of -helical and 
-sheets structures when the spectra were performed in aqueous solutions. However about 
20 to 50% of alpha helical structures were detected when the protein was analyzed in 
organic solvant. Tertiary studies with using NMR confirmed that HIV Tat was generally an 
unfolded protein (Bayer, Kraft et al. 1995; Shojania and O'Neil 2006). They also 
demonstrated that the cysteine and basic regions are highly flexible and the N-terminal 
region is localized between the hydrophobic core and the glutamic rich domains (Watkins, 
Campbell et al. 2008). The X-ray cristallographic determination of Tat structure is not 
available. In summury all the available data indicated that Tat contains no ordered -helical 
or -sheet structures. Thus the biological active Tat protein seems to be conformation 
independent and perhaps only a limited gain of structure is necessary for its function. All 
these studies suggest that Tat protein does not have a defined secondary or tertiary 
structures and that biological active Tat protein is natively unfolded and only a limited gain 
of structure is necessary for its function. 
2.1.2 HIV-1 Tat secretion and internalization 
Despite the importance of extracellular Tat, few studies have focused on its mechanism of 
secretion from infected cells and its entry into uninfected cells (Rayne and Debaisieux et al. 
2010; Vendeville and Rayne et al. 2004) (Westendorp, Frank et al. 1995). In fact, HIV Tat 
protein does not have a signal sequence and seems to be secreted by infected cells by an non 
conventionnal pathway. It is found present in the sera of HIV-1 infected patients at the 
nanomolar level (Ensoli, Buonaguro et al. 1993; Xiao, Neuveut et al. 2000) a value which 
may be underestimated since Tat may be trapped by its potential receptors, and particularly 
the heparan sulfates which are largely expressed on cell surfaces. Thus, the concentration of 
Tat, in vivo, is probably higher in the vicinity of the active HIV replication sites. After its 
secretion, Tat protein is taken up by neighboring cells infected or not. Despite the previous 
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viable cells essentially by endocytosis. This entry is mediated by the basic domain of Tat, 
also named PTD (protein transduction domain) and used for the development of peptidic 
vectors (Futaki and Suzuki 2001). 
2.2 Tat activates the production of IL-10 in human monocytes 
Our group has shown that HIV-1 Tat protein, by acting at cell membrane level, induces the 
production of IL-10, by non infected human monocytes (Badou and Bennasser 2000; 
Bennasser and Bahraoui 2002). To this end monocytes from healthy donors were purified 
and stimulated during 24 hours with increasing concentrations of recombinant Tat protein. 
Results showed that Tat protein induced strong and dose dependent IL-10 production. In 
contrast in the absence of Tat no IL-10 production was observed. This Tat induced IL-10 
production persists after 48 and 72 hours of Tat stimulation. The amount of IL-10 produced 
by monocytes in response to Tat is dose and stimulation time dependent. Specifity of Tat 
effect was demonstrated by showing that chemically modified Tat, after H2O2 oxidation, 
becomes unable to stimulate IL-10 production. The specificity of Tat effect was further 
demonstrated by showing that when the stimulation of monocytes was performed in the 




Tat 1-86 at 10 and 100 nM were incubated with or without anti-Tat antibody 2.5 �g/mL or were 
oxidated by H2O2 treatment. After 1 hour treatment, Tat treated or not, was incubated with human 
primary monocytes for 24h. IL-10 production was measured by ELISA.  
Fig. 8. HIV-1 Tat induces specifically IL-10 production by human monocytes. 
To determine the active domain of Tat that is responsible for the activity of Tat, monocytes 
were stimulated with GST-Tat deleted mutants including GST-Tat 1-72 (deleted form RGD 
domain), GST-Tat 1-55 (deleted from RGD and glutamate domains), GST-Tat 1-54 (deleted 
from RGD and basic domains), GST-Tat 20-72 (deleted from the N-Terminal domain), and 
GST-Tat 30-72 (deleted from de N-Terminal domain). Only GST-Tat deleted mutants but 
containing the N-terminal domain continues to stimulate IL-10 production. While the 
deleted mutants GST-Tat 20-72 and GST-Tat 30-72 as GST alone were unable to stimulate IL-
10 production (figure 9). These data underlined the importance of the N-Terminal domain in 
IL-10 Tat induced activity.  
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Monocytes were treated with 1 and 10 nM of wild type GST-Tat 1-101 or deleted mutant of Tat or GST 
alone as negative control. After 24 h of stimulation IL-10 production was measured by ELISA. 
Fig. 9. The N-terminal domain of Tat : 1-45 is sufficient to induce IL-10 production by 
human monocytes. 
As previously demonstrated in different report Tat protein is able to enter cells and to 
localize in the nucleus. So Tat protein is able to activate IL-10 production by acting at the cell 
membrane level or inside the cell. To understand its mechanism of action during the first 
steps of the activation, Tat protein was immobilized by coating in wells before adding 
purified human monocytes. In this condition, immobilized Tat leads to a dose dependent 
production of IL-10 indicating that Tat mediates its action by acting at the cell membrane. 
These results are in line with the capacity of the Tat deleted mutant, GST-Tat 1-45, to 
stimulate IL-10 production. In contrast to native Tat protein, the deleted mutant GST-Tat 1-
45 is unable to penetrate into cells because it lacks the basic domain, responsible for 
penetration and nuclear localization of Tat.  
The specific receptor implicated in this interaction remains to be characterized, despite the 
fact that different regions of Tat have been implicated in interaction with various receptors: 
the N-terminal region with CD26 receptor (Gutheil, Subramanyam et al. 1994), the tripeptide 
RGD with integrins v3 and 51 of DC, and the basic region with membrane lipids and the 
VEGFR of endothelial cells (Rubartelli, Poggi et al. 1998). Other reports, demonstrated the 
interaction of the cysteine rich region of Tat 24-51 with CCR2, CCR3 and CCR5 chemokine 
receptors and the heparan sulfate proteoglycans (Johri, Mishra et al. 2010; Ensoli, Buonaguro 
et al. 1993). It has been proposed that Tat could interact with the coreceptor CXCR4 and thus 
competitively inhibit infection by X4-tropic HIV-1 strains (Xiao, Neuveut et al. 2000). In this 
way, Tat contributes to immune system disorders as it induces apoptosis of T-lymphocytes, 
inhibits MHC class I expression, alters cell activity by blocking L-type channels (Li, Li et al. 
2009).  
Using chemical inhibitors and molecular analysis, we showed that Tat-cell interaction lead 
to activation of different signaling pathways including PKC. In fact, the PKC pathway, one 
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induction. Downstream PKC, activation of MAP kinases and NF-B pathways by Tat is 
crucial for Tat induced IL-10 (Bennasser and Bahraoui 2002; Leghmari and Bennasser 2008; 
Leghmari and Bennasser 2008; Contreras 2008). 
2.3 Analysis of the activated signaling pathways 
Calcium and PKC pathways are activated following the action of the phospholipase C 
(PLC). Implication of PLC signaling in the production of IL-10 following Tat activation was 
evaluated by using U73122, an inhibitor of PLC. In the presence of this inhibitor a strong 
inhibition, more than 50% of the production of IL-10 by Tat was observed. Thus, the 
activation of PKC signaling pathways known to induce the expression of cytokine genes 
was further investigated.  
2.3.1 Tat activates PKC pathway 
2.3.1.1 The PKC pathway 
The PKC belongs to the serine/threonine kinase family. It represents a key element 
recruited to regulate cell responses to external stimuli. Eleven PKC isoforms have been 
identified and classified into three groups based on their ability to be activated by Ca2+ and 
DAG (Spitaler and Cantrell 2004). The classical PKC- and -, isoforms are activated 
by Ca2+ and DAG, the novel PKC-θ, -η, -δ and -, are Ca2+ independent but DAG dependent, 
finally the atypical PKC and - (also named - in murine cells) are Ca2+ and DAG 
independent (Lee, Duan et al. 2008) (figure 10). PKC are single polypeptide chains of 
heterogeneous size, ranging from 67.2 kDa for PKC to 83.5 kDa for, PKC. Each PKC 
isoform is the product of a separate gene, except for PKC- and PKC-which are 
alternative spliced variants of the same gene. At the structural level, PKC contained four 
conserved domains (C1 to C4) (figure 10) and five variable regions (V1 to V5) that encode 
isoform-specific properties. The conserved region mediates binding to the activating 
cofactors: C1 for DAG or to PMA when used as pharmacological tool, and C2 for Ca2+. 
2.3.1.2 Effects of HIV-1 Tat on PKC pathway 
The implication of PKC pathway in the control of IL-10 production mediated by Tat was 
analyzed by complementary approaches. Pre-treatment of cells with Ro31-8220, an inhibitor 
of all PKC isozymes inhibits totally Tat induced IL-10, thus demonstrating the crucial role of 
PKC pathway. In agreement with the essential role of PKC pathway, Tat becomes unable to 
stimulate IL-10 production in monocyte previously treated during 48h with PMA. In order 
to understand the nature of PKC isoforms activated by Tat and essential for IL-10 
production, monocytes isolated from healthy donors were cultured in the presence of Tat at 
10 or 100nM and cytoplasmic and membrane proteins were isolated after 30 min or after 1 or 
2 hours. Whereas PKC is localized in the cytoplasm in unstimulated human monocytes, Tat 
stimulation induces in a dose dependent manner, PKC translocation to the membrane 
indicating PKC activation. This activation observed after 30min of Tat stimulation reaches a 
peak in 1h and decreases after 2 hours of stimulation. Thus HIV-1 Tat induces PKC 
activation in a dose and time dependent manner in human monocytes. To investigate the 
involvement of PKC activation in Tat-induced IL-10 production, monocytes were incubated 
with different PKC inhibitors. Ro318220 as well as Gö6983 which inhibits several PKC 
isoforms including PKC (IC50= 7 nM), PKC- (IC50 = 6 nM), PKC- (IC50 = 10 nM), 
PKC-(IC50= 60 nM) and PKC- (IC50 = 20 M) totally inhibit IL-10 production (Bennasser 
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and Bahraoui 2002; Leghmari and Bennasser 2008; Contreras 2008). Gö6976 which inhibits 
classical PKC isoforms - and - has no effect on the capacity of Tat to induce IL-10 
production by monocytes. Altogether, these results suggest that PKC isoforms - -and 
 are not primarily involved in the signaling pathways implicated in IL-10 production. To 
evaluate the implication of PKC-and  two other inhibitors were used. Hispidin, PKC- 
and  inhibitor (IC50 = 20 M), and rottlerin, an inhibitor of PKC-(IC50 = 3-6 M). 
Hispidin used at 2-20 M inhibits IL-10 production by Tat in a dose dependent manner, an 
inhibition of 60% is reached in the presence of 20 M of Hispidin. The implication of PKC- 
in IL-10 production was further evaluated by using rottlerin 5-30 M. In these conditions an 
inhibition reaching 90% was observed. Interestingly, PKC- and PKC inhibitors used 
separately at 2 and 5 M inhibited IL-10 production induced by Tat by 15 and 45% 
respectively, but when used in combination, they inhibited IL-10 production by 85% thus 




The three subgroups of PKC have been identified and their regulatory domains identified. The classical 
PKC isoforms (cPKC) share all typical regulatory features: the autoinhibitory pseudosubstrate motif, 
two DAG-binding C1 domains (C1a and C1b) and the calcium-binding C2 domain. Novel PKC isoforms 
(nPKC) lack a calcium-binding motif but contain an extended N-ter domain that can receive regulatory 
signals. They are regulated by DAG. The catalytic activity of atypical PKC isoforms (aPKC) is 
independent of DAG and calcium, and they seem to be regulated by regulatory proteins in association 
with the nuclear localization signal (NLS) and nuclear export signal (NES) in their regulatory domain 
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domains adapted from Spitaler et Cantrell 2004.  
After ligand-receptor interaction on the cell surface, phospolipids are hydrolyzed by PLC, 
producing DAG and IP3 both acting as second messengers. Subsequently, DAG activates 
PKC, which in turn phosphorylates a range of cellular proteins. More precisely activation of 





induction. Downstream PKC, activation of MAP kinases and NF-B pathways by Tat is 
crucial for Tat induced IL-10 (Bennasser and Bahraoui 2002; Leghmari and Bennasser 2008; 
Leghmari and Bennasser 2008; Contreras 2008). 
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and Bahraoui 2002; Leghmari and Bennasser 2008; Contreras 2008). Gö6976 which inhibits 
classical PKC isoforms - and - has no effect on the capacity of Tat to induce IL-10 
production by monocytes. Altogether, these results suggest that PKC isoforms - -and 
 are not primarily involved in the signaling pathways implicated in IL-10 production. To 
evaluate the implication of PKC-and  two other inhibitors were used. Hispidin, PKC- 
and  inhibitor (IC50 = 20 M), and rottlerin, an inhibitor of PKC-(IC50 = 3-6 M). 
Hispidin used at 2-20 M inhibits IL-10 production by Tat in a dose dependent manner, an 
inhibition of 60% is reached in the presence of 20 M of Hispidin. The implication of PKC- 
in IL-10 production was further evaluated by using rottlerin 5-30 M. In these conditions an 
inhibition reaching 90% was observed. Interestingly, PKC- and PKC inhibitors used 
separately at 2 and 5 M inhibited IL-10 production induced by Tat by 15 and 45% 
respectively, but when used in combination, they inhibited IL-10 production by 85% thus 
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pseudosubstrate peptide, and the cysteine rich region that contributes to the increased 
affinity of PKC to PS by interacting with DAG. These PS binding domains have also been 
reported to be involved in affinity, PKC localization, membrane translocation and binding to 
potential receptors. In resting cells, PKC is localized in the cytoplasm in an inactive form 
where the pseudosubstrate sequence upstream from C1 binds to the catalytic domain, but 
cannot be phosphorylated since it lacks a phospho-receptor amino acid. Upon activation, 
Ca2+ and or phosphoinositides induce a conformational change leading to the release of the 
pseudosubstrate. Thus the catalytic site becomes accessible to anchoring proteins called 
RACK (receptor for activated kinase) or substrates STICK (substrate that interacts with C-
kinase). This PKC activation is accompanied by a translocation from the cytoplasm to the 
membrane. Subsequent to membrane translocation and PKC activation, a second messenger 
seems to be stimulated and leads to the phosphorylation of PKC binding proteins thus, 
reducing their affinity for PKC and PS. 
 
In the cytoplasm, PKC is present as an inactive form. After its activation by phosphorylation, it 
undergoes conformational modifications leading to its translocation from the cytoplasmic to the 
membrane compartment. In membrane compartment, PKC associates with a second messenger DAG 
(and in the case of classical PKC isoforms, calcium) produced after receptor stimulation. Binding to the 
second messengers is also required for the release of the pseudosubstrate motif from the active site to 
give an active enzyme. 
Fig. 11. Activation of PKC pathway  
We next investigated which isoforms of PKC are activated by Tat protein. Monocytes were 
incubated with Tat at 10 nM for 15, 30 min or 1 hour and PKC localization was analyzed by 
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western blot using specific antibodies. Results showed that as soon as 15 min Tat induces 
translocation to the membrane of four PKC isoforms: PKC-, PKC-, PKC-, and PKC-. 
To further analyze the implicated PKC isoforms in Tat induced IL-10 production, these PKC 
isoforms activated by Tat were targeted with isoform specific antisense oligonucleotides. 
Monocytes were pre-incubated during 24 hours with PKC-, PKC-, PKC-, and PKC-or 
with the corresponding sense sequences as negative controls. After 24h monocytes were 
stimulated during 1h by Tat at 10 nM and then the level of each isoform in the cytoplasmic 
and membrane compartments were determined by western blot (Bennasser and Bahraoui 
2002). Treatment with 5 M of PKC- antisense oligonucleotide down regulates PKC- 
expression and the use of 15 M oligonucleotide totally inhibits PKC- expression. The use 
of antisense PKC- inhibits specifically PKC-, since PKC-is still detected in the same 
monocytes and is activated by Tat at 10 nM (figure 12). The same specificity of inhibition  
 
 
Monocytes were treated with sense or antisense oligonucleotides (5, 15 M) specific for PKC- PKC-
 PKC- PKC-fter washing, cells were stimulated with HIV-1 Tat protein at 10 nM for 1 hour. 
Isoform specific PKC inhibition was assessed by western blot (bottom). IL-10 production was measured 
by ELISA 24h later (Sirianni, Vincenzi et al. 1998). In each case, specific inhibition of each isoform was 
verified by visualizing in the same cell extracts another PKC isoform activation by Tat. 
Fig. 12. Effects of isoform specific PKC inhibition with antisense oligonucleotides on Tat 
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was observed with the other isoforms: PKC-,  and  antisense oligonucleotides caused a 
specific down regulation in the level of their corresponding isoforms (figure 12). In 
agreement with the data obtained with chemical inhibitors, an inhibition of Tat induced IL-
10 was observed in the presence of antisense oligonucleotides directed against PKC- 
and. In contrast no significant inhibition was observed with antisense oligonucleotides 
directed against PKC-and - (figure 12) (Bennasser and Bahraoui 2002).  
Overall, it was shown that HIV-1 Tat, activates four PKC isoforms in human monocytes: 
PKC-, PKC- PKC-, and PKC-These data introduce a way to explore the role of PKC 
in signaling pathways in Tat activated monocytes and on search for the partners of PKC- 
and  involved in the production of IL-10, an immunosuppressive cytokine that participates 
in the deregulation of the immune system as early as the asymptomatic stage of HIV-1 
infection. 
Monocytes were treated with sense or antisense oligonucleotides (5, 15 M) specific for 
PKC- PKC- PKC- PKC-fter washing, cells were stimulated with HIV-1 Tat 
protein at 10 nM for 1 hour. Isoform specific PKC inhibition was assessed by western blot 
(bottom). IL-10 production was measured by ELISA 24h later (Sirianni, Vincenzi et al. 1998). 
In each case, specific inhibition of each isoform was verified by visualizing in the same cell 
extracts another PKC isoform activation by Tat. 
2.3.2 Tat activate NF-B pathway 
In this part, we will describe the NF-B signaling pathways implicated in the IL-10 
production induced by Tat protein in the human monocytes, and the mechanism of NF-B 
regulation exploited by this viral protein.  
NF-B is a major transcriptional regulator for the expression of cytokines that are involved 
in the control of the immune and inflammatory response (Baeuerle and Baltimore 1996; 
Baldwin 1996). NF-B is a dimeric transcription factor that consists of REL family members, 
including RelA/p65, c-Rel, RelB, p50 and p52 (Li and Verma 2002). p50 and p52 are derived 
from the larger precursors p105 and p100, respectively, through proteolytic processing by 
the proteasome. All NF-B proteins contain a highly conserved REL-homology domain 
(RHD) that is responsible for DNA binding, dimerization, nuclear translocation and 
interaction with the inhibitory proteins IB within the cytoplasm. The IB proteins, bind to 
NF-B and block its nuclear import and, thereby, its transcriptional activity. The p105 and 
p100 precursors also contain the IB-like repeats that must be degraded to generate the 
mature p50 and p52 subunits, respectively. In contrast to the other NF-B family members, 
p50 lacks a transactivation domain and therefore, usually forms heterodimers with p65 to 
bind to NF-B sites in the nucleus. Homodimers p50:p50 can also be formed but they act as a 
suppressor of inflammatory cytokine gene expression (Ghosh, May et al. 1998). Three 
distinct NF-B activating pathways have emerged (Viatour, Merville et al. 2005) (figure 13).  
Most of our knowledge concerns the “canonical” pathway, which mostly targets ubiquitous 
heterodimers p65:p50 and p50:c-Rel. The critical event in initiating this pathway is 
activation of an IB-phosphorylating protein kinase, IKKKK2, which occurs within the 
“IKK signalosome”, in association with a structurally homologous kinase, IKKIKK1, and 
an adaptor protein, IKKNEMO (Yamaoka, Courtois et al. 1998). IKK-mediated 
phosphorylation of IBand leads to its proteasomal degradation and, hence, activation of 
its associated NF-B dimers that translocate in the nucleus. This pathway is normally 
triggered in response to microbial and viral infections or exposure to pro-inflammatory  
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The classical, alternative and atypical NF-κB-activating pathways as illustrated by the TNF-α-mediated, 
CD40-mediated and DNA-damage-mediated NF-κB activation pathways, respectively. In the classical 
NF-κB-activating pathway, upon binding of TNF-α to TNFR1, SODD is released from the receptor and 
triggers the sequential recruitment of the adaptors TRADD, RIP and TRAF2 to the membrane. Then, 
TRAF2 mediates the recruitment of the IKK complex composed of IKKα, IKKβ and NEMO. Hsp90 and 
Cdc37 are also part of the IKK complex and are required for- IKK activation. Activation of the IKK 
complex leads to the phosphorylation of IκBα at specific residues, ubiquitination and its degradation 
via the proteasome pathway. Then, the heterodimer p50–p65 is released and migrates to the nucleus 
where it binds to specific κB sites and activates a variety of NF-κB target genes. The alternative pathway 
is triggered by binding of the CD40 ligand to its receptor, leading to recruitment of TRAF proteins and 
the sequential activation of NIK and IKKα, which induces the processing of the inhibitory protein p100. 
p100 proteolysis releases p52 which forms heterodimers with RelB. This pathway is NEMO-
independent and relies on IKKα homodimers. The atypical pathway, which is triggered by DNA 
damage relies on sequential p38 and CK2 activations, and involves phosphorylation and degradation of 
subsequent IκBα via an IKK-independent pathway. Abbreviations: CK2, casein kinase 2; ELKS, Glu-
Leu-Lys-Ser; Hsp90, heat shock protein 90; IκB, inhibitor of NF-κB; IKK, IκB kinase; NEMO, NF-κB 
essential modulator; NF-κB, nuclear factor-κB; NIK, NF-κB-inducing kinase; RIP, receptor-interacting 
protein; RSK1, ribosomal S6 kinase 1; SODD, silencer of death domains; TNF-α, tumour necrosis factor 
α; TNFR1, TNF receptor 1; TRADD, TNF-receptor-associated death domain protein; TRAF, TNF-
receptor-associated factor; Ub, ubiquitin. 
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cytokines such as tumour necrosis factor TNF By contrast, the “alternative” pathway, 
occurs independently of IKK or NEMO, but is dependent on NF-B -inducing kinase and 
IKK Activation of this pathway leads to a limited proteasomal processing of the NF-B  
precursor protein, allowing the resulting p52 fragment to translocate to the nucleus in 
association with some NF-B proteins (mainly RelB) (Xiao, Harhaj et al. 2001). This pathway is 
triggered by cytokines such as lymphotoxin B (Dejardin, Droin et al. 2002), or CD40 ligand 
(Coope, Atkinson et al. 2002), and by viruses such as the Epstein-Barr virus (Eliopoulos, 
Caamano et al. 2003). The third signaling pathway is classified as “atypical” because it is 
independent of IKK proteins but it still requires the proteasome and is triggered by DNA 
damage such as UV oxidative stress (Imbert, Rupec et al. 1996; Tergaonkar, Bottero et al. 2003). 
However, recent data suggest another role for IKK in NF-B dependent gene expression in 
response to cytokine treatment (Anest, Hanson et al. 2003; Yamamoto, Verma et al. 2003). 
Independently of its previously described cytoplasmic role, IKK functions in the nucleus 
by activating the expression of NF-B-responsive genes after TNF- stimulation. IKK 
recruited to NF-B-responsive promoters, interacts with the histone acetyltransferase 
CBP/p300 (CREB-binding protein). Then it mediates phosphorylation and subsequent 
acetylation of specific residues of histone H3 leading to the NF-B binding sites accessibility.  
In inactivated cells, NF-B is sequestreted in the cytoplasm by the inhibitory protein IB, 
which masks its nuclear localization sequence. In order to be active, NF-B. The 
involvement of NF-B was first tested by the capacity of Tat to activate the nuclear 
translocation of this factor by using the mobility shift technic assay. These experiments were 
performed with an oligonucleotide containing an NF-B site and showed the formation of a 
complex with nuclear extracts of monocytes stimulated with Tat (figure 14). The observed 
interaction between NF-B and the probe seems to be specific, since no complex was 
observed when the protein extract was incubated in the same conditions with the mutated 
NF-B site (Badou and Bennasser 2000).  
In agreement with the inability of this mutant to stimulate the production of IL-10, no 
complex was detected in these conditions. These results showed that Tat induces NF-B 
activation specifically in monocytes. Then the region of Tat involved in NF-B activation 
was investigated by stimulating monocytes with different GST-Tat deleted mutants. EMSA 
analysis showed that only, the C-terminally deleted mutants GST-Tat 1-72 and GST-Tat 1-45 
activate NF-B as the wild type GST-Tat 1-101. In contrast, no activation was observed with 
GST-Tat 30-72 or GST alone (figure 14). These results showed that NF-B activation 
correlates with the ability of Tat and Tat mutant to mediate IL-10 production. In addition the 
role of NF-B activation in the production of IL-10 was evaluated. Monocytes were treated 
with non toxic doses of TLCK (an inhibitor of NF-B pathways), and then stimulated with 
Tat at 10 nM. Then, NF-B activation and IL-10 production were analyzed by EMSA and 
ELISA respectively. In this conditions no NF-B activation nor IL-10 production were 
obtained. Thus, Tat activates transcriptional factor NF-B, one of the substrates of PKC, 
thereby causing induction of IL-10 gene.  
Three distinct NF-B activating pathways have emerged. Interestingly by using the same 
approache we showed that Tat protein is also able to stimulate the nuclear translocation of 
p52 in addition of p65 (figure 15). This results suggest that Tat protein activates both 
classical and alternative NF-B pathways, while TNF- activates only the classical pathway. 
The critical event in initiating this pathway is activation of an IB-phosphorylating protein 
kinase, IKKIKK2, which occurs within the “IKK signalosome”, in association with a 
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structurally homologous kinase, IKKIKK1, and an adaptor protein, IKKNEMO (Yamaoka, 
Courtois et al. 1998). IKK-mediated phosphorylation of Ileads to its proteasomal 
degradation and, hence, activation of its associated NF-B dimers that translocate in the 
nucleus. This pathway is normally triggered in response to microbial and viral infections or 
exposure to pro-inflammatory cytokines such as tumour necrosis factor TNF-. By contrast, 
the “alternative” pathway, occurs independently of IKK or NEMO, but is dependent on NF-
B inducing kinase and IKK Activation of this pathway leads to a limited proteasomal 
processing of the NF-B 2/p100 precursor protein, allowing the resulting p52 fragment to 
translocate to the nucleus in association with some NF-B proteins (mainly RelB).  
 
 
Nuclear protein extracts of human monocytes treated with wild type GST-Tat 1-101 or Tat deleted 
mutants or negatif control GST at 10 nM for 16 h were incubated with a 32P-labeled NF-B probe 
sequence containing the wild type NF-�B site. To verify that NF-B activation was specifically 
mediated by Tat, monocytes were treated with chemically mutated Tat (oxidized Tat), and nuclear 
extracts were analyzed by EMSA. 
Fig. 14. Activation of NF-B by HIV-1 Tat 1-45 in human monocytes. 
The analysis of signaling pathways allowed to demonstarte the crucial role of NF-B 
transctivation factor as showed by the capacity of Tat to activate the nuclear translocation of 
the transcription factor NF-B which is shown to be required for the IL-10 production 
(Badou and Bennasser 2000). At the light of the known mechanisms of NF-B activation 
pathways, the molecular mechanisms recruited by Tat to activate NF-B was further 
investigated. To this end, and in order to use transfection approach, we have developed and 
validated the U937 promonocytic cells as model, in addition to primary human monocytes. 
Treated in the same conditions as primary human monocytes, U937 monocytic cells 
produced IL-10 (Leghmari and Bennasser 2008; Contreras 2008). U937 promonocytic cells 
previously cotransfected with a NF-B reporter plasmid, pNF-BLuc, expressing the 
luciferase gene under the control of four NF-B sites and the pCMV-Gal, expressing the -
galactosidase gene under the control of the CMV promoter were treated by different 
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in a dose dependent manner. In agreement with the data obtained in primary human 
monocytic cells, only, the totally Tat protein or its N-terminal fragment Tat 1-45 are able to 
activate NF-B. In contrast no activation was observed with Tat 30-72 or with GST alone 
(Figure 13, 14). 
 
 
Tat induces recruitment of p65 and p52 to the IL-10 promoter. (A) Primary monocytes (107 cells) were 
stimulated or not with Tat 1-86 (10 nM) or TNF-(20 ng/ml). Nuclear extracts were prepared and 
analyzed by Western blot. Anti-TFIIB was used as a loading control. (B) Monocytes were treated or not 
with 10nM Tat 1-86 for 30 min, and ChIP assays were performed with anti-p65, anti-p52 or without (N) 
antibodies. The proportion of co-immunoprecipitated IL-10 promoter was analyzed by quantitative 
realtime PCR. 
Fig. 15. Tat activates classical and alternative NF-B pathways. 
Using negative transdominant mutants of NIK, IKK and IKK, we showed that their 
expression inhibit strongly NF-B activation induced by Tat. Interestingly when both IKK 
and IKK are inhibited simultaneously by their corresponding negative transdominants, 
NF-B activation was totally inhibited. In summury our data indicate that Tat induced NF-
B activation requires NIK, IKK and IKK kinases.  
To adress the question whether Tat was also able to induce nuclear translocation of IKK, 
nuclear extracts from Tat treated cells was analysed by SDS-PAGE and western blot using 
antibodies specific to IKK. This analysis clearly showed that Tat protein is able to stimulate 
IKK translocation from the cytoplasm to the nucleus. This activation is also obtained with 
wild type Tat protein and its N-terminal fragment but not with Tat 30-72. However, recent 
data suggest another role for IKK in NF-B dependent gene expression in response to 
cytokine treatment. Independently of its previously described cytoplasmic role, IKK 
functions in the nucleus by activating the expression of NF-kB-responsive genes after TNF- 
stimulation. IKK recruited to NF-B-responsive promoters, interacts with the histone 
acetyltransferase CBP/p300 (CREB-binding protein). Then it mediates phosphorylation and 
subsequent acetylation of specific residues of histone H3 leading to the NF-B binding sites 
accessibility.  
In summury, Tat protein secreted by infected cells will be taken up by neighboring cells to 
activate HIV-1 replication in HIV-1 infected latent cells, and also to activate non infected 
cells to produce different chemokines and cytokines including IL-10 a highly 
immunosuppressive cytokine greatly implicated in the dysregulation of the immune system 
in HIV-1 infected patients. The analysis of the signaling pathway activated by Tat 
underlined the crucial role of PKC and NF-B pathways. 
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HIV-1 infection hijacks the cellular machinery and uses cellular signaling pathways to its 
own advantage. Early secreted Tat protein, as gp120 via its interaction with CD4 receptor 
and CCR5 coreceptor, trigger a signaling cascade which activates calcium and protein kinase 
C pathways (Contreras 2008; Sieczkarski S et al. 2003 ). All these signaling pathways 
regulate cell activation by acting on the state of cell differentiation, transcription activation, 
cell survival or cytoskeleton dynamics which are required for viral replication (Lamph et al 
1988; Burnette et al 1993; Llewellyn et al 2006). 
Among the activated pathways, PKC pathway plays a critical role for HIV-1 replication. 
Indeed, PKCs stimulate NF-B ( Meichle et al 1990; Junttila et al. 2003; Taunton et al. 2001) 
via the phosphorylation of IκB. NF-B binds to the HIV promoter and is involved in 
initiation and elongation of transcription. In addition, PKCs activate other transcription 
factors like AP-1 and NF-AT, which have specific binding sites on the HIV-1 promoter. 
Thus, activation of PKCs can reverse HIV-1 latency in infected T cells and in cell lines (Guy 
et al. 1987). Moreover, PKCs have been suggested to phosphorylate a number of viral 
proteins such as p17 Gag (Yang et al. 1999), Nef (Popik et al. 1998; Ghosh et al. 1990; 
Hamamoto et al. 1990) and Rev ( Fantuzzi et al. 2000). The PKC pathway is also critical for 
the step of entry of a number of enveloped viruses like rhabdoviruses, alphaviruses and 
herpesviruses (Yang et al 1999) and for type 2 adenovirus (Owen et al. 1996). Thus, the 
understanding of the signaling pathways implicated in the stimulation of virus replication 
or in the production of immunopathogenic cytokines may suggest possible targeted 
therapeutic approaches to neutralize such key steps. 
Taking into account the role of Tat protein in viral replication and induction of 
immunological and neurological disorders, this Tat protein represents a potential vaccine 
candidate (Caputo, Gavioli et al. 2009). Tat protein appears to be an effective candidate to 
include for an HIV vaccine, since its gene product is produced early during the viral life 
cycle. Targeting the immune responses against Tat which plays an important role in viral 
infectivity and pathogenicity could aid in lowering the viral load through the destruction of 
HIV-1 replicating cells by CTL or antibody dependent cell-cytotoxicity. It is important to 
underline the critical role of HIV-1 Tat in the dysregulation of the immune system by the the 
induction of the higly immunosuprressive cytokine: IL-10 (Badou and Bennasser 2000). 
Interestingly several reports showed that humoral or cellular responses against Tat are 
associated with the control of HIV-1 infection as showed by the low viral load and the 
protection against AIDS progression (Wieland et al 1990; Krone et al. 1988; Reiss 1990; Re 
1996; Rezza et al. 2005; Zagury et al. 1998). In agreement with these observations the group 
of Ensoli showed that vaccination of macaque with native Tat protein allowed protection 
against viral infection and disease development (Cafaro et al. 1999; Maggiorella et al. 2004). 
However, experiments performed by other groups showed no protection, or only a partial 
protection in rhesus macaques immunized with native or denatured Tat protein (Allen et al. 
2002; Silvera et al. 2002; Goldstein et al. 2000; Pauza et al. 2000). This apparent discrepancy 
may be related to the nature of animal used cynomolgus versus rhesus and the nature of the 
virus used for the challenge, SHIV89.6P, SIVmac239 or SHIV33. 
It is interesting to note that a therapeutic phase I clinical trial in human, using recombinant 
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1. Introduction  
Several lymphotropic viruses manipulate host innate immune response to escape immune 
recognition and improve viral replication and spreading. From this point of view HIV 
(Human Immunodeficiency Virus-1) represents a paradigmatic example (for review see 
Peterlin & Trono, 2003). HIV-1 encodes the classical structural and enzymatic factors of all 
retroviruses codified from the gag (group-specific antigen), pol (polymerase) and env 
(envelope) genes. In addition it codes two regulatory proteins that are essential for viral 
replication (i.e., the transcriptional transactivator Tat and the regulator of virion gene 
expression Rev) and four accessory proteins (i.e., the ill-named ‘negative effector’ Nef, the 
viral infectivity factor Vif, the viral protein r Vpr and the viral protein u Vpu). With time has 
become increasingly clear that the so-called accessory proteins carry out several critical 
functions for both viral replication and pathogenesis (Malim & Emerman, 2008). In 
particular, the Nef protein was demonstrated to be an important virulence factor of primate 
lentiviruses. In fact Nef-defective HIV leads to an attenuated clinical phenotype with 
reduced viral loads in mouse models, monkeys, and in human disease (Daniel et al., 1992; 
Deacon et al., 1995; Gulizia et al., 1997; Kestler et al., 1991; Kirchhoff et al., 1995) and nef 
transgenic mice develop an AIDS-like disease (Hanna et al., 1998) confirming that this viral 
protein is a major determinant of pathogenicity.  
Studies on structure and mechanism of action of the protein highlighted its multifunctional 
properties at cellular and molecular level. The open reading frame encoding Nef is located 3′ 
of the env gene, overlaps the untranslated sequences of the 3′ viral long terminal repeat and 
is translated from multiply spliced transcripts. Nef is expressed early and most abundantly 
during the infection cycle together with Tat and Rev and evidences have been reported of 
possible expression also before integration of the proviral genome (Wu & Marsh, 2001). It 
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conserved, effects via specific protein-protein interaction motifs (Arold & Baur, 2001; Doms 
& Trono, 2000; Geyer et al., 2001, Foster et al., 2011). In general, Nefs from all primate 
lentiviruses (i.e. HIV-1, HIV-2, and SIV) share multiple activities in vitro, but differences 
between the ability of human and simian immunodeficiency viruses to induce Nef-mediated 
internalization of the CD3 component of the T-cell receptor complex have been observed 
and have been correlated with the greater pathogenicity of HIV and the reduction of T-cell 
activation in simian immunodeficiency virus (SIV) (Schindler et al., 2006). It has been also 
observed that HIV-1 Nef treatment of uninfected cells in culture causes internalization of the 
protein in some cell types and/or activates specific intracellular signalling pathways. 
Interestingly, Nef has been found inside uninfected B cells of lymphoid follicles from 
infected individuals (Qiao et al., 2006) and recently it has been provided experimental 
evidencies that it can be transferred to uninfected cells from the infected ones via cellular 
protrusions and/or exosomes (Lenassi et al., 2010; Muratori et al., 2009; Xu et al., 2009) 
opening a new road to deepen our insight on the roles of this multifunctional protein. This 
review will focus on those recent observations trying to provide a unifying reading. 
2. Nef: A multifunctional viral adaptor 
Nef is a protein of about 200 aminoacids and the different alleles may vary slightly in length. 
Sequence analysis has identified a number of conserved motifs that are responsible for 
protein–protein interactions and for specific biological functions. The protein is co-
translationally modified by N-terminal myristoylation and is phosphorylated on specific 
aminoacid residues. Its membrane binding is critical for Nef function on cell signalling and 
membrane trafficking and requires both the covalently attached myristic acid moiety and a 
cluster of N-terminal basic residues (Bentham et al., 2006; Gerlach et al., 2010; Szilluweit et 
al., 2009). Myristoylation appears only a weak membrane-targeting signal, but the N-
terminal basic residues, especially the arginine-rich cluster (R17 to R22), are needed for the 
stable association of the viral protein with cellular membranes. Nef appears to be a 
cytoplasmic protein partially associated with cell membrane and often accumulated in 
perinuclear regions. Cellular-fractionation assays from transient transfection experiments 
showed that less than 60% of the protein is localized at membranes, while the remaining 
portion was found to be cytosolic (Kaminchik et al., 1994). Structurally the 24-29 kDa HIV-1 
Nef protein adopts a two-domain structure encompassing a flexible membrane anchor 
domain (residues 2-61 in NefSF2) and a folded core domain (residues 62-210). The core 
domain, again, contains a C-terminal flexible loop of 33 residues (152-184) that is thought to 
mediate trafficking interactions (Geyer et al., 2001). Arold and Baur speculated that after 
translation the protein adopts a close conformation where the myristoyl moiety interacts 
with a hydrophobic region on the core domain, which could explain why the majority of the 
protein is localized in the cytosol and not attached to membranes (Arold & Baur, 2001). 
Biochemical indication for myristoylation-dependent conformational changes in HIV-1 Nef 
has been obtained (Breuer et al., 2006; Dennis et al., 2005). Indeed, Nef is readily soluble in 
aqueous solution, suggesting the shielding of the lipid moiety within the protein. Protein 
structures of Nef have been determined for the core domain by NMR spectroscopy and X-
ray crystallography (Arold et al., 1997; Grzesiek et al., 1997; Lee et al., 1996) and for the 
flexible anchor domain by NMR (Geyer et al., 1999), but not yet for the full-length protein 
due to the low stability and solubility and the high degree of intrinsic flexibility. The protein 
mediates a multitude of functions, increasing the production and infectivity of viral particles 
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and inducing alteration of specific cellular signalling and trafficking pathways. It has been 
also demonstrated that the protein is able to induce the transient translocation to the cell 
membrane of the Polycomb Group protein Eed, a nuclear transcriptional repressor, leading 
to a potent stimulation of Tat-dependent HIV transcription (Witte et al., 2004). The 
cytoplasmic translocation of Eed seems to result in the removal of a block on Tat-mediated 
HIV transcription essential to promote viral transcription at low concentrations of the 
transactivator protein found at the very early phase of the infection or reactivation from 
latency. It has been proposed that Nef adopts different structural conformations inside the 
cell that allows different localizations and interaction with different partners, realizing the 
so called ”Nef interaction cycle” (Arold & Baur, 2001). In particular, Nef, after translation, 
could adopt the closed conformation in which its binding sites are mainly hidden (closed 
conformation). Contact with the cell membrane could then trigger a conformational change 
via the interaction of the negative charges of the membrane lipid heads with the positive 
charges in the N-terminus of Nef, thus relieving the interaction between the N-terminus and 
the core. This conformational change could also expose several motifs capable of binding 
signalling molecules (signalling conformation), many of which are present in lipid rafts. The 
association of Nef molecules with the membrane might persist for only a short period of 
time because of the exposure of the core loop, which would then bind molecules of the 
cellular endocytotic machinery mediating internalization of Nef together with specific 
interaction partners. 
The best characterized Nef functions are: (a) acceleration of endocytosis and lysosomal 
degradation of CD4, thereby avoiding both super-infection of infected cells and the 
interaction of budding virions with CD4 of the infected cells; (b) down-regulation of HLA-A 
and -B MHC-I molecules thereby protecting infected cells from recognition and lysis by 
cytotoxic T lymphocytes (CTL); (c) induction of a pre-activation state in CD4+ T cells 
favouring viral gene expression (Simmons et al., 2001); (d) regulation of apoptosis, 
promoting apoptosis in bystander uninfected cells meanwhile protecting the infected cells 
by apoptotic stimuli through more than one mechanism (Das & Jameel, 2005). Nef perturbs 
the trafficking of many different plasma membrane-associated proteins but how Nef traffics 
within the endosomal system to reach the perinuclear endosomal region where it is 
concentrated at steady state is not yet understood (Burtey et al., 2007; Roeth & Collins, 2006). 
The list of cellular proteins whose transport is affected has continued to grow over the past 
several years. To date it has been reported to decrease the cell surface expression of MHC-I, 
MHC-II, CD4, CD28, transferrin and mannose receptors, CD80, CD86, CD8, and CCR5 and 
to increase the expression of TNF, LIGHT, DC-SIGN, and the invariant chain (Anderson et 
al., 1993; Chaudhry et al., 2005; Lama & Ware, 2000; Madrid et al., 2005; Schindler et al., 
2003; Schwartz et al., 1996; Sol-Foulon et al., 2002; Stove et al., 2005; Stumptner-Cuvelette et 
al., 2001). The acceleration of endocytosis and lysosomal degradation of the transmembrane 
glycoprotein CD4 was one of the first discovered actions. To recruit CD4 into the 
endocytotic pathway, Nef acts as an adaptor between CD4 and components of the clathrin 
coated pits. In T cells this involves disruption of the CD4-Lck tyrosine kinase complex by 
Nef and its interaction with adaptor protein (AP) complexes and the regulatory subunit of 
the vacuolar proton pump v-ATPase. Nef binds also to the beta subunit of COPI coatomers 
(-COP) to direct CD4 to a degradation pathway. Surprisingly, Nef uses different domains 
and mechanism to downregulate MHC-I molecules (Blagoveshchenskaya et al., 2002; Doms 
& Trono, 2000). Regarding the Nef ability to induce a state of pre-activation in T cells several 
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glycolipid enriched membrane microdomains (i.e., GEMs also called lipid “rafts”) and 
proteins of the submembrane TCR environment including the adaptor proteins Vav and 
LAT, and the kinases Lck, PAK and PKC (Renkema & Saksela, 2000). Mutational analysis 
suggests that most of the signaling molecules that bind to Nef interact with its core domain, 
often via the Pro-rich sequence that binds the SH3 domain of Src kinases. Nef displays high 
(i.e. nanomolar) affinity for the SH3 domain of Hck and Lyn, and rather modest (i.e. 
micromolar) affinity for those of Lck, Fyn and Src. In vivo, the individual tissue distribution 
of Src kinases become relevant because Hck is restricted to macrophages, therefore in T cells 
Nef might interact with lower-affinity targets such as Fyn or Lck. As far as regulation of 
apoptosis concerns, it appears that Nef causes bystander cell apoptosis in uninfected cells 
through its induction of FasL expression on the infected CD4+ T cell (Xu et al., 1999; Xu et 
al., 1997). Conversely, it inhibits apoptosis in virally infected host T cells both through its 
concomitant suppressive effects on ASK1, a key intermediate in the Fas and TNF death 
signaling cascade, and via Akt-indipendent phosphorylation of Bad (Geleziunas et al., 1996; 
Geleziunas et al., 2001; Wolf et al., 2001). In addition it has been described to inhibit p53-
mediated apoptosis binding the tumor suppressor (Greenway et al., 2002).  
As a consequence of Nef ability to bind multiple targets it is plausible that depending on 
Nef subcellular localization and the availability of particular subset of targets (for example 
Hck versus Lck tyrosine kinase), certain Nef effects dominate over others in a time- and cell 
type-dependent manner thus differing in infected monocyte/macrophages versus T 
lymphocytes, DC, astrocytes or microglial cells (see Quaranta et al., 2009 for the different 
regulatory effects of Nef in immune cells). In macrophages, that are important target of HIV 
infection and reservoir of the virus, Nef expression induces the release of a set of paracrine 
factors including a marked increase of CCL2/MIP-1 and CCL4/MIP-1 chemokines. These 
factors are able to recruit T cells and make them susceptible to HIV replication (Swingler et 
al., 2003; Swingler et al., 1999). In particular, Nef expression in macrophages induces also the 
production of the soluble forms of the intercellular adhesion molecule ICAM-1 (sICAM) and 
of the coactivation molecule CD23 (sCD23). sICAM and sCD23 act on B cells that cooperate 
with macrophages in inducing T cell recruitment and their permissivity to productive 
infection in vitro. The effects of Nef expression in macrophages mimics those of CD40 
Ligand (CD40L) in activating the CD40 signalling cascades suggesting that Nef intersects a 
macrophages pathway that is regulated by the CD40 receptor and requires nuclear factor 
kappa B (NF-B) activation (Swingler et al., 2003; Swingler et al., 1999). 
3. Effects induced by extracellular Nef in uninfected cells 
Evidences that Nef produced by recombinant DNA technology can induce cell signalling 
effects when added to cell cultures has been provided (Alessandrini et al., 2000; Brigino et 
al., 1997; Fujii et al., 1996c; Fujinaga et al., 1995; Huang et al., 2004; James et al., 2004; 
Lehmann et al., 2006; Okada et al., 1998; Okada et al., 1997; Qiao et al., 2006; Quaranta et al., 
1999; Quaranta et al., 2003; Tobiume et al., 2002; Varin et al., 2003). Different Nef alleles have 
been expressed in E. coli and both myristoylated (myr+) or not myristoylated (myr-) proteins 
have been produced (Breuer et al., 2006; Dennis et al., 2005). Myr+ Nef was obtained via co-
trasformation of E. coli with expression vectors coding the viral protein and the human N-
myristoyl-transferase and supplementing the culture medium with myristic acid. Purified 
myr+ and myr- wild type (wt) Nef proteins showed different oligomerisation properties in 
vitro. Indeed, myristoylated Nef prevails in a monomeric state in solution whereas the 
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nonlipidated protein forms dimers, trimers, or even oligomers of greater magnitude. When 
cell signalling effects induced by myr+ and myr- wtNef were compared in cultures of 
human monocyte-derived macrophages (MDMs), myr+ wt Nef was found to be much more 
active than the myr- protein (Mangino et al., 2007; Olivetta et al., 2003). Table 1 briefly 
summarizes the effects induced by cell treatment with Nef. In particular, negative effects on 
CD4+ T cell survival has been described (Fujii et al., 1996a; b; Fujii et al., 1996c), e.g. Nef 
treatment of CD4+ T lymphocytes in culture induced apoptosis via the interaction with the 
CXCR4 receptor (Huang et al., 2004; James et al., 2004). On immature dendritic cells (iDCs) 
exogenous Nef enhances CXCR4 expression and up-regulates MHC-II molecules, possibly 
favouring their migration and nonspecific CD4+ T cell activation (Quaranta et al., 2002). 
Exogenous Nef enters iDCs, promoting their functional and morphological differentiation. 
Specifically, Nef promotes interleukin (IL)-12 release, which closely fits with nuclear factor 
NF-B activation, and targets Vav promoting its tyrosine phosphorylation associated with 
its nucleus-to-cytoplasm redistribution. Nef induces also the rearrangement of actin 
microfilaments, leading to uropod and ruffle formation and increases the capacity of DCs to 
form clusters with allogeneic CD4+ T cells, improving immunological synapse formation 
(Quaranta et al., 2003). In addition to iDCs, Nef is internalized by primary human MDMs 
and IgD+ B cells in culture (Alessandrini et al., 2000; Qiao et al., 2006). Myr+ Nef treatment 
of primary human IgD+ B cells induced to differentiate in culture by the addition of CD40L, 
IL-4 and IL-10 inhibits switching to IgG, IgA, and IgE by inducing the negative regulators I-
B- and SOCS proteins, which block CD40L and cytokine signalling rendering Nef-
containing B cell less responsive to CD4+ T cell help (Qiao et al., 2006). Nef treatment of 
primary human MDMs down-regulated CD4 surface expression, thus reproducing an effect 
widely observed in cells endogenously expressing the viral protein. In addition, myr+ Nef 
treatment of MDMs induces the rapid (15-30’) activation of IKK/NF-B, MAPKs (i.e., 
ERK1/2, JNK and p38) and IRF-3, the main transcriptional regulator of the IFN gene 
expression, thereafter regulating the expression of many cellular transcripts (Federico et al., 
2001; Mangino et al., 2007; Olivetta et al., 2003; Percario et al., 2003). The prompt 
transcriptional reprogramming leads in 2 hours to the synthesis and release of a set of 
proinflammatory cytokines/chemokines, including TNF, IL-1, IL-6, CCL2/MIP-1 and 
CCL4/MIP-1, and of IFN that, in turn, immediately activate the signal transducers and 
activators of transcription STAT1, -2 and -3 in autocrine and paracrine manner. A transient 
STAT1, -2 and -3 tyrosine phosporylation was also observed early after (i.e. 8-16 hrs later) in 
vitro infection of 7-day old human MDMs with nef-expressing Δenv, but not Δnef/Δenv, HIV-
1 pseutotypes suggesting that intracellular signalling induced in Nef-treated MDMs might 
also be activated via Nef intracellular expression soon after MDMs infection with HIV-1 or 
viral reactivation from latency. In an attempt to identify the Nef structural motifs required 
for the activation of those signaling pathways, MDMs were treated with different myr+ 
recNefSF2 proteins lacking specific conserved aminoacid residues (Mangino et al., 2007). In 
particular, the viral protein was modified in the consensus sequence required for 
myristoylation (mutant G2→A), in the polyproline-rich region (mutant 
P76XXP79XR81→AXXAXA), in the domain required for the interaction with CD4 (mutant 
C59AWL62→AAAA) or with elements of the endocytic machinery, such as the V1H subunit 
of the vacuolar-membrane ATPase (mutant E178D179→AA) or the adaptor protein complex 
(mutant L168L169→AA) Finally a Nef protein with a deletion of the first 44 amino acids (ΔN-
term) was also used. Overall the experimental results indicated that myristoylation of the 





glycolipid enriched membrane microdomains (i.e., GEMs also called lipid “rafts”) and 
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Nef might interact with lower-affinity targets such as Fyn or Lck. As far as regulation of 
apoptosis concerns, it appears that Nef causes bystander cell apoptosis in uninfected cells 
through its induction of FasL expression on the infected CD4+ T cell (Xu et al., 1999; Xu et 
al., 1997). Conversely, it inhibits apoptosis in virally infected host T cells both through its 
concomitant suppressive effects on ASK1, a key intermediate in the Fas and TNF death 
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nonlipidated protein forms dimers, trimers, or even oligomers of greater magnitude. When 
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term) was also used. Overall the experimental results indicated that myristoylation of the 





term Nef were the only two Nef mutants unable to induce signalling. These data were in 
agreement with lack of induction of STAT1, STAT2 and STAT3 tyrosine phosphorylation in 
MDMs 8 to 16 h after infection with VSV-G Δenv HIV-1 pseudotypes expressing the G2→A 
Nef mutant (Mangino et al., 2007; Percario et al., 2003). As previously mentioned 
myristoylation of Nef is a weak membrane-targeting signal and N-terminal basic residues, 
especially an arginine-rich cluster (R17 to R22), are needed for the stable association of the 
viral protein with cellular membranes. Presently, it is not possible to exclude the hypothesis 
that also these residues are important together with myristoylation for the activation of  
NF-B and IRF-3 in MDMs.  
Regarding the production of IFN we propose that Nef, abundantly expressed early after 
HIV infection together with Tat and Rev, induces IFN at a very early stage of viral infection 
or soon after reactivation of viral gene expression in latently infected cells, before the 
appearance of other viral proteins that can inhibit type I IFN production or mechanisms of 
action to allow the viral release from infected cells. In fact, even if type I IFNs inhibit the 
release of retroviral particles and their infectivity in cells chronically infected by the simplest 
retroviruses without inducing relevant reduction of viral proteins synthesis (Peng et al., 
2006; Pitha-Rowe & Pitha, 2007), the lentivirus HIV has evolved specific strategies to inhibit 
IFN-mediated antiretroviral effects at least via Vif and Vpu accessory protein functions. 
Both these viral proteins are produced later than the early HIV regulatory protein Nef and 
inhibit the function of APOBEC3 and tetherin, two cellular antiretroviral proteins 
specifically increased by type I IFN via positive transcriptional regulation (Malim & 
Emerman, 2008). In addition a recent analysis of antiviral defences in CD4+ cells during 
HIV-1 infection indicates that viral expression can also direct a global disruption of innate 
immune signalling through suppression of IRF-3 (Doehle et al., 2009). In particular, a 
marked depletion of IRF-3, but not IRF-7, was observed in HIV-1-infected cells which 
supported robust viral replication. Indeed, IRF-3 depletion was dependent on a productive 
HIV-1 replication cycle and caused the specific disruption of Toll-like and RIG-I-like 
receptors innate immune signalling. In agreement with these in vitro results, IRF-3 levels 
were found reduced in vivo within CD4+ T cells from patients with acute HIV-1 infection, 
but not from long-term non-progressors (Doehle et al., 2009). A decrease of IRF-3 expression 
after HIV-1 infection was observed also in THP-1 cells, a human monocyte/macrophage-like 
cell line, as HIV-1 infection progressed over a 48-h period. The ability of Nef to induce 
transient IFNβ production in HIV-1 infected cells in vivo needs to be investigated. Nef might 
induce IFNβ production in cells neighbouring the infected ones if the protein is secreted or 
released after cell lysis or when transferred via cell-to-cell contact to uninfected cells 
(Peterlin, 2006). This cytokine could exert its effects on bystander cells, such as the 
plasmacytoid dendritic cells, priming them to IFN production. Other HIV products (i.e., 
gp120) induce the production of type I IFNs in MDMs, as well as in PBMCs (Ankel et al., 
1994; Capobianchi et al., 1993; Capobianchi et al., 1992; Gessani et al., 1994). Induction of 
both IFN and - as a consequence of in vitro infection of MDMs cultures has been reported 
(Gessani et al., 1994; Szebeni et al., 1991) and a rapid and transient elevations in IFN has 
been observed during the cytokine storms that accompany the increase in plasma viremia in 
acute HIV-1 infection (Stacey et al., 2009). It is interesting to note that in early 1980’s one of 
the first clear-cut HIV isolate was obtained using cultured T lymphocytes, derived from a 
lymphonode biopsy specimen of a patient with lymphadenopathy, with the help of IL-2 and 
anti-IFN serum (Barre-Sinoussi et al., 1983). 
 





Cell type Induced Effects 
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- Inhibition of M- and Dual-tropic 
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primary hu MDMs -- Activation of NF-kB, MAPKs and 
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- Synthesis of pro-inflammatory cyto- 
and chemokines including CCL2/MIP-
1, CCL4/MIP-1β, TNF, IL-1, IL-6 
and IFN that induce STAT1, STAT2 
and STAT3 phosphorylation in autocrine 
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- Induction of IRF-1 
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- Stimulation of HIV transcription 
through NF-κB, AP-1 and c-JNK 
signaling 
Table 1. Effects induced by cell treatment with recombinant Nef 
Regarding the response of astrocytes to extracellular Nef, treatment of uninfected cells (i.e. 
human glioblastoma/astrocytoma cell line U373MG) with the purified viral proteins Nef 
induces the synthesis of C3 (Speth et al., 2002). A significant difference in the C3 synthesis in 
Nef-treated cells was visible after 3 days and maximal effect was reached after 9 days. 
Besides Nef, also whole HIV virions and gp41 were biologically active in upregulating C3, 
whereas Tat, gp120, and gp160 were not (Speth et al., 2002). The complement system is of 





term Nef were the only two Nef mutants unable to induce signalling. These data were in 
agreement with lack of induction of STAT1, STAT2 and STAT3 tyrosine phosphorylation in 
MDMs 8 to 16 h after infection with VSV-G Δenv HIV-1 pseudotypes expressing the G2→A 
Nef mutant (Mangino et al., 2007; Percario et al., 2003). As previously mentioned 
myristoylation of Nef is a weak membrane-targeting signal and N-terminal basic residues, 
especially an arginine-rich cluster (R17 to R22), are needed for the stable association of the 
viral protein with cellular membranes. Presently, it is not possible to exclude the hypothesis 
that also these residues are important together with myristoylation for the activation of  
NF-B and IRF-3 in MDMs.  
Regarding the production of IFN we propose that Nef, abundantly expressed early after 
HIV infection together with Tat and Rev, induces IFN at a very early stage of viral infection 
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anti-IFN serum (Barre-Sinoussi et al., 1983). 
 





Cell type Induced Effects 
Alessandrini  
et al., 2000 
NL4-3 primary hu MDMs - CD4 downmodulation 
- Inhibition of M- and Dual-tropic 
strains replication  
Brigino et al., 1997 LAV  PBMC 
H9 
U937 
- IL-10 induction in a 
calcium/calmodulin dependent 
manner 
Creery et al., 2002  PBMC 
primary hu monocytes 
- CD14 upregulation 
Federico et al., 2001 
Mangino et al., 2007 
Olivetta et al., 2003 





primary hu MDMs -- Activation of NF-kB, MAPKs and 
IRF-3 signalling pathways 
- Synthesis of pro-inflammatory cyto- 
and chemokines including CCL2/MIP-
1, CCL4/MIP-1β, TNF, IL-1, IL-6 
and IFN that induce STAT1, STAT2 
and STAT3 phosphorylation in autocrine 
and paracrine manner 
- Induction of IRF-1 
Fujii et al.,  
1996 a,b,c 
 
NL4-3 CD4+ T lymphocytes - Cytotoxic effects on T cells 
- Inhibition of proliferaton 
Fujinaga et al., 1995  MOLT-20-2 - HIV reactivation from latency 
Huang et al., 2004 NL4-3 PBMC 
Jurkat 
- Apoptosis induction through Nef-
CXCR4 interaction 
James et al., 2004 NL4-3 Jurkat 
H9 
- Apoptosis induction 
Okada et al., 1997 





- Fas-independent apoptosis induction 
Qiao et al., 2006 BaL primary B cells - Suppression of CD40-dependent Ig 
class switching 
Quaranta et al., 1999 ELI hu monocyte 
/macrophages 
IL-15 synthesis induction 
Quaranta et al., 2002 
Quaranta et al., 2003 
ELI primary hu Dendritic Cells - DC maturation 
- Cytoskeleton rearrangements 
through Vav/Rac-1 dependent 
signaling 
Tobiume et al., 2002   - HIV activation from latency through 
Ras/MAPKs signaling 






- Stimulation of HIV transcription 
through NF-κB, AP-1 and c-JNK 
signaling 
Table 1. Effects induced by cell treatment with recombinant Nef 
Regarding the response of astrocytes to extracellular Nef, treatment of uninfected cells (i.e. 
human glioblastoma/astrocytoma cell line U373MG) with the purified viral proteins Nef 
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limited access due to the blood-brain barrier. The complement factor C3 is a central protein 
of the cascade, and its fragments (C3b, iC3b, C3d, and C3a) affect many cellular processes in 
the brain, such as activation of signalling pathways and modulation of cytokine synthesis. In 
general, all complement proteins can be synthesized by various brain cells, including 
astrocytes, neurons, microglia, and oligodendrocytes, with astrocytes being the most potent 
complement producers. Although normal synthesis in the brain is low, inflammatory 
cytokines such as IFN and TNF considerably increase complement production, especially 
of complement factor C3. Increased levels of C3 and C4 were found in the cerebrospinal 
fluid of HIV-infected patients with neurological symptoms and signs of central nervous 
system dysfunction, supporting the hypothesis of an association between complement and 
HIV-induced neurodegeneration. HIV-induced upregulation of C3 expression in astrocytes 
may be an important reason for increased complement levels in the cerebrospinal fluid of 
HIV-infected patients. HIV-1 increased the C3 levels in astrocyte culture supernatants from 
30 to up to 400 ng/ml. Signal transduction studies revealed that adenylate cyclase activation 
with upregulation of cyclic AMP is the central signalling pathway to mediate that increase. 
Furthermore, activity of protein kinase C was necessary for HIV induction of C3, since 
inhibition of protein kinase C by prolonged exposure to the phorbol ester tetradecanoyl 
phorbol acetate partly abolished the HIV effect.  
Confocal microscopy analysis of human MDMs treated with myr- and myr+ Nef–FITC 
indicated that both proteins are internalized and localize in an intracytoplasmic punctate 
pattern and at the cell margin (Alessandrini et al., 2000; Olivetta et al., 2003) as described for 
cells that endogenously express the protein (Greenberg et al., 1997). The protein lacking the 
acceptor signal for myristoylation (G2→A Nef) is internalized, but loose at least in part the 
co-localization signal with the cell membrane (Alessandrini et al., 2000). The wt protein does 
not bind MDMs at 4 °C suggesting that it does not recognize specific receptor on the cell 
membrane, but it might be internalized exploiting the endocytic/pinocytotic MDMs 
machinery. Indeed Nef was shown to perturb model membranes opening an avenue for its 
translocation through cell membranes (Gerlach et al., 2010; Szilluweit et al., 2009). 
All these experimental evidences suggest that extracellular Nef if present in vivo could 
induce specific cellular response in uninfected cells that might contribute directly and 
indirectly to the onset of AIDS. Indeed the presence of extracellular Nef in infected 
individuals has not been extensively evaluated. The viral protein has been found in the 
serum of some HIV-1 infected patients at concentration ranging from 1 to 10 ng/ml (Fujii et 
al., 1996c). This concentration might be even higher in the lymphonodal germinal centers, 
where virion-trapping dendritic cells, virion-infected CD4+ T cells and macrophages are 
densely packed (Pantaleo et al., 1991). In addition antibodies directed against this viral 
protein have been found in HIV-1 infected seronegative individuals supporting the possible 
detection of extracellular molecule (Ameisen et al., 1989). Nef can be released in culture 
supernatant of 293, Jurkat and THP-1 cells transfected with HIV-1NL4-3-, HIV-2- or SIV-Nef 
expressing vectors indicating that it can be secreted (James et al., 2004). The genetic 
characterization of Nef-induced secretion has identified that the N-terminal 70 amino acids 
were sufficient for induction of secretion of Nef- containing vescicles in several cell lines and 
identified critical aminoacid residues: (1) a basic cluster of four arginine residues (aa 17, 19, 
21, 22), (2) the phosphofurin acidic cluster sequence (PACS; Glu62–65), and (3) a previously 
uncharacterized domain spanning amino acid residues 66–70 (VGFPV), which has been 
named the secretion modification region (SMR). Interestingly, in vivo analysis performed on 
infected follicles of lymphoid tissue showed the presence of Nef positive IgD+ B cells at the 
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edge of the germinal center and in the interfollicular area even if these cells were unlikely to 
be infected by HIV-1 (Qiao et al., 2006). This observation suggested that Nef, produced 
inside the HIV infected cells via the transcription of the proviral genome, can be transferred 
in vivo to bystander non infected cells.  
4. Nef transfer from infected to uninfected cells 
The transfer of HIV viral proteins by nanotubes (Sowinski et al., 2008) and the transfer of 
Nef by vesicles (Campbell et al., 2008) has been recently documented. Interestingly in 
September 2009, Xu and collaborators (Xu et al., 2009) reported that HIV-1 infected 
macrophages form B cell–targeting conduits in response to Nef expression. These conduits 
translocate membrane-bound Nef and Nef-containing endosomes from macrophages to 
follicular B cells via a mechanism propelled by actin, mediated by Vav and dependent on 
GTPases. These results provided the evidence that infected cells can transfer the viral 
protein via cell to cell contact to uninfected cells. It appears that Nef-mediated activation of 
membrane trafficking is bidirectional, connecting endocytosis with exocytosis as occurs in 
activated T cells. Interestingly Nef expression induced an extensive secretory activity also in 
infected and, surprisingly, in non infected T cells, leading to the massive release of 
microvesicle clusters, a phenotype observed in vitro and in 36%–87% of primary CD4+ T 
cells from HIV-infected individuals. Consistent with exocytosis in noninfected cells, Nef is 
transferred to bystander cells upon cell-to-cell contact and subsequently induces secretion in 
an Erk1/2-dependent manner. Thus, Nef alters membrane dynamics mimicking those of 
activated T cells and causing a transfer of infected cell signalling to bystander cells 
(Muratori et al., 2009). Based on these findings, it was hypothesized that Nef transfer could 
potentially explain the effects observed in bystander cells in vivo. In agreement with this 
hypothesis conduits-mediated shuttling of Nef from infected macrophages to B cells 
attenuated IgG2 and IgA class switching in systemic and intestinal lymphoid follicles 
suggesting that HIV-1 exploits intercellular ‘highways’ as a ‘Trojan horse’ to deliver Nef to B 
cells and evade specific humoral immunity systemically and at mucosal sites of entry. The 
stronger virus-specific IgG2 and IgA responses observed in Long Term Non Progressor 
infected by Nef-deficient HIV-1 further supports this possibility (Xu et al., 2009). In addition 
Lenassi et al. (Lenassi et al., 2010) demonstrated that the expression of Nef not only 
augmented the production of the exosomes from T cells (Jurkat, SupT1 and primary T cells) 
but also resulted in the packaging of Nef into these vesicles which, upon contact, leads to an 
activation-induced cell death in the resting CD4+ T lymphocytes (bystander cells). It is 
known that subsets of cellular proteins are specifically targeted to exosomes reflecting the 
site of their formation. Proteomic profiling of Nef exosomes originating from Jurkat and 
SupT1 cells indicates that Nef exosomes form at the plasma membrane in Jurkat and in 
Multivescicular Bodies in SupT cells. Instead Nef exosomes from PBLs represent a mixture 
of secreted vesicles of plasma membrane and late endosomal origin. Therefore, Nef 
increases the production of exosomes from several distinct cellular compartments. Nef 
release through exosomes was conserved also during HIV-1 infection of peripheral blood 
lymphocytes (PBLs). Thus, HIV-infected cells export Nef in bioactive vesicles that might 
facilitate the depletion of CD4+ T cells in vivo.  
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Fig. 1. Schematic representation of Nef-induced signalling and transfer in uninfected cells.  
A: Nef treatment of MDMs induces signal transduction events followed by production of 
inflammatory chemo/cytokines and IFN; B: infected MDMs transfer Nef via cellular 
protusions; C: exogenous Nef induces apoptosis in T cells via interaction with CXCR4; D: T 
cells expressing Nef release Nef-containing – exosomes that are transferred to bystander cells; 
E: extracellular Nef induces up regulation of specific maturation markers in immature DC. 
5. Perspectives and future directions 
In recent years, it has become apparent that many viruses induce signal transduction events 
in concert with virus entry and/or as a consequence of the intracellular expression and 
release of viral proteins. These events can trigger a variety of changes in the cell, including 
induction of apoptosis, cytoskeleton rearrangements and global reprogramming of cellular 
transcription to favour viral replication or persistence. At the same time the innate sensing 
 
HIV-1 Nef Transfer and Intracellular Signalling in Uninfected Cells 
 
71 
of some viral components by cells triggers signal transduction pathways to induce antiviral 
responses. At present, we are only beginning to decipher the mechanism and the 
consequences of these events to viral replication and pathogenesis in the host. As far as Nef 
concerns, its ability to induce exosome formation and cell to cell connection mediating its 
transfer and the transfer of signalling molecules between cells open new road to understand 
its complex role in HIV-1-host interaction and highlights the complexity of functions of 
biological molecules. How Nef is able to switch on signalling events in uninfected cells and 
the patho-physiological relevance of this phenomenon requires further investigations and 
might disclosure new therapeutic targets for treatment of seropositive patients. 
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1. Introduction  
Over time a single patient can be infected by multiple intra- or intersubtype human 
immunodeficiency viruses type 1 (HIV-1) strains. These so-called dual infections are divided 
into co-infections and superinfections. HIV-1 co-infection is described as a second infection 
taking place before measurable HIV-1 antibody production by the immune system 
(seroconversion) and HIV-1 superinfection is defined as a second infection occurring after 
seroconversion. Here the focus lays on superinfections, which have implications for HIV-1 
transmission, treatment and vaccine development (Gottlieb et al., 2004). Moreover 
superinfections can give rise to HIV-1 circulating recombinant forms (CRF); this 
significantly increases the global epidemiology (Gottlieb et al., 2007). Also due to these 
recombination events, two different drug resistant HIV-1 viruses could lead to multi drug 
resistance or even to more pathogenic viruses (Gottlieb et al., 2004, Blackard et al., 2004, 
Fernandez Larrosa et al., 2006).  
Another important issue that is not extensively surveyed in literature is the clinical 
relevance of HIV-1 superinfection, as most descriptions rely on case reports and not on 
controlled cohort studies. The individual cases differ in severity, as several superinfected 
patients with rapidly progressive HIV-1 disease have been described since 2002, but 
superinfection cases were also found by coincidence in long-term non-progressors (LTNPs). 
These patients were able to control HIV-1 disease before and sometimes also after the 
superinfection event. So it is not resolved yet how superinfection affects disease progression 
in general and, if any, specific host or viral factors are involved. In this chapter, first an 
overview will be given of HIV-1 superinfected patients from several studies, with regard to 
HIV-1 disease progression. Disease progression is indicated by an increase in the HIV-1 
plasma viral load, a decrease in the CD4+ T-cell count, acquired immunodeficiency 
syndrome (AIDS) related events and/or the start of antiretroviral treatment. These 
outcomes are compared to values of disease progression for single HIV-1 infected patients, 
resulting in an indication of the clinical relevance of HIV-1 superinfection.  
2. Experimental studies with multiple lentivirus strains 
An in vitro HIV-1 superinfection system for the analysis of viral dynamics and production 
of pseudotypes was used by Fernandez Larrosa et al. (2006). In vitro superinfected cells 
showed higher cell mortality, favoured viral spread and enhanced viral replication 
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result in progressive disease, as viral replication, a marker of pathogenicity, is enhanced 
after superinfection. A second study also showed that superinfection of cells infected with a 
defective HIV-1 virus, with a second replication-competent strain, results in the production 
of highly cytopathogenic HIV-1 particles (Iwabu et al., 2006).  
In an in vivo cat model, both co- and superinfection compared to monoinfection with the 
related lentivirus feline immunodeficiency virus (FIV) increases neuroinflammation and 
subsequent neurodegeneration in the cat brain, also indicating enhanced pathogenicity 
(Afkhami-Goli et al., 2009).  
A mathematical model of the within-host dynamics of HIV superinfection suggested that 
only superinfection with a fitter strain will lead to faster progression to AIDS (Fung et al., 
2010). Probably, the HIV-1 superinfections in patients that are clinically detected are 
productive superinfections that indeed largely occur with fitter strains (Kozaczynska et al., 
2010). Superinfections with less-fit strains may go unnoticed in vivo due to a low or 
localized replication of the less-fit strain. Another computer simulation study suggested that 
regulated superinfection of single cells might increase HIV-1 fitness through recombination 
(Leontiev and Hadany, 2010). Enhanced viral fitness is often associated with increased 
replication and pathogenicity. If different strains superinfect single cells, adaptation of HIV-
1 could be more optimal than if only a single strain is present. Superinfection should be 
regulated so that competition for host resources does not result in less virions produced per 
cell as compared to single infected cells. If that happens, superinfection will not increase 
viral fitness. However, the authors speculate that HIV-1 is able to regulate superinfections 
by multiple virions. Indeed, this phenomenon is called superinfection resistance (SIR), and 
has been observed for many retrovirus infections (for a review, see: Nethe et al., 2005). SIR 
can be induced by simply down-regulating the virus receptor on the cell surface, but more 
complex retroviruses, such as HIV, often carry accessory genes specifically involved in 
resistance to superinfection of an already infected cell.  
Thus, the few in vivo (FIV), in vitro (HIV-1) or in silico (HIV-1) studies that have been 
performed with lentiviruses with emphasis on growth characteristics, suggest that infection 
with multiple strains results in enhanced replication capacity, fitness and pathogenicity.  
3. Disease progression in HIV-1 single infected patients 
3.1 Markers of disease progression 
Accepted indicators for HIV disease progression, especially in the post-ART (antiretroviral 
therapy) era, are increases in the plasma viral load and/or decreases in the CD4+ T-cell 
count below a certain limit (Mellors et al., 1997), although these markers are not clearly 
correlated (Rodríguez et al., 2006), and should preferentially be combined (Mellors et al., 
1997). Korenromp et al. (2009) collected and analysed longitudinal viral load and CD4+ T-
cell count data from untreated HIV-1 infected patients included in 30 studies and 16 cohorts, 
from the moment of seroconversion. The plasma viral loads of these patients ranged 
between 3.7 log10 and 5.6 log10 copies/ml, with an overall median of 4.4 log10 copies/ml. No 
significant change was seen in this median viral load for over 8 years. Mean CD4+ T-cell 
counts decreased from 600 to 360 cells/μl in 8 years. This is in agreement with the typical 
progression to AIDS in untreated HIV-1 infected patients within 8-10 years after infection 
(Gottlieb et al., 2004). However, the course of infection is variable; with approximately 5% of 
HIV-1 infected patients developing AIDS within 3 years, whereas up to 12% of the infected 
patients remain free of AIDS for over 20 years (Mellors et al., 1997). 
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The viral setpoint, e.g. the plasma viral load level stabilization after the acute infection 
period, has been found to be highly predictive of the rate of disease progression (Geskus et 
al., 2007). However, another study found that setpoint and disease progression are only 
linked in patients of European descent, and not in Africans (Müller et al., 2009).  
Nowadays, HIV-1 disease progression until the occurrence of an AIDS-defining event or 
death from AIDS as a clinical end-point is replaced with CD4+ T-cell count decline to a 
certain level (mostly the level that indicates start of ART) or the start of antiretroviral 
treatment. Treatment is currently initiated in most western countries when CD4+ T-cell 
levels are below 350 cells/µl. 
3.2 Disease progression profiles among risk groups  
HIV-1 incidence varies among risk groups. Some risk groups in the western world, for 
example men having sex with men (MSM) and intravenous drug users (IDUs), have a high 
risk of acquiring HIV-1. The route of infection could be related to the type of initial immune 
response, which could theoretically influence the pattern of disease progression.  
Pehrson et al. (1997) compared the disease progression parameters for HIV-1 infected MSM 
and IDUs, using the criteria of AIDS defining events and death from AIDS as endpoint 
markers. They observed a significant lower HIV-1 disease progression for IDUs. A similar 
outcome was found in an Italian study of 1078 HIV-1 seroconverters, were IDUs began 
antiretroviral therapy significantly later than homo- or heterosexual patients, even when 
corrected for CD4+ T-cell counts (Dorrucci et al., 1997). Such a difference in disease 
progression between MSM and IDUs was not seen in 12 European cohorts, where only a 
higher pre-AIDS mortality was obvious for IDUs (Prins and Veugelers, 1997). A similar 
outcome was seen in the Swiss Cohort Studies, where a uniform mortality risk was found 
among the sexes and risk groups, with only an increased risk of death for IDU without 
CD4+ cell depletion at entry, also probably not attributable to HIV-1 infection (van 
Overbeck et al., 1994). In homosexual men from different continents, no differences were 
found in time to development of AIDS, and also year of infection (before or after 1985) did 
not affect disease progression (Biggar, 1990). Adults with haemophilia infected through 
blood transfusion progressed slower towards AIDS than homosexual men before the 
introduction of ART due to the highly increased risk of Kaposi’s sarcoma in the latter group 
(Biggar, 1990).  
Overall, an age-related effect was seen whereby younger age at seroconversion was mostly 
beneficial (Biggar, 1990; Rosenberg et al., 1994; Collaborative Group on AIDS Incubation, 
2000). However, perinatally infected children were found to have a much lower survival in 
the pre-ART era than children infected post-natally from breastfeeding (Marston et al., 
2011).  
Gender differences between men and women have also been reported, with women 
generally having lower initial HIV-1 plasma viral loads independent of exposure group, e.g. 
heterosexual or IDU (Rezza et al., 2000) or within an IDU cohort (Sterling et al., 2001), but 
this difference was not associated with lower disease progression rates (Sterling et al., 2001). 
Concluding, disease progression profiles after HIV infection do generally not differ within 
and between risk groups. HIV-1 infected individuals do show variation in progression over 
time depending on the specific host characteristics, which includes age at seroconversion. 
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3.3 Disease progression in relation to HIV-1 subtype 
HIV-1 group M is a highly variable virus. By now 9 subtypes (named A-D, F-G, J-K) are 
circulating worldwide accompanied by at least 48 described CRF’s (circulating recombinant 
forms) and numerous URF’s (unique recombinant forms) (Hemelaar et al., 2011). 
Distribution of these virus strains is variable, with all strains being present in Africa, but 
specific strains dominating epidemics on other continents. For an overview of the 
geographical distribution of HIV-1 strains in 2000-2007, see: Hemelaar et al. (2011).  
It is reasonable to assume that HIV-1 isolates differ in their pathogenicity. Indeed, 
attenuated circulating virus strains that promote long-term disease free survival have been 
described, e.g. a nef-deleted strain found in Australia among blood-product recipients 
(Deacon et al., 1995). It is less clear if subtypes in general also differ in their capacity to 
induce AIDS, irrespective of host genetics. Most studies, mainly in African women, that 
describe a difference indicate that subtype D induces faster disease progression, especially 
when compared with subtype A (Kanki et al., 1999; Kaleebu et al., 2001; Vasan et al., 2006; 
Baeten et al., 2007; Kiwanuka et al., 2008). One Swedish/African study found similar rates of 
disease progression among persons infected with either subtypes A, B, C or D (Alaeus et al., 
1999), in line with an Israeli study that showed no differences in progression between 
Ethiopian immigrants infected with subtype C and Israeli homosexual men infected with 
subtype B (Galai et al., 1997). In contrast, Singaporese seroconverters infected with 
CRF01_AE had an increased rate of CD4+ T-cell decline and a shorter time to initiation of 
ART than their non-CRF01_AE infected counterparts (Ng et al., 2011).  
Env-V3 loop variation within a subtype can also affect disease progression, as Brazilians 
infected with a variant subtype B strain (B’-GWGR motif) had a lower progression towards 
AIDS and a lower chance of experiencing AIDS-defining events than Brazilian patients 
infected with the US/European subtype B strain (B-GPGR motif) (Casseb et al., 2002; de 
Brito et al., 2006).  
Concluding, it is not unlikely that some subtypes, primarily subtype D and possibly 
CRF01_AE are more pathogenic than other HIV-1 subtypes, but generally subtypes do not 
differ appreciably in disease-inducing potential. However, when comparing disease 
progression in cohorts, it would be advisable to mainly evaluate patients infected with a 
certain subtype or recombinant form.  
3.4 Disease progression in relation to host genetics 
Infection of a host species by a pathogen is counteracted first by the innate and secondly by 
the adaptive immune system. The immune system of vertebrates has evolved into a highly 
variable gene complex, so that immune responses between individuals can differ depending 
upon the specifically inherited alleles.  
Genome-wide association studies have suggested that the major genetic variation associated 
with control of HIV infection in humans is found in the Major Histocompatibility Complex 
(MHC) located on chromosome 6 (Fellay et al., 2007; International HIV Controllers Study, 
2010). Decreased disease progression and lower plasma viral load at setpoint have been 
associated with carrying MHC class I alleles HLA-B*2705, HLA-B*5701/02/03 and HLA-
B*5801 (reviewed by Goulder and Watkins, 2008, for a specific study, see: Altfeld et al., 
2003). Rapid disease progression and high plasma viral load at setpoint is found in 
individuals carrying HLA-B*1801, HLA-B*3502/03, or HLA-B*5802 alleles. However, it has 
been observed that HIV-1 strains are escaping from HLA-B pressure (Goulder et al., 2001; 
 
Clinical Relevance of HIV-1 Superinfection 
 
83 
Cornelissen et al., 2009). Immune escape had already been described for individual patients, 
but more importantly, it is now also visible in the general epidemic. 
Specific HLA alleles differ in their distribution worldwide, so that HIV disease progression 
related to HLA variation can differ not only between individuals, but also between 
populations. In a Swiss cohort study, a lower average CD4+ T-cell decline was seen for 
patients from African descent compared with Europeans (Müller et al., 2009). Earlier in a UK 
cohort, it was already observed that African descent was associated with lower plasma viral 
load after correction for CD4+ T-cell counts, compared with European ancestry (Smith et al., 
2003). However, an earlier in-depth analysis of published studies did not reveal obvious 
differences in progression towards AIDS-defining events in correlation with race or 
ethnicity (Hessol and Palacio, 1996). Probably, in a certain population advantageous and 
disadvantageous alleles are generally more or less balanced, and other cofactors are also of 
importance. Therefore, although the inherited HLA type is important for the individual 
patient with regard to disease progression, ethnicity itself is no indicator for (loss of) control 
of HIV replication.  
Variation in other genes is also implicated in disease progression rates, be it delayed or 
accelerated (reviewed by Fellay, 2009). Especially polymorphisms in the chemokine 
receptors CCR2 and CCR5 promoter regions have been found to be influential, as is the 
CCR5-Δ32 variant that is only present in Caucasians. In a large study on HIV controllers, the 
only variation outside the MHC-I regions that was significantly associated with control of 
infection, were polymorphisms in CCR2/CCR5, albeit only in European samples 
(International HIV Controllers Study, 2010).  
Concluding, host genetic variation is important in HIV-1 disease progression, but it is not 
practically possible to compare only individuals with a similar genetic make-up. Also, viral 
factors are important, making disease outcome in the individual patient a trade-off between 
host and viral genetics. Besides, HIV might be in the process of circumventing adverse host 
factors, as is ongoing for some HLA-B alleles. Another important issue is the level of 
expression of a certain trait, e.g. how well functions the adaptive immune system, and the 
balance between traits is of importance. Consequently, one has to recognize that host (and 
viral) genetics influence disease progression, but is complicated in practice to draw firm 
conclusions, even when genetic information would be entirely available.  
4. Clinical progression and HIV-1 superinfection 
4.1 HIV-1 superinfection: Introduction 
In the earlier days of the epidemic, many were sceptic about the existence of HIV-1 
superinfections, e.g. a re-infection with an unrelated HIV-1 strain after seroconversion. For 
some time, it was assumed that infection with HIV would protect against such a second 
infection. Recombinant strains observed already early in the epidemic were explained as 
having been generated by HIV co-infection during the acute, early phase of the infection 
when the adaptive immunity is not fully developed, or be the ultimate result of long-term 
evolution (Gonzalez et al., 2003).  
The first reported HIV-1 superinfection was detected in an MSM who experienced an acute 
retroviral syndrome in 1998 after infection with a CRF01_AE strain, and who was 
superinfected with a HIV-1 subtype B strain in 2001 (Jost et al., 2002). In the same year a 
second HIV-1 superinfected patient was described, another MSM who controlled initial 
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researchers did not find HIV-1 superinfections when examining their diverse cohorts (Tsui 
et al., 2004; Diaz et al., 2005), many others did, so that the concept of HIV-1 superinfection 
being a regular event was gradually accepted. For example, Hu et al. (2005) identified two 
superinfected individuals amongst 80 HIV-1 infected Thai IDUs with a sample available 12 
months after seroconversion, and concluded that superinfection is not an uncommon event. 
In several cohorts, especially in Africa, sometimes high incidences of HIV-1 dual infections 
were found (Manigart et al., 2004; Chohan et al., 2005; Piantadosi et al., 2007), so that the 
authors reached conclusions similar to Hu et al. However, most studies do not report on 
clinical progression of the superinfected individuals, leaving the question whether or not 
HIV-1 superinfection is harmful to the individual patient.  
4.2 Superinfection cases with rapid clinical progression 
Gottlieb et al. (2004) found amongst 34 HIV-1 positive patients, 4 patients who were co-
infected with HIV-1 (3 MSM and one African female sex worker) and one MSM who was 
intrasubtype superinfected with HIV-1 subtype B. He had a rapid CD4+ T-cell decrease after 
initial infection and became superinfected approximately 1 year after seroconversion 
(Gottlieb et al., 2007). Antiretroviral treatment was initiated half a year after superinfection. 
In these five patients, a CD4+ T-cell count of <200 cells/µl was reached <3.1 years after 
seroconversion and AIDS-defining events occurred <3.4 years after seroconversion. Due to 
the rapid disease progression in HIV-1 dually infected patients, including a superinfected 
patient, compared with single infected patients; the authors suggested a general association 
between dual infection and HIV-1 disease progression.  
A fast progressing MSM, reaching an AIDS diagnosis within 1.5 years from primary 
infection and infected with two unrelated HIV-1 populations early in infection, had already 
been reported in 1997 (Liu et al., 1997). It was, however, in this study unclear whether the 
source partner had a dual infection or whether the second HIV-1 population in this patient 
originated from a second source.  
Published reports on rapid disease progression after HIV-1 superinfection are rare, and only 
one of them concerns an actually confirmed superinfection (Gottlieb et al., 2004). In single 
HIV-1 infection cases, rapid progression to AIDS is also infrequent, and estimated to occur 
in only 5% of patients.  
4.3 Superinfection cases with markers of increased clinical progression 
The first case of superinfection to be described involved an MSM with initial CRF01_AE 
infection who acquired a subtype B superinfection when interrupting his ART regimen (Jost 
et al., 2002). The superinfection was accompanied by transient fatigue and fever, a rebound 
in the plasma viral load remaining at 200,000-400,000 copies/ml and a steady decline of the 
CD4+ T-cell count. ART was resumed four months after the rebound in plasma viral load.  
In a Swiss IDU cohort, two CRF11_cpx superinfections after initial subtype B infection were 
found in chronically infected patients that had low viral loads without antiretroviral 
treatment for years (Yerly et al., 2004). In both patients, a Caucasian female and an African 
male patient, HIV-1 superinfection was associated with an acute retroviral syndrome, stably 
increased viral loads and a significant decrease of the CD4+ T-cell counts. 
Three HIV-1 superinfection cases were reported from a North American Acute Infection and 
Early Disease cohort of HIV infected patients (Smith et al., 2004). The superinfections 
occurred within 6-12 months from primary infection, and were associated with a 
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unfavourable change in disease markers. Within 6 months of superinfection, the plasma 
viral loads of these 3 patients increased with a mean of 1.6 log10 copies/ml and the CD4+ T-
cell count decreased with a mean of 132 cells/µl. Two of the three individuals were initially 
infected with a drug resistant HIV-1 strain and became superinfected with a wild-type 
strain. The third individual was initially infected with a wild-type strain and became 
superinfected with a drug resistant strain (see also: Smith et al., 2005). In all individuals the 
superinfecting strain was fitter than the initial infecting strain, so that a change in 
antiretroviral susceptibility was seen. In two individuals the wild-type superinfecting strain 
masked the initial drug resistant strain.  
A similar observation was published by Koelsch et al. (2003), were a male patient initially 
infected with a subtype B drug-resistant strain was superinfected with a wild-type subtype 
B strain four months later. After primary infection, the patient had a low viral load of 
around 6000 viral RNA copies/ml at setpoint, in line with the finding that drug-resistance 
mutations often decrease viral fitness (see: De Luca, 2006). After superinfection, the viral 
load increased sharply to 200,000 copies/ml and CD4+ T-cells declined steadily from 792 
cells/μl at enrolment to ± 500 cells/μl four months post-infection (immediately before 
superinfection) till 283 cells/μl eleven months post-infection (approximately 7 months after 
superinfection), suggestive of increased disease progression.  
Drug-resistant virus strains have also been identified in further superinfection cases. An 
MSM first infected with a multidrug resistant HIV-1 subtype B strain was superinfected 10 
months later with another multidrug resistant subtype B strain from a new partner (Brenner 
et al., 2004). The first infection was associated with low viremia: 1305 copies/ml decreasing 
to undetectable levels without antiretroviral treatment four months after infection. 
Superinfection was associated with a rise in the plasma viral load from undetectable levels 
to 13,888 copies/ml. CD4+ T-cell counts were not documented during that time, although 
they were very high after the acute infection phase (1200 cells/μl).  
In a cohort of female South African sexworkers infected with HIV-1 subtype C, many 
intrasubtype dual infections were observed during primary infection (Grobler et al., 2004). It 
was unclear how many of these dual infections could be attributed to early superinfections. 
Dual infection was significantly associated with an elevated viral setpoint compared to the 
single infected patients. No superinfections were detected in any patient during follow-up. 
A triple HIV-1 infection in a Dutch MSM was reported by van der Kuyl et al. (2005). In 
March 2001 the patient was diagnosed with an HIV-1 subtype B infection. His plasma viral 
load was then approximately 3.4 log10 copies/ml and his CD4+ T-cell count was around 850 
cells/μl. Retrospective analysis showed that he became superinfected with another subtype 
B strain in October 2002. His plasma viral load was then 4.5 log10 copies/ml with a CD4+ T-
cell count of 550 cells/μl. No medical symptoms were reported by the patient around the 
time of the first superinfection. However, in July 2003, the patient presented with acute fever 
and an increased plasma viral load of 6 log10 copies/ml and a decreased CD4+ T-cell count 
of 300 cells/μl. Analysis of the viral genotype indicated that he was again superinfected, this 
time with a CRF01_AE strain. After the second superinfection, the plasma viral load 
stabilized at an increased level while the CD4+ T-cell counts continued to decrease. 
Therefore, ART was initiated in June 2005, two years after the second superinfection.  
An African female barworker, who was initially infected with a HIV-1 ACD recombinant 
strain, became superinfected 6 till 9 months after seroconversion with an AC recombinant 
strain. At that time, the plasma viral load was 5.6 log10 copies/ml (McCutchan et al., 2005), 
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showed recurring short episodes of malaise, fever, cough, diarrhoea and had moderate 
weight loss, symptoms indicative of an acute HIV infection. Genotyping indeed indicated 
that a superinfection with an AC recombinant strain had occurred around that time. Three 
months after superinfection a setpoint value of 4.8 log10 copies/ml was maintained, while 
CD4+ T-cell count declined from 482 cells/µl to 377 cells/µl 24 to 30 months after primary 
infection, suggestive of increased disease progression.  
An Asian-American MSM presenting with an acute HIV-1 infection syndrome was found to 
be infected with a multi-drug resistant HIV-1 subtype B strain, of which he controlled 
viremia after the acute infection period (Yang et al., 2005). His viral load was 1000 
copies/ml, and his CD4+ T-cell count rose above 600 cells/μl after an initial decline to 396 
cells/μl). However, before he could reach long-term non-progressor status, he was 
superinfected 4 months later with a distinct, drug-sensitive subtype B strain. Viremia 
immediately rose to 30,000-40,000 copies/ml with a concomitant decline in CD4+ T-cell 
counts to 450 cells/μl. Ten months after the first infection CD4+ T-cell counts decreased 
further to <400 cells/μl. 
Smith et al. (2006) described 3 superinfected homosexual male patients from the USA and 
compared them to 11 control patients primarily to analyse (neutralizing) antibody profiles. 
Over the study period (6 months after first antibody measurement), viral loads (ΔHIV RNA) 
showed a significant increase (p=0.02) in the superinfected patients compared to the control 
group, but there was no statistically significant difference (p = 0.29) in the CD4+ T-cell count 
reductions (ΔCD4) between the groups.  
Reports describing increased disease progression, mainly inferred from rising plasma viral 
load or decreasing CD4+ T-cell counts, but not always in combination, are more common. In 
some cases, increasing plasma viral load can be attributed to re-infection with a virus that 
has higher replication capacity, e.g. in the case of infection with a drug-sensitive virus after 
primary infection with a drug-resistant strain. Also, in other cases with enhanced 
progression, superinfection could have occurred with a fitter strain. Possibly, cases with 
increased disease progression are more easily detected, as patients suddenly presenting 
with adverse clinical characteristics are more likely to be scrutinized.  
4.4 Superinfection cases with low or normal clinical progression 
HIV-1 superinfection events in IDU’s which did obviously not result in enhanced disease 
progression were reported from Thailand (Ramos et al., 2002). In October 1996, a female 
patient was found to be infected with the recombinant strain CRF01_AE. She became 
superinfected with HIV-1 subtype B, probably 3-6 weeks after initial infection. Her plasma 
viral load varied within 2 logs (mean 4 log10 copies/ml), while the CD4+ T-cell counts 
remained around 500 cells/µl, only dropping below this number once. A second, male 
patient was identified with an initial HIV-1 subtype B infection in August 1996. He became 
superinfected 5-9 months later with strain CRF01_AE and experienced fluctuating viral 
loads between 3.7 log10 and 4.9 log10 copies/ml for 3 years. His CD4+ T-cell counts remained 
>500 cells/µl. Both patients showed at the time before superinfection limited or absent 
specific T-cell and antibody immune responses (see also: Promadej-Lanier et al., 2009).  
Analysis of a Swiss IDU cohort revealed three subtype B/CRF11_cpx co-infected patients 
and a transient subtype B superinfection in an initially CRF11_cpx infected female 
individual in a cohort with recent HIV infection (Yerly et al., 2004). No symptoms were 
associated with the transient superinfection, and both the plasma viral load and CD4+ T-cell 
counts were stable in this patient. 
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Manigart et al. (2004) reported 2 superinfected women out of 147 HIV-1 infected commercial 
sex workers in a cohort from Burkina Faso. In November 1999 the first woman was found to 
be single infected with CRF02_AG. In samples from January 2001 onwards, a second virus 
strain, CRF06_cpx, was always present. Plasma viral load levels increased till July 2001, with 
a steady decline thereafter. A second woman was found to be HIV-1 seropositive with a 
CRF02_AG infection in March 2000 and a plasma viral load of around 55,000 copies/ml. A 
subsequent superinfection with CRF06_cpx occurred before November 2000 with a tripling 
of the plasma viral load in the November 2000 sample. Thereafter, her plasma viral load 
decreased to 11,000 copies/ml. Unfortunately, she was lost to follow-up after she died in 
2001 from obstetric complications.  
A superinfected Kenyan female sex worker from the pre-antiretroviral therapy period was 
presented by Fang et al. (2004). In February 1985, this patient from Nairobi tested HIV-1 
seropositive and was, retrospectively, found to be infected with a subtype A strain. In April 
1992, at least 7 years after primary infection, she presented an acute febrile illness with chills 
and had a greatly decreased CD4+ T-cell count (<100 cells/μl) compared with a 
measurement in March 1991 (794 cells/μl). A superinfection with a subtype C strain was 
suspected but due to a lack of samples, only in later samples from 1995 and 1997 subtype C 
sequences could be detected from subtype A/C recombinant strains that had already been 
formed then. The patient never received antiretroviral treatment. From 1994, symptoms 
indicating the onset of the AIDS phase, e.g. weight loss, tuberculosis and cryptococcal 
infection appeared and she died in 1998, e.g. over 14 years after her primary HIV-1 infection 
(Fang et al., 2004). In this cohort of sex-workers, mean survival was 4.4 years, and surviving 
over 10 years was rare, suggesting that this woman had a remarkably slow disease 
progression despite an HIV-1 superinfection in the chronic phase of the infection. 
Also from Kenya, but now from its second-largest city Mombasa, three additional 
superinfection cases in a cohort of intermediate risk heterosexual women were described 
during the 1993-2000 period (Chohan et al., 2005). During follow-up, none of these women 
received antiretroviral therapy. All three women were inter-subtype superinfected with 
HIV-1; two women were infected with a subtype D strain and became superinfected with an 
subtype A strain, while the third women was infected with a subtype C strain and was 
superinfected with an A/C recombinant strain. The first patient experienced a 
superinfection 264-385 days after primary HIV infection. Follow-up was done for 2282 days 
(> 6 years), and during this time her plasma viral load was high (≈ 6 log10 copies/ml), but 
stable, with no obvious increase at the estimated time of superinfection. The second woman 
experienced an HIV-1 superinfection 303-591 days after primary HIV infection. She was 
followed for 2069 days (> 5.5 years), during which her plasma viral load was stable at 5 log10 
copies/ml. The third woman became superinfected between 101-485 days after primary HIV 
infection. During follow-up (1262 days ≈ 3.5 years), her plasma viral load rose from a very 
low level of 1.7 log10 copies/ml at day 485 to the modest level of 4.1 log10 copies/ml at end-
point. It is possible, however, that in this patient, viraemia continues to rise after the 3.5 
years of follow-up. But even then, this patient cannot be classified as a fast progressor.  
From the same Kenyan cohort, 7 additional HIV-1 superinfection cases were reported two 
years later (Piantadosi et al., 2007). Four of these women were inter-subtype superinfected, 
while the other 3 were superinfected with a second strain of the same subtype. The women 
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years after seroconversion. Plasma viral load changes were measured before and after the 
superinfection moment, and were either similar or modestly increased in the subjects. Only 
one of the intra- and one of the inter-subtype infected women showed a 1.5 log10 increase in 
her plasma viral load. CD4+ T-cell counts measured at the first moment after superinfection 
ranged between 553-628 cells/μl for 3 patients, between 296-309 cells/μl for 2 other patients, 
and were not available for the two remaining women. Unfortunately, no CD4+ T-cell counts 
were available from earlier moments. The two patients with the lowest available CD4+ T-
cell counts had both been superinfected around 2.5 years from their primary HIV infection 
moment, suggesting that the relatively low CD4+ T-cell counts were not necessarily due to 
an already advanced disease stage. Four patients had viral load data for more than 2 years 
after superinfection (range 2.1-5 years). In all four, including a patient with 309 CD4+ 
cells/μl, the plasma viral load was stable at around 5 log10 copies/ml. The other patient with 
<300 CD4+ T-cells/μl after superinfection also had a stable viral load after approximately 
one year of follow-up. So, in this female African cohort, HIV-1 superinfection was not 
correlated with plasma viral load increases. In 2008, two more superinfected women from 
this cohort were described (Piantadosi et al., 2008). One woman was intrasubtype 
superinfected with two subtype A strains, and also showed no significant plasma viral load 
increases after more than 3.5 years of follow-up, although her viral load had increased from 
4.3 log10 copies/ml to 4.9 log10 copies/ml directly after superinfection. The other patient, 
infected with a subtype D strain, did however show continuous plasma viral load increases 
in the three years after superinfection with a subtype A strain. On the other hand, the 
plasma viral load of this patient was already increasing during the mono-infection period.  
Pernas et al. (2006) described a Spanish HIV-1 triple infected patient who was an IDU but 
also had unprotected heterosexual contacts. In 1987 this patient became infected with a 
subtype A HIV-1 strain. Antiretroviral treatment was started in 1996 due to strongly 
declining CD4+ T-cell counts. Plasma viral load data were only available from 1998 onward. 
The patient was poorly compliant, and treatment was interrupted several times voluntarily. 
In 1999, twelve years after primoinfection, the patient was found to have been superinfected, 
probably at the same moment, with both a subtype B and a subtype C strain. The 
superinfecting strain B had several drug resistance mutations in the pol gene. After the 
superinfection moment, the patient’s viral load increased steadily from 4.2 log10 copies/ml 
directly after superinfection till 5.3 log10 copies/ml in 2001. His CD4+ T-cell count 
decreasing accordingly; from approx. 280 cells/μl directly after superinfection till 55 cells/μl 
in February 2003.  
Patients with no obvious increased disease progression after HIV-1 superinfection have 
been mainly reported from cohort studies examining viral diversity in general. It is 
remarkable that most non-progressors described above are women (15 women versus 2 
males in the mentioned studies). However, this probably has to do with the time-frame of 
the studies. Female sex-workers in Africa have probably been exposed to repeated HIV-1 
infections from the start of the epidemic due to their risk behaviour. The male cohorts 
examined mainly consist of MSM from Europe and the USA. In this risk group, risk 
behaviour, and thus risk exposure sharply diminished after HIV-1 diagnosis before the 
availability of ART (Rachinger et al., 2010). In line with this reduced risk behaviour, no HIV-
1 superinfections were reported from MSM cohorts before the year 2000 (Gonzalez et al., 
2003; Rachinger et al., 2010).  
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4.5 Superinfection cases in long-term non progressors  
Long-term non progressors (LTNPs) are HIV-1 infected patients who control viral 
replication without anti-retroviral therapy to low levels and have stable CD4+ T-cell counts 
in the normal range for over 10 years. Only a minor group of HIV-1 infected patients are 
LTNPs (Deeks et al., 2007; Canducci et al., 2009). An even smaller LTNP subgroup is 
constituted of the so-called elite HIV controllers. Elite HIV controllers are atypical HIV-1 
infected patients who have continuous undetectable viral loads of <50 copies/ml, and no 
decline in CD4+ T-cell count for at least 10 years, also without the help of antiretroviral 
therapy (Deeks et al., 2007; Clerc et al., 2009).  
Casado et al. (2007) reported two HIV-1 infected LTNP patients, who remained in control of 
their HIV-1 infection even after a potential superinfection. The patients were an IDU who 
was HIV-1 infected for at least 18 years and an MSM who was infected for at least 20 years. 
Both had CD4+ T-cell counts of >500 cells/ml, remained asymptomatic and antiretroviral 
therapy naïve. In time, the IDU had multiple peaks in the viral load and a slow decrease in 
CD4+ T-cell count whereas the MSM had undetectable viral loads and a steady CD4+ T-cell 
count. The time of HIV-1 infection for both patients was estimated based on the genetic 
distance to a reconstructed most recent common ancestor. These calculations suggested that 
the IDU was most likely co-infected with two HIV-1 subtype B strains, but a superinfection 
could not be ruled out, and that the MSM became HIV-1 subtype B superinfected 9 years 
after initial infection. Both patients did not show any indications for faster disease 
progression after long-term follow-up, suggesting that here a putative superinfection is not 
associated with progressive HIV-1 disease. However, the presumed superinfection event is 
based on nucleotide distance estimation, and not on actual sampling, so that the 
superinfection could in reality be a co-infection and vice versa. Still, no increased disease 
progression is seen in these two LTNP’s, whether or not they have been co- or superinfected.  
A haemophiliac harbouring two separate clusters of replication-competent HIV-1 subtype B 
strains was controlling his HIV-1 infection without antiretroviral treatment and with > 90% 
of plasma viral load measurements being below 400 copies/ml (Lamine et al., 2007). The 
patient received contaminated blood products, most likely on distinct occasions. He was 
thus possibly superinfected, but did not experience disease progression after more than 10 
years of follow-up.  
An HIV-1 elite controller who showed HIV-1 viremic control before and after superinfection 
was described from The Netherlands (Rachinger et al., 2008). The patient, an MSM, was 
diagnosed HIV-1 positive in 1991. His viral load was under the detection limit of the assays 
used then, and the CD4+ T-cell counts were > 600 cells/μl from 1996 onwards. In May 2005, 
the plasma viral load of the elite controller increased. In April 2006, the viral load peaked at 
25,000 copies/ml. Sequence analysis of the 2006 sample showed that a superinfection with 
another subtype B strain had occurred. Indeed, the patient reported unprotected sexual 
intercourse with a new partner at that time. HIV-1 RNA levels continued to decline again till 
around 1000-2000 copies/ml during November 2006 – March 2008, suggesting that the 
former elite controller was regaining control of his HIV-1 viremia. CD4+ T-cell counts, 
however, were slowly declining to 480 cells/μl in March 2008 (approximately 2 years after 
superinfection), suggestive of disease progression. Two other patients, the source partner 
and a second partner that had been infected with the same virus strain, showed rapidly 
decreasing CD4+ T-cell counts and high viral loads. Therefore, this specific virus strain is 
not attenuated. Host factors are important in controlling infection, and indeed, the index 
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4.5 Superinfection cases in long-term non progressors  
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However, not all (initial) controllers of HIV viral replication are able to control a second HIV 
infection. Streeck et al. (2008) described a HIV–controller who rapidly lost control due to an 
HIV-1 superinfection. The patient, expressing the protective HLA-B27 allele, had at initial 
infection a peak viral load of 5.7 log10 copies/ml and a CD4+ T-cell count of approximately 
900 cells/µl. He controlled viral replication as early as 22 days after infection with a plasma 
viral load well below 10,000 copies/ml, most likely due to his rapidly increasing CD8+ T-
cell immune responses. However after 1.4 years, the viral load increased to 5.6 log10 
copies/ml followed by a steady decrease in CD4+ T-cell count. Three years after initial 
infection (1.5 years after superinfection) the CD4+ T-cell count was below 300 cells/µl. 
Phylogenetic analysis of viral sequences showed that the patient was superinfected with a 
distinct subtype B HIV strain. The superinfecting strain dominated the blood plasma for the 
following 3 years with no control of viral replication.  
Clerc et al. (2010) also showed that elite controllers are not exempt from HIV-1 
superinfection and risk of disease progression. Two HIV-1 infected IDU elite controllers 
contracted an HIV-1 superinfection and subsequently experienced progressive disease. In 
1996, a Swiss woman was tested positive for HIV-1 infection with a subtype B strain. For 
over 6 years, she had undetectable plasma viral loads and CD4+ T-cell counts >800 cells/µl. 
However in July 2002, she presented with a syndrome of high fever, general weakness and 
multiple adenopathies. A viral load of 5.9 log10 copies/ml was measured with a decreased 
CD4+ T-cell count (600 cells/µl). A diagnosis of acute retroviral syndrome was made due to 
superinfection with a CRF11_cpx strain. In August 2007 she started with antiretroviral 
therapy, as her CD4+ T-cell count was then as low as 240 cells/µl, and had already been 
around the 400 cells/µl level from January 2005 onwards. After the superinfection moment, 
the plasma viral load had always been high.  
An African male IDU patient with the protective HLA B*81 allele was tested HIV-1 subtype 
B positive in March 1999. His viral load was undetectable and he had normal CD4+ T-cell 
counts. In October 2002, he showed fatigue, general weakness and multiple new 
adenopathies. His plasma viral load was then 5 log10 copies/ml and the CD4+ T-cell count 
decreased from 1225 to 674 cells/µl. Also this patient was superinfected with a CRF11_cpx 
strain and showed HIV-1 disease progression. After superinfection, the plasma viral load 
remained high at around 5 log10 copies/ml, while CD4+ T-cell counts dropped below 400 
cells/µl. Nineteen months after the HIV-1 superinfection event the patient died from a drug 
overdose and was lost to follow-up.  
A homosexual male patient infected with an attenuated HIV-1 subtype B strain that lacked 
the nef gene lost control of HIV-1 replication when he was subsequently superinfected with 
a wild-type subtype B strain (Braibant et al., 2010). The patient had been included in a 
French long-term nonprogressors cohort after 10 years of seropositivity with 5 years of 
stable CD4+T-cell counts >600 cells/µl. However, in March 1999, almost 4 years after 
inclusion in the cohort, plasma viral load increased progressively to 10,350 copies/ml and 
CD4+ T-cell counts declined <600 cells/µl, necessitating the start of antiretroviral therapy. 
Retrospective analysis showed that the patient had been superinfected with a wild-type 
subtype B strain around the time of inclusion in the controller cohort. Although control of 
HIV-1 replication was lost by this patient after superinfection, disease progression was 
relatively slow, e.g. 4 years after superinfection, CD4+ T-cell counts were still around 500 
cells/µl, and plasma viral load was only slowly increasing till ±10,000 copies/ml. 
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LTNPs and elite controllers are not free from HIV-1 superinfection. This should come as no 
surprise, because although these atypical patients are able to control replication of HIV, they 
are fully susceptible to infection with the virus. How viral control is achieved is not 
completely clear. Favourable HLA-B types are associated with control, as are infections with 
low-replicating virus variants. In the latter case, re-infection with a more competent strain 
could easily result in loss-of-control. If the adaptive immune system is controlling the virus, 
there is a possibility that control will not be lost or can be regained after superinfection. 
From the above described patient cases, it is clear that all hypothetical situations exist in real 
life, but that control is more often lost than recovered.  
5. Conclusion  
The course of an HIV-1 infection in humans varies greatly. From rapid progression to AIDS 
within a few years to control of viral replication for more than 20 years: it all exists. The 
studies presented above indicate that patients who get infected with a second HIV-1 strain 
follow similar divergent tracks of disease progression: from rapid to no obvious 
progression. Assigning HIV-1 superinfection cases (leaving out the questionable cases) into 
progression or non-progression categories results in 20 cases immediately exhibiting 
markers of disease progression versus 21 cases that do not, e.g. in 50% of cases HIV-1 
superinfection results in an accelerated loss of viral control. However, larger studies, e.g. 
case-control studies, are needed to assess the effect of HIV-1 superinfection upon disease 
progression in a controlled way, as most reports published have low numbers of 
superinfected patients.  
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1. Introduction  
The immune system comprises complex cellular and humoral systems, which are forming 
an interactive network to recognize and eradicate invading pathogens. Foreign molecules 
present on viruses, bacteria and parasites, but not on host cells, are discriminated from self 
through pathogen-associated molecular patterns. Upon entry of the pathogen into the body 
immediate non-specific immune responses are triggered and within a short time the innate 
immune system is completely activated. The innate immune system is composed of multiple 
humoral and cellular players, including cytokines, complement proteins, acute-phase 
proteins, dendritic cells, macrophages, NK cells, that co-operate in a complex to generate an 
efficient defense against infection (Figure 1). At best, these immediate innate immune 
responses are able to clear infection or bridge the period until the adaptive, specific immune 
response is taking effect. 
 
 
Fig. 1. Induction of Immune responses 
Among the first components activated during the innate immune response is the 
complement system that together with interferons, cytokines and chemokines stimulate 
innate immune cells, such as dendritic cells (DCs), natural killer (NK) cells, natural killer T 
(NKT) cells, monocytes, or macrophages. These factors act in concert until the adaptive arm 
of immunity is established. Thus, to control the infection process in the acute phase a co-
ordinated action of the innate immune elements is essential.  
In the beginning of an infection viruses and microbes developed different strategies to avoid 
the attack of the innate immune system. Also the human immunodeficiency virus (HIV) is 
able to overcome innate and adaptive immune responses in infected individuals and 
 5 
Innate Immune Responses in HIV-Infection 
Wilfried Posch, Cornelia Lass-Flörl and Doris Wilflingseder 
Innsbruck Medical University, Division of Hygiene and Medical Microbiology 
Austria 
1. Introduction  
The immune system comprises complex cellular and humoral systems, which are forming 
an interactive network to recognize and eradicate invading pathogens. Foreign molecules 
present on viruses, bacteria and parasites, but not on host cells, are discriminated from self 
through pathogen-associated molecular patterns. Upon entry of the pathogen into the body 
immediate non-specific immune responses are triggered and within a short time the innate 
immune system is completely activated. The innate immune system is composed of multiple 
humoral and cellular players, including cytokines, complement proteins, acute-phase 
proteins, dendritic cells, macrophages, NK cells, that co-operate in a complex to generate an 
efficient defense against infection (Figure 1). At best, these immediate innate immune 
responses are able to clear infection or bridge the period until the adaptive, specific immune 
response is taking effect. 
 
 
Fig. 1. Induction of Immune responses 
Among the first components activated during the innate immune response is the 
complement system that together with interferons, cytokines and chemokines stimulate 
innate immune cells, such as dendritic cells (DCs), natural killer (NK) cells, natural killer T 
(NKT) cells, monocytes, or macrophages. These factors act in concert until the adaptive arm 
of immunity is established. Thus, to control the infection process in the acute phase a co-
ordinated action of the innate immune elements is essential.  
In the beginning of an infection viruses and microbes developed different strategies to avoid 
the attack of the innate immune system. Also the human immunodeficiency virus (HIV) is 





thereby attenuates the immunity of the host. In the last years the interest in innate immune 
responses to control HIV infection significantly increased and this book chapter will 
describe various interactions and evasion strategies of HIV and innate immune elements 
with a special focus on complement and dendritic cells.  
2. Interactions of HIV with humoral components of the innate immune system 
Following entry of HIV into the host, humoral components of the innate immune system, 
such as complement system, interferons, cyto- and chemokines, are spontaneously activated 
and will be discussed here. Together with dendritic cells, which are among the first cells of 
the immune system to interact with HIV, the innate humoral components attract other cells 
of the immune system, e.g. NK cells or macrophages, to the sites of infection and a first line 
of defense is established. To ensure a logical configuration of the chapter, we will first 
summarize interactions of HIV with humoral components of the innate system and 
subsequently with cellular responses, although these actions cannot be separated and are 
proceeding in parallel at mucosal surfaces. 
2.1 Interactions of HIV with the complement system 
The complement system plays a crucial role during viral infection respecting both innate 
and adaptive immune responses. It constitutes the first barrier to control HIV propagation 
and can be activated via three different biochemical pathways: the classical, the MBL, and 
the lectin pathway (Fig. 2). The classical complement pathway was the first way to be 
identified, and activation of the classical pathway occurs when the first component of the 
pathway, C1, binds the Fc region of either natural or specific IgG antibody immune-
complexed with viral antigen. The classical pathway is also triggered in an antibody-
independent manner when C1 directly binds to virions or infected cells.  
The alternative pathway is activated by direct recognition of certain microbial structures 
and the (mannan-binding) lectin (MBL) pathway is triggered by binding of terminal 
mannose residues on microbial glycoproteins and glycolipids (Fig. 2). All three pathways 
converge in the cleavage of C3, the main complement component, to the anaphylatoxin C3a 
and the opsonin C3b. This cleavage initiates a cascade of further activation events. C3b is 
covalently deposited on the microbial surface and joins with the C3 convertase to generate 
the C5 convertase. This convertase again cleaves C5 into C5a (anaphylatoxin) and C5b. C5b 
triggers the formation of the membrane attack complex (MAC), that consists of C5b, C6, C7, 
C8 and polymeric C9 molecules (Fig. 2). The formation of the MAC disrupts the microbial 
membrane, resulting in lysis of infected cells or pathogens (Stoiber et al., 2007; Speth et al., 
2008). Figure 2 summarizes the activation events of the complement cascade using the 
example of a viral particle. 
An appropriate control of the over 30 complement proteins, that are participating in the 
activation of the three different complement pathways, is crucial to prevent spontaneous 
activation and destruction of bystander cells. Thus, the complement system is tightly 
controlled by the ‘regulators of complement activation’ or RCAs. RCAs are present in fluid 
phase and also membrane-bound on the surface of host cells. Among the most important 
RCAs are secreted fH (factor H), C4bp (C4-binding protein), MCP (membrane-cofactor 
protein), CD55 (DAF), CD59, and CR1 (Spear et al., 1995; Spiller et al., 1997; Da Costa et al., 
1999; Carroll, 2000).  
 




Fig. 2. Activation of Complement (C) 
Upon entering the host HIV-1 spontaneaously activates the complement system via gp120 
and gp41, even in the absence of HIV-specific antibodies, and is hence already coated with 
complement fragments at the initial stages of infection. After seroconversion, adaptive 
immunity is fully activated, as reflected by the generation of specific anti-HIV-1 antibodies 
and activated T cells. Activation of complement is strongly enhanced due to the Ab-C1 
interactions, and deposition of complement fragments on virions dramatically increased by 
virus-bound Abs. Accordingly, opsonized infectious viral particles accumulate in HIV-1-
positive individuals during the acute and chronic phase of infection and complement 
activation results in multifaceted outcomes. Despite the clearance and neutralization of HIV-
1 virions by action of complement, it also accounts for the spread and maintenance of HIV 
during the infection. During the budding process, HIV acquires membrane-anchored RCAs 
such as CD59, CD55 and binds fH in fluid-phase (Frank et al., 1996). Therefore the virus is 
efficiently protected from complement-mediated lysis (CoML). Only at early stages of 
infection, CoML is suggested to contribute to the control of the virus before the adaptive 
immunity is fully activated. At later stages of infection, CoML seems to play a minor role in 
reducing the viral burden in infected individuals (Stoiber et al., 2007; Huber et al., 2008).  
HIV that is not killed by complement-mediated lysis, persists covered with C3 fragments in 
the host. Thus, opsonized HIV accumulates in all so far tested compartments of the host, 
such as blood, lymphatic tissue (LT), brain, mothers milk, or seminal fluid and is able to 
interact with complement receptor (CR)-positive cells, e.g. DCs, macrophages, NK cells, B 
cells or follicular dendritic cells (FDCs). Opsonized virions were found to bind to 
complement receptor-expressing cells, which can promote enhanced viral infectivity and 
transmission in vitro. 
Furthermore, it was shown that complement by itself or together with dendritic cells is 
involved in priming antiviral T cell immunity, therefore suggesting that complement not 
only triggers CoML but mediates adaptive immune responses (Kopf et al., 2002; 
Banki/Posch et al., 2010). C3-deficiency impeded priming of CD4+ and CD8+ T cells in an 
influenza virus model (Kopf et al., 2002), thus supporting this thesis. The exact mechanisms 
of complement-mediated T cell priming have not yet been resolved, but as recently shown, 
priming of naive CD8+ T cells was significantly enhanced when DCs were exposed to 
complement-opsonized HIV compared to DCs stimulated with non-opsonized HIV 
(Banki/Posch et al., 2010). This was also confirmed in vivo using the Friend Murine 
Leukemia Virus model (Banki/Posch et al., 2010). Therefore, the failure to induce efficient T 
cell responses in the absence of complement can be explained by the fact that dendritic cells 
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resulting in efficient activation of the adaptive immunity. Without C3 the antigen-presenting 
capacity of DCs, and consequently T cell priming, could be defective, which has to be 
further investigated. In addition, the appropriate cytokine environment for T cell priming 
could be altered in the absence of C3 and therefore weaken antigen-presentation.  
Beside inducing T cell immunity, complement opsonization of HIV particles also accounts 
for the generation of a huge viral reservoir in infected individuals. This can be explained by 
the extracellular binding of C3d-opsonized HIV-particles to follicular dendritic cells (FDCs) 
in germinal centers (Kacani et al., 2000). Up to 90% of viral particles were shown to bind via 
C3d-CR2 interactions on FDCs, creating an additional reservoir for infectious HIV (Pantaleo, 
1995; Haase, 1999).  
In summary, HIV-complement interactions are very complex and contribute on the one 
hand to reduction of the viral load by lysis or neutralization due to opsonization, and on the 
other hand to spread of the virus by allowing attachment and maintenance to and on CR-
expressing cells. 
2.2 Induction of type I interferons and cytokines in acute HIV-infection 
During the early stages of HIV infection, high-level viral replication, loss in CD4+ T cell 
number and function, and an up-regulation of proinflammatory and immunoregulatory 
cytokines can be measured.As recently described, an ordered increase in plasma levels of 
multiple cytokines and chemokines was observed in acute HIV-infection (Stacey et al., 2009):  
 Rapid and transient elevations in IFNα and IL-15 levels were succeeded by 
 a large increase in inducible protein 10 (IP-10),  
 rapid and sustained increases in tumor necrosis factor alpha (TNF-α and monocyte 
chemotactic protein-1 (MCP-1),  
 a more slowly induction of proinflammatory cytokines such as IL-6, IL-8, IL-12, and 
IFN-γ and  
 late up-regulation of the immunoregulatory cytokine IL-10.  
Plasmacytoid DCs (pDCs) act as the principal source of systemic IFNα production in many 
viral infections. pDCs were shown in vitro to produce cytokines following the endocytosis of 
HIV virions (Beignon et al., 2005) and they are responsible for early elevations in plasma 
IFNα, and together with myeloid dermal dendritic cells (DCs) in an early increase of IL-15, 
and TNFα levels. Myeloid DCs are made responsible for the slower and more-prolonged 
secretion of an array of cytokines including IL-6, IL-8, IL-12, IL-18, TNFα, and IL-10. This 
part of the chapter will review the most important facts about some of the cytokines and 
their functions in acute HIV infection. 
Type I interferons and APOBEC3G in acute HIV infection 
Interferons inhibit viral replication within host cells (“interfere”), but they do also have 
other functions, like activating immune cells, such as NK cells or macrophages, or up-
regulating antigen-presentation to T cells. IFNα/β elicit potent antiviral activities in both 
virally infected and non-infected cells (Katze et al., 2002) and they additionally enhance the 
antiviral activity of NK cells and macrophages. Furthermore, IFNα/β induce maturation of 
immature pDCs, which is associated with increased expression of CD83, co-stimulatory 
molecules and enhanced secretion of cytokines, e.g. IFNα, TNFα and IL-6 (Cella et al., 
1999) . IFN-secretion during infection causes symptoms like fever or aching muscles.  
IFNα inhibits HIV replication, the mechanism by which it blocks replication of HIV in vivo 
are not known. The anti-HIV effects of IFNα were ascribed to a number of functions 
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mediated by this cytokine, including inhibition of early steps in viral replication, inhibition 
of HIV gene expression, and effects on viral assembly and budding. HIV-1 activates 
plasmacytoid dendritic cells (pDCs) via toll like receptors (TLRs) and induces the secretion 
of IFNα. IFNα secretion is triggered from pDCs in acute HIV-infection via TLR7, TLR8 or 
TLR9 signaling (Beignon et al., 2005; Lee et al., 2006; Meier et al., 2007; Mandl et al., 2008; 
Zhang et al., 2009). TLRs are pattern recognition receptors (PRRs), which recognize 
conserved motifs specific for microorganisms. Certain viral proteins and viral single- or 
double-stranded RNAs are detected mainly by TLRs 7 [ssRNA]/8 [ssRNA]/9 [dsRNA] 
(Kadowaki et al., 2001; Diebold et al., 2004; Mandl et al., 2008). In acute HIV infection IFNα 
has a protective role, while chronic immune activation and inflammation associated with the 
production of type I interferon are major determinants of disease progression in primate 
lentivirus infections (Stoddard et al., 2010). IFNα drives the expression of several IFN 
regulatory factors (IRFs), and the induction of IFN-stimulated genes (ISGs) by an autocrine 
positive feedback loop. In turn, ISGs promote proliferation of immune cells and induce an 
antiviral state in cells. 
IFNα was also demonstrated to potently induce APOBEC3G (Apolipoprotein B mRNA-
editing enzyme-catalytic polypeptide-like 3G) to abrogate HIV Vif neutralization of 
APOBEC3 proteins (Peng et al., 2006). APOBEC3G, a cytidine deaminase, is an innate 
intracellular protein with lethal activity against HIV and exerts this intrinsic anti–HIV 
activity by introducing lethal G-to-A hypermutations in the viral genome (Casartelli et al., 
2010). While HIV+ patients with progressive disease show a significant decline in pDCs over 
time, long term non-progressors (LTNPs) maintain high levels of these cells and this may be 
of importance in the innate response in these patients. 
TNF- in acute HIV infection 
TNF-αis a pro-inflammatory cytokine that mediates many inflammatory and immune 
functions (rev. in Armitage, 1994). It is produced by NK cells, macrophages, monocytes, T 
cells, B cells and neutrophils and exerts its actions via binding to TNF-R1 and TNF-R2. 
Attachment of HIV to TNF-R1 and subsequent activation of NFB were demonstrated to 
significantly increase HIV-1 replication in cells of the macrophage lineage (Griffin et al., 
1991; Naif et al., 1994; Herbein and Gordon, 1997). This enhancement was further amplified 
by IFN-(Han et al., 1996) and a positive autocrine TNF-αloop initiated by HIV-1 infection 
of monocyte-derived macrophages resulted in increased HIV-1 production (Esser et al., 
1991, 1996, 1998). In contrast, ligation of TNF-α to TNF-R2 resulted in inhibition of HIV-1 
replication (Herbein and Gordon, 1997).  
Interleukins 
IL-15 in acute HIV-infection 
The activation of DCs by HIV determines a progressive accumulation of various cytokines, 
including IL-15, which subsequently acts as potent inducer of NK cell activation and 
cytotoxicity. DC-NK cell cross-talk represents a key mode of the cellular network regulating 
the links between innate and the adaptive immune response (Moretta, 2002; Moretta et al., 
2006). IL-15 is produced during acute HIV-1 and SIV (simian immunodeficiency virus) 
infection and exerts an influence on viremia and viral set point. The viral set point was 
significantly increased during acute SIV-infection upon administration of IL-15. To identify 
cytokine biomarkers in plasma during acute HIV-1 infection that predict HIV disease 
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months post infection. Only a small panel of plasma cytokines during acute HIV-1 infection 
was predictive of long-term HIV disease prognosis in this group, namely IL-12p40, IL-
12p70, IFN-, IL-7 and IL15. While IL-12p40, IL-12p70 and IFN- were significantly 
associated with lower viral load, IL-7 and IL-15 were associated with higher viral load 
(Roberts et al., 2010).  
IL-6 in acute HIV-infection 
IL-6 is a pro-inflammatory cytokine produced by macrophages, DCs, T and B cells in 
response to bacterial and viral infections. IL-6 mediates B cell stimulation, monocyte 
differentiation and induction of IL-4-producing cells (Rincon et al., 1997). It helps 
augmenting HIV-1 replication in macrophages and U1 cells (macrophage lineage) and 
enhances TNF-α-induced up-regulation of HIV-1 production (Poli et al., 1990; Poli and 
Fauci, 1992). 
IL-10 in acute HIV-infection 
IL-10 is an anti-inflammatory cytokine produced by monocytes/macrophages, DCs and 
activated T and B cells. This cytokine blocks macrophage activation and inhibits secretion of 
the pro-inflammatory cytokines IL-1, IL-6, IL-8, IL-12 or TNF- (rev. in Moore et al, 2002). 
IL-10 was shown to interfere with HIV-infection at the early stages of HIV-1 infection 
although it does not alter CCR5 surface expression (Montaner et al., 1994; Wang et al., 1998). 
Pre-treatment of monocytes with IL-10 significantly decreased HIV-1 RNA expression and 
this inhibition of HIV replication was associated with down-modulation of IL-6- and TNF-a 
production by IL-10 (Weissman et al., 1994; Naif et al., 1994). 
2.3 Induction of -chemokines (MIP-1, MIP-1, RANTES) in acute HIV-infection 
MIP-1α (CCL3) , MIP-1 (CCL4) and regulated upon activation normal T-cell expressed and 
secreted (RANTES, CCL5) were the first three factors of the -chemokine family identified 
as suppressors of HIV infection (Cocchi et al., 1995). These chemokines have been identified 
to bind the G-protein coupled receptors CCR5, which acts as co-factor for macrophage-(R5) 
and dual-(R5X4)-tropic HIV-1 strains. Similarly, the ligand of CXCR4, SDF-1 (CXCL12) was 
shown to suppress infection with T cell-(X4-)tropic HIV strains (Bleul et al., 1996; Oberlin et 
al., 1996). Polymorphisms in the CCR5 locus, in particular a 32 bp gene deletion (CCR532) 
results in a decreased susceptibility to infection with macrophage-(R5)-tropic HIV-1 strains 
(Kramer et al., 2005). CCR532- heterocygotic individuals can be infected with R5-tropic 
HIV, but exhibit a significantly slower disease progression, whereas CCR532-homocygotic 
individuals are susceptible to infection with X4-tropic HIV-1 strains.  
3. Interactions of HIV with cellular components of the innate immune system 
Very little is known respecting the earliest events after HIV transmission in the genital tract 
or the rectal mucosa and most findings about these early events were acquired from in vivo 
models of SIV-infected macaques (Haase, 2005). The in vivo SIV models and ex vivo analyses 
in the human system pursue to identify cells and soluble factors involved in HIV-
transmission (Haase, 2005; Hladik and McElrath, 2008). R5-tropic HIV-1 particles are 
selectively captured by epithelial cells and subsequently transfered to CCR5-expressing 
target cells underneath the epithelia. This could be responsible for the selective preferential 
transmission of R5-tropic HIV-1 strains (Meng et al., 2002). Langerhans cells (LCs) or other 
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dendritic cells are present at the port of the mucosal entry site (in the underlying tissues of 
the vagina and cervix) and trap pathogens with their processes that extend to the luminal 
surface. Thus, viruses cross the mucosal barrier by attachment or infection of DCs, by 
transcytosis (M cells) or by infection of intraepithelial lymphocytes and macrophages (Fig. 
3). Various cells of the innate immune system account for building the first line defense 
against HIV until the adaptive immune response is fully developed. Among those are LCs, 
myeloid DCs, pDCs, that recruite and activate NK cells (Fig. 3), macrophages, and NKT 
cells, which will be discussed in this part of the chapter. 
3.1 Dendritic cells in acute HIV infection 
Dendritic cells are the most potent antigen-presenting cells and can be divided into 
conventional myeloid DCs (LCs, dermal DCs, blood DCs) and plasmacytoid DCs (Table 1, 
adapted from Altfeld et al., 2011). They differ respecting their location, their C-type lectin and 
TLR expression, their role in HIV-infection, their cytokine production and their function 
(Table 1, Altfeld et al., 2011). As described very recently (Sabado et al., 2010), depletion of 
both, myeloid and plasmacytoid DCs from the circulation already occurs during the early 
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phases of HIV infection. The depletion from the circulation is suggested to be due to 
preferential re-distribution of both DC types from blood to lymphoid organs. This re-
distribution is based on the ability of the DCs to up-regulate chemokine-receptor 7 (CCR7), 
that causes migration of DCs to the lymph nodes along a CCL19/CCL21 gradient. The 
reduction in circulating DC numbers was shown not to be transient, but also detectable in 
the chronic phase of infection and under highly-active antiretroviral therapy (Sabado et al., 
2010). Restoration of circulating DCs might represent a key factor in providing an improved 
immune response against the virus. 
3.1.1 Langerhans cells and HIV 
Langerhans cells (LCs) build the first line defense against mucosal infections because they 
are situated ideally in mucosal tissues to catch pathogens (Fig. 3). LCs survey the basal and 
suprabasal layers of the stratified squamous epithelium of the skin and oral and ano-genital 
mucosa for invading pathogens (Katz et al., 1979; Romani et al., 1985; rev. in DeJong and 
Geijtenbeek, 2010). Upon capture of Ags, LCs start to mature, which is represented by up-
regulation of CCR7, co-stimulatory molecules CD80/CD86/CD40, MHC class I and class II 
molecules and CD83 and by down-regulation of Langerin and E-cadherin (Merad et al., 
2008). These mature LCs migrate to the lymph node to present the captured Ag to T cells, 
thus inducing an efficient immune response (Merad et al., 2008). Despite their important 
function in initiating adaptive immune responses, LCs additionally exert innate immune 
functions as recently shown (De Witte et al., 2007). LCs characteristically express a specific 
set of TLRs (TLR2, 3, 5), high levels of CD1a, the C-type lectin Langerin and intracellular 
Birbeck granules that might be crucial to their innate function (Valladeau et al., 2000; Liu, 
2001; Flacher et al., 2006; Fahrbach et al., 2007, Romani et al., 2010). Langerin interacts with 
HIV-1 and other pathogens like fungi and bacteria. After heterosexual contact with an HIV-
infected individuum, the chance to acquire HIV-1 is very low (0.01-0.1%) (Wu and 
KewalRemani, 2006) and LCs are the first cells to encounter HIV due to their location in the 
mucosal stratified epithelium. Attachment of HIV-gp120 to Langerin leads to internalization 
of the viral particle and subsequent degradation in the Birbeck granules, that are 
characteristic for LCs (De Witte et al., 2007). Thus, LCs are protected from infection with 
incoming, non-opsonized HIV particles and HIV-1 is not disseminated through the host (De 
Witte et al., 2007). Although LCs express the primary receptor for HIV-1, CD4, and the 
chemokine co-receptor CCR5, they are not productively infected by the virus. This is 
probably due to efficient capture of the virus by Langerin and targeting of HIV-1 to Birbeck 
granules, where it is degraded (De Witte et al., 2007). The rapid internalization of HIV-1 into 
LCs prevents also transmission to the main target cells of the virus, CD4+ T cells. The 
degradation of HIV in Birbeck granules and the prevention of virus transfer to CD4+ T cells 
renders Langerin as a protective anti-HIV barrier. When, in addition, sexually transmitted 
infections (STIs) are present, the anti-HIV-1-barrier of LCs is abrogated and HIV-1 
transmission to CD4+ T cells by LCs is promoted (DeJong et al., 2008, 2010; Ogawa et al., 
2009). The by-passing of the anti-HIV-effect due to additional STIs results from direct 
interaction of the STIs with Langerin and therefore competition for HIV-1 binding, Langerin 
inhibition by high viral loads, lower Langerin surface expression by Poly(I:C) or HSV2 
(DeJong et al., 2010), up-regulation of HIV entry receptors and down-regulation of 
restriction factors (Ogawa et al., 2009), or inflammation-induced TNF- production by 
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Candida albicans or Neisseria gonorrhoea (DeJong et al., 2008). In summary, during acute co-
infection the anti-viral function of LCs is significantly reduced due to competition for 
Langerin. This facilitates HIV-1 infection of LCs and thereby promotes HIV-1 transfer to and 
infection of CD4+ T cells. 
3.1.2 Dermal dendritic cells and HIV 
In addition to LCs, interstitial dendritic cells are among the first cells to encounter HIV at 
mucosal surfaces (Fig. 3). They are underlying the epithelium and differ from LCs, since 
they do not contain Birbeck granules and express heterogenous amounts of CD1a (Bell et al., 
1999). Interstitial DCs are localized in the dermis and oral, vaginal and colonic lamina 
propria (Pavli et al., 1990, 1993; Lenz et al., 1993; Nestle et al., 1993; McLellan et al., 1998). 
They are characterized by the expression of CD11c, high concentrations of various C-type 
lectin receptors, TLRs 2, 3, 4 and 5 and secretion of IL-1, IL-6, IL-10, IL-12, IL-15, and IL-23 
upon pathogenic stimulation (Liu, 2001). Also dermal dendritic cells can be functionally 
divided in immature and mature DCs (iDCs, mDCs) based on their T cell stimulatory 
capacity (Banchereau and Steinman, 1998). Following antigen exposure, iDCs undergo 
major changes and mature (described under 3.1.1). Upon entry of HIV into the host, the 
virus has to be transported from mucosal surfaces to lymphatic tissues, where it is 
transmitted to its primary targets, CD4+ T lymphocytes. As mentioned above, this process is 
thought to be contrived by DCs. By clustering T cells, DCs may both activate antiviral 
immunity as well as facilitate spread of the virus. In vitro experiments showed that DCs 
efficiently capture and transfer HIV to T cells and initiated a vigorous infection (Pope et al., 
1995; McDonald et al., 2003; Pruenster/Wilflingseder et al, 2005; Wilflingseder et al, 2007). 
These experiments imply that in vivo HIV exploits DCs at mucosal sites as shuttles to CD4+ T 
cells in the lymph nodes. Preferential expression of CCR5 on immature LCs and DCs restricts 
the transmission of X4-tropic isolates at the site of infection. Additionally, ex vivo analyses 
revealed that X4-tropic HIV replicate worse in DCs and LCs compared to R5-tropic viruses 
(Granelli-Piperno et al, 1998; Kawamura et al, 2000; Ganesh et al, 2004). Productive infection of 
DCs and LCs with HIV is relatively inefficient compared to HIV-infection of CD4+ T cells and 
HIV- or SIV-infected DCs are rarely detected in vivo (rev. in Piguet and Steinman, 2007). Virus 
is very efficiently transmitted to T cells either via de novo (´cis´-transfer) or without (´trans´-) 
infection despite the low-level productive infection of DCs (Turville et al, 2004). Especially C-
type lectins such as Dendritic cell-specific ICAM-3-grabbing non-integrin (DC-SIGN) on 
dermal DCs was implicated in the transfer of HIV to T cells in the lymph nodes (Geijtenbeek et 
al., 2003; Turville et al., 2004). Similar to Langerin, DC-SIGN has high affinity for mannose and 
fucose structures. Dermal iDCs express the C-type lectin DC-SIGN and recently a second 
dermal DC subtype, expressing CD103 and Langerin, but no Birbeck granules, was described 
(Ginhoux et al., 2009). DC-SIGN captures low titres of HIV-1 through its interaction with the 
HIV-1 glycoprotein gp120 (Geijtenbeek et al., 2000) and this DC-SIGN/virus interaction 
protects HIV from degradation within the cells in contrast to the anti-viral action of Langerin 
on LCs (Geijtenbeek et al., 2000). DC-SIGN-complexed HIV-1 is stable and retains the 
infectivity for prolonged periods in contrast to DC-SIGN-bound antibody and probably other 
ligands that are internalized into lysosomal compartments for processing (Geijtenbeek et al., 
2000; Engering et al., 2002). These studies suggest that DC-SIGN-bound HIV-1 particles hide 
near the cell membrane in DCs and are not degraded. After ligating DC-SIGN, HIV is indeed 





phases of HIV infection. The depletion from the circulation is suggested to be due to 
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2009). The by-passing of the anti-HIV-effect due to additional STIs results from direct 
interaction of the STIs with Langerin and therefore competition for HIV-1 binding, Langerin 
inhibition by high viral loads, lower Langerin surface expression by Poly(I:C) or HSV2 
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Candida albicans or Neisseria gonorrhoea (DeJong et al., 2008). In summary, during acute co-
infection the anti-viral function of LCs is significantly reduced due to competition for 
Langerin. This facilitates HIV-1 infection of LCs and thereby promotes HIV-1 transfer to and 
infection of CD4+ T cells. 
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DCs and LCs with HIV is relatively inefficient compared to HIV-infection of CD4+ T cells and 
HIV- or SIV-infected DCs are rarely detected in vivo (rev. in Piguet and Steinman, 2007). Virus 
is very efficiently transmitted to T cells either via de novo (´cis´-transfer) or without (´trans´-) 
infection despite the low-level productive infection of DCs (Turville et al, 2004). Especially C-
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ligands that are internalized into lysosomal compartments for processing (Geijtenbeek et al., 
2000; Engering et al., 2002). These studies suggest that DC-SIGN-bound HIV-1 particles hide 
near the cell membrane in DCs and are not degraded. After ligating DC-SIGN, HIV is indeed 





to CD4+ T cells and also leads to enhancement of infection in these co-cultures and facilitates 
‘trans’-infection of the T cells (Geijtenbeek et al., 2000).  
Besides C-type lectins, other molecules, such as adhesion molecules e.g. ICAM-1 
(Pruenster/Wilflingseder et al, 2005) are described to further contribute to DC-HIV 
interaction. In all compartments tested so far (plasma, seminal fluid, lymphatic tissues), HIV 
is opsonized with C3 complement fragments and after seroconversion additionally with 
HIV-specific IgGs. Similar to the interaction of non opsonized HIV with C-type lectin 
receptors on DCs, receptors such as complement receptors (CRs) or Fc receptors (FcR) 
contribute to the attachment of the complement- or IgG-coated virus. If the virus is 
opsonized, the DC-SIGN- or ICAM-dependent interactions play a minor role for the 
attachment of HIV to DCs as well as the DC-mediated cis and trans HIV-infection 
(Pruenster/Wilflingseder et al, 2005). Complement-opsonization of HIV significantly 
enhanced the productive infection of DCs compared to non-opsonized HIV and also acted 
as an endogenous adjuvant for the DC-mediated induction of virus-specific CTLs 
(Wilflingseder et al., 2007; Banki/Posch et al., 2010). These results emphasize a role of DCs 
in combination with complement-coating of the virus in priming adaptive T cell responses. 
Vigorous trans-infection of CD4+ T cells by DCs was shown to be promoted by infectious 
synapse formation independent on the attachment mechanism (C-type lectin receptors, 
adhesion molecules, CRs [own unpublished observations]) (rev. by Piguet and Sattentau, 
2004). The receptors involved in the HIV attachment have to be re-arranged and are 
recruited to the DC-T cell junctions (McDonald et al., 2003). Microscopic analyses of DC-
CD4+ T cells revealed re-arrangement and recruitment of CD4 and chemokine-co-receptor to 
the infectious synapse on the T cell site and of HIV on the DC site (McDonald et al., 2003). 
Thereby, dermal DCs contribute not only to shuttle HIV from the mucosal site to the 
lymphatic tissue but also to efficiently transmit of HIV to its main targets, CD4+ T cells. 
Beside the support of DCs in HIV dissemination, DCs produce high amounts of cytokines, 
such as IL-12 or interferons, which belong to the first line of the host defense against invading 
organisms. They are also able to activate NK cells via secretion of pro-inflammatory cytokines 
(IL-12, IL-15, IL-18) and other factors, thus enhancing their cytotoxicity to virally infected cells 
(Chehimi et al., 1989; Mellman and Steinman, 2001, Yu et al., 2001).  
In terms of modulation of DC function by HIV infection in vivo, it is not clear if DC defects 
are resulting from the direct exposure to HIV or if they are due to production of host cell 
factors during infection. Circulating lipopolysaccharide (LPS) or other pathogen-derived 
factors were also implicated in chronic immune activation, which is monitored during HIV 
infection (Brenchley et al., 2006). Bacterial stimuli like LPS could result in maturation of 
iDCs thus rendering these cells tolerant to subsequent stimuli. Ex vivo tests of DCs from 
chronically infected individuals demonstrated that they were less potent in responding to 
other TLR stimuli as well as in stimulating T cell responses compared to DCs from non-
infected individuals (Donaghy et al., 2003; Martinson et al., 2007). 
DCs are furthermore involved in the generation of regulatory T cells and thus induce both, 
immunity and tolerance. DCs shown to induce tolerance are plasmacytoid DCs (pDCs). 
(Steinman, 2000).  
3.1.3 pDCs and HIV 
Plasmacytoid DCs or type 1 IFN-producing cells, are innate immune cells specialized in 
releasing massive amounts of IFN and IFN upon viral challenge, including HIV (Fig. 3) 
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(Siegal et al., 1999). This blood DC population expresses high levels of HLA-DR and the 
characteristic markers BDCA-2 and CD123 (Table 1), but not CD11c, a marker of myeloid 
DCs (Table 1) (O´Doherty et al., 1994; Dzionek et al., 2001). pDCs are key initiators of the 
innate immune response in vivo and they can prime adaptive immunity due to the afore 
mentioned production of high type I interferon levels, especially upon exposure to viral 
products (Cella et al., 1999; Siegal et al, 1999). pDCs recognize pathogenic single-stranded 
RNA or unmethylated DNA mainly by TLR7 and TLR9. Due to the intracellular localization 
of these TLRs, the viruses have to be ingested by the cells and endosomal maturation must 
occur to activate NFkB- and MAPK-signals through MyD88. Once activated, pDCs mature 
and produce large amounts of pro-inflammatory and antiviral cytokines (Kadowaki et al., 
2000; Ito et al., 2002; Colonna et al., 2004). pDCs do not only act as pro-inflammatory cells, 
but also provide negative regulatory signals and thereby induce tolerance (Ochando et al., 
2006). pDCs express indoleamine 2,3-dioxygenase (IDO) and programmed death ligand 1 
(PDL-1) that are associated with the negative modulation of T cell responses and regulatory 
T cell induction (Boasso et al., 2007, 2008; Chen et al., 2008). As shown, constant exposure of 
pDCs to HIV results in their chronic hyperactivation coming along with production of type I 
interferon and IDO, which exerts cytotoxic as well as suppressive effects on T cells 
(Herbeuval and Shearer, 2007). In acute HIV-infection pDCs recruit and activate NK cells to 
the sites of infection as well as to the lymph nodes (Gerosa et al., 2002; Megjugorac et al., 2004). 
The activation is due to IFN released from pDCs, which was demonstrated to induce 
increased perforin expression in NK and CD8+ T cells. The pDC-NK cell activation is bi-
directional, since activated NK cells deplete immature pDCs to possibly select the more 
immunogenic mature pDCs at the sites on infection (Pertales et al., 2003a, 2003b; Ferlazzo and 
Munz, 2004). This process is called ‘DC-editing’ (Ferlazzo et al., 2002). Beside NK cell 
recruitment and activation, pDC-produced IFN promotes maturation and migration of DCs. 
pDCs are not as efficient in antigen-presentation as myeloid DCs and they are not located in 
high amounts at the site of pathogen entry. Due to their spontaneous antiviral and NK 
priming activity they are supposed to control the virus in the acute phase of infection and it 
is unlikely that they are involved in HIV capture, transport and transmission. 
Deficiencies in pDC function were among the earliest observations of immune dysfunction 
in HIV-1 infection. Loss of pDCs in blood of chronically infected individuals has been 
ascribed to cell death and/or to a failure of bone marrow progenitors to differentiate into 
pDCs. Additionally, a low productive virus replication of IFN-producing pDCs has been 
shown in vivo and in vitro by R5- and X4-tropic HIV variants (Donaghy et al., 2003; Schmidt 
et al, 2004). It is not known so far, if infection of pDCs plays a role for IFNα-secretion. 
3.2 NK and NK T cells in acute HIV infection 
Natural killer (NK) cells are lymphocytes deriving from bone marrow precursors. They 
circulate as mature populations in blood and spleen and are activated by type I interferons 
(Fig. 3). Classical NK cells do not express T cell antigen receptors (TCR) and are CD3-
negative. They produce high levels of certain cyto- and chemokines, such as MIP-1α, MIP-
1, RANTES, TNFα, GM-CSF or IFN-and mediate significant levels of cytotoxic activity by 
exocytosis of granules containing perforin and granzymes. NK cells thus efficiently 
contribute to innate immune responses due to their spontaneous cytotoxic action against 
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iDCs thus rendering these cells tolerant to subsequent stimuli. Ex vivo tests of DCs from 
chronically infected individuals demonstrated that they were less potent in responding to 
other TLR stimuli as well as in stimulating T cell responses compared to DCs from non-
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(Siegal et al., 1999). This blood DC population expresses high levels of HLA-DR and the 
characteristic markers BDCA-2 and CD123 (Table 1), but not CD11c, a marker of myeloid 
DCs (Table 1) (O´Doherty et al., 1994; Dzionek et al., 2001). pDCs are key initiators of the 
innate immune response in vivo and they can prime adaptive immunity due to the afore 
mentioned production of high type I interferon levels, especially upon exposure to viral 
products (Cella et al., 1999; Siegal et al, 1999). pDCs recognize pathogenic single-stranded 
RNA or unmethylated DNA mainly by TLR7 and TLR9. Due to the intracellular localization 
of these TLRs, the viruses have to be ingested by the cells and endosomal maturation must 
occur to activate NFkB- and MAPK-signals through MyD88. Once activated, pDCs mature 
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pDCs to HIV results in their chronic hyperactivation coming along with production of type I 
interferon and IDO, which exerts cytotoxic as well as suppressive effects on T cells 
(Herbeuval and Shearer, 2007). In acute HIV-infection pDCs recruit and activate NK cells to 
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The activation is due to IFN released from pDCs, which was demonstrated to induce 
increased perforin expression in NK and CD8+ T cells. The pDC-NK cell activation is bi-
directional, since activated NK cells deplete immature pDCs to possibly select the more 
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pDCs are not as efficient in antigen-presentation as myeloid DCs and they are not located in 
high amounts at the site of pathogen entry. Due to their spontaneous antiviral and NK 
priming activity they are supposed to control the virus in the acute phase of infection and it 
is unlikely that they are involved in HIV capture, transport and transmission. 
Deficiencies in pDC function were among the earliest observations of immune dysfunction 
in HIV-1 infection. Loss of pDCs in blood of chronically infected individuals has been 
ascribed to cell death and/or to a failure of bone marrow progenitors to differentiate into 
pDCs. Additionally, a low productive virus replication of IFN-producing pDCs has been 
shown in vivo and in vitro by R5- and X4-tropic HIV variants (Donaghy et al., 2003; Schmidt 
et al, 2004). It is not known so far, if infection of pDCs plays a role for IFNα-secretion. 
3.2 NK and NK T cells in acute HIV infection 
Natural killer (NK) cells are lymphocytes deriving from bone marrow precursors. They 
circulate as mature populations in blood and spleen and are activated by type I interferons 
(Fig. 3). Classical NK cells do not express T cell antigen receptors (TCR) and are CD3-
negative. They produce high levels of certain cyto- and chemokines, such as MIP-1α, MIP-
1, RANTES, TNFα, GM-CSF or IFN-and mediate significant levels of cytotoxic activity by 
exocytosis of granules containing perforin and granzymes. NK cells thus efficiently 
contribute to innate immune responses due to their spontaneous cytotoxic action against 





balance of activating and inhibitory NK cell receptors (Moretta et al, 2001; Moretta, 2002; 
Lanier, 2005) and they are able to kill HIV-infected target cells by direct lysis or by antibody-
dependent cell-mediated cytotoxicity (ADCC) (Tasca et al, 2003; Bonaparte and Barker, 
2004). ADCC is mediated in classical NK cells through their cell surface receptors for 
immunoglobulins (FcR). Additionally, NK cells initiate priming of the adaptive immunity 
due to their cross-talk with DCs. As mentioned above, NK cells activate DCs by cell-cell 
contact or secretion of cytokines and vice versa, DC-derived cytokines and membrane-
bound molecules play a key role in NK cell activation (Zitvogel, 2002; Andrews et al, 2003; 
Ferlazzo et al, 2004; Cooper et al., 2004; Moretta et al, 2006; Newman et al, 2006). Their killer 
inhibitory receptors (KIRs), which transmit an inhibitory signal, if they encounter MHC 
class I molecules on a cell surface, are crucial in killing virus-infected cells. Two subsets of 
classical NK cells can be distinguished by their expression of CD16 and CD56. >95% of the 
NK cells belong to the CD16highCD56low subset, which is responsible for the direct lysis of 
cells and the ADCC (Nagler et al, 1989; Caligiuri et al, 1990). The remaining 5% CD16low/-
CD56high subset produces high concentrations of IFN- and TNF-α, but this sub-population 
exerts a very low cytotoxic potential (Ahmad and Menezes, 1996). In HIV-infected 
individuals NK cell responses were shown to be impaired and the defects comprised 
cytotoxic activity of NK cells as well as secretion of CCR5-ligands MIP1α, MIP1 and 
RANTES (Scott-Algara et al, 1992; Mavilio et al, 2003; Kottilil, 2003). The HIV-mediated 
impairment of NK cells becomes manifest early after infection and continues during HIV 
progression and can be attributed to several factors:  
HIV-infected individuals might have a down-regulation in intracellular perforin and 
granzyme A stores, which would account for the decreased cytotoxic capacity of NK cells in 
HIV-infection (Portales et al., 2003). 
Another explanation might be the change in the expression patterns of various activating 
and inhibitory NK cell receptors during HIV-infection (DeMaria et al., 2003). 
Chronic viral stimulation may also lead to inappropriate activation of peripheral NK cells, 
thus resulting in NK cell exhaustion or anergy (Alter et al., 2005; Mavilio et al., 2005).  
Finally, CD4+ NK cells may be a reservoir for HIV-1 in vivo and further investigation is 
necessary to explore this possibility. 
A population of T cells sharing characteristics with classical NK cells has been identified 
based on expression of NK cell markers, and this population was named NK T cells 
(McDonald, 1995). NK T cells, a rare population of T lymphocytes, comprise only 0.01 ~ 1% 
of human peripheral blood mononuclear cells and play an important role in the innate 
immune defense (Motsinger et al, 2002). NK T cells are important immunoregulatory cells, 
producing both, high amounts of IFN- ( double-negative NK T cells), a major TH1 
cytokine, and IL-4 and IL-13 ( CD4+ NK T cells), the major TH2 type cytokines (Gumperz et 
al, 2002; Lee et al, 2002). Thus NK T cells may provide quicker help for a cell- (IFN-) or 
antibody-mediated (IL-4) response than conventional T cells through recruiting and 
stimulating other effector cells, such as NK cells, macrophages, DCs and conventional T 
cells. NK T cells can in addition act directly cytolytic through involving the 
perforin/granzymes and the Fas/FasL pathway (Metelitsa et al., 2001).  
A semi-invariant TCR (NK T TCR) is expressed on NK T cells consisting of an invariant -
chain, and a restricted TCR--chain repertoire (rev. in Godfrey and Kronenberg, 2004). NK T 
cells recognize self or foreign glycolipids presented by the non-polymorphic MHC class I-
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like molecule CD1d (Bendelac et al, 1997; Joyce, 2001). NK T cells are stimulated by type I 
interferons or pro-inflammatory cytokines (IL-15, IL-12, IL-18). Therefore, also NK T cells 
need a cross-talk with DCs to be fully activated (pDCs  type I IFNs, DCs  IL-12).  
Upon HIV-1 infection NK T cells are rapidly and selectively depleted from the circulation. 
The NK T cell numbers are dramatically reduced in HIV-infected individuals compared to 
healthy donors (Motsinger et al., 2002; Van der Vliet et al, 2004). In vivo studies showed that 
the decrease in NK T cell numbers significantly correlated with higher viral loads in infected 
individuals (Motsinger et al., 2002) and that these HIV-susceptible cells were rapidly 
destroyed in vitro by R5-tropic HIV-strains (Motsinger et al., 2002). The mature NK T 
phenotype is induced by persistent stimulation of the cells with unidentified self-Ags or Ag-
independent mechanisms and the high expression of CCR5 on the surface renders NK T 
cells permissive for HIV. They are not only efficiently infected by HIV but also contribute to 
the viral spread due to activating resting by-stander CD4+ T cells (Unutmaz et al., 1999).  
The rapid loss of NK T cells during early HIV-infection causes subsequent depletion of 
important immunoregulatory functions, which are involved in tumor immunity, defense 
against other invading pathogens and autoimmune diseases. This might facilitate 
establishment of other opportunistic infections or tumor development frequently detected at 
later stages of the disease. NKT cells are important cells of the innate immune system, which 
are selectively and rapidly depleted by HIV-1 infection. Stimulation of the surviving NK T 
cells is additionally impeded due to down-regulation of CD1d on antigen-presenting cells.  
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like molecule CD1d (Bendelac et al, 1997; Joyce, 2001). NK T cells are stimulated by type I 
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are selectively and rapidly depleted by HIV-1 infection. Stimulation of the surviving NK T 
cells is additionally impeded due to down-regulation of CD1d on antigen-presenting cells.  
 
 





3.3 Macrophages in acute HIV infection 
Macrophages resident at mucosal sites are proposed to play an important role during 
HIV-1 pathogenesis. Macrophages bridge innate and adaptive immunity similar to DCs, 
NK and NK T cells. They are recognizing, internalizing and degrading microorganisms 
and clear cell debris via TLRs, C-type lectins (Dectin-1), Fc receptors and complement 
receptor 3. Furthermore, macrophages present pathogen-derived peptides via MHC class 
II, thus initiating adaptive immune responses, and secret pro-inflammatory cytokines. 
Upon HIV-infection they are among the first cells encountered by the virus, but they are 
able to resist to HIV-mediated cytopathic effects. Therefore, macrophages are thought to 
serve as major cellular HIV reservoir together with latently infected resting CD4+ T cells 
for long-term infection. Productively infected macrophages were detected in both 
untreated patients and those receiving antiretroviral therapy (ART), but the HIV infection 
within macrophages was not associated with virus-induced cytopathic effects (Koenig et 
al, 1986; Sharkey et al, 2000). The infectious virus is retained in macrophages for a 
prolonged period of time and the virus may be released from macrophages delayed and 
in a different compartment – thus macrophages contribute to persistence and spread of 
the virus (Crowe et al., 2003; Montaner et al., 2006; Carter and Ehrlich, 2008). As detected 
in NK or NK T cells, the functions of macrophages were found to be impaired by HIV-1 
infection in vitro and in vivo. In vivo macrophages from HIV-infected individuals were 
found to be defective for phagocytosis of apopotic cells (Torre et al., 2002). In vitro HIV-1 
impeded with phagocytosis via CR3 or FcR and also impaired internalization of Candida 
albicans and Toxoplasma gondii (Crowe et al., 1994; Kedzierska et al., 2002; Azzam et al., 
2006; Leeansyah et al., 2007). As recently shown, Nef was a crucial factor in disrupting 
phagocytosis in HIV-1–infected cells (Mazzolini et al., 2010). 
HIV and its accessory genes alter macrophage immune responses, macrophage cell cycle 
and enhance their own viral replication in macrophages (Margottin et al, 1998; Hassaïne et 
al, 2001; Federico et al, 2001; Coberley et al, 2004; Olivetta et al, 2005). HIV mediated a pro-
inflammatory gene expression pattern in macrophages as demonstrated by microarray 
analyses, and this pro-inflammatory cytokine profile is suggested to enhance virus 
replication and persistence of chronically activated macrophages in vivo. In addition to up-
regulation of pro-inflammatory cytokines, IFN- and NFB-responsive cyto- and chemokines 
were increased upon HIV-1 infection. Up-regulation of these IFN- and NFB-responsive 
cyto- and chemokines may promote recruitment of CD4+ T cells and macrophages to sites of 
infection, which would promote the viral spread (Cicala et al, 2002; Izmailova et al, 2003; 
Woelk et al, 2004). Only low expression levels of CD4 are detected on the surface of 
macrophages; in contrast high levels of heparan sulfate proteoglycans (such as syndecan), 
macrophage mannose receptor (MR), and elastase are expressed (Nguyen and Hildreth, 
2003; Bristow et al, 2003; De Parseval et al, 2005). HIV can attach and internalize into 
macrophages via these receptors. Expression of both chemokine co-receptors, CCR5 and 
CXCR4, was verified on primary human macrophages, and they can be infected with R5-, 
dual- and X4-tropic virus isolates in vitro and in vivo (Verani et al, 1998; Liu et al, 1996; 
Samson et al, 1998; Clapham and McKnight, 2002). Once ingested by macrophages, HIV 
accumulates in endocytic compartments similar to multivesicular bodies, which facilitate 
HIV assembly and escape immune surveillance (Kramer et al, 2005). This accumulation of 
HIV in the cytoplasmic vesicles of macrophages results in persistent storage of infectious 
virions and a delayed rapid infection of CD4+ T cells (Sharova et al, 2005). When a 
virological synapse is formed between a macrophage and a T cell, the virus is efficiently 
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transmitted. Therefore tissue macrophages were claimed to act as ´Trojan horse´, that hide 
the virus from the immune system and disseminate the virus even after months.  
3.4 Monocytes in acute HIV infection 
Similar to DCs, LCs and macrophages, monocytes provide a first line of defense against 
invading pathogens and act as key mediators of innate immune mechanisms. On the other 
hand, they are also targets for monocyte-tropic pathogens, such as Listeria, cytomegalovirus 
and HIV (Drevets and Leenen, 2000). Monocytes express CD4, CCR5 and CXCR4 and are in 
particular susceptible to macrophage-tropic HIV strains. Similar to macrophages, monocytes 
are resistant to the cytopathic effects of HIV, they represent a key virus reservoir and may 
also disseminate HIV in different locations such as the brain (Kedzierska and Crowe, 2002; 
Crow et al., 2003). Early in acute infection, HIV and SIV enter the central nervous system 
(CNS) and macrophages and monocytes seem to play a crucial role in the 
neuropathogenesis of HIV-infection and to contribute to HIV-mediated dementia due to 
production of pro-inflammatory cytokines and neurotoxins (Chakrabarti et al., 1991; 
Kedzierska and Crowe, 2002). The induction of pro-inflammatory cytokines is thought to 
facilitate the entry of monocytes into the brain by disrupting the blood-brain and blood-
cerebrospinal fluid barrier (Persidsky et al., 2000; Eugenin and Berman, 2003). In particular, 
CCL2 was associated with inflammation of the CNS (Mahad and Ransohoff, 2003). This 
cytokine is mainly secreted by monocytes and macrophages and initiates migration of T 
cells and other monocytes into the CNS and promotion of neuronal cell-death during HIV 
and SIV infection (Gartner and Liu, 2002; Fantuzzi et al., 2003). HIV-1 Tat activates microglial 
and perivascular cells to produce pro-inflammatory proteins, thereby leading to monocyte 
infiltration into the brain (Pu et al, 2003). Other features promoted by Tat following infection 
with HIV were chemotaxis of monocytes, their adhesion to the endothelium, and their 
recruitment into extra-vascular tissues. This modulation of the chemotactic activity seems to be 
mediated by the Tat cysteine-rich domain (Albini et al, 1998). 
Thus, monocytes represent a prinicpal reservoir for HIV persistence due to the long storage 
period of infectious viral particles and infectious HIV was shown to be recovered from 
patients obtaining ART. HIV thus affects multiple immune functions of 
monocytes/macrophages (chemotaxis, phagocytosis, intracellular killing, APC function, 
cytokine production) and thereof allows establishment as well as re-activation of other 
opportunistic infections (Kedzierska and Crowe, 2002).  
3.5 T cells in acute HIV infection 
T cells are primarily situated in the gastrointestinal mucosa and play an important role in 
the first line of defense against viral, bacterial, and fungal pathogens. T cells make up 50% 
of all lymphocytes in the intraepithelial compartment and about 10% of lymphocytes in the 
lamina propria (James et al., 1986; Targan et al., 1995). T cells recognize soluble protein 
and non-protein Ags, but the mechanism of recognition remains elusive. T cells 
participate in the immune response to various viruses, including herpes simplex virus, 
Epstein-Barr virus, and HIV-1 (Maccario et al., 1995). Co-culture of T cells with HIV-1 
infected lymphocytes resulted in increased cytotoxicity and production of HIV-1-suppresive 
mediators against the infected cells (Wallace et al., 1996; Poccia et al., 1999; Cipriani et al., 
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cells during acute infection and, despite HAART, persist into the chronic phase, but the 
factors involved in these changes remain to be investigated. 
4. Conclusions 
In summary, innate immune responses contribute significantly to the first line of defense 
against invading HIV-1 particles on the one hand, but the virus has evolved different 
strategies to escape from the innate immune system on the other hand. While Langerhans 
Cells and plasmacytoid dendritic cells exert efficient antiviral actions by degrading the virus 
via Birbeck granules (LCs) or secreting high amounts of type I interferons (especially IFNα), 
interstitial dermal dendritic cells are suggested to contribute in viral transport and 
dissemination. The antiviral functions of LCs are also reversed upon co-infection with other 
STIs or microbes due to the competition of the pathogens for Langerin. The competition for 
Langerin allows attachment of HIV-1 to its main receptors, CD4 and the chemokine-co-
receptor CCR5, on LCs and thus facilitates infection of LCs and subsequent transfer to CD4+ 
T cells in the lymph nodes. This process of ‘cis’-infection of DCs, migration to the lymphatic 
tissues and transmission to CD4+ T cells is also thought to be contrived by dermal DCs. The 
virus is furthermore efficiently protected against complement-mediated lysis due to 
acquisition of regulators of complement activation during the budding process from the 
host cell (CD55, CD59) and additionally in fluid-phase (fH). Thus, most of the virus is 
opsonized with C3-fragments in vivo, which allows interaction with complement-receptor 
expressing cells at mucosal surfaces. Therefore the host immune system itself has to reverse 
the protection of the virus against complement-mediated lysis. As recently demonstrated 
(Banki/Posch et al., 2010), complement-opsonization acts as endogenous adjuvant for the 
dendritic cell-mediated induction of retrovirus-specific CTLs in vitro and in vivo, which was 
the first evidence that specific CTLs are efficiently stimulated in a complement- and DC-
dependent manner. This enhanced and efficient CTL-stimulatory capacity of DCs upon 
complement-opsonization of HIV may provide a host-cell protecting mechanism at the 
beginning of infection and understanding the exact interplay between differentially 
opsonized retroviral particles and APCs is of prime importance for DC-based vaccination 
strategies against retroviral infections. Not only benefits result from the complement 
opsonization of HIV- such complement-opsonized particles can also be ingested by CR3-
expressing macrophages and monocytes, the major reservoirs of long-term HIV-persistence 
beside latently infected CD4+ T cells. These cells facilitate HIV assembly and escape immune 
surveillance by hiding the particles from the immune system and by allowing efficient 
transfer of the particles to target cells in a delayed manner and another compartment. 
Instead of destroying the virus at the initial phases of infection, macrophages and 
monocytes seem to act as ´Trojan horse´ by actively contributing to the spread of HIV over 
long time periods. Beside LCs and pDCs, T cells, primarily located in the gastrointestinal 
mucosa, NK and NK T cells, that are activated by IFN-secreted pDCs, build an important 
first line of defense against viral, bacterial, and fungal pathogens. HIV-1 counteracts this 
innate immune barrier by changing their functions and decreasing their numbers by yet 
mainly undefined mechanisms. The HIV-mediated loss in numbers of important innate 
immune cells, such as pDCs, NK and NK T cells or T cells, is associated with a modified 
cytokine microenvironment, which may additionally account for the chronic establishment 
of HIV-infection in the host. Because it is difficult identifying infected individuals very soon 
after exposure, little is known respecting the earliest events of HIV transmission in the 
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genital tract or rectal mucosa. Most of the findings are deriving from in vivo models of SIV 
infection (rev. in Haase, 2005) and from ex vivo models aimed to identify cells and factors 
affecting the transmission of HIV (rev. in Hladik and McElrath, 2008). Even when using 
animal models the exact process how the virus infiltrates mucosal barriers to establish a 
productive infection in the host is extremely complex to evaluate. There are multiple innate 
soluble and cellular factors acting together upon entry of HIV into the host – yet, the innate 
mechanisms and even the specific adaptive immune responses fail to restrict the replication 
of HIV in most infected individuals indicating the selection of viral mutants that are able to 
efficiently escape these early and late cellular and humoral immune responses. In the last 
years, increasing evidence suggests that especially immunologic and virologic events 
occuring during primary infection irreversibly weaken the immune system, which is not 
able to restore and gradually fails to resist viral and opportunistic infections. 
5. References 
Ahmad, A, Menezes, J (1996) Antibody-dependent cellular cytotoxicity in HIV infections, 
Faseb J. 10:258-266 
Albini, A et al., (1998) Identification of a novel domain of HIV tat involved in monocyte 
chemotaxis, J Biol Chem 273:15895-15900 
Alter, G. et al. (2005) Sequential deregulation of NK cell subset distribution and function 
starting in acute HIV-1 infection, Blood 106, 3366–3369  
Altfeld, M, Fadda, L, Frleta, D, Bhardwaj, N, (2011) DCs and NK cells: critical effectors in the 
immune response to HIV-1, Nat Rev Immunol. Mar;11(3):176-86 
Andrews, DM, Scalzo, AA, Yokoyama, WM, Smyth, MJ, Degli-Esposti, MA (2003) 
Functional interactions between dendritic cells and NK cells during viral infection, 
Nat Immunol 4:175-181 
Armitage, R, (1994) Tumor necrosis factor receptor superfamily members and their ligands. 
Curr Opin Immunol; 6: 407–413 
Azzam, R, Kedzierska, K, Leeansyah, E, et al. (2006) Impaired complement-mediated 
phagocytosis by HIV type-1-infected human monocyte-derived macrophages 
involves a cAMP-dependent mechanism, AIDS Res Hum Retroviruses 22(7):619–629 
Banchereau, J, Steinman, RM, (1998) Dendritic cells and the control of immunity, Nature 
392:245-252 
Bánki, Z*, Posch, W*, Ejaz, A, Oberhauser, V, Willey, S, Gassner, C, Stoiber, H, Dittmer, U, 
Dierich, MP, Hasenkrug, KJ, Wilflingseder, D, (2010) Complement as an 
endogenous adjuvant for dendritic cell-mediated induction of retrovirus-specific 
CTLs, PLoS Pathog. Apr 29;6(4):e1000891 *equal contribution 
Beignon, AS, McKenna, K, Skoberne, M, Manches, O, DaSilva, I, Kavanagh, DG, Larsson, M, 
Gorelick, RJ, Lifson, JD, Bhardwaj, N, (2005) Endocytosis of HIV-1 activates 
plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions, J Clin 
Invest. Nov;115(11):3265-7 
Bell, D, Young, JW, Banchereau, J, (1999) Dendritic cells, Adv. Immunol 72,255-324 
Bendelac, A, et al.,(1997) Selection and adaptation of cells expressing major 
histocompatibility complex class I-specific receptors of the natural killer complex, J 





cells during acute infection and, despite HAART, persist into the chronic phase, but the 
factors involved in these changes remain to be investigated. 
4. Conclusions 
In summary, innate immune responses contribute significantly to the first line of defense 
against invading HIV-1 particles on the one hand, but the virus has evolved different 
strategies to escape from the innate immune system on the other hand. While Langerhans 
Cells and plasmacytoid dendritic cells exert efficient antiviral actions by degrading the virus 
via Birbeck granules (LCs) or secreting high amounts of type I interferons (especially IFNα), 
interstitial dermal dendritic cells are suggested to contribute in viral transport and 
dissemination. The antiviral functions of LCs are also reversed upon co-infection with other 
STIs or microbes due to the competition of the pathogens for Langerin. The competition for 
Langerin allows attachment of HIV-1 to its main receptors, CD4 and the chemokine-co-
receptor CCR5, on LCs and thus facilitates infection of LCs and subsequent transfer to CD4+ 
T cells in the lymph nodes. This process of ‘cis’-infection of DCs, migration to the lymphatic 
tissues and transmission to CD4+ T cells is also thought to be contrived by dermal DCs. The 
virus is furthermore efficiently protected against complement-mediated lysis due to 
acquisition of regulators of complement activation during the budding process from the 
host cell (CD55, CD59) and additionally in fluid-phase (fH). Thus, most of the virus is 
opsonized with C3-fragments in vivo, which allows interaction with complement-receptor 
expressing cells at mucosal surfaces. Therefore the host immune system itself has to reverse 
the protection of the virus against complement-mediated lysis. As recently demonstrated 
(Banki/Posch et al., 2010), complement-opsonization acts as endogenous adjuvant for the 
dendritic cell-mediated induction of retrovirus-specific CTLs in vitro and in vivo, which was 
the first evidence that specific CTLs are efficiently stimulated in a complement- and DC-
dependent manner. This enhanced and efficient CTL-stimulatory capacity of DCs upon 
complement-opsonization of HIV may provide a host-cell protecting mechanism at the 
beginning of infection and understanding the exact interplay between differentially 
opsonized retroviral particles and APCs is of prime importance for DC-based vaccination 
strategies against retroviral infections. Not only benefits result from the complement 
opsonization of HIV- such complement-opsonized particles can also be ingested by CR3-
expressing macrophages and monocytes, the major reservoirs of long-term HIV-persistence 
beside latently infected CD4+ T cells. These cells facilitate HIV assembly and escape immune 
surveillance by hiding the particles from the immune system and by allowing efficient 
transfer of the particles to target cells in a delayed manner and another compartment. 
Instead of destroying the virus at the initial phases of infection, macrophages and 
monocytes seem to act as ´Trojan horse´ by actively contributing to the spread of HIV over 
long time periods. Beside LCs and pDCs, T cells, primarily located in the gastrointestinal 
mucosa, NK and NK T cells, that are activated by IFN-secreted pDCs, build an important 
first line of defense against viral, bacterial, and fungal pathogens. HIV-1 counteracts this 
innate immune barrier by changing their functions and decreasing their numbers by yet 
mainly undefined mechanisms. The HIV-mediated loss in numbers of important innate 
immune cells, such as pDCs, NK and NK T cells or T cells, is associated with a modified 
cytokine microenvironment, which may additionally account for the chronic establishment 
of HIV-infection in the host. Because it is difficult identifying infected individuals very soon 
after exposure, little is known respecting the earliest events of HIV transmission in the 
 
Innate Immune Responses in HIV-Infection 
 
115 
genital tract or rectal mucosa. Most of the findings are deriving from in vivo models of SIV 
infection (rev. in Haase, 2005) and from ex vivo models aimed to identify cells and factors 
affecting the transmission of HIV (rev. in Hladik and McElrath, 2008). Even when using 
animal models the exact process how the virus infiltrates mucosal barriers to establish a 
productive infection in the host is extremely complex to evaluate. There are multiple innate 
soluble and cellular factors acting together upon entry of HIV into the host – yet, the innate 
mechanisms and even the specific adaptive immune responses fail to restrict the replication 
of HIV in most infected individuals indicating the selection of viral mutants that are able to 
efficiently escape these early and late cellular and humoral immune responses. In the last 
years, increasing evidence suggests that especially immunologic and virologic events 
occuring during primary infection irreversibly weaken the immune system, which is not 
able to restore and gradually fails to resist viral and opportunistic infections. 
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Cys1-Cys6, Cys2-Cys5, Cys3-Cys4 (Tang et al., 1999). The -defensins are formed by the fusion 
of two truncated -defensin nonapeptides that are connected by fusion of the N- and C-
termini (Leonova et al., 2001; Tang et al., 1999; Tran et al., 2002). 
Human defensins are produced mainly by leukocytes and epithelial cells. HNPs 1-3 were 
first isolated from neutrophilic granulocytes (polymorphonucleated neutrophilic leukocytes; 
PMN), and account for 30-50% of total proteins in azurophil granules of neutrophils (Ganz 
et al., 1985). HNP4 comprising less than 2% of defensins in neutrophils has a relatively 
distinct sequence but similar structure with HNPs 1-3 (Ganz, 2003; Wilde et al., 1989). While 
neutrophils produce the highest amount of HNPs, these peptides can be found in other 
immune cells including natural killer cells, B cells,  T cells, and monocytes/macrophages, 
immature dendritic cells (Agerberth et al., 2000; Rodriguez-Garcia et al., 2007). In addition, 
cells can absorb and internalize HNPs intracellularly (Ganz, 1987; Mackewicz et al., 2003; 
Zaharatos et al., 2004), underlining the complexity in defining true HNP producing cells and 
the questions regarding the function of the up-taken defensins. HNPs have been detected in 
placenta, spleen, thymus, intestinal mucosa, saliva, and cervical mucus plugs (Agerberth et 
al., 2000; Cunliffe, 2003; Fellermann and Stange, 2001; Hein et al., 2002). HNPs can be 
released by chemokines, FC receptor cross-linking, phorbol myristate acetate (Chalifour et 
al., 2004; Ganz, 1987; Jan et al., 2006; Tanaka et al., 2003). Activation of toll-like receptors 
(TLRs) 2 and 5 by the outer membrane protein A of Klebsiella pneumoniae and flagellin of 
Escherichia coli, respectively, triggers the release of HNPs 1-3 by the CD3+CD56+ natural 
killer T cells (Chalifour et al., 2004). Additionally, direct interactions of Mycobacterium bovis 
BCG with eosinophils induces the production and release of HNPs 1-3 through TLR2 (Driss 
et al., 2008). Elevation of HNPs has been reported in the vaginal mucosa of women with N. 
gonorrhoeae (GC), T. vaginalis, or C. trachomatis (CT) (Simhan et al., 2007; Valore et al., 2006; 
Wiesenfeld et al., 2002), suggesting their role in mucosal immunity against infection in vivo 
(Heine et al., 1998; Wiesenfeld et al., 2002).  
HD5, the most abundant AMPs in the small intestine, is constitutively expressed by paneth 
cells but can be found in other tissues such as the salivary glands, the female genital tract 
and the inflamed large bowel (Cunliffe et al., 2001; Fahlgren et al., 2003; Fellermann and 
Stange, 2001; George et al., 2008; Quayle et al., 1998; Salzman et al., 2007; Svinarich et al., 
1997). Rhesus macaque, an animal model used for studying HIV pathogenesis, expresses six 
paneth cell defensins but their coding sequences are distinct from HD5 and HD6 (Tanabe et 
al., 2004). Analysis of intestinal specimens from patients with ileal Crohn’s disease (CD), a 
chronic mucosal inflammation, suggests that NOD2 and Wnt signaling transcription factor 
Tcf-4 protein may modulate the level of HD5 gene expression (Wehkamp et al., 2004) 
(Wehkamp et al., 2007). HD5 is induced at the genital mucosa in patients with bacterial 
vaginosis, GC and CT infections (Fan et al., 2008; Porter et al., 2005), although the 
mechanism remains to be defined.  
Six human -defensins (HBD1, -2, -3, -4,-5,-6) have been identified and characterized  
(Pazgier et al., 2006; Yamaguchi et al., 2002; Yang et al., 2004). Although additional human 
-defensins (Schutte et al., 2002) have been identified by gene-based searches. HBDs are 
expressed by epithelial cells and hematopeotic cells (Duits et al., 2002; Ganz, 2003; Yang et 
al., 2004). While HBD1 is often constitutively expressed, expression of HBD2 and HBD3 can 
be induced by viruses, bacteria, microbial products and pro-inflammatory cytokines, such as 
tumor-necrosis factor (TNF) and interleukin-1 (IL-1) (Duits et al., 2003; Ganz, 2003; Proud et 
al., 2004; Sorensen et al., 2005; Yang et al., 2001). HBD1, HBD2 and HBD3 have been 
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detected in various epithelial tissues (Fellermann and Stange, 2001; Garcia et al., 2001; 
Harder et al., 2001). Both human - and -defensins have been found in breast milk 
(Armogida et al., 2004; Jia et al., 2001), suggesting a role for defensins in protecting infants 
from infection.  
The mechanisms of induction of HBD1, HBD2 and HBD3 have been shown to be distinct 
from each other (Pazgier et al., 2006). HBD2 can be induced by TLR2, TLR3, TLR4, TLR7, 
NOD1 and NOD2 signaling in various epithelial cells and keratinocytes (Hertz et al., 2003; 
Nagy et al., 2005; Pivarcsi et al., 2005; Uehara et al., 2007; Vora et al., 2004). Stimulation of 
TLR3 has been shown to induce HBD1 and HBD2 expression in uterine epithelial cells 
(Schaefer et al., 2005). Induction of HBD2 and HBD3 but not HBD1 in bronchial epithelial 
cells in response to human rhinovirus infection is mediated by activation of nuclear factor-
B (NF-B)  but not of IL-1 (Proud et al., 2004). As TLR3 activation also induced HBD2 and 
HBD3, it is possible that intracellular double-stranded RNA generated during replication of 
rhinovirus may be involved in the regulation of HBDs (Duits et al., 2003; Proud et al., 2004). 
Similarly, HBD2 and HBD3 are induced in normal human oral epithelium cells, even in the 
absence of HIV-1 replication (Quinones-Mateu et al., 2003). Interestingly, a recent study 
reported that both X4- and R5-tropic viruses cannot induce HBD2 gene expression in the 
MatTeck oral tissue model nor primary gingival epithelial cells (Nittayananta et al., 2009). 
Additionally, high concentrations of X4 virus HIV-1Lai block HBD2 gene expression by 50% 
(Nittayananta et al., 2009). In oral epithelium, TLR2 and NOD1/2 ligands synergistically 
activate NF-B and induce HBD2 gene expression (Uehara and Takada, 2008). Cytokines 
such as IL-1 and IL-17 also play important roles in the regulation of HBD2 expression. 
Induction of HBD2 by IL-17A is mediated by PI3K pathway and MAPK pathway to activate 
NF-B in airway epithelial cells, whereas regulation of HBD2 by the activation of NF-B is 
not dependent on PI3K pathway in bronchial epithelial cell, (Huang et al., 2007; Jang et al., 
2007; Kao et al., 2008), indicating that specific pathways involved in regulation of HBDs are 
cell type dependent.  
2.2 Immunological and biological functions of defensins 
Defensins have a wide range of functions in modulating innate and adaptive 
immunity(Yang et al., 2004) as well as biological aspects including metabolisms and 
angiogenesis  (Coffelt and Scandurro, 2008; Joseph et al., 2008; Kruse and Kristensen, 2008; 
Liu et al., 2008; Rehaume and Hancock, 2008; Saraheimo et al., 2008). Both HNPs and HBDs 
exhibit chemotactic activity for T cells, monocytes and immature DCs and can induce 
production of cytokines and chemokines (Yang et al., 2004) (Chertov et al., 1996; Yang et al., 
2000). HNP1 also regulates the release of IL-1 and enhances phagocytosis (Shi et al., 2007; 
Tecle et al., 2007). HBDs1-3 recruit memory T cells and immature DCs through binding to 
CCR6, the receptor for the CC-chemokine ligand 20 (CCL20; also known as MIP3) (Yang et 
al., 1999; Zlotnik and Yoshie, 2000). HBD2 has multiple activities on mast cells, including 
induction of cell migration, degranulation and prostaglandin D2 production (Niyonsaba et 
al., 2003). Murine -defensin-2 can recruit bone-marrow-derived immature DCs through 
CCR6 and can induce DC maturation through TLR4 (Biragyn et al., 2002). HBD3 activate 
antigen-presenting cells such as monocytes and DCs through TLRs 1 and 2 (Funderburg et 
al., 2007). HBD3 activates antigen presenting cells (DCs and monocytes) via TLR1/2 
(Funderburg et al., 2007). Defensins are frequently induced by pro-inflammatory cytokines 
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induce cytokines and chemokines. HNPs upregulate the expression of CC-chemokines and 
IL-8 in macrophages and epithelial cells, respectively (Guo et al., 2004; Van Wetering et al., 
1997). HBD2, known to be inducible in response to bacterial infection and pro-inflammatory 
cytokines (Ganz, 2003; Yang et al., 2004) can up-regulate IL-6, IL-8, IL-10, MCP-1, IL-1, 
MIP-1 and RANTES in PBMCs (Boniotto et al., 2006). HD5 can induce IL-8 (Liu et al., 2007) 
that enhances HIV infection in cervical tissues (Narimatsu et al., 2005). 
Defensins can bind to other host proteins to modulate immune or metabolic functions 
(Rehaume and Hancock, 2008). HNPs bind to low-density lipoprotein receptor-related 
proteins and interact with protein kinase C and , leading to decreased smooth muscle 
contraction in response to phenylephrine (Nassar et al., 2002). HNPs also interact with 
adrenocorticotrophic hormone (ACTH) receptors and heparan sulfate-containing 
proteoglycan (HSPGs) to modulate other biological activities (Higazi et al., 1996; Higazi et 
al., 2000). HNP1 has been shown to inhibit the activity of conventional PKC isoforms in a 
cell-free system (Charp et al., 1988). This PKC inhibitory activity appears to be important for 
HNP1-mediated inhibition of HIV replication in primary CD4+ T cells (Chang et al., 2005). 
As defensins display various biological functions, the roles of defensins in HIV-associated 
metabolic disorders or cancers in addition to HIV transmission and pathogenesis remain to 
be investigated.  
3. Effect of defensins on HIV infection in vitro: Mechanism(s) of action  
In contrary to the traditional role of defensins to defense host against pathogens, recent 
studies indicate that specific defensins can inhibit or enhance HIV infection. With respect to 
anti-HIV activities of defensins, these peptides have a dual role in antiviral activity. One 
aspect of antiviral activities involves direct interaction with viral envelopes possibly by 
disrupting virus envelopes similar to their antibacterial activity or by preventing viral entry. 
However, in contrast to anti-bacterial activities of defensins, there is no direct evidence 
supporting that defensins directly inactivate HIV virion by membrane disruption.  The other 
involves indirect antiviral activity through interactions with potential target cells. These 
defensin–cell interactions are complex and at least in part mediated by interacting with cell 
surface glycoproteins and/or interfering with cell-signaling pathways that are required for 
viral replication. HD5 and HD6, induced in cervicovaginal epithelial cells in response to GC 
infection, enhance HIV infectivity (Klotman et al., 2008). The enhancing effect of HD5 and 
HD6 was more pronounced with R5 virus compared with X4 virus, indicating a potential 
clinical relevance as R5 virus is preferentially transmitted during primary infection. The 
specific mechanism is discussed as the following and activities of defensins and other 
antimicrobial peptides on HIV replication is summarized in Table 1. 
The in vitro functions of defensins appear to be affected by factors such as the source of 
defensins, serum and salt. Different antiviral mechanisms of defensins may be operative in 
mucosal surfaces versus blood depending on the salt concentration or the presence of 
serum. This appears to be the case with the direct antiviral effect. Serum and salt conditions 
did alter the direct effect of defensins on the virion (Daher et al., 1986), (Chang et al., 2005; 
Quinones-Mateu et al., 2003). Some defensins (e.g. HNPs but not HD5 or HD6) at high 
concentrations are known to cause cytotoxicity in the absence of serum, which is associated 
with changes in cell membrane permeability, similar to their anti-bacterial activity. This 
cytotoxicity can be abolished by the presence of serum (Okrent et al., 1990 ;Van Wetering et 
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al., 1997) and defensin-mediated cytotoxicity may partially account for the antiviral effect 
(Mackewicz et al., 2003). While most defensins display potent direct antibacterial activities 
in conditions of low salt (Lehrer et al., 1993), neither a low concentration of salt nor the 
absence of serum are required for the chemotactic effects of defensins (Chertov et al., 1996; 
Yang et al., 1999). It is not clear whether other functions of defensins are altered depending 
on the environment.  
 
 
Table 1. Effect of defensins on HIV infection 
Inhibition of HIV replication by synthetic guinea-pig, rabbit and rat -defensins was first 
reported in 1993 (Nakashima et al., 1993), when it was shown that these peptides could inhibit 
HIV-1 infection in vitro following viral entry into transformed CD4+ T cells in the presence of 
serum (Nakashima et al., 1993). HNPs1-3 block HIV infection through multiple mechanisms 
(Furci et al., 2007; Zhang et al., 2002) (Chang et al., 2003; Mackewicz et al., 2003). HNPs1 -3 all 
have similar activities against HIV primary isolates (Wu et al., 2005), in contrast to their 
differential chemotactic activities on monocytes, where HNP3 has no effect (Territo et al., 
1989). They can inhibit HIV-1 replication by a direct interaction with the virus as well by 
affecting multiple steps of HIV life cycle (Chang et al., 2003; Chang et al., 2005; Furci et al., 





induce cytokines and chemokines. HNPs upregulate the expression of CC-chemokines and 
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Quinones-Mateu et al., 2003). Some defensins (e.g. HNPs but not HD5 or HD6) at high 
concentrations are known to cause cytotoxicity in the absence of serum, which is associated 
with changes in cell membrane permeability, similar to their anti-bacterial activity. This 
cytotoxicity can be abolished by the presence of serum (Okrent et al., 1990 ;Van Wetering et 
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al., 1997) and defensin-mediated cytotoxicity may partially account for the antiviral effect 
(Mackewicz et al., 2003). While most defensins display potent direct antibacterial activities 
in conditions of low salt (Lehrer et al., 1993), neither a low concentration of salt nor the 
absence of serum are required for the chemotactic effects of defensins (Chertov et al., 1996; 
Yang et al., 1999). It is not clear whether other functions of defensins are altered depending 
on the environment.  
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Inhibition of HIV replication by synthetic guinea-pig, rabbit and rat -defensins was first 
reported in 1993 (Nakashima et al., 1993), when it was shown that these peptides could inhibit 
HIV-1 infection in vitro following viral entry into transformed CD4+ T cells in the presence of 
serum (Nakashima et al., 1993). HNPs1-3 block HIV infection through multiple mechanisms 
(Furci et al., 2007; Zhang et al., 2002) (Chang et al., 2003; Mackewicz et al., 2003). HNPs1 -3 all 
have similar activities against HIV primary isolates (Wu et al., 2005), in contrast to their 
differential chemotactic activities on monocytes, where HNP3 has no effect (Territo et al., 
1989). They can inhibit HIV-1 replication by a direct interaction with the virus as well by 
affecting multiple steps of HIV life cycle (Chang et al., 2003; Chang et al., 2005; Furci et al., 





effect on the virus prior to infection of a cell (Chang et al., 2005). In the presence of serum and 
at non-cytotoxic concentrations (low dose), HNP1 acts on primary CD4+ T cells and blocks 
HIV-1 infection at the steps of nuclear import and transcription by interfering with PKC 
signaling (Chang et al., 2005). The post-entry inhibitory effect of HIV infection occurs in 
primary CD4+ T cells and macrophages but not in several transformed T-cell lines (Chang et 
al., 2003; Chang et al., 2005). In the presence of serum, HNP1 did not affect expression of cell-
surface CD4 and HIV-coreceptors on primary CD4+ T cells (Chang et al., 2005), whereas HNP2 
down-regulates CD4 expression  in the absence of serum (Furci et al., 2007). HNPs block HIV-
mediated cell-cell fusion and the early steps of HIV infection by interacting with HIVgp120 
and CD4 through their lectin-like properties (Furci et al., 2007). In macrophages, HNP1 and 
HNP2 upregulate the expression of CC-chemokines, which could contribute to inhibition of 
HIV through competition for receptors (Guo et al., 2004). CC-chemokines can also induce the 
release of HNPs from neutrophils by degranulation (Jan et al., 2006). Both effects could play a 
role in vivo in an innate immune response to HIV. At the mucosal surface, HNPs might work 
to directly inactivate the virions in the absence of serum; however, in the presence of serum, 
their inhibitory effect would largely be on the infected cell. HNPs1-3 have been reported to act 
as lectins and bind to HIV envelope glycoprotein gp120 and to CD4 with high affinity (Wang 
et al., 2004). The binding to gp120 is strongly attenuated by serum, thus accounting for the loss 
of the direct virion effect in the presence of serum. Interestingly, in contrast to HNPs1-3, HNP4 
acts in a lectin-independent manner and does not bind to CD4 or HIV gp120 (Wang et al., 
2004; Wu et al., 2005). However, HNP4 inhibits HIV replication more effectively than HNP1, -2 
and -3 (Wu et al., 2005).  
Other -defensins, including HD5 and HD6, mouse paneth cell cryptdin-3 and cryptdin-4, 
and rhesus macaque myeloid -defensin-3 (RMAD3) and RMAD4 have been tested for their 
ability to block HIV infection (Klotman et al., 2008; Tanabe et al., 2004). While HD5 did not 
exhibit any effect on X4 HIV-1LAI infection of transformed CD4+ T cell lines (Tanabe et al., 
2004), HD5 and HD6 significantly enhanced infectivity of HIV-1 R5 strains (Klotman et al., 
2008). At high concentrations associated with cytotoxicity, RMAD4 blocks HIV replication, 
whereas, cryptdin-3 enhances viral replication. Studies on the molecular mechanism of the 
HIV enhancing effect of HD5 and HD6 indicate that defensins enhance HIV infection 
through promoting HIV attachment (Rapista et al., 2011). In addition, HD5 but not HD6 
competes with heparan for binding to HIV. Importantly, these defensins have been shown 
to block in vitro anti-HIV activity of polyanionic microbicides, which have failed to protect 
women against HIV infection, and to interfere with anti-HIV activity of HIV entry and 
fusion inhibitors under specific conditions (Ding et al., 2011; Rapista et al., 2011).   
The anti-HIV activities of HBD2 and HBD3 have been demonstrated under different 
conditions (Quinones-Mateu et al., 2003; Sun et al., 2005). Similar to HNP1 (Chang et al., 
2005), HBD2 and HBD3 have dual anti-HIV activities through direct interactions with the 
virus and by altering the target cell. The binding of defensins to cellular membranes and 
HIV virions has been demonstrated by electron microscopy, although membrane disruption 
is not apparent (Quinones-Mateu et al., 2003). HBD2 does not affect viral fusion but inhibits 
the formation of early reverse transcribed HIV DNA products (Sun et al., 2005). There are 
conflicting reports on the downregulation of expression of HIV co-receptors by -defensins. 
In studies reported by Sun et al. (Sun et al., 2005), HBD1 and HBD2 did not modulate cell-
surface HIV co-receptor expression by primary CD4+ T cells, whereas Quinones-Mateu et al. 
(Quinones-Mateu et al., 2003) showed HBD2- and HBD3-mediated downregulation of 
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surface CXCR4 but not CCR5 expression by peripheral blood mononuclear cells (PBMCs) at 
high salt conditions and in the absence of serum. Interestingly, HBD2 is constitutively 
expressed in healthy adult oral mucosa but the level seems to be diminished in HIV-infected 
individuals (Sun et al., 2005). 
Retrocyclins, and RTD1, -2 and -3 act as lectins and can inhibit HIV entry (Cole et al., 2002; 
Munk et al., 2003; Wang et al., 2003; Wang et al., 2004). Retrocyclin and RTD1,-2 and -3 
inhibit several HIV-1 X4 and R5 viruses including primary isolates (Munk et al., 2003; Wang 
et al., 2003; Wang et al., 2004).  Unlike - and -defensins, retrocyclin does not appear to 
directly inactivate the HIV virion although it is not clear whether the experiments reported 
to date were performed under serum-free condition (Cole et al., 2002). Retrocyclin does 
however bind to HIV gp120 as well as CD4 with high affinity, which is consistent with 
inhibition of viral entry (Cole et al., 2002),(Munk et al., 2003). This high-binding affinity to 
glycosylated gp120 and CD4 is mediated through interactions with their O-linked and N-
linked sugars (Wang et al., 1998). Serum strongly reduces their binding to gp120 (Wang et 
al., 2004). RTD1 binds directly to the C-terminal heptad repeat of HIV envelope protein 
gp41, blocking formation of the six helix bundle required for fusion (Gallo et al., 2006). 
Recently, high concentrations of RTD1 and HNP1 have been shown to down-regulate 
CXCR4 in PBMCs in the absence of serum (Nittayananta et al., 2009). Studies on retrocyclin-
1 analogues indicate that modification of this peptide can enhance its potency against HIV in 
vitro (Owen et al., 2004), suggesting their potential use as a microbicide.  
4. Role of Defensins in HIV pathogenesis and transmission 
Depending on the preparation of samples and analytical methods, the levels of defensins 
can be varied from one report to another. In addition, defensins have been found to interact 
with other cellular proteins in plasma (Higazi et al., 1996; Panyutich and Ganz, 1991; 
Panyutich et al., 1994), which may affect the measurement of defenisn levels by ELISA. In 
healthy donors, the plasma concentration of HNPs1-3 is ranging from ~150-500 ng/ml 
(Mukae et al., 2002). The levels of defensins in the plasma or at the mucosa are frequently 
elevated in patients with infections or diseases (Coffelt and Scandurro, 2008; Ihi et al., 1997). 
For examples, defensin levels in plasma from patients with sepsis reach 900-170,000 ng/ml 
(Panyutich et al., 1993).  Using liquid chromatography-tandem mass spectrometry, the levels 
of HNPs in the saliva from healthy donors range from 1 to 10 ug/ml, whereas the level of 
HBDs 1-2 range from undetectable to 33 ng/ml (Gardner et al., 2009). The level of HNPs in 
cervicovaginal fluid from healthy women ranges from 250 ng/ml to 5 g/ml depending on 
the laboratories (Levinson et al., 2009; Simhan et al., 2007). 
HNPs1-3 The role of HNPs in HIV pathogenesis was first suggested that HNPs 1-3 were to 
account for the soluble anti-HIV activity of CD8+ T cells (CAF) isolated from patients 
infected with HIV but remaining free of AIDS for a prolonged period (long-term 
nonprogressors, LTNPs) (Zhang et al., 2002). These peptides were detected in the media of 
stimulated CD8+ T cells from normal healthy controls and LTNPs but not from HIV 
progressors. Subsequent studies on the cell source of defensins revealed that HNPs were 
probably produced by co-cultured monocytes and residual granulocytes of allogenic normal 
donor irradiated PBMCs that were used as feeder cells, but they were not produced by the 
CD8+ T cells themselves (Mackewicz et al., 2003; Zaharatos et al., 2004). Using similar co-
culture systems, levels of HNPs1-3 were measured in CD8+ T-cell supernatants and cervical-





effect on the virus prior to infection of a cell (Chang et al., 2005). In the presence of serum and 
at non-cytotoxic concentrations (low dose), HNP1 acts on primary CD4+ T cells and blocks 
HIV-1 infection at the steps of nuclear import and transcription by interfering with PKC 
signaling (Chang et al., 2005). The post-entry inhibitory effect of HIV infection occurs in 
primary CD4+ T cells and macrophages but not in several transformed T-cell lines (Chang et 
al., 2003; Chang et al., 2005). In the presence of serum, HNP1 did not affect expression of cell-
surface CD4 and HIV-coreceptors on primary CD4+ T cells (Chang et al., 2005), whereas HNP2 
down-regulates CD4 expression  in the absence of serum (Furci et al., 2007). HNPs block HIV-
mediated cell-cell fusion and the early steps of HIV infection by interacting with HIVgp120 
and CD4 through their lectin-like properties (Furci et al., 2007). In macrophages, HNP1 and 
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to directly inactivate the virions in the absence of serum; however, in the presence of serum, 
their inhibitory effect would largely be on the infected cell. HNPs1-3 have been reported to act 
as lectins and bind to HIV envelope glycoprotein gp120 and to CD4 with high affinity (Wang 
et al., 2004). The binding to gp120 is strongly attenuated by serum, thus accounting for the loss 
of the direct virion effect in the presence of serum. Interestingly, in contrast to HNPs1-3, HNP4 
acts in a lectin-independent manner and does not bind to CD4 or HIV gp120 (Wang et al., 
2004; Wu et al., 2005). However, HNP4 inhibits HIV replication more effectively than HNP1, -2 
and -3 (Wu et al., 2005).  
Other -defensins, including HD5 and HD6, mouse paneth cell cryptdin-3 and cryptdin-4, 
and rhesus macaque myeloid -defensin-3 (RMAD3) and RMAD4 have been tested for their 
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2008). At high concentrations associated with cytotoxicity, RMAD4 blocks HIV replication, 
whereas, cryptdin-3 enhances viral replication. Studies on the molecular mechanism of the 
HIV enhancing effect of HD5 and HD6 indicate that defensins enhance HIV infection 
through promoting HIV attachment (Rapista et al., 2011). In addition, HD5 but not HD6 
competes with heparan for binding to HIV. Importantly, these defensins have been shown 
to block in vitro anti-HIV activity of polyanionic microbicides, which have failed to protect 
women against HIV infection, and to interfere with anti-HIV activity of HIV entry and 
fusion inhibitors under specific conditions (Ding et al., 2011; Rapista et al., 2011).   
The anti-HIV activities of HBD2 and HBD3 have been demonstrated under different 
conditions (Quinones-Mateu et al., 2003; Sun et al., 2005). Similar to HNP1 (Chang et al., 
2005), HBD2 and HBD3 have dual anti-HIV activities through direct interactions with the 
virus and by altering the target cell. The binding of defensins to cellular membranes and 
HIV virions has been demonstrated by electron microscopy, although membrane disruption 
is not apparent (Quinones-Mateu et al., 2003). HBD2 does not affect viral fusion but inhibits 
the formation of early reverse transcribed HIV DNA products (Sun et al., 2005). There are 
conflicting reports on the downregulation of expression of HIV co-receptors by -defensins. 
In studies reported by Sun et al. (Sun et al., 2005), HBD1 and HBD2 did not modulate cell-
surface HIV co-receptor expression by primary CD4+ T cells, whereas Quinones-Mateu et al. 
(Quinones-Mateu et al., 2003) showed HBD2- and HBD3-mediated downregulation of 
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surface CXCR4 but not CCR5 expression by peripheral blood mononuclear cells (PBMCs) at 
high salt conditions and in the absence of serum. Interestingly, HBD2 is constitutively 
expressed in healthy adult oral mucosa but the level seems to be diminished in HIV-infected 
individuals (Sun et al., 2005). 
Retrocyclins, and RTD1, -2 and -3 act as lectins and can inhibit HIV entry (Cole et al., 2002; 
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Recently, high concentrations of RTD1 and HNP1 have been shown to down-regulate 
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1 analogues indicate that modification of this peptide can enhance its potency against HIV in 
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For examples, defensin levels in plasma from patients with sepsis reach 900-170,000 ng/ml 
(Panyutich et al., 1993).  Using liquid chromatography-tandem mass spectrometry, the levels 
of HNPs in the saliva from healthy donors range from 1 to 10 ug/ml, whereas the level of 
HBDs 1-2 range from undetectable to 33 ng/ml (Gardner et al., 2009). The level of HNPs in 
cervicovaginal fluid from healthy women ranges from 250 ng/ml to 5 g/ml depending on 
the laboratories (Levinson et al., 2009; Simhan et al., 2007). 
HNPs1-3 The role of HNPs in HIV pathogenesis was first suggested that HNPs 1-3 were to 
account for the soluble anti-HIV activity of CD8+ T cells (CAF) isolated from patients 
infected with HIV but remaining free of AIDS for a prolonged period (long-term 
nonprogressors, LTNPs) (Zhang et al., 2002). These peptides were detected in the media of 
stimulated CD8+ T cells from normal healthy controls and LTNPs but not from HIV 
progressors. Subsequent studies on the cell source of defensins revealed that HNPs were 
probably produced by co-cultured monocytes and residual granulocytes of allogenic normal 
donor irradiated PBMCs that were used as feeder cells, but they were not produced by the 
CD8+ T cells themselves (Mackewicz et al., 2003; Zaharatos et al., 2004). Using similar co-
culture systems, levels of HNPs1-3 were measured in CD8+ T-cell supernatants and cervical-





infected patients, and normal controls (Trabattoni et al., 2004). Higher levels of HNPs were 
found in CD8+ T cells from HIV-exposed seronegative individuals and HIV patients 
compared to normal controls.  
D’Agostino et al. recently found that HIV-infected patients have a higher level of HNPs in 
plasma than healthy donors (D'Agostino et al., 2009). Using a co-culture system with 
radiated PBMCs, higher levels of HNPs in CD8+ T cells were found in patients with HIV 
infection compared to the healthy donors, and the intracellular HNP levels were further 
increased in stimulated CD8+ T cells. The intracellular level of HNPs in neutrophils is 
higher in HIV-infected patients than healthy donors. There is no significant difference in the 
plasma level of HNPs in HIV-infected patients with or without antiviral treatment (ART). 
However, reduction of HNPs in CD8+ T cell was found in HIV-infected patients on ART. 
Interestingly, this reduction in the HNP level was not found in HIV-infected patients on 
ART with virologic failure. In contrast to the report by D’Agostino et al.,  Rodriguez-Garcia 
et al. did not observe any association between plasma levels of HNPs and immunologic or 
virolgoic parameters (Rodriguez-Garcia et al., 2010). This report also described an increase 
in HNPs1-3 in dendritic cells, differentiated in vitro, in HIV controllers but not non-
controllers compared to healthy controls. While it was suggested that increased HNPs1-3 
production by dendritic cells in HIV-infected patients is associated with slower disease 
progression, analysis of specific immune cell subsets without further manipulation is 
needed to clarify the role of HNPs in HIV disease progression. 
The association between production of HNPs1-3 in breast milk and transmission of HIV has 
also been investigated (Kuhn et al., 2005). In a case-controlled study of HIV-positive women, 
levels of HNPs in breast milk correlated with HIV RNA copy number in breast milk, which 
was a strong predictor of transmission. However, after adjusting for breast milk HIV copy 
number, higher levels of HNPs in breast milk were associated with a decreased incidence of 
intrapartum or postnatal HIV transmission. Bosire and colleagues performed similar studies 
to determine the correlation between the level of HNPs in breast milk and transmission risk 
in a cohort of 260 HIV-1-infected pregnant women in Nairobi followed for 12 months 
postpartum with their infants (Bosire et al., 2007). Analysis of breast milk from these women 
at month 1 postpartum demonstrated that women with detectable alpha-defensins and 
significantly higher mean breast milk HIV-1 RNA levels than women with undetectable 
alpha-defensins. Increased alpha-defensins concentrations in breast milk were also 
associated with subclinical mastitis and increased CC-chemokines in breast milk. 
Interestingly, in contrast to the report by Kuhn et al. (Kuhn et al., 2005), the level of 
defensins are not associated with vertical transmission, indicating a complex interplay 
between innate effectors, inflammation and HIV transmission. 
There is a correlation between the abundance of several anti-HIV proteins, including 
HNPs1-3 and cell-associated HIV replication in lymphoid follicles compared with 
extrafollicular lymphoid tissue (Folkvord et al., 2005). Expression of these antiviral proteins 
is significantly lower in the follicular region, where HIV replication is concentrated, 
compared with the extrafollicular regions in lymph nodes from HIV-positive individuals.  
Cationic peptides including defensins are required for anti-HIV activity of vaginal fluid 
from healthy women (Venkataraman et al., 2005). While it is well established that sexual 
transmitted infections (STIs) significantly increase the likelihood of HIV transmission 
(Chesson and Pinkerton, 2000; Cohen et al., 1997; Galvin and Cohen, 2004; Mabey, 2000; 
Plummer, 1998) and that levels of defensins including HNPs, HBDs and HD5 in genital 
fluid, are elevated in patients with STIs (Porter et al., 2005; Simhan et al., 2007; Valore et al., 
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2006; Wiesenfeld et al., 2002), the role of defensins in HIV transmission seems to be complex. 
Studies using a cohort of HIV uninfected sex workers in Kenyan demonstrated the 
association between an increase in HNPs and LL-37 levels in the IgA-depleted 
cervicovaginal secretions from women with bacterial STIs and increase in HIV acquisition, 
despite that cervicovaginal secretions with high levels of HNPs and LL-37 exhibited anti-
HIV activity in vitro (Levinson et al., 2009). This study underscores the complex role of 
defensins in HIV transmission at the vaginal mucosa and the urgent need to define the effect 
of elevated innate effectors on immune responses that contribute to enhanced HIV 
acquisition.  
HBDs Significant correlations between the single-nucleotide polymorphism (SNPs) -44C/G 
and -20G/A in 5’ untranslated region of DEFB1 (coding for HBD1) and a risk of perinatal 
transmission of HIV-1 in Italian and Brazilian populations, respectively (Braida et al., 2004; 
Milanese et al., 2006). The SNP -52G/G genotype is associated with reduced HIV-1 RNA in 
breast milk, but not in plasma in Mozabican HIV-infected women (Baroncelli et al., 2008). 
Interestingly, the functional analysis of promoter indicates that these SNPs suppress 
expression (Milanese et al., 2007). Studies on the role of HBD1 in mother-to-child 
transmission of HIV indicated that the -52G/G genotype and the -44/-52G haplotype 
exhibited a protective role against HIV infection in children, whereas the -52G/G genotype 
and the -44G/-52G haplotype were associated with low levels of HIV plasma viremia and a 
lower risk of maternal HIV transmission in mothers (Ricci et al., 2009). Although HBD1 does 
not exhibit any effect on HIV infection in vitro, the presence of SNP may affect HIV 
transmission by modulating immune response.  
The role of defensins in protection against HIV infection has been studied in HIV-exposed 
seronegative (ESN) individuals. ESN expressed significantly greater mRNA copy numbers 
of HBD2 and 3 in oral mucosa than healthy controls, while no difference in mRNA copy 
numbers of HBD-1, 2 and 3 in vaginal and endocervical mucosa was observed between ESN 
and controls (Zapata et al., 2008). In addition, homozygosity for the A692G polymorphism is 
significantly more frequent in ESN than in seropositive individuals (Zapata et al., 2008). 
Sequence analysis of -defensin pseudogenes  in ESN female sex-workers from Thailand 
revealed that all subjects had premature stop codons (Yang et al., 2005). Therefore, 
restoration of endogenous -defensin production does not account for the resistance to HIV-
1 infection in these women. 
5. Conclusion  
Defensins play an important role in innate immune response. These peptides display 
versatile functions in modulating various immunological and biological aspects. Aberrant 
defensin expression has been associated with many human diseases (de Leeuw and Lu, 
2007), although studies on the role of defensins in HIV pathogenesis and transmission in 
humans just began to reveal the complex functions of defensins in modulating HIV 
infection. While the innate immune system is evolutionarily conserved among multicellular 
organisms, it is challenging to find a suitable animal model to study the role of defensins in 
HIV pathogenesis and transmission due to complex diversity of defensins in mammals as 
well as apparent differences in mechanisms of action.  Recently, increased expression of 
rhesus enteric a-defensins (REDs) in response to SIV infection was reported (Zaragoza et al., 
2011). Additionally, decreased RED protein levels correlate with enteric opportunistic 
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radiated PBMCs, higher levels of HNPs in CD8+ T cells were found in patients with HIV 
infection compared to the healthy donors, and the intracellular HNP levels were further 
increased in stimulated CD8+ T cells. The intracellular level of HNPs in neutrophils is 
higher in HIV-infected patients than healthy donors. There is no significant difference in the 
plasma level of HNPs in HIV-infected patients with or without antiviral treatment (ART). 
However, reduction of HNPs in CD8+ T cell was found in HIV-infected patients on ART. 
Interestingly, this reduction in the HNP level was not found in HIV-infected patients on 
ART with virologic failure. In contrast to the report by D’Agostino et al.,  Rodriguez-Garcia 
et al. did not observe any association between plasma levels of HNPs and immunologic or 
virolgoic parameters (Rodriguez-Garcia et al., 2010). This report also described an increase 
in HNPs1-3 in dendritic cells, differentiated in vitro, in HIV controllers but not non-
controllers compared to healthy controls. While it was suggested that increased HNPs1-3 
production by dendritic cells in HIV-infected patients is associated with slower disease 
progression, analysis of specific immune cell subsets without further manipulation is 
needed to clarify the role of HNPs in HIV disease progression. 
The association between production of HNPs1-3 in breast milk and transmission of HIV has 
also been investigated (Kuhn et al., 2005). In a case-controlled study of HIV-positive women, 
levels of HNPs in breast milk correlated with HIV RNA copy number in breast milk, which 
was a strong predictor of transmission. However, after adjusting for breast milk HIV copy 
number, higher levels of HNPs in breast milk were associated with a decreased incidence of 
intrapartum or postnatal HIV transmission. Bosire and colleagues performed similar studies 
to determine the correlation between the level of HNPs in breast milk and transmission risk 
in a cohort of 260 HIV-1-infected pregnant women in Nairobi followed for 12 months 
postpartum with their infants (Bosire et al., 2007). Analysis of breast milk from these women 
at month 1 postpartum demonstrated that women with detectable alpha-defensins and 
significantly higher mean breast milk HIV-1 RNA levels than women with undetectable 
alpha-defensins. Increased alpha-defensins concentrations in breast milk were also 
associated with subclinical mastitis and increased CC-chemokines in breast milk. 
Interestingly, in contrast to the report by Kuhn et al. (Kuhn et al., 2005), the level of 
defensins are not associated with vertical transmission, indicating a complex interplay 
between innate effectors, inflammation and HIV transmission. 
There is a correlation between the abundance of several anti-HIV proteins, including 
HNPs1-3 and cell-associated HIV replication in lymphoid follicles compared with 
extrafollicular lymphoid tissue (Folkvord et al., 2005). Expression of these antiviral proteins 
is significantly lower in the follicular region, where HIV replication is concentrated, 
compared with the extrafollicular regions in lymph nodes from HIV-positive individuals.  
Cationic peptides including defensins are required for anti-HIV activity of vaginal fluid 
from healthy women (Venkataraman et al., 2005). While it is well established that sexual 
transmitted infections (STIs) significantly increase the likelihood of HIV transmission 
(Chesson and Pinkerton, 2000; Cohen et al., 1997; Galvin and Cohen, 2004; Mabey, 2000; 
Plummer, 1998) and that levels of defensins including HNPs, HBDs and HD5 in genital 
fluid, are elevated in patients with STIs (Porter et al., 2005; Simhan et al., 2007; Valore et al., 
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2006; Wiesenfeld et al., 2002), the role of defensins in HIV transmission seems to be complex. 
Studies using a cohort of HIV uninfected sex workers in Kenyan demonstrated the 
association between an increase in HNPs and LL-37 levels in the IgA-depleted 
cervicovaginal secretions from women with bacterial STIs and increase in HIV acquisition, 
despite that cervicovaginal secretions with high levels of HNPs and LL-37 exhibited anti-
HIV activity in vitro (Levinson et al., 2009). This study underscores the complex role of 
defensins in HIV transmission at the vaginal mucosa and the urgent need to define the effect 
of elevated innate effectors on immune responses that contribute to enhanced HIV 
acquisition.  
HBDs Significant correlations between the single-nucleotide polymorphism (SNPs) -44C/G 
and -20G/A in 5’ untranslated region of DEFB1 (coding for HBD1) and a risk of perinatal 
transmission of HIV-1 in Italian and Brazilian populations, respectively (Braida et al., 2004; 
Milanese et al., 2006). The SNP -52G/G genotype is associated with reduced HIV-1 RNA in 
breast milk, but not in plasma in Mozabican HIV-infected women (Baroncelli et al., 2008). 
Interestingly, the functional analysis of promoter indicates that these SNPs suppress 
expression (Milanese et al., 2007). Studies on the role of HBD1 in mother-to-child 
transmission of HIV indicated that the -52G/G genotype and the -44/-52G haplotype 
exhibited a protective role against HIV infection in children, whereas the -52G/G genotype 
and the -44G/-52G haplotype were associated with low levels of HIV plasma viremia and a 
lower risk of maternal HIV transmission in mothers (Ricci et al., 2009). Although HBD1 does 
not exhibit any effect on HIV infection in vitro, the presence of SNP may affect HIV 
transmission by modulating immune response.  
The role of defensins in protection against HIV infection has been studied in HIV-exposed 
seronegative (ESN) individuals. ESN expressed significantly greater mRNA copy numbers 
of HBD2 and 3 in oral mucosa than healthy controls, while no difference in mRNA copy 
numbers of HBD-1, 2 and 3 in vaginal and endocervical mucosa was observed between ESN 
and controls (Zapata et al., 2008). In addition, homozygosity for the A692G polymorphism is 
significantly more frequent in ESN than in seropositive individuals (Zapata et al., 2008). 
Sequence analysis of -defensin pseudogenes  in ESN female sex-workers from Thailand 
revealed that all subjects had premature stop codons (Yang et al., 2005). Therefore, 
restoration of endogenous -defensin production does not account for the resistance to HIV-
1 infection in these women. 
5. Conclusion  
Defensins play an important role in innate immune response. These peptides display 
versatile functions in modulating various immunological and biological aspects. Aberrant 
defensin expression has been associated with many human diseases (de Leeuw and Lu, 
2007), although studies on the role of defensins in HIV pathogenesis and transmission in 
humans just began to reveal the complex functions of defensins in modulating HIV 
infection. While the innate immune system is evolutionarily conserved among multicellular 
organisms, it is challenging to find a suitable animal model to study the role of defensins in 
HIV pathogenesis and transmission due to complex diversity of defensins in mammals as 
well as apparent differences in mechanisms of action.  Recently, increased expression of 
rhesus enteric a-defensins (REDs) in response to SIV infection was reported (Zaragoza et al., 
2011). Additionally, decreased RED protein levels correlate with enteric opportunistic 





differ and it is not clear whether REDs could represent HD5. Future studies focusing on the 
development of a better animal model for studying innate immunity in HIV transmission 
and pathogenesis as well as careful assessments of immune responses in patients with 
reduced or elevated levels of defensins will shed light on the development of better 
strategies for HIV therapeutics.  
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HIV infection is associated with a progressive loss of CD4+ T cells, leading to an acquired 
immunodeficiency syndrome (AIDS). The CD4+ T-cell depletion is due to the direct 
destruction of infected CD4+ T cells, as well as to an impaired production of T cells in the 
thymus. Our understanding of the exact role of the thymus in HIV-1 infection and HIV-1 
pathogenesis remains incomplete, although substantial progress has been made over the last 
decade. De Novo generation of naïve human T cells occurs in the thymus, seeded with 
CD34+ progenitor cells, migrating from the bone marrow. These progenitor cells 
sequentially undergo a process of tightly controlled differentiation, including the 
rearrangement of T cell receptor genes, ultimately leading to the generation of functionally 
mature CD4+ and CD8+ single-positive (SP) T cells. Much has been learned of the types of 
cells in the thymus that are targets for CXCR4-tropic and CCR5-tropic HIV-1 isolates. 
Several groups provided evidence that HIV can infect thymocytes at various developmental 
stages. In addition, HIV activates the natural type-I-interferon (IFN)-producing 
plasmacytoid dendritic cells (pDC) that may induce bystander effects resulting in chronic 
immune activation. Evidence is also mounting that HIV induces abnormal development of 
regulatory T (Treg) cells in the thymus, either by direct infection or by enhancement of their 
survival and function, mediated by host-derived pro-inflammatory molecules. Collectively, 
these events compromise thymic function resulting in a decreased thymic output and a 
general decline in peripheral CD4+ T-cell numbers. Here we aim to discuss the cellular 
targets for CCR5-tropic and CXCR4-tropic HIV-1 isolates in the thymus, and how virus 
tropism relates to architectural differences observed in the HIV-infected thymus. In 
addition, we will discuss the role of pDC and Treg in HIV pathogenicity, and the impact of 
type I IFN on T cell regeneration. Finally, we will review the present status on the use of 
humanized mouse and non-human primate models to study HIV-1 infection of the thymus. 
2. Thymic seeding progenitor cells 
T cells uniquely complete their development in the specialized environment of the thymus, 
which in addition to TCR T cells also supports development of functionally different 
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types of T cells, including TCR T cells, NKT cells, and regulatory T cells. The human 
thymus is seeded by hematopoietic progenitor cells that arrive via the blood and initially 
originate from the fetal liver (between week 6-20 of gestation) and later from the fetal bone 
marrow (from week 20 of gestation) and adult bone marrow. Our current understanding is 
that the thymus remains active through an advanced age, suggesting that thymic seeding 
progenitor cells (TSPs) should be present in adult blood. It is well established that all 
hematopoietic precursors in humans are present within a population of cells that express 
CD34 (Payne & Crooks, 2002), and this marker is useful in elucidating pathways in the 
development of particular hematopoietic lineages. In umbilical cord blood (UCB), 
CD34+CD45RA+CD7+ cells are found to have T, B, and NK and some granulocyte-
macrophage (GM) precursor activities (Haddad et al., 2004; Hao et al., 2001). Phenotypically 
these cells resemble the CD34+CD38low Early Thymic Progenitor cells (ETP), which are 
present within the thymus and have T cell, NK cell, and Dendritic Cell (DC) precursor 
activities (Res et al., 1996). The ETP have not yet undergone T cell receptor (TCR) gene 
rearrangements confirming that they form the most immature population in the thymus 
(Dik et al., 2005). This, together with the observation that ETP co-express CD10, makes it 
tempting to speculate that they are the direct progeny of the 
CD34+CD45RA+CD7+CD10+CD38low UCB cells (Hao et al., 2001). In addition, the notion that 
the human thymus harbors multipotential precursors indicates that T cell commitment takes 
place within this organ (Bhandoola et al., 2003). While these results are in line with data 
obtained in the mouse, more recent studies suggested that the murine thymus can be seeded 
not only by multipotent precursors, but also by precursor cells that are lineage restricted 
(Petrie & Kincade, 2005; Porritt et al., 2004). If that would be the case in humans, such 
lineage restricted cells should be present in UCB, but conflicting results were reported on 
this issue. One study failed to find evidence for the presence of TCR rearrangements in UCB 
CD34+ cells (Blom et al., 1997), but another study reported the presence of complete TCRδ 
and partial TCRβ (Dβ-Jβ) rearrangements in CD34+CD7+ cord blood precursors (Ktorza et 
al., 1996). It is obvious that re-analysis preferentially by single-cell PCR analysis of the 
recently identified rare CD34+CD45RA+CD7+ UCB population is required to solve this issue 
(Haddad et al., 2004; Hao et al., 2001). T cell–restricted precursors were convincingly 
identified in human bone marrow (Klein et al., 2003a), but whether these cells can migrate to 
the thymus is unclear. In the mouse it was demonstrated that for the proper seeding of 
progenitor cells into the thymus the collective action of the chemokine receptors CCR7 and 
CCR9 is required (Zlotoff et al., 2010). The role of these chemokine receptors to direct 
human progenitor cells into the thymus has not been established. In summary, at least a 
proportion of the precursors that seed the human thymus are multipotent. It remains elusive 
whether or not some of the precursors that migrate into the thymus are lineage restricted 
before entrance, and which signals control their thymic seeding. 
3. Cellular stages in the development of early thymic progenitor cells into 
mature T Cells 
In the thymus different regions can be distinguished, including the cortex and the medulla 
(Figure 1). The early steps in T cell development are induced in the cortex, which is 
characterized by a high cell density resulting from a high degree of proliferating immature 
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thymocytes. In addition, an area of low cell density can be observed, which is known as the 
medulla. Based on phenotype and status of the TCR gene rearrangements we have gained 
significant insight in the various transitional stages of T cell development in the human 
thymus (Figure 2) (Spits et al., 1998; Spits, 2002). The ETP, lacking TCR rearrangements, are 
enclosed within a population of cells that express CD34, but lack CD1a expression. The 
downstream CD34+CD1a+ population is committed to the T cell lineage because they are 
unable to develop into non-T cells (Dalloul et al., 1999; Galy et al., 1993; Res & Spits, 1999; 
Spits et al., 1998). The cells that subsequently upregulate CD4 and downregulate CD34 are 
generally referred to as CD4 immature single-positive (CD4 ISP) (Hori et al., 1991). 
Downstream of the CD4 ISP subset are CD4+CD8+− (early double-positive) and 
CD4+CD8++ populations (Galy et al., 1993; Hori et al., 1991), which are the precursors of 
double-positive (DP) TCR+ cells. During the early stages in T cell development, the TCR 
loci undergo sequential rearrangements in the order of TCR >  > β >  (Blom et al., 1999; 
Dik et al., 2005; Verschuren et al., 1998). Depending on differences in the sensitivity of the 
assay used to measure TCR rearrangements productive TCRβ V-DJ rearrangements were 
either found in the CD34+CD1a+ cells (Dik et al., 2005) or in the CD4 ISP cells (Blom et al., 
1999). It cannot be excluded, however, that a small contamination in the sorted CD34+CD1a+ 
cells in combination with a highly sensitive PCR detection assay was responsible for the 
positive signal (Dik et al., 2005). Only productive, in-frame TCRβ rearrangements result in 
the production of a TCRβ protein, which together with the CD3 subunits and the invariable 
pre-TCR- (pT) chain ensures cell surface expression of a pre-TCR. At this stage a process 
referred to as β-selection occurs in distinct populations of cells that differ in CD4 and CD8 
expression. Both CD4 ISP and CD4+CD8α+β− early double-positive subsets were found to 
contain intracytoplasmic (ic) TCRβ− and icTCR+ cells (Blom et al., 1999; Carrasco et al., 
1999). Ten to twenty percent of the CD4 ISP are icTCRβ+, and in contrast to the TCRβ− CD4 
ISP, these icTCRβ+ CD4 ISP are larger and express elevated levels of CD28 and CD71 
(Taghon et al., 2009). A larger proportion is β-selected after upregulation of CD8 (Carrasco 
et al., 1999; Trigueros et al., 1998). Hence, these findings suggest that expression of a TCRβ 
protein and the ensuing β-selection occur within a certain developmental window and are 
not tightly coupled to regulation of CD4, CD8α, and CD8β expression. 
Activation of the pre-TCR on the cell surface induces TCR-selection, which is a collective 
process leading to survival and proliferation of the cells, allelic exclusion, and induction of 
TCRrearrangements (Spits, 2002). Subsequently, CD4+CD8+ DP T cells express a mature 
TCR complex on their cell surface, which is followed by positive and negative selection 
(Klein et al., 2009; Siggs et al., 2006). Positive selection mediated by the cortical thymic 
epithelial cells secures the survival of T cells that recognize self-major histocompatibility 
(MHC) antigens complexed with self-peptides with low/intermediate affinity. Conversely, 
high affinity self-peptide MHC complexes expressed by thymic dendritic cells (DC) in the 
medulla are pivotal for deletion of auto-reactive T cells, which is called negative selection. In 
the majority of cases when no interaction of TCR and MHC complexes can be established, 
the cells are unable to survive and die as a result of death by neglect. Positively selected 
thymocytes differentiate into T cells that express CD27 and CD45RA and high levels of 
CD3/TCR (CD3hi) similar to naive T cells present in cord blood. Finally, lineage 
determination signals enforce the differentiation into either the helper CD4+ T cell or 
cytotoxic CD8+ T cells lineages.  
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Fig. 1. Photomicrograph of the thymus. This section of human thymus (original 
magnification x10, courtesy of Dr. B. Jamieson, UCLA, Los Angeles, USA) was stained with 
hematoxylin/eosin and shows the cortex (C), which is a dense area of proliferating 
lymphocytes (thymocytes), and the medulla (M), where fewer cells localize and negative 
selection takes place. It is believed that progenitor cells enter the thymus at the cortico-




Fig. 2. Schematic model of human T cell development. Shown is the expression of cell 
surface markers on thymic progenitor cells and during the different stages of human T cell 
development in the thymus (black indicates expression, white indicates no expression). In 
addition, the status of T cell receptor (TCR)  and gene rearrangements is shown. 
Hematopoietic stem cell (HSC), common lymphoid progenitor (CLP), early thymic 
progenitor (ETP), immature single positive (ISP), early double positive (EDP), single 
positive (SP), germline (GL), Diversity-Joining TCR(D-J), Variable-DJ TCR(VDJ), 
Variable-Joining TCR (VJ). 
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4. Role of cytokines in T cell development 
A role for interleukin (IL)-7 in the development of T cells in the thymus has been 
highlighted by many groups. The IL-7 receptor consists of two chains, IL-7R and gamma 
common (c), which is also part of the receptors for IL-2, IL-4, IL-9, IL-15, and IL-21. Genetic 
defects in the genes encoding for c (Noguchi et al., 1993; Russell et al., 1993), IL-7R (Giliani 
et al., 2005; Puel et al., 1998), or the Janus kinase Jak3, a component of the IL-7-induced 
signal transduction pathway (Macchi et al., 1995; Russell et al., 1995), account for the 
majority of severe combined immune deficiencies (SCID). This disease is characterized by 
strongly reduced numbers of T cells. The most frequent form of SCID is caused by 
mutations in the c-encoding gene (reviewed in (Fischer et al., 2005)). In these patients, T 
and NK cells are absent, but in contrast to what is observed in c-deficient mice, B cell 
development is normal (Noguchi et al., 1993; Russell et al., 1993). While IL-7R-deficient 
patients also display a profound T cell deficiency, they have near normal NK and B cell 
numbers (Giliani et al., 2005; Puel et al., 1998). This indicates that human T cell 
development, but not survival and proliferation of lymphoid precursors, specifically and 
critically depends on IL-7. The precise function of IL-7, which is produced by thymic 
epithelial cells, in human T cell development remains incompletely understood. Expansion 
and differentiation of developing T cells in a FTOC is inhibited by blocking the IL-7R 
signaling pathway using anti-IL-7 and anti-IL-7R antibodies (Pallard et al., 1999; Plum et al., 
1996). This indicates that IL-7 has a crucial role in mediating survival and proliferation of 
human T cell precursors. It has been reported that this is likely mediated by IL-7-induced 
Phosphoinositide Kinase-3 (PI3K) activation through one tyrosine residue at position 449 in 
the cytoplasmic tail of the IL-7R chain (Pallard et al., 1999). Based on the notion that the 
distribution of subsets in the thymuses of IL-7R-deficient mice was near normal, it was 
argued that IL-7 does not appear to be critical for differentiation of mouse TCR T cells in 
the thymus (Peschon et al., 1994). In humans, however, there is evidence that IL-7 is 
important for differentiation of human T cells. First, differentiation of CD34+ precursors in a 
FTOC in the presence of anti-IL-7R antibody is almost completely blocked at the transition 
of CD34+CD1a+ cells into CD4 ISP (Plum et al., 1996). Second, according to one report, 
thymocytes from c-deficient infants possess TCRβ D-J but lack V-DJβ rearrangements 
(Sleasman et al., 1994). Although a function of IL-7 in TCRβ rearrangements in human pre-T 
cells has yet to be confirmed, it may reflect the complete lack of T cells in many c- and IL-
7R-deficient patients (Giliani et al., 2005; Pesu et al., 2005). Conversely, IL-7 is required for 
peripheral T cell homeostasis in humans (Napolitano et al., 2001), which raises the 
alternative possibility that the combined defects in early T cell development and in T cell 
homeostasis are causal to the absolute T cell deficiency in c-deficient patients. Collectively, 
these results indicate that IL-7 is indispensable for human T cell development, and 
moreover suggests that IL-7 is more critical for human than for mouse T cell development. 
5. HIV tropism vs. thymic architecture 
HIV can enter the cell through two major co-receptors, CXCR4 and CCR5, which are 
chemokine G-protein coupled receptors. Under physiological conditions CXCR4 ligates the 
chemokine CXCL12/SDF-1, while CCR5 can be engaged by several chemokines, including 
RANTES (CCL5) or the macrophage inflammatory proteins MIP-1α (CCL3) and MIP-1β 
(CCL4) (Rossi & Zlotnik, 2000). Based on the expression pattern of these chemokine 
 
HIV-Host Interactions 152 
 
Fig. 1. Photomicrograph of the thymus. This section of human thymus (original 
magnification x10, courtesy of Dr. B. Jamieson, UCLA, Los Angeles, USA) was stained with 
hematoxylin/eosin and shows the cortex (C), which is a dense area of proliferating 
lymphocytes (thymocytes), and the medulla (M), where fewer cells localize and negative 
selection takes place. It is believed that progenitor cells enter the thymus at the cortico-




Fig. 2. Schematic model of human T cell development. Shown is the expression of cell 
surface markers on thymic progenitor cells and during the different stages of human T cell 
development in the thymus (black indicates expression, white indicates no expression). In 
addition, the status of T cell receptor (TCR)  and gene rearrangements is shown. 
Hematopoietic stem cell (HSC), common lymphoid progenitor (CLP), early thymic 
progenitor (ETP), immature single positive (ISP), early double positive (EDP), single 
positive (SP), germline (GL), Diversity-Joining TCR(D-J), Variable-DJ TCR(VDJ), 
Variable-Joining TCR (VJ). 
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4. Role of cytokines in T cell development 
A role for interleukin (IL)-7 in the development of T cells in the thymus has been 
highlighted by many groups. The IL-7 receptor consists of two chains, IL-7R and gamma 
common (c), which is also part of the receptors for IL-2, IL-4, IL-9, IL-15, and IL-21. Genetic 
defects in the genes encoding for c (Noguchi et al., 1993; Russell et al., 1993), IL-7R (Giliani 
et al., 2005; Puel et al., 1998), or the Janus kinase Jak3, a component of the IL-7-induced 
signal transduction pathway (Macchi et al., 1995; Russell et al., 1995), account for the 
majority of severe combined immune deficiencies (SCID). This disease is characterized by 
strongly reduced numbers of T cells. The most frequent form of SCID is caused by 
mutations in the c-encoding gene (reviewed in (Fischer et al., 2005)). In these patients, T 
and NK cells are absent, but in contrast to what is observed in c-deficient mice, B cell 
development is normal (Noguchi et al., 1993; Russell et al., 1993). While IL-7R-deficient 
patients also display a profound T cell deficiency, they have near normal NK and B cell 
numbers (Giliani et al., 2005; Puel et al., 1998). This indicates that human T cell 
development, but not survival and proliferation of lymphoid precursors, specifically and 
critically depends on IL-7. The precise function of IL-7, which is produced by thymic 
epithelial cells, in human T cell development remains incompletely understood. Expansion 
and differentiation of developing T cells in a FTOC is inhibited by blocking the IL-7R 
signaling pathway using anti-IL-7 and anti-IL-7R antibodies (Pallard et al., 1999; Plum et al., 
1996). This indicates that IL-7 has a crucial role in mediating survival and proliferation of 
human T cell precursors. It has been reported that this is likely mediated by IL-7-induced 
Phosphoinositide Kinase-3 (PI3K) activation through one tyrosine residue at position 449 in 
the cytoplasmic tail of the IL-7R chain (Pallard et al., 1999). Based on the notion that the 
distribution of subsets in the thymuses of IL-7R-deficient mice was near normal, it was 
argued that IL-7 does not appear to be critical for differentiation of mouse TCR T cells in 
the thymus (Peschon et al., 1994). In humans, however, there is evidence that IL-7 is 
important for differentiation of human T cells. First, differentiation of CD34+ precursors in a 
FTOC in the presence of anti-IL-7R antibody is almost completely blocked at the transition 
of CD34+CD1a+ cells into CD4 ISP (Plum et al., 1996). Second, according to one report, 
thymocytes from c-deficient infants possess TCRβ D-J but lack V-DJβ rearrangements 
(Sleasman et al., 1994). Although a function of IL-7 in TCRβ rearrangements in human pre-T 
cells has yet to be confirmed, it may reflect the complete lack of T cells in many c- and IL-
7R-deficient patients (Giliani et al., 2005; Pesu et al., 2005). Conversely, IL-7 is required for 
peripheral T cell homeostasis in humans (Napolitano et al., 2001), which raises the 
alternative possibility that the combined defects in early T cell development and in T cell 
homeostasis are causal to the absolute T cell deficiency in c-deficient patients. Collectively, 
these results indicate that IL-7 is indispensable for human T cell development, and 
moreover suggests that IL-7 is more critical for human than for mouse T cell development. 
5. HIV tropism vs. thymic architecture 
HIV can enter the cell through two major co-receptors, CXCR4 and CCR5, which are 
chemokine G-protein coupled receptors. Under physiological conditions CXCR4 ligates the 
chemokine CXCL12/SDF-1, while CCR5 can be engaged by several chemokines, including 
RANTES (CCL5) or the macrophage inflammatory proteins MIP-1α (CCL3) and MIP-1β 
(CCL4) (Rossi & Zlotnik, 2000). Based on the expression pattern of these chemokine 
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receptors on leukocytes a clear distinction can be made between CXCR4 (X4)-tropic and 
CCR5 (R5)-tropic viruses (Deng et al., 1996; Dragic et al., 1996; Feng et al., 1996). In bone 
marrow, on average 40% of the CD34+ progenitor cells express the chemokine receptor 
CXCR4 (Ishii et al., 1999). This subset was shown to have restricted lymphoid precursor 
activities, and resemble the CD34+CXCR4+ cells in neonatal UCB, which are likely the 
precursors of human CLPs (Haddad et al., 2004; Hao et al., 2001). CCR5 is expressed on the 
cell surface of only a minority of freshly isolated CD34+ CB cells (1–21%), although at the 
intracellular level more than 80% of the CD34+CB cells expressed abundant CCR5 receptors 
(Basu & Broxmeyer, 2009). While chemotaxis of CD34+CB cells was not induced by the 
CCR5 ligands CCL3, CCL4 and CCL5, they transiently enhanced chemotaxis mediated by 
CXCL12, the ligand for CXCR4 (Basu & Broxmeyer, 2009). Whether CD34+ cells can be 
infected by HIV has been the subject of great discussion through the years. Recently, Carter 
et al. (Carter et al., 2010) demonstrated that CD34+ cells can be infected by both X4 and R5-
tropic viruses in vitro as well as in vivo, thus potentially becoming a significant reservoir of 
HIV. In the thymus, both CXCR4 and CCR5 are expressed as well (Figure 3) (Berkowitz et 
al., 1998b; Gurney & Uittenbogaart, 2006; Kitchen & Zack, 1997; Kitchen & Zack, 1999; 
Pedroza-Martins et al., 1998; Zaitseva et al., 1998; Zamarchi et al., 2002; Zhang et al., 1998). 
Several studies have shown that expression of CXCR4 and CCR5 are modulated during 
thymocyte development (Berkowitz et al., 1998b; Gurney & Uittenbogaart, 2006; Zaitseva et 
al., 1998). CXCR4 is expressed on the majority of thymocytes at all stages of differentiation 
with the highest level of CXCR4 expression on the CD34+ and CD4 ISP subsets (Berkowitz et 
al., 1998b; Hernandez-Lopez et al., 2002; Zaitseva et al., 1998). It was observed that CXCL12, 
in synergy with IL-7, mediates survival of these thymic progenitor subsets (Hernandez-
Lopez et al., 2002). In accord with its co-receptor profile, CD4 ISP cells are infected with X4-
tropic HIV-1, which has a cytopathic effect in the thymus resulting in a major depletion of 
cells (Gurney & Uittenbogaart, 2006; Kitchen & Zack, 1997). On more mature stages of T cell 
development CXCR4 is downregulated (Berkowitz et al., 1998b; Gurney & Uittenbogaart, 
2006; Zaitseva et al., 1998). Notably, however, infected CD8+ T cells are detected in the HIV-
1 infected thymus, which can be explained by the observation that immature thymocytes, 
before they have differentiated into single positive thymocytes, can be infected by X4-tropic 
HIV-1 (Gurney & Uittenbogaart, 2006; Kitchen & Zack, 1997; Lee et al., 1997). Just prior to 
emigration from the thymus CXCR4 is again upregulated (Gurney & Uittenbogaart, 2006). 
Taken together, X4-tropic viruses can infect cells that are present in both the cortex and the 
medulla (Jamieson et al., 1995; Uittenbogaart et al., 1996). It is important to keep in mind 
that most of this work has been done with HIV laboratory strains that are highly cytopathic 
and may not be representative of what is happening in vivo in humans. This is enforced by 
the finding that HIV pediatric isolates from newborn children are not as cytopathic as the 
laboratory strains in infecting thymocytes at least in vitro (Pedroza-Martins et al., 1998).  
Unlike CXCR4, the expression of CCR5 is much less widespread (Berkowitz et al., 1998a). 
CCR5 is detected on a relatively small proportion of thymocytes, including mature CD4 and 
CD8 single positive T cells which express CD27 but lack CD45RA (Berkowitz et al., 1998b; 
Gurney & Uittenbogaart, 2006), and is downregulated just prior to exiting the thymus 
(Berkowitz et al., 1998a; Gurney & Uittenbogaart, 2006). R5-tropic viruses are less 
cytopathic, which may at least in part be explained by the restricted co-receptor expression 
on a small subset, resulting in a much slower depletion of thymocytes (Jamieson et al., 1995). 
Moreover, the CCR5 expressing thymocytes are confined in the medullary area, which 
constrains prevalent replication of R5 viruses throughout the thymus (Berkowitz et al., 
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1998a). Notably, like X4-tropic viruses, R5 strains are capable of depleting thymocytes 
leading to reduced cellularity in the thymus. One explanation can be that in addition to 
TCR+ T cells, other CCR5+ cells are found in the thymus, including conventional DC 
(cDC), plasmacytoid DC (pDC), macrophages, CD161+ T cells and γδ T cells (Gurney et al., 
2002; Gurney et al., 2004; Keir et al., 2002; Rozmyslowicz et al., 2010; Schmitt et al., 2006). 
Another explanation can be that pDC (see paragraph below) in response to the virus 
produce large amounts of type I IFNs (Gurney et al., 2004), which contributes to immune 
activation followed by cell death and T cell depletion. The pDC are likely more susceptible 
to R5-tropic HIV infection as they express CCR5 at higher levels compared to single positive 
thymocytes (Gurney et al., 2004). It was recently reported that IFN- induced expression of 
CCR5 on CD4 ISP thymocytes, which consequently expands the tropism for R5-tropic 
viruses (Stoddart et al., 2010). This, together with the observation that thymi from HIV-
infected individuals present with higher CCR5 expression on mature thymocytes as 
compared with thymocytes from uninfected individuals (Bandera et al., 2010), enforces the 
notion that immune activation has a detrimental role in thymic depletion. 
 
 
Fig. 3. Expression of chemokine receptors CXCR4 and CCR5 on cells at different stages 
during T cell development in the human thymus. The solid line arrows indicate high 
expression of the different cell surface markers, while the dotted line arrow indicates low 
expression. T cell receptor (TCR), single positive (SP). 
6. Role of pDC in HIV pathogenesis in the thymus 
Rare immune subsets like DC, play significant roles in the regulation of the immune system 
(Banchereau et al., 2000a; Banchereau et al., 2000b; Cella et al., 1999; Cella et al., 2000; 
Grouard et al., 1997; Kadowaki et al., 2000). Among the different types of DC subsets are 
pDC, which are present in cord and peripheral blood, T cell areas of the lymph nodes and in 
the medullary area of the thymus, and have the capacity to produce high levels of type I 
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receptors on leukocytes a clear distinction can be made between CXCR4 (X4)-tropic and 
CCR5 (R5)-tropic viruses (Deng et al., 1996; Dragic et al., 1996; Feng et al., 1996). In bone 
marrow, on average 40% of the CD34+ progenitor cells express the chemokine receptor 
CXCR4 (Ishii et al., 1999). This subset was shown to have restricted lymphoid precursor 
activities, and resemble the CD34+CXCR4+ cells in neonatal UCB, which are likely the 
precursors of human CLPs (Haddad et al., 2004; Hao et al., 2001). CCR5 is expressed on the 
cell surface of only a minority of freshly isolated CD34+ CB cells (1–21%), although at the 
intracellular level more than 80% of the CD34+CB cells expressed abundant CCR5 receptors 
(Basu & Broxmeyer, 2009). While chemotaxis of CD34+CB cells was not induced by the 
CCR5 ligands CCL3, CCL4 and CCL5, they transiently enhanced chemotaxis mediated by 
CXCL12, the ligand for CXCR4 (Basu & Broxmeyer, 2009). Whether CD34+ cells can be 
infected by HIV has been the subject of great discussion through the years. Recently, Carter 
et al. (Carter et al., 2010) demonstrated that CD34+ cells can be infected by both X4 and R5-
tropic viruses in vitro as well as in vivo, thus potentially becoming a significant reservoir of 
HIV. In the thymus, both CXCR4 and CCR5 are expressed as well (Figure 3) (Berkowitz et 
al., 1998b; Gurney & Uittenbogaart, 2006; Kitchen & Zack, 1997; Kitchen & Zack, 1999; 
Pedroza-Martins et al., 1998; Zaitseva et al., 1998; Zamarchi et al., 2002; Zhang et al., 1998). 
Several studies have shown that expression of CXCR4 and CCR5 are modulated during 
thymocyte development (Berkowitz et al., 1998b; Gurney & Uittenbogaart, 2006; Zaitseva et 
al., 1998). CXCR4 is expressed on the majority of thymocytes at all stages of differentiation 
with the highest level of CXCR4 expression on the CD34+ and CD4 ISP subsets (Berkowitz et 
al., 1998b; Hernandez-Lopez et al., 2002; Zaitseva et al., 1998). It was observed that CXCL12, 
in synergy with IL-7, mediates survival of these thymic progenitor subsets (Hernandez-
Lopez et al., 2002). In accord with its co-receptor profile, CD4 ISP cells are infected with X4-
tropic HIV-1, which has a cytopathic effect in the thymus resulting in a major depletion of 
cells (Gurney & Uittenbogaart, 2006; Kitchen & Zack, 1997). On more mature stages of T cell 
development CXCR4 is downregulated (Berkowitz et al., 1998b; Gurney & Uittenbogaart, 
2006; Zaitseva et al., 1998). Notably, however, infected CD8+ T cells are detected in the HIV-
1 infected thymus, which can be explained by the observation that immature thymocytes, 
before they have differentiated into single positive thymocytes, can be infected by X4-tropic 
HIV-1 (Gurney & Uittenbogaart, 2006; Kitchen & Zack, 1997; Lee et al., 1997). Just prior to 
emigration from the thymus CXCR4 is again upregulated (Gurney & Uittenbogaart, 2006). 
Taken together, X4-tropic viruses can infect cells that are present in both the cortex and the 
medulla (Jamieson et al., 1995; Uittenbogaart et al., 1996). It is important to keep in mind 
that most of this work has been done with HIV laboratory strains that are highly cytopathic 
and may not be representative of what is happening in vivo in humans. This is enforced by 
the finding that HIV pediatric isolates from newborn children are not as cytopathic as the 
laboratory strains in infecting thymocytes at least in vitro (Pedroza-Martins et al., 1998).  
Unlike CXCR4, the expression of CCR5 is much less widespread (Berkowitz et al., 1998a). 
CCR5 is detected on a relatively small proportion of thymocytes, including mature CD4 and 
CD8 single positive T cells which express CD27 but lack CD45RA (Berkowitz et al., 1998b; 
Gurney & Uittenbogaart, 2006), and is downregulated just prior to exiting the thymus 
(Berkowitz et al., 1998a; Gurney & Uittenbogaart, 2006). R5-tropic viruses are less 
cytopathic, which may at least in part be explained by the restricted co-receptor expression 
on a small subset, resulting in a much slower depletion of thymocytes (Jamieson et al., 1995). 
Moreover, the CCR5 expressing thymocytes are confined in the medullary area, which 
constrains prevalent replication of R5 viruses throughout the thymus (Berkowitz et al., 
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1998a). Notably, like X4-tropic viruses, R5 strains are capable of depleting thymocytes 
leading to reduced cellularity in the thymus. One explanation can be that in addition to 
TCR+ T cells, other CCR5+ cells are found in the thymus, including conventional DC 
(cDC), plasmacytoid DC (pDC), macrophages, CD161+ T cells and γδ T cells (Gurney et al., 
2002; Gurney et al., 2004; Keir et al., 2002; Rozmyslowicz et al., 2010; Schmitt et al., 2006). 
Another explanation can be that pDC (see paragraph below) in response to the virus 
produce large amounts of type I IFNs (Gurney et al., 2004), which contributes to immune 
activation followed by cell death and T cell depletion. The pDC are likely more susceptible 
to R5-tropic HIV infection as they express CCR5 at higher levels compared to single positive 
thymocytes (Gurney et al., 2004). It was recently reported that IFN- induced expression of 
CCR5 on CD4 ISP thymocytes, which consequently expands the tropism for R5-tropic 
viruses (Stoddart et al., 2010). This, together with the observation that thymi from HIV-
infected individuals present with higher CCR5 expression on mature thymocytes as 
compared with thymocytes from uninfected individuals (Bandera et al., 2010), enforces the 
notion that immune activation has a detrimental role in thymic depletion. 
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pDC, which are present in cord and peripheral blood, T cell areas of the lymph nodes and in 
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IFN, i.e. IFN and IFN in response to viruses and other stimuli (Bendriss-Vermare et al., 
2001; Cella et al., 1999; Foster et al., 2000; Kadowaki et al., 2000; Olweus et al., 1997; Res et 
al., 1999; Siegal et al., 1999; Vandenabeele et al., 2001). Type I IFNs are survival factors for 
pDC, while maturation of pDC depends on IL-3 (Grouard et al., 1997). Exposure of 
peripheral blood pDC to virus, or alternatively IFN- or IL-3 either in combination with 
CD40L or TNF-α, leads to the appearance of pDC with a mature phenotype illustrated by 
the finding that they express increased levels of HLA Class II and costimulatory molecules 
(Kadowaki et al., 2000; Kohrgruber et al., 1999). PDC can differentiate in vitro into mature 
DC capable of stimulating CD4+ naïve T cells to proliferate and differentiate, and depending 
on the environmental signals polarize T cells into T helper 2 (Th2) (Rissoan et al., 1999) or 
Th1 cells (Cella et al., 2000). Also, pDC have the ability to shape CD8+ T cell responses either 
directly (Gilliet & Liu, 2002) or via crosspressentation (Hoeffel et al., 2007), and NKT cell 
responses (Kadowaki et al., 2001a). However, the central role of pDC in vivo is likely that of 
an IFN-α/ producing cell, and not an antigen presenting cell (Haeryfar, 2005).  
In response to enveloped RNA and DNA viruses (Milone & Fitzgerald-Bocarsly, 1998), 
including live and inactivated HIV-1 (Beignon et al., 2005; Ferbas et al., 1994; Fong et al., 
2002; Hardy et al., 2007; Yonezawa et al., 2003), human pDC are the main producers of 
IFN-α (Ferbas et al., 1994; Ishikawa et al., 2005; Milone & Fitzgerald-Bocarsly, 1998; Siegal et 
al., 1999). In contrast to conventional cDC, pDC do not produce interleukin-12 (IL-12) (Ito et 
al., 2006). The capacity of IFN-α production in response to virus is already present at the 
pro-pDC stage (Blom et al., 2000) and can be sustained during activation and maturation 
(Cella et al., 1999). IFN-α produced by pDC induces maturation of conventional cDC and 
thereby provides a link between innate and adaptive immunity (Ito et al., 2001). Several 
viral infections induce IFN-α, but the pathways that lead to IFN-α production are likely 
different. Recent reports suggest that in HIV-1 infection IFN-α production by pDC is 
stimulated through interaction of HIV-1 RNA with Toll like receptor (TLR)7 (Beignon et al., 
2005; Hardy et al., 2007; O'Brien et al., 2011). Although it has been shown that pDC can be 
productively infected by R5-tropic and X4-tropic HIV-1 (Gurney et al., 2004; Keir et al., 
2002), IFN-α production by pDC does not depend on productive HIV-1 infection (Beignon et 
al., 2005; Hardy et al., 2007). Furthermore, pDC express TLR9, which after engagement by 
oligodeoxynucleotides (ODNs) containing unmethylated CpG motifs mimicking bacterial 
DNA, activate the cells to secrete high levels of type I IFNs (Kadowaki et al., 2001b).  
Development of pDC both in human and mouse depends on FLT3L (Blom et al., 2000; Gilliet 
et al., 2002). Furthermore, the Ets transcription factor Spi-B and the basic helix-loop-helix 
factor E2-2 are essential for the development of human pDC in vitro as well as in vivo (Cisse 
et al., 2008; Nagasawa et al., 2008; Schotte et al., 2003; Schotte et al., 2004). In the human 
thymus a cell type very similar to peripheral pDC was identified. These CD3- cells express 
CD4, CD45RA and high levels of CD123 and are localized at the cortico-medullary junction 
and in the medulla (Bendriss-Vermare et al., 2001; Olweus et al., 1997; Res et al., 1999; 
Schmitt et al., 2000; Vandenabeele et al., 2001). There are similarities but also differences 
between thymic and peripheral pDC. Both thymic and peripheral pDC respond, in addition 
to IL-3, also to GM-CSF (Ghirelli et al., 2010; Vandenabeele et al., 2001). Like the peripheral 
pDC, the thymic pDC have the capacity to develop into mature DC, but some differences 
were observed in the expression of certain cell surface antigens (Res et al., 1999). Thymic 
pDC consistently express CD2, CD5 and CD7, while peripheral pDC do not express CD7 
and are heterogeneous with respect to the expression of CD2 and CD5 (Bendriss-Vermare et 
al., 2001; Res et al., 1999; Schmitt et al., 2006). Interestingly, thymic pDC constitutively 
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express low levels of IFN-α, which is upregulated by HIV-1 infection in vivo (Gurney et al., 
2004). Moreover, thymic pDC produce less IFN-α upon infection with virus (Schmitt et al., 
2006). These differences may imply either that thymic and peripheral pDC are different 
subsets, or that these alterations are enforced by the thymic microenvironment.  
The role of pDC in controlling HIV-1 replication is still incompletely resolved. Several 
reports describe a decrease in frequency and function of peripheral blood pDC in HIV-1-
infected patients (Chehimi et al., 2002; Donaghy et al., 2001; Feldman et al., 2001; 
Pacanowski et al., 2001; Soumelis et al., 2001). A decrease in pDC has been correlated with 
an increase in HIV-1 RNA virus load and opportunistic infections, suggesting that a loss of 
these cells may contribute to disease progression in HIV-1-infected patients (Donaghy et al., 
2001; Siegal et al., 2001). This decrease in peripheral blood pDC may be due to HIV-1 
induced cell death or migration of pDC from the peripheral blood to lymphoid tissues. In 
accord with the latter option, it was reported that HIV-1 infection induces pDC maturation 
resulting in expression of CCR7 and migration to lymph nodes (Schmidt et al., 2005), which 
is a major site of HIV-1 pathogenesis (Herbeuval et al., 2006). While pDC can suppress HIV-
1 replication in vitro (Gurney et al., 2004; Yonezawa et al., 2003) and ex vivo (Meyers et al., 
2007), pDC through their production of IFN-α have also been found to contribute to HIV 
pathogenesis by TRAIL-mediated apoptosis of uninfected CD4+ T cells (Herbeuval et al., 
2006). Recent data suggest that despite a decrease in pDC numbers in peripheral blood of 
HIV infected individuals, their production of TLR7/8 agonist induced cytokine/chemokine 
is even higher than that of pDC of non-infected individuals thereby contributing to chronic 
immune activation (Sabado et al., 2010). With respect to thymic pDC, these are also targets 
for CXCR4- and CCR5-tropic HIV as they express CD4 in addition to both CXCR4 and 
CCR5. Notably, the expression level of CCR5 on pDC is higher than on thymocytes, 
suggesting that pDC are more susceptible to CCR5-tropic HIV infection than thymocytes 
(Gurney et al., 2004; Ho Tsong Fang et al., 2008; Schmitt et al., 2000). Studies in the SCID-hu 
Thy/Liv mouse model (see paragraph on “Humanized mouse models to study HIV-1 
immuno-pathogenesis”) show that pDC are productively infected by HIV and that HIV 
infection induces IFN- production resulting in upregulation of MHC-I and the interferon 
stimulated gene (ISG), MxA (Gurney et al., 2004; Keir et al., 2002; Schmitt et al., 2006). 
Recently, the suggestion was raised that as a consequence of upregulated MHC-I expression 
levels in the thymus, the generation of dysfunctional CD8+ T cells with low expression of 
CD8 was induced resulting from altered negative selection (Favre et al., 2011). While no 
conclusive evidence was presented, when true this may have detrimental effects on 
thymopoiesis in the HIV-1-infected thymus, and contribute to the immunodeficiency of HIV 
disease. 
7. Impact of IFN-alpha on T cell regeneration 
Type I IFNs, including IFN- and –, are important cytokines that have been classically 
described to have an immunoregulatory function with central roles as antiviral mediators 
(Brassard et al., 2002; Grandvaux et al., 2002). However, type I IFNs have additional effects 
besides their well-known antiviral function. It has been shown that high concentrations of 
IFN- interfered with T and B cell development in mice (Lin et al., 1998). In the thymus, an 
80% decrease in the overall cellularity and a 50% reduction of the CD4+CD8+ DP population 
was observed (Lin et al., 1998). Considering the key role of IL-7 during T cell development 
(see paragraph above “Role of cytokines in T cell development”) it was speculated that type 
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IFN, i.e. IFN and IFN in response to viruses and other stimuli (Bendriss-Vermare et al., 
2001; Cella et al., 1999; Foster et al., 2000; Kadowaki et al., 2000; Olweus et al., 1997; Res et 
al., 1999; Siegal et al., 1999; Vandenabeele et al., 2001). Type I IFNs are survival factors for 
pDC, while maturation of pDC depends on IL-3 (Grouard et al., 1997). Exposure of 
peripheral blood pDC to virus, or alternatively IFN- or IL-3 either in combination with 
CD40L or TNF-α, leads to the appearance of pDC with a mature phenotype illustrated by 
the finding that they express increased levels of HLA Class II and costimulatory molecules 
(Kadowaki et al., 2000; Kohrgruber et al., 1999). PDC can differentiate in vitro into mature 
DC capable of stimulating CD4+ naïve T cells to proliferate and differentiate, and depending 
on the environmental signals polarize T cells into T helper 2 (Th2) (Rissoan et al., 1999) or 
Th1 cells (Cella et al., 2000). Also, pDC have the ability to shape CD8+ T cell responses either 
directly (Gilliet & Liu, 2002) or via crosspressentation (Hoeffel et al., 2007), and NKT cell 
responses (Kadowaki et al., 2001a). However, the central role of pDC in vivo is likely that of 
an IFN-α/ producing cell, and not an antigen presenting cell (Haeryfar, 2005).  
In response to enveloped RNA and DNA viruses (Milone & Fitzgerald-Bocarsly, 1998), 
including live and inactivated HIV-1 (Beignon et al., 2005; Ferbas et al., 1994; Fong et al., 
2002; Hardy et al., 2007; Yonezawa et al., 2003), human pDC are the main producers of 
IFN-α (Ferbas et al., 1994; Ishikawa et al., 2005; Milone & Fitzgerald-Bocarsly, 1998; Siegal et 
al., 1999). In contrast to conventional cDC, pDC do not produce interleukin-12 (IL-12) (Ito et 
al., 2006). The capacity of IFN-α production in response to virus is already present at the 
pro-pDC stage (Blom et al., 2000) and can be sustained during activation and maturation 
(Cella et al., 1999). IFN-α produced by pDC induces maturation of conventional cDC and 
thereby provides a link between innate and adaptive immunity (Ito et al., 2001). Several 
viral infections induce IFN-α, but the pathways that lead to IFN-α production are likely 
different. Recent reports suggest that in HIV-1 infection IFN-α production by pDC is 
stimulated through interaction of HIV-1 RNA with Toll like receptor (TLR)7 (Beignon et al., 
2005; Hardy et al., 2007; O'Brien et al., 2011). Although it has been shown that pDC can be 
productively infected by R5-tropic and X4-tropic HIV-1 (Gurney et al., 2004; Keir et al., 
2002), IFN-α production by pDC does not depend on productive HIV-1 infection (Beignon et 
al., 2005; Hardy et al., 2007). Furthermore, pDC express TLR9, which after engagement by 
oligodeoxynucleotides (ODNs) containing unmethylated CpG motifs mimicking bacterial 
DNA, activate the cells to secrete high levels of type I IFNs (Kadowaki et al., 2001b).  
Development of pDC both in human and mouse depends on FLT3L (Blom et al., 2000; Gilliet 
et al., 2002). Furthermore, the Ets transcription factor Spi-B and the basic helix-loop-helix 
factor E2-2 are essential for the development of human pDC in vitro as well as in vivo (Cisse 
et al., 2008; Nagasawa et al., 2008; Schotte et al., 2003; Schotte et al., 2004). In the human 
thymus a cell type very similar to peripheral pDC was identified. These CD3- cells express 
CD4, CD45RA and high levels of CD123 and are localized at the cortico-medullary junction 
and in the medulla (Bendriss-Vermare et al., 2001; Olweus et al., 1997; Res et al., 1999; 
Schmitt et al., 2000; Vandenabeele et al., 2001). There are similarities but also differences 
between thymic and peripheral pDC. Both thymic and peripheral pDC respond, in addition 
to IL-3, also to GM-CSF (Ghirelli et al., 2010; Vandenabeele et al., 2001). Like the peripheral 
pDC, the thymic pDC have the capacity to develop into mature DC, but some differences 
were observed in the expression of certain cell surface antigens (Res et al., 1999). Thymic 
pDC consistently express CD2, CD5 and CD7, while peripheral pDC do not express CD7 
and are heterogeneous with respect to the expression of CD2 and CD5 (Bendriss-Vermare et 
al., 2001; Res et al., 1999; Schmitt et al., 2006). Interestingly, thymic pDC constitutively 
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express low levels of IFN-α, which is upregulated by HIV-1 infection in vivo (Gurney et al., 
2004). Moreover, thymic pDC produce less IFN-α upon infection with virus (Schmitt et al., 
2006). These differences may imply either that thymic and peripheral pDC are different 
subsets, or that these alterations are enforced by the thymic microenvironment.  
The role of pDC in controlling HIV-1 replication is still incompletely resolved. Several 
reports describe a decrease in frequency and function of peripheral blood pDC in HIV-1-
infected patients (Chehimi et al., 2002; Donaghy et al., 2001; Feldman et al., 2001; 
Pacanowski et al., 2001; Soumelis et al., 2001). A decrease in pDC has been correlated with 
an increase in HIV-1 RNA virus load and opportunistic infections, suggesting that a loss of 
these cells may contribute to disease progression in HIV-1-infected patients (Donaghy et al., 
2001; Siegal et al., 2001). This decrease in peripheral blood pDC may be due to HIV-1 
induced cell death or migration of pDC from the peripheral blood to lymphoid tissues. In 
accord with the latter option, it was reported that HIV-1 infection induces pDC maturation 
resulting in expression of CCR7 and migration to lymph nodes (Schmidt et al., 2005), which 
is a major site of HIV-1 pathogenesis (Herbeuval et al., 2006). While pDC can suppress HIV-
1 replication in vitro (Gurney et al., 2004; Yonezawa et al., 2003) and ex vivo (Meyers et al., 
2007), pDC through their production of IFN-α have also been found to contribute to HIV 
pathogenesis by TRAIL-mediated apoptosis of uninfected CD4+ T cells (Herbeuval et al., 
2006). Recent data suggest that despite a decrease in pDC numbers in peripheral blood of 
HIV infected individuals, their production of TLR7/8 agonist induced cytokine/chemokine 
is even higher than that of pDC of non-infected individuals thereby contributing to chronic 
immune activation (Sabado et al., 2010). With respect to thymic pDC, these are also targets 
for CXCR4- and CCR5-tropic HIV as they express CD4 in addition to both CXCR4 and 
CCR5. Notably, the expression level of CCR5 on pDC is higher than on thymocytes, 
suggesting that pDC are more susceptible to CCR5-tropic HIV infection than thymocytes 
(Gurney et al., 2004; Ho Tsong Fang et al., 2008; Schmitt et al., 2000). Studies in the SCID-hu 
Thy/Liv mouse model (see paragraph on “Humanized mouse models to study HIV-1 
immuno-pathogenesis”) show that pDC are productively infected by HIV and that HIV 
infection induces IFN- production resulting in upregulation of MHC-I and the interferon 
stimulated gene (ISG), MxA (Gurney et al., 2004; Keir et al., 2002; Schmitt et al., 2006). 
Recently, the suggestion was raised that as a consequence of upregulated MHC-I expression 
levels in the thymus, the generation of dysfunctional CD8+ T cells with low expression of 
CD8 was induced resulting from altered negative selection (Favre et al., 2011). While no 
conclusive evidence was presented, when true this may have detrimental effects on 
thymopoiesis in the HIV-1-infected thymus, and contribute to the immunodeficiency of HIV 
disease. 
7. Impact of IFN-alpha on T cell regeneration 
Type I IFNs, including IFN- and –, are important cytokines that have been classically 
described to have an immunoregulatory function with central roles as antiviral mediators 
(Brassard et al., 2002; Grandvaux et al., 2002). However, type I IFNs have additional effects 
besides their well-known antiviral function. It has been shown that high concentrations of 
IFN- interfered with T and B cell development in mice (Lin et al., 1998). In the thymus, an 
80% decrease in the overall cellularity and a 50% reduction of the CD4+CD8+ DP population 
was observed (Lin et al., 1998). Considering the key role of IL-7 during T cell development 
(see paragraph above “Role of cytokines in T cell development”) it was speculated that type 
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I IFNs might interfere with IL-7 signaling. Consistent with this it was shown that type I IFNs 
inhibited IL-7-driven expansion of CD4-CD8-CD44+CD25+ (also known as double negative 
(DN)2) cells in murine fetal thymus organ cultures (Su et al., 1997).  
The main producers of type I IFNs are pDC, which express TLR7 and TLR9 enabling them 
to sense nucleic acids derived from viruses or bacteria (Kadowaki et al., 2001b; Cella et al., 
1999; Kadowaki et al., 2000). In addition to secondary lymphoid organs and peripheral 
blood, pDC are present in the thymus, where they locate in the medulla and at the cortico-
medullary junction (Bendriss-Vermare et al., 2001; Res et al., 1999; Vandenabeele et al., 
2001). As this latter location is where TSP cells enter the thymus, it is conceivable that 
thymic pDC affect T cell development. In line with this it was demonstrated that IFN- 
when exogenously added as recombinant protein, impaired early human T cell 
development by interfering with the IL-7 signaling pathway (Schmidlin et al., 2006). 
Moreover, similar findings were observed when pDC were activated either by HIV-1 or the 
TLR9 agonist CpG-ODN in a co-culture setup in which thymic progenitor cells were 
induced to differentiate into both T cells and pDC (Schmidlin et al., 2006). Addition of 
neutralizing antibodies against type I IFNs in this system relieved the block in T cell 
development illustrating that type I IFNs produced by activated pDC have a detrimental 
effect on early T cell progenitor cells (Schmidlin et al., 2006). It remains largely elusive 
whether type I IFNs affect later stages of T cell development. This is not unlikely, however, 
given the architectural localization of pDC in the medulla, and the finding that the majority 
of thymocytes express the type I IFN receptor (CD118) on their surface (Keir et al., 2002). In 
fact, IFN-α was reported to interfere with IL-7–induced maturation at the transition of 
human CD3+CD1a+ to CD3+/hiCD1a– thymocytes (Schmidlin et al., 2006). In addition, IFN- 
induced the up-regulation of MHC class I expression in the thymus (Keir et al., 2002). This 
may cause adverse T cell selection in the thymus by changing the avidity of the TCR for 
MHC potentially depleting part of the mature CD8+ T cell repertoire. 
8. Role of regulatory T cells in HIV pathogenesis in the thymus 
CD4+CD25+ regulatory T (Treg) cells are a distinct subset of CD4+ T cells, which play a 
significant role in the generation and maintenance of peripheral tolerance (Maloy & Powrie, 
2001; Sakaguchi, 2000; Sakaguchi, 2005). Although in humans Treg cells in the periphery 
constitute a small subset of the total T-cells (1%-2%) (Baecher-Allan et al., 2001), there is 
accumulating evidence that they play a significant role in the negative control of a broad 
spectrum of immune responses to antigens, such as in tumor immunity, organ 
transplantation, allergy, and microbial immunity (reviewed in (Sakaguchi, 2005)). Treg cells 
are identified by their constitutive expression of the alpha chain of the interleukin 2 (IL-2) 
receptor (CD25) and the presence of the forkhead/winged-helix transcription repressor 
FoxP3 (scurfin) (Baecher-Allan et al., 2001; Fontenot et al., 2003; Hori et al., 2003; Khattri et 
al., 2003; Yagi et al., 2004). There is mounting evidence that FoxP3 plays a crucial role in the 
development and function of human (Walker et al., 2003; Yagi et al., 2004) and murine 
(Fontenot et al., 2005) CD4+CD25+ Treg cells (reviewed in (Fontenot & Rudensky, 2005)). In 
addition to FoxP3, the cytokine IL-2 is essential for the development of Treg cells in the 
thymus and their maintenance in the periphery (reviewed in (Sakaguchi, 2005)). Although 
Treg cells show low levels of proliferation in vitro (Baecher-Allan et al., 2001), peripheral 
expansion of thymus-derived natural Treg (nTreg) cells ensures maintenance of the 
peripheral Treg pool in the adult mouse (Hori et al., 2002). In addition, antigen-dependent 
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proliferation of Treg cells has been shown in vivo (Klein et al., 2003b; von Boehmer, 2005). 
The mechanism of T cell suppression by Treg cells is dependent on direct cell-cell contact 
(reviewed in (von Boehmer, 2005)). However, in addition to the direct effects of Treg cells, 
bystander effects include the production of cytokines (IL-10 and TGF-) that have 
suppressive effects on immune responses (reviewed in (von Boehmer, 2005)). 
In mice and rats as well as humans, nTreg cells develop intrathymically (Jordan et al., 2001; 
Kasow et al., 2004) and acquire their regulatory function while still in the thymus (Itoh et al., 
1999; Saoudi et al., 1996; Stephens et al., 2001). Treg cells are continuously produced in the 
thymus as a distinct lineage contiguous with peripheral blood Treg cells (reviewed in 
(Fontenot et al., 2005; Sakaguchi, 2005)). There is recent evidence that thymic pDC play a 
role in the development of nTreg (Hanabuchi et al., 2010; Martin-Gayo et al., 2010). Both 
pDC and Treg cells are located closely together in the thymic medulla, which may suggest 
interactions between them (Martin-Gayo et al., 2010; Res et al., 1999; Watanabe et al., 2005). 
In addition to the induction of Treg cells by cDC activated with the IL-7 like cytokine thymic 
stromal lymphopoietin (TSLP) (Watanabe et al., 2005), FoxP3+ Treg cells can also be induced 
in the thymus by pDC after these have been stimulated with TSLP (Hanabuchi et al., 2010). 
The role of TSLP activation of pDC in the development of thymic Treg is however still 
unclear as Martin-Gayo et al. found that thymic pDC were unresponsive to TSLP, but 
responsive to CD40L and IL-3 (Martin-Gayo et al., 2010). It is interesting to note that nTreg 
cells generated in the presence of cDC have opposite IL-10/TGF- cytokine profiles from 
those generated wih pDC (Martin-Gayo et al., 2010). Thus, the interaction of pDC and cDC 
with Treg cells may play an important role in the development of tolerance in the thymus.  
In contrast to adult peripheral blood, Treg cells in the human fetal and postnatal thymus 
(Annunziato et al., 2002; Cupedo et al., 2005; Kasow et al., 2004) and in cord blood (Takahata 
et al., 2004; Thornton et al., 2004) have a naïve phenotype, although they suppress the 
proliferation of CD25-negative T cells, similar to Treg cells in the periphery. Treg cells 
identified by high expression of CD25 and FoxP3 are already present in the human fetal 
thymus and secondary lymphoid organs (Cupedo et al., 2005; Darrasse-Jeze et al., 2005). T 
cells expressing GITR, CTLA-4 and CD122 and high levels of CD25, corresponding to the 
phenotype of Treg cells, develop in the human thymus at the CD4+CD8+ stage during 
transition of CD27- to CD27+ stage (Cupedo et al., 2005). When Treg cells leave the thymus 
and enter fetal secondary lymphoid tissues, lymph nodes and spleen, they acquire a 
memory/activated phenotype (Cupedo et al., 2005). In the normal functioning immune 
system there is a balance between the interactions of Treg cells and effector T cells, whereas 
deficiency of functional Treg cells leads to inappropriate immune responses to microbial 
infections and autoimmunity as exemplified in humans who suffer from the X-linked 
immunodeficiency syndrome (IPEX) with a mutation in FoxP3 (reviewed in (Fontenot et al., 
2005; Sakaguchi, 2005)). In addition to CD4+ Treg cells, CD8+CD25+ Treg cells have been 
identified in the thymus (Cosmi et al., 2003). The CD8+CD25+ Treg cells express FoxP3 
mRNA, but lower levels of CD25 than the CD4+ Treg cells (Cosmi et al., 2003). 
There is ample evidence that Treg cells play a significant role in infectious diseases 
including viral infections (reviewed in (Belkaid & Rouse, 2005; Mills & McGuirk, 2004)). In 
humans, circulating peripheral Treg cells suppress CD4+ and CD8+ antiviral immune 
responses in chronic viral infections, such as HCV (Cabrera et al., 2004), CMV and HIV 
(Aandahl et al., 2004; Andersson et al., 2005; Eggena et al., 2005; Kinter et al., 2004; Oswald-
Richter et al., 2004; Weiss et al., 2004). There is a clear measurable restoration of antiviral 
immune responses to CMV and HIV in vitro when CD4+CD25+ T cells are completely 
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I IFNs might interfere with IL-7 signaling. Consistent with this it was shown that type I IFNs 
inhibited IL-7-driven expansion of CD4-CD8-CD44+CD25+ (also known as double negative 
(DN)2) cells in murine fetal thymus organ cultures (Su et al., 1997).  
The main producers of type I IFNs are pDC, which express TLR7 and TLR9 enabling them 
to sense nucleic acids derived from viruses or bacteria (Kadowaki et al., 2001b; Cella et al., 
1999; Kadowaki et al., 2000). In addition to secondary lymphoid organs and peripheral 
blood, pDC are present in the thymus, where they locate in the medulla and at the cortico-
medullary junction (Bendriss-Vermare et al., 2001; Res et al., 1999; Vandenabeele et al., 
2001). As this latter location is where TSP cells enter the thymus, it is conceivable that 
thymic pDC affect T cell development. In line with this it was demonstrated that IFN- 
when exogenously added as recombinant protein, impaired early human T cell 
development by interfering with the IL-7 signaling pathway (Schmidlin et al., 2006). 
Moreover, similar findings were observed when pDC were activated either by HIV-1 or the 
TLR9 agonist CpG-ODN in a co-culture setup in which thymic progenitor cells were 
induced to differentiate into both T cells and pDC (Schmidlin et al., 2006). Addition of 
neutralizing antibodies against type I IFNs in this system relieved the block in T cell 
development illustrating that type I IFNs produced by activated pDC have a detrimental 
effect on early T cell progenitor cells (Schmidlin et al., 2006). It remains largely elusive 
whether type I IFNs affect later stages of T cell development. This is not unlikely, however, 
given the architectural localization of pDC in the medulla, and the finding that the majority 
of thymocytes express the type I IFN receptor (CD118) on their surface (Keir et al., 2002). In 
fact, IFN-α was reported to interfere with IL-7–induced maturation at the transition of 
human CD3+CD1a+ to CD3+/hiCD1a– thymocytes (Schmidlin et al., 2006). In addition, IFN- 
induced the up-regulation of MHC class I expression in the thymus (Keir et al., 2002). This 
may cause adverse T cell selection in the thymus by changing the avidity of the TCR for 
MHC potentially depleting part of the mature CD8+ T cell repertoire. 
8. Role of regulatory T cells in HIV pathogenesis in the thymus 
CD4+CD25+ regulatory T (Treg) cells are a distinct subset of CD4+ T cells, which play a 
significant role in the generation and maintenance of peripheral tolerance (Maloy & Powrie, 
2001; Sakaguchi, 2000; Sakaguchi, 2005). Although in humans Treg cells in the periphery 
constitute a small subset of the total T-cells (1%-2%) (Baecher-Allan et al., 2001), there is 
accumulating evidence that they play a significant role in the negative control of a broad 
spectrum of immune responses to antigens, such as in tumor immunity, organ 
transplantation, allergy, and microbial immunity (reviewed in (Sakaguchi, 2005)). Treg cells 
are identified by their constitutive expression of the alpha chain of the interleukin 2 (IL-2) 
receptor (CD25) and the presence of the forkhead/winged-helix transcription repressor 
FoxP3 (scurfin) (Baecher-Allan et al., 2001; Fontenot et al., 2003; Hori et al., 2003; Khattri et 
al., 2003; Yagi et al., 2004). There is mounting evidence that FoxP3 plays a crucial role in the 
development and function of human (Walker et al., 2003; Yagi et al., 2004) and murine 
(Fontenot et al., 2005) CD4+CD25+ Treg cells (reviewed in (Fontenot & Rudensky, 2005)). In 
addition to FoxP3, the cytokine IL-2 is essential for the development of Treg cells in the 
thymus and their maintenance in the periphery (reviewed in (Sakaguchi, 2005)). Although 
Treg cells show low levels of proliferation in vitro (Baecher-Allan et al., 2001), peripheral 
expansion of thymus-derived natural Treg (nTreg) cells ensures maintenance of the 
peripheral Treg pool in the adult mouse (Hori et al., 2002). In addition, antigen-dependent 
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proliferation of Treg cells has been shown in vivo (Klein et al., 2003b; von Boehmer, 2005). 
The mechanism of T cell suppression by Treg cells is dependent on direct cell-cell contact 
(reviewed in (von Boehmer, 2005)). However, in addition to the direct effects of Treg cells, 
bystander effects include the production of cytokines (IL-10 and TGF-) that have 
suppressive effects on immune responses (reviewed in (von Boehmer, 2005)). 
In mice and rats as well as humans, nTreg cells develop intrathymically (Jordan et al., 2001; 
Kasow et al., 2004) and acquire their regulatory function while still in the thymus (Itoh et al., 
1999; Saoudi et al., 1996; Stephens et al., 2001). Treg cells are continuously produced in the 
thymus as a distinct lineage contiguous with peripheral blood Treg cells (reviewed in 
(Fontenot et al., 2005; Sakaguchi, 2005)). There is recent evidence that thymic pDC play a 
role in the development of nTreg (Hanabuchi et al., 2010; Martin-Gayo et al., 2010). Both 
pDC and Treg cells are located closely together in the thymic medulla, which may suggest 
interactions between them (Martin-Gayo et al., 2010; Res et al., 1999; Watanabe et al., 2005). 
In addition to the induction of Treg cells by cDC activated with the IL-7 like cytokine thymic 
stromal lymphopoietin (TSLP) (Watanabe et al., 2005), FoxP3+ Treg cells can also be induced 
in the thymus by pDC after these have been stimulated with TSLP (Hanabuchi et al., 2010). 
The role of TSLP activation of pDC in the development of thymic Treg is however still 
unclear as Martin-Gayo et al. found that thymic pDC were unresponsive to TSLP, but 
responsive to CD40L and IL-3 (Martin-Gayo et al., 2010). It is interesting to note that nTreg 
cells generated in the presence of cDC have opposite IL-10/TGF- cytokine profiles from 
those generated wih pDC (Martin-Gayo et al., 2010). Thus, the interaction of pDC and cDC 
with Treg cells may play an important role in the development of tolerance in the thymus.  
In contrast to adult peripheral blood, Treg cells in the human fetal and postnatal thymus 
(Annunziato et al., 2002; Cupedo et al., 2005; Kasow et al., 2004) and in cord blood (Takahata 
et al., 2004; Thornton et al., 2004) have a naïve phenotype, although they suppress the 
proliferation of CD25-negative T cells, similar to Treg cells in the periphery. Treg cells 
identified by high expression of CD25 and FoxP3 are already present in the human fetal 
thymus and secondary lymphoid organs (Cupedo et al., 2005; Darrasse-Jeze et al., 2005). T 
cells expressing GITR, CTLA-4 and CD122 and high levels of CD25, corresponding to the 
phenotype of Treg cells, develop in the human thymus at the CD4+CD8+ stage during 
transition of CD27- to CD27+ stage (Cupedo et al., 2005). When Treg cells leave the thymus 
and enter fetal secondary lymphoid tissues, lymph nodes and spleen, they acquire a 
memory/activated phenotype (Cupedo et al., 2005). In the normal functioning immune 
system there is a balance between the interactions of Treg cells and effector T cells, whereas 
deficiency of functional Treg cells leads to inappropriate immune responses to microbial 
infections and autoimmunity as exemplified in humans who suffer from the X-linked 
immunodeficiency syndrome (IPEX) with a mutation in FoxP3 (reviewed in (Fontenot et al., 
2005; Sakaguchi, 2005)). In addition to CD4+ Treg cells, CD8+CD25+ Treg cells have been 
identified in the thymus (Cosmi et al., 2003). The CD8+CD25+ Treg cells express FoxP3 
mRNA, but lower levels of CD25 than the CD4+ Treg cells (Cosmi et al., 2003). 
There is ample evidence that Treg cells play a significant role in infectious diseases 
including viral infections (reviewed in (Belkaid & Rouse, 2005; Mills & McGuirk, 2004)). In 
humans, circulating peripheral Treg cells suppress CD4+ and CD8+ antiviral immune 
responses in chronic viral infections, such as HCV (Cabrera et al., 2004), CMV and HIV 
(Aandahl et al., 2004; Andersson et al., 2005; Eggena et al., 2005; Kinter et al., 2004; Oswald-
Richter et al., 2004; Weiss et al., 2004). There is a clear measurable restoration of antiviral 
immune responses to CMV and HIV in vitro when CD4+CD25+ T cells are completely 
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removed (Aandahl et al., 2004; Weiss et al., 2004). Although Treg cells produce 
immunosuppressive cytokines, IL-10 and TGF-1 in response to p24 antigen stimulation, the 
down modulation seen by CD4+CD25+ T cells is cell-cell contact dependent and independent 
of IL-10 and TGF- (Kinter et al., 2004; Weiss et al., 2004). The impact of Treg cells on HIV-1 
infection is still unclear and may depend on the stage of infection. Early in viral infection, 
the proportion of Treg cells is unaltered as compared to normal controls (Aandahl et al., 
2004). Elevated levels of circulating HIV specific CD25hiCD4+ T cells were observed in a 
majority of healthy, yet chronically, HIV infected individuals (Kinter et al., 2004). However, 
Treg cell numbers declined proportionately with the loss of CD4+ T cells and disease 
progression (Kinter et al., 2004; Oswald-Richter et al., 2004). Treg cells were increased in 
tonsils, but decreased in the peripheral blood of untreated chronically HIV infected 
individuals, indicating that viral antigenic stimulation may have increased Treg cells in the 
lymphoid tissue and may have a detrimental effect on local immune responses (Andersson 
et al., 2005). A recent study in HIV infected individuals undergoing cardiac surgery showed 
that Treg cells were increased in the thymus of HIV-infected individuals as compared to 
uninfected individuals (Bandera et al., 2010). In a study of treatment naïve, chronically HIV 
infected individuals in Uganda, depletion of Treg cells was associated with immune 
activation (Eggena et al., 2005). The underlying mechanism suggests a complex balance 
between Treg cells and effector T cells. In summary, it will be of significant clinical value to 
determine at which stages of disease and in which tissues Treg cells have detrimental or 
protective effects on the immunopathology observed in HIV infection.  
9. SIV pathogenic and non-pathogenic models 
The use of animal models has been of great importance to study the thymus in HIV 
infection. In this regard the non-human primate models, and the SCID-hu and humanized 
mouse models, as discussed in the next section, are providing a great deal of knowledge on 
the role of the thymus in HIV infection. Studies in pathogenic and non-pathogenic models of 
simian immunodeficiency virus (SIV) infected non-human primates have further increased 
our understanding on the role of the thymus in HIV infection. In the non-pathogenic model 
SIV infection of its natural hosts (chimpanzees, sooty mangabeys, African green monkeys, 
and others) does not lead to depletion of CD4+ T lymphocytes and AIDS, in contrast to the 
pathogenic model in which SIV infects its non-natural host (rhesus macaques) (reviewed in 
(Silvestri, 2008)). Effective innate immune responses including IFN- and ISG are induced, 
but rapidly controlled in acute SIV infection of sooty mangabeys (SM) (Bosinger et al., 2009) 
and African Green monkeys (Diop et al., 2008; Jacquelin et al., 2009). However, acute SIV 
infection of rhesus macaques (RM) induces chronic immune activation and continuous 
expression of ISG (Bosinger et al., 2009). An increase in the ISG, MxA mRNA was found in 
lymphoid tissues, including the thymus, in SIV infected rhesus macaques. However, the 
elevated MxA levels did not correlate with control of viral infection in the animals (Abel et 
al., 2002) and are likely a sign of immune activation. Non-responsiveness to TGF-1 was 
found to play a role in the lack of resolution of immune activation in rhesus macaques 
(Ploquin et al., 2006). Chronic immune activation was recognized many years ago as a major 
player in poor prognosis HIV infected individuals (Giorgi et al., 1999). Thus interference 
with immune activation was explored by administration of an antibody to the IFN- 
receptor in SIV infected macaques, which reduced the loss of CD4+ T cells in these animals 
(Tovey et al., 1994). 
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Studies of lymphoid tissues in SIV infected macaques have shed light on the differences 
between changes in T lymphocytes in peripheral blood and primary (thymus) and 
secondary lymphoid organs. In the thymus and secondary lymphoid organs proliferation of 
T lymphocytes and absolute CD4+ T lymphocytes were increased in acute SIV infection, but 
decreased in peripheral blood (Sopper et al., 2003). However in animals with first indication 
of AIDS, thymocytes were severely decreased (Sopper et al., 2003). Increased levels of 
thymocyte proliferation were also observed by Wykrzykowska et al. (Wykrzykowska et al., 
1998) after an initial increase in apoptosis and depletion of thymic progenitors. Apoptosis in 
SIV infected macaques correlated with peak viremia and disruption of the apoptotic 
pathway (Rosenzweig et al., 2000). Pathogenicity of the virus on the level of apoptosis in the 
thymus was observed in macaques infected with a pathogenic and non-pathogenic HIV/SIV 
hybrid virus (SHIV) (Iida et al., 2000). Recent thymic emigrants can be determined by 
measuring T cell receptor excision circles (TRECs) in peripheral blood and provide a mirror 
of thymic function. Increased or stable levels of TRECs were found early after infection, but 
TREC levels decreased later when depletion of CD4+ thymocytes and apoptosis were 
observed in one of the animals (Sodora et al., 2002). Elevated TREC levels as compared to 
non-infected controls were observed in macaques infected with a less pathogenic SIVnef 
virus indicating that the thymus can maintain its function in the presence of low viral loads 
(Ho Tsong Fang et al., 2005). However the thymus as the major player in maintaining naïve 
peripheral CD4+ T cells has been disputed. Proliferation of peripheral T lymphocytes does 
also play a role in maintaining peripheral T cell homeostasis. Thymectomies of juvenile SIV 
infected macaques showed that TRECs in peripheral blood decreased after thymectomies. 
However, thymectomy in the SIV infected animals did not impact their clinical course or the 
ratio of CD45RA+ to CD45RA-CD4+ T cells (Arron et al., 2005). 
10. Humanized mouse models to study HIV-1 immuno-pathogenesis 
A small, easy-to-handle animal model that would facilitate the study of the pathophysiology 
of acute HIV-1 infection has been warranted after we were confronted with the HIV 
pandemic in the 1980s. Normal mice cannot be studied due to the limited species tropism of 
HIV, and therefore humanized mouse models have been instrumental to study HIV 
infections. Over the last decades significant progress has been made in the generation of 
humanized mouse models (Figure 4) with a functional human immune system, which has 
not only added to our insight into the development of human stem cells and the 
reconstitution of a human immune system in an in vivo setting, but also initiated studies on 
the preclinical testing of novel antiviral compounds, and the evaluation of vaccines.  
Initially, humanized mice were generated using mice with the scid mutation in the C.B-17 
mouse strain (Bosma et al., 1983). Such mice lack mature T and B cells due to a mutation in 
the prkdc gene, which is involved in rearrangement of TCR and Ig genes (Kirchgessner et al., 
1995). Adoptive transfer of human peripheral blood lymphocytes (PBL) in C.B-17 SCID 
mice, which is commonly referred to as the human (hu) PBL-SCID model, resulted in the 
reconstitution of mature human T and B cells (Mosier et al., 1988). Although these 
transferred human lymphocytes only survived for a short period of time limiting long-term 
studies, hu-PBL-SCID mice have been used to study certain aspects of HIV-1 infection, 
including the importance of the state of activation of human CD4+ T cells at the time of 
primary infection in determining HIV-1 pathogenicity (Fais et al., 1999; Rizza et al., 1996). 
Resolutions to bypass the limited survival time of human lymphocytes were obtained by the 
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removed (Aandahl et al., 2004; Weiss et al., 2004). Although Treg cells produce 
immunosuppressive cytokines, IL-10 and TGF-1 in response to p24 antigen stimulation, the 
down modulation seen by CD4+CD25+ T cells is cell-cell contact dependent and independent 
of IL-10 and TGF- (Kinter et al., 2004; Weiss et al., 2004). The impact of Treg cells on HIV-1 
infection is still unclear and may depend on the stage of infection. Early in viral infection, 
the proportion of Treg cells is unaltered as compared to normal controls (Aandahl et al., 
2004). Elevated levels of circulating HIV specific CD25hiCD4+ T cells were observed in a 
majority of healthy, yet chronically, HIV infected individuals (Kinter et al., 2004). However, 
Treg cell numbers declined proportionately with the loss of CD4+ T cells and disease 
progression (Kinter et al., 2004; Oswald-Richter et al., 2004). Treg cells were increased in 
tonsils, but decreased in the peripheral blood of untreated chronically HIV infected 
individuals, indicating that viral antigenic stimulation may have increased Treg cells in the 
lymphoid tissue and may have a detrimental effect on local immune responses (Andersson 
et al., 2005). A recent study in HIV infected individuals undergoing cardiac surgery showed 
that Treg cells were increased in the thymus of HIV-infected individuals as compared to 
uninfected individuals (Bandera et al., 2010). In a study of treatment naïve, chronically HIV 
infected individuals in Uganda, depletion of Treg cells was associated with immune 
activation (Eggena et al., 2005). The underlying mechanism suggests a complex balance 
between Treg cells and effector T cells. In summary, it will be of significant clinical value to 
determine at which stages of disease and in which tissues Treg cells have detrimental or 
protective effects on the immunopathology observed in HIV infection.  
9. SIV pathogenic and non-pathogenic models 
The use of animal models has been of great importance to study the thymus in HIV 
infection. In this regard the non-human primate models, and the SCID-hu and humanized 
mouse models, as discussed in the next section, are providing a great deal of knowledge on 
the role of the thymus in HIV infection. Studies in pathogenic and non-pathogenic models of 
simian immunodeficiency virus (SIV) infected non-human primates have further increased 
our understanding on the role of the thymus in HIV infection. In the non-pathogenic model 
SIV infection of its natural hosts (chimpanzees, sooty mangabeys, African green monkeys, 
and others) does not lead to depletion of CD4+ T lymphocytes and AIDS, in contrast to the 
pathogenic model in which SIV infects its non-natural host (rhesus macaques) (reviewed in 
(Silvestri, 2008)). Effective innate immune responses including IFN- and ISG are induced, 
but rapidly controlled in acute SIV infection of sooty mangabeys (SM) (Bosinger et al., 2009) 
and African Green monkeys (Diop et al., 2008; Jacquelin et al., 2009). However, acute SIV 
infection of rhesus macaques (RM) induces chronic immune activation and continuous 
expression of ISG (Bosinger et al., 2009). An increase in the ISG, MxA mRNA was found in 
lymphoid tissues, including the thymus, in SIV infected rhesus macaques. However, the 
elevated MxA levels did not correlate with control of viral infection in the animals (Abel et 
al., 2002) and are likely a sign of immune activation. Non-responsiveness to TGF-1 was 
found to play a role in the lack of resolution of immune activation in rhesus macaques 
(Ploquin et al., 2006). Chronic immune activation was recognized many years ago as a major 
player in poor prognosis HIV infected individuals (Giorgi et al., 1999). Thus interference 
with immune activation was explored by administration of an antibody to the IFN- 
receptor in SIV infected macaques, which reduced the loss of CD4+ T cells in these animals 
(Tovey et al., 1994). 
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Studies of lymphoid tissues in SIV infected macaques have shed light on the differences 
between changes in T lymphocytes in peripheral blood and primary (thymus) and 
secondary lymphoid organs. In the thymus and secondary lymphoid organs proliferation of 
T lymphocytes and absolute CD4+ T lymphocytes were increased in acute SIV infection, but 
decreased in peripheral blood (Sopper et al., 2003). However in animals with first indication 
of AIDS, thymocytes were severely decreased (Sopper et al., 2003). Increased levels of 
thymocyte proliferation were also observed by Wykrzykowska et al. (Wykrzykowska et al., 
1998) after an initial increase in apoptosis and depletion of thymic progenitors. Apoptosis in 
SIV infected macaques correlated with peak viremia and disruption of the apoptotic 
pathway (Rosenzweig et al., 2000). Pathogenicity of the virus on the level of apoptosis in the 
thymus was observed in macaques infected with a pathogenic and non-pathogenic HIV/SIV 
hybrid virus (SHIV) (Iida et al., 2000). Recent thymic emigrants can be determined by 
measuring T cell receptor excision circles (TRECs) in peripheral blood and provide a mirror 
of thymic function. Increased or stable levels of TRECs were found early after infection, but 
TREC levels decreased later when depletion of CD4+ thymocytes and apoptosis were 
observed in one of the animals (Sodora et al., 2002). Elevated TREC levels as compared to 
non-infected controls were observed in macaques infected with a less pathogenic SIVnef 
virus indicating that the thymus can maintain its function in the presence of low viral loads 
(Ho Tsong Fang et al., 2005). However the thymus as the major player in maintaining naïve 
peripheral CD4+ T cells has been disputed. Proliferation of peripheral T lymphocytes does 
also play a role in maintaining peripheral T cell homeostasis. Thymectomies of juvenile SIV 
infected macaques showed that TRECs in peripheral blood decreased after thymectomies. 
However, thymectomy in the SIV infected animals did not impact their clinical course or the 
ratio of CD45RA+ to CD45RA-CD4+ T cells (Arron et al., 2005). 
10. Humanized mouse models to study HIV-1 immuno-pathogenesis 
A small, easy-to-handle animal model that would facilitate the study of the pathophysiology 
of acute HIV-1 infection has been warranted after we were confronted with the HIV 
pandemic in the 1980s. Normal mice cannot be studied due to the limited species tropism of 
HIV, and therefore humanized mouse models have been instrumental to study HIV 
infections. Over the last decades significant progress has been made in the generation of 
humanized mouse models (Figure 4) with a functional human immune system, which has 
not only added to our insight into the development of human stem cells and the 
reconstitution of a human immune system in an in vivo setting, but also initiated studies on 
the preclinical testing of novel antiviral compounds, and the evaluation of vaccines.  
Initially, humanized mice were generated using mice with the scid mutation in the C.B-17 
mouse strain (Bosma et al., 1983). Such mice lack mature T and B cells due to a mutation in 
the prkdc gene, which is involved in rearrangement of TCR and Ig genes (Kirchgessner et al., 
1995). Adoptive transfer of human peripheral blood lymphocytes (PBL) in C.B-17 SCID 
mice, which is commonly referred to as the human (hu) PBL-SCID model, resulted in the 
reconstitution of mature human T and B cells (Mosier et al., 1988). Although these 
transferred human lymphocytes only survived for a short period of time limiting long-term 
studies, hu-PBL-SCID mice have been used to study certain aspects of HIV-1 infection, 
including the importance of the state of activation of human CD4+ T cells at the time of 
primary infection in determining HIV-1 pathogenicity (Fais et al., 1999; Rizza et al., 1996). 
Resolutions to bypass the limited survival time of human lymphocytes were obtained by the 
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transfer of human pluripotent progenitor cells ensuring development of multiple 
hematopoietic lineages. In such an optimized setting, human fetal thymic (FT) lobes and 
pieces of fetal liver (FL) were transplanted under the kidney capsule in C.B-17 SCID mice 
(McCune et al., 1988). In this hu-thymus (Thy)/liver (Liv) SCID mouse model almost 
exclusively T cells developed, which transiently migrated from the human thymus graft to 
the periphery. When compared to the first model, also this latter model suffers from the 
disadvantage that human T cell survival is reduced, although this is more apparent later 
after transplantation. This hu-Thy/Liv-SCID model has been extensively used for the 
analysis of human hematopoiesis, especially T cells, and as an animal model of HIV 
infection (McCune, 1997). HIV-1 injection in the thymic implant of hu-Thy/Liv-SCID mice 
resulted in significant HIV-1 infection not only in the Thy/Liv implant, but also in the 
spleen and peripheral blood, which indicated that HIV-1 infection could spread from the 
thymus to the peripheral lymphoid compartment (Kollmann et al., 1994). The effect of HIV-1 
infection on thymocyte maturation and depletion depended upon the strain of HIV-1 
infecting the thymus (Kollmann et al., 1995).  
  
 
Fig. 4. Humanized mouse models to study HIV-1 infection in vivo. Several ways to generate 
humanized mouse models have been established (see text for further details). Human 
peripheral blood lymphocytes (hu-PBL) are injected in severe combined immunodeficient 
(SCID) mice to generate hu-PBL-SCID mice. Pieces of fetal liver (Liv) and thymus (Thy) can 
be grafted in SCID mice to generate the hu-Thy/Liv-SCID mouse. To create a human 
immune system (HIS) mouse, newborn immunodeficient mice are injected intrahepatically 
with CD34+CD38- human stem cells (HSC) after cell sorting from the fetal liver (or 
alternatively cord blood, bone marrow, mobilized peripheral blood, not shown). 
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To further optimize the humanized mouse model approaches were established to 
repopulate sublethally irradiated C.B-17 SCID mice with progenitor cells from human bone 
marrow or umbilical cord blood (Lapidot et al., 1992; Vormoor et al., 1994). In addition to 
development of T cells these mice also developed B cells and myeloid cells, which presented 
the potential to establish a humanized mouse model with a functional human immune 
system. Ablation of mouse NK cells further increased the frequency of thymopoiesis in 
animals reconstituted with human umbilical cord blood cells. This was not only 
demonstrated when using antibodies to deplete mouse NK cells (Kerre et al., 2002), but also 
when using recipient mice with a NK cell deficient genetic background (Greiner et al., 1998). 
Reconstitution of mice that are either defective in NK cell activity (non-obese diabetic 
(NOD)/SCID mice (Ogasawara et al., 2003) or NOD/SCID/β2m–/– mice (Kollet et al., 2000) 
or have impaired NK cell development (NOD/SCID/γc–/– mice (Hiramatsu et al., 2003) 
were shown to have improved human T cell development. Despite their promise, however, 
repopulation of human T cells in the periphery of these mice are suboptimal (Hiramatsu et 
al., 2003; Kerre et al., 2002; Kollet et al., 2000). In addition to the genetic background, also the 
age of the mice upon reconstitution of HSC appears crucially important. Several groups 
observed that injection of human HSC to sublethally irradiated newborn BALB/c Rag2–/–c–
/– (BALB-Rag/) mice improved the reconstitution success rate (Gimeno et al., 2004; 
Traggiai et al., 2004). More than 80% of these humanized mice, either referred to as "human 
adaptive immune system Rag2–/–c–/– mice" (huAIS-RG) (Traggiai et al., 2004) or “human 
immune system BALB-Rag2–/–c–/–” (HIS BALB-Rag/) (Gimeno et al., 2004), exhibited at 
least 10% or more human CD45+ cells in peripheral blood and other lymphoid organs. 
Similar improvements were observed in newborn NOD/SCID/γc–/– (NOG) mice (Ishikawa 
et al., 2003; Ishikawa et al., 2005; Ito et al., 2002; Shultz et al., 2005) and to a lesser extent in 
newborn NOD/SCID/2m–/– mice when used as recipient of HSC (Kollet et al., 2000). 
Part of the human CD4+T cells in the spleen and peripheral blood of NOG mice express the 
co-receptors CXCR4 and CCR5 (Watanabe et al., 2007). In the thymus, CXCR4 is expressed 
on the majority of CD4+CD8+ thymocytes as well as on small numbers of CD4+CD8– cells 
and CD4–CD8+ cells, while CCR5 was only expressed on a minor proportion of the 
thymocytes (Watanabe et al., 2007). Notably, early after HIV-1 infection of huNOG mice no 
viremia could be detected, and a detectable viral load was only observed late after infection 
using high doses of R5-tropic or X4-tropic HIV-1. No significant decline in the CD4/CD8 
ratio was observed after R5-tropic virus infection of huNOG mice (Watanabe et al., 2007). 
Conversely, the HIS BALB-Rag/ mice infected with a high dose R5-tropic HIV-1 did 
develop an inversion of the CD4/CD8 T-cell ratio in peripheral blood (Berges et al., 2006; 
Gorantla et al., 2007). After X4-tropic virus infection of huNOG mice a CD4+ cell decline was 
detected at later time points (Watanabe et al., 2007). These findings suggest that humanized 
mice are less susceptible to low dose infection and undergo a slow course of CD4 T-cell 
depletion as compared to HIV-1 infected individuals. In addition, immune responses to 
HIV-1 infection in HIS mice generated from newborns are suboptimal resulting in only poor 
development of virus-specific antibodies and absence of HIV-specific T cell responses (An et 
al., 2007; Baenziger et al., 2006; Gorantla et al., 2007; Sato et al., 2010).  
A more sophisticated HIS mouse model has been generated using NOD/SCID mice that 
were co-transplantated with human fetal Thy/Liv and CD34+ HSC either from fetal liver 
(Lan et al., 2006; Tonomura et al., 2008) or bone marrow (BLT mice) (Melkus et al., 2006). 
BLT mice mounted stronger antigen-specific T-cell responses and T cell–dependent IgG 
production after in vivo antigen immunization (Melkus et al., 2006; Tonomura et al., 2008). 
Notably, a detectable viral load was observed in BLT mice after low dose infection with R5-
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transfer of human pluripotent progenitor cells ensuring development of multiple 
hematopoietic lineages. In such an optimized setting, human fetal thymic (FT) lobes and 
pieces of fetal liver (FL) were transplanted under the kidney capsule in C.B-17 SCID mice 
(McCune et al., 1988). In this hu-thymus (Thy)/liver (Liv) SCID mouse model almost 
exclusively T cells developed, which transiently migrated from the human thymus graft to 
the periphery. When compared to the first model, also this latter model suffers from the 
disadvantage that human T cell survival is reduced, although this is more apparent later 
after transplantation. This hu-Thy/Liv-SCID model has been extensively used for the 
analysis of human hematopoiesis, especially T cells, and as an animal model of HIV 
infection (McCune, 1997). HIV-1 injection in the thymic implant of hu-Thy/Liv-SCID mice 
resulted in significant HIV-1 infection not only in the Thy/Liv implant, but also in the 
spleen and peripheral blood, which indicated that HIV-1 infection could spread from the 
thymus to the peripheral lymphoid compartment (Kollmann et al., 1994). The effect of HIV-1 
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repopulate sublethally irradiated C.B-17 SCID mice with progenitor cells from human bone 
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system. Ablation of mouse NK cells further increased the frequency of thymopoiesis in 
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demonstrated when using antibodies to deplete mouse NK cells (Kerre et al., 2002), but also 
when using recipient mice with a NK cell deficient genetic background (Greiner et al., 1998). 
Reconstitution of mice that are either defective in NK cell activity (non-obese diabetic 
(NOD)/SCID mice (Ogasawara et al., 2003) or NOD/SCID/β2m–/– mice (Kollet et al., 2000) 
or have impaired NK cell development (NOD/SCID/γc–/– mice (Hiramatsu et al., 2003) 
were shown to have improved human T cell development. Despite their promise, however, 
repopulation of human T cells in the periphery of these mice are suboptimal (Hiramatsu et 
al., 2003; Kerre et al., 2002; Kollet et al., 2000). In addition to the genetic background, also the 
age of the mice upon reconstitution of HSC appears crucially important. Several groups 
observed that injection of human HSC to sublethally irradiated newborn BALB/c Rag2–/–c–
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Similar improvements were observed in newborn NOD/SCID/γc–/– (NOG) mice (Ishikawa 
et al., 2003; Ishikawa et al., 2005; Ito et al., 2002; Shultz et al., 2005) and to a lesser extent in 
newborn NOD/SCID/2m–/– mice when used as recipient of HSC (Kollet et al., 2000). 
Part of the human CD4+T cells in the spleen and peripheral blood of NOG mice express the 
co-receptors CXCR4 and CCR5 (Watanabe et al., 2007). In the thymus, CXCR4 is expressed 
on the majority of CD4+CD8+ thymocytes as well as on small numbers of CD4+CD8– cells 
and CD4–CD8+ cells, while CCR5 was only expressed on a minor proportion of the 
thymocytes (Watanabe et al., 2007). Notably, early after HIV-1 infection of huNOG mice no 
viremia could be detected, and a detectable viral load was only observed late after infection 
using high doses of R5-tropic or X4-tropic HIV-1. No significant decline in the CD4/CD8 
ratio was observed after R5-tropic virus infection of huNOG mice (Watanabe et al., 2007). 
Conversely, the HIS BALB-Rag/ mice infected with a high dose R5-tropic HIV-1 did 
develop an inversion of the CD4/CD8 T-cell ratio in peripheral blood (Berges et al., 2006; 
Gorantla et al., 2007). After X4-tropic virus infection of huNOG mice a CD4+ cell decline was 
detected at later time points (Watanabe et al., 2007). These findings suggest that humanized 
mice are less susceptible to low dose infection and undergo a slow course of CD4 T-cell 
depletion as compared to HIV-1 infected individuals. In addition, immune responses to 
HIV-1 infection in HIS mice generated from newborns are suboptimal resulting in only poor 
development of virus-specific antibodies and absence of HIV-specific T cell responses (An et 
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Notably, a detectable viral load was observed in BLT mice after low dose infection with R5-
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tropic virus, which was associated with the depletion of human CD4+ T cells in the blood 
(Brainard et al., 2009). Also, it was demonstrated that B cells in BLT mice were able to mount 
robust virus-specific antibody responses, although these responses were delayed as 
compared to adult human HIV infection (Brainard et al., 2009). Besides the intravenous 
route of HIV infection, HIS mice can be infected with HIV by relevant intravaginal and 
intrarectal routes (Berges et al., 2008; Denton et al., 2008; Sun et al., 2007). Taken together, 
this advanced humanized BLT mouse model shows great potential as a model to study HIV 
infection in vivo and holds promise for prospective studies to test the efficacy of candidate 
HIV vaccines and to validate the activity of antimicrobial agents acting at mucosal surfaces. 
11. Summary and conclusion 
Our knowledge of HIV infection of the thymus is primarily derived from animal models 
except for incidental reports of HIV infection in vivo in infants, children and adults (Bandera 
et al., 2010; Brunner et al., 2011; Calabro et al., 1995; Gaulton et al., 1997; Haynes et al., 1999; 
Rosenzweig et al., 1994). Indirect evidence of the impact of antiretroviral therapy on 
recovery of the thymus has been obtained through imaging studies and measurements of 
TRECs (Dion et al., 2007; Halnon et al., 2005; Lee et al., 2006; McCune et al., 1998 and 
reviewed in (Ho Tsong Fang et al., 2005)). It is clear that the thymus plays an important role 
in HIV infection and in the regeneration of naïve CD4+ T cells. Thymocytes, but also minor 
thymocyte subsets are targets for CCR5- and CXCR4-tropic HIV. These subsets include 
CD4+ TCR, TCR and CD161+ cells resembling NK-T cells (Gurney et al., 2002), Treg, 
cDC and pDC. Furthermore, pDC stimulated with HIV produce high levels of IFN- and 
thereby contribute to immune activation in particular when IFN- levels are not controlled. 
Notably, insufficient T cell regeneration may not only be at the level of the thymus, but also 
at the level of hematopoietic stem cells. This is illustrated by the recent finding that the 
function and numbers of CD34+ hematopoietic stem cells in peripheral blood of HIV 
infected individuals are impaired despite control of viral replication (Sauce et al., 2011). 
Also, impaired progenitor cell function of umbilical cord blood CD34+ cells, including 
decreased cloning efficiency and generation of CD4+ T lymphocytes in fetal thymic organ 
culture, was observed in HIV-negative infants born to HIV-positive mothers (Nielsen et al., 
2001). Consistent with these results, failure of hematopoiesis leading to impaired T cell 
regeneration was observed in SIV infected macaques and found to be unrelated to viral 
loads (Thiebot et al., 2005). Finally, a recent observation suggests that CD34+ cells can also be 
infected with HIV (Carter et al., 2010). Collectively, these results imply that HIV in addition 
to thymic destruction can also adversely affect thymic progenitor cells, likely caused by 
immune activation, and thereby contribute to T cell depletion in HIV infected individuals.  
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infection in vivo and holds promise for prospective studies to test the efficacy of candidate 
HIV vaccines and to validate the activity of antimicrobial agents acting at mucosal surfaces. 
11. Summary and conclusion 
Our knowledge of HIV infection of the thymus is primarily derived from animal models 
except for incidental reports of HIV infection in vivo in infants, children and adults (Bandera 
et al., 2010; Brunner et al., 2011; Calabro et al., 1995; Gaulton et al., 1997; Haynes et al., 1999; 
Rosenzweig et al., 1994). Indirect evidence of the impact of antiretroviral therapy on 
recovery of the thymus has been obtained through imaging studies and measurements of 
TRECs (Dion et al., 2007; Halnon et al., 2005; Lee et al., 2006; McCune et al., 1998 and 
reviewed in (Ho Tsong Fang et al., 2005)). It is clear that the thymus plays an important role 
in HIV infection and in the regeneration of naïve CD4+ T cells. Thymocytes, but also minor 
thymocyte subsets are targets for CCR5- and CXCR4-tropic HIV. These subsets include 
CD4+ TCR, TCR and CD161+ cells resembling NK-T cells (Gurney et al., 2002), Treg, 
cDC and pDC. Furthermore, pDC stimulated with HIV produce high levels of IFN- and 
thereby contribute to immune activation in particular when IFN- levels are not controlled. 
Notably, insufficient T cell regeneration may not only be at the level of the thymus, but also 
at the level of hematopoietic stem cells. This is illustrated by the recent finding that the 
function and numbers of CD34+ hematopoietic stem cells in peripheral blood of HIV 
infected individuals are impaired despite control of viral replication (Sauce et al., 2011). 
Also, impaired progenitor cell function of umbilical cord blood CD34+ cells, including 
decreased cloning efficiency and generation of CD4+ T lymphocytes in fetal thymic organ 
culture, was observed in HIV-negative infants born to HIV-positive mothers (Nielsen et al., 
2001). Consistent with these results, failure of hematopoiesis leading to impaired T cell 
regeneration was observed in SIV infected macaques and found to be unrelated to viral 
loads (Thiebot et al., 2005). Finally, a recent observation suggests that CD34+ cells can also be 
infected with HIV (Carter et al., 2010). Collectively, these results imply that HIV in addition 
to thymic destruction can also adversely affect thymic progenitor cells, likely caused by 
immune activation, and thereby contribute to T cell depletion in HIV infected individuals.  
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1. Introduction 
1.1 Th cell development 
Regulation of T helper (Th) cell differentiation and proliferation depends on which 
cytokines are present in the microenvironment of a naïve Th cell. Induction of specific 
transcription factors results in programming of the naïve Th0 cell into one of several subsets. 
Currently there are four well characterized Th cell subsets, namely Th1, Th2, Th17, and the T 
regulatory (Treg) cells (Figure 1). In this chapter we will be focusing on the Th1, Th17, and 
Treg cell populations. However, at this point it is also worth mentioning the relatively 
newly described Th9 and follicular (Tfh) cell subsets. Here we briefly discuss the 
differentiation pathways taken by a Th0 cell that ultimately results in the formation of these 
different subsets.  
Since the early 1980’s, the Th1/Th2 paradigm has been well-studied. Th1 cells are known for 
expression of the signature cytokine IFN-γ and resulting anti-viral activities. The necessary 
driving cytokine for these cells is IL-12 in conjunction with the Th1-specific transcription 
factor T-bet (Hsieh, Macatonia et al., 1993; Seder, Gazzinelli et al., 1993;Szabo, Sullivan et al., 
2002). IL-27, related to IL-12, has been recently shown to play a role in the induction of Th1 
cells, while also actively repressing development of other subsets. On the other hand, Th2 
cells are largely recognized to support humoral immunity and are induced by the presence 
of IL-4 and resulting activation of the STAT6 transcription factor(Kaplan, Schindler et al., 
1996;Kurata, Lee et al., 1999). Equally important is the activation of the GATA binding 
protein 3 (GATA-3), the main regular of Th2 development (Pai, Truitt et al., 2004;Zhu, Min 
et al., 2004). The newly defined Th17 cells have been implicated in a number of 
inflammatory disorders and are recognized as key Th cells that trigger massive 
proinflammatory responses. They are characterized by production of IL-17 and 
differentiation of these cells requires both tumor growth factor (TGF)-β and IL-6 which act 
together to promote development of the Th17 subset (Bettelli, Carrier et al., 2006; Mangan, 
Harrington et al., 2006). Additionally important to the generation of these cells is IL-23, 
which functions to aid in the development and proliferation of Th17 cells. The key 
transcription factors required belong to the retinoic acid-related orphan receptors (ROR) 
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family; both ROR-α and RORγt have been shown to be critical to Th17 development (Yang, 
Pappu et al., 2008). The Treg cell subset is crucial to the regulation of immune responses as 
these cells play a suppressive role, mainly via the expression of the anti-inflammatory 
cytokine IL-10. These cell subsets are unique from the other subsets as they can be formed 
either in the thymus (known as “naturally” occurring Tregs or nTreg) or as a result of TGF-β 
stimulation and T cell receptor (TCR) triggering (known as “inducible” Tregs or 
iTreg)(Murai, Krause et al., 2010). The main transcription factor for the development of these 
cells is Foxp3 which is only expressed in Treg cells (Zheng & Rudensky, 2007). Th9 cells 
have been recently identified as IL-21-dependent CD4 T cells producing IL-9, although a key 
function has yet to be identified for these cells, it appears that they may be involved in 
inflammation and allergy (Xing, Wu et al., 2011; Ma, Tangye et al., 2010; Wong, Ye et al., 
2010). The Tfh cells are newly defined to be efficient producers of IL-10 and IL-21 (Suto, 
Kashiwakuma et al., 2008; Crotty, 2011). These cells generally express high levels of CXCR5 
and are responsible for providing support for B cells (Crotty, 2011). Key to the 
differentiation of these cells, are IL-6 and IL-21 which mediate the induction of the 
transcription factor Bcl-6 (Nurieva, Chung et al., 2009).  
 
 
Fig. 1. CD4 T cell Differentiation Pathways: Naïve T cells (Th0) cells can differentiate into 
different subsets of T cells depending on the cytokine(s) present in the cell environment. 
Shown in this diagram are the cytokines required for each cell type, the transcription factors 
required for each cell type (in italics), and the main cytokine(s) produced by each cell type 
(in bold). 
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The IL-12 family of cytokines is composed of IL-12, IL-23, and IL-27, with each of these 
cytokines playing a different role in Th cell development. Proper regulation of the 
development and differentiation of CD4 T cells is critical to an effective immune response. 
As these cells are the main target of HIV infection, the resulting loss and imbalance of the Th 
cell subsets are a hallmark of HIV and AIDS. The remainder of this chapter will be devoted 
to a discussion of the impact of HIV infection on the function and expression of the IL-12 
cytokine family members as it relates to Th cell differentiation and function with a focus on 
how Th1, Th17, and Treg CD4 T cell subsets are affected. 
2. IL-12 and HIV infection 
IL-12 is critically involved in generating cell-mediated immune responses to infectious agents, 
including HIV. Biologically active IL-12p70, a dimer of IL-12p35 and IL-12p40, is secreted by 
activated monocytes, macrophages, and dendritic cells. IL-12 expression drives the 
production and development of the Th1 subset of T cells, and is responsible for the 
induction of IFN- expression from these cells(Alber, Al-Robaiy et al., 2006).  
IL-12 production is impaired in HIV-infected individuals and in cells infected in vitro with 
HIV (Chehimi, Starr et al., 1999; Daftarian, Diaz-Mitoma et al., 1995; Boucher, Parato et al., 
2010;Buisson, Benlahrech et al., 2009). In terms of IL-12 receptor chain expression (IL-12R1 
and IL-12R2), one study reported that resting peripheral blood mononuclear cells (PBMC) 
from HIV positive patients and HIV negative controls did not express IL-12Rβ1 or IL-12Rβ2 
chains on their cell surface (Jones, Young et al., 2003). Upon examination of mRNA levels, 
the group found that levels of both receptor subunits were markedly reduced in HIV 
positive patients compared to HIV negative controls. Culture of activated cells with IL-12 
resulted in upregulation of the IL-12R2 chain suggesting that treatment with IL-12 may 
serve to recapitulate IL-12R levels and thus IL-12 responses (Jones, Young et al., 2003). In 
contrast, a recent study demonstrated that unstimulated CD4 T cells from HIV-1 positive 
patients expressed a two-fold increase of IL-12Rβ1 subunit compared with cells from HIV-1 
negative controls (de Arquer, Pena et al., 2007). Similar to Jones et al (2003), this group 
found that stimulation of the CD4 T cells with IL-12 resulted in the enhancement of IL-
12R2. Together these two findings illustrate the potential importance of restoring IL-12 
mediated responses, particularly in view of the role of IL-12 in Th1 cell differentiation and 
IFN- production.  
The above observations suggest that although the virus inhibits IL-12 production, the 
immune cells attempt to bolster responses via upregulation of IL-12 receptor levels, which 
leads to speculation that treatment with IL-12 may be beneficial to patients. In in vitro 
models using T cells isolated from HIV patients, enhanced immune responses are observed 
upon treatment of these cells with recombinant IL-12 (Landay, Clerici et al., 1996). Vectors 
expressing IL-12 have also been used successfully in candidate vaccines in animal models 
(Chong, Egan et al., 2007; Boyer, Robinson,et al., 2005; Egan, Chong et al., 2005;Hirao, Wu et 
al., 2008). IL-12 is important for the priming of antigen-specific T cells, as demonstrated by a 
study using IL-12 deficient mice. Mice were immunized with HIV gp120 cDNA vectors and 
the cytotoxic T cell response in IL-12 deficient mice was significantly lower compared to 
wild type mice. Furthermore, reconstitution of IL-12 in the deficient mice was able to restore 
T cell responsiveness (Gupta et al., 2008). However, toxicity of IL-12 as a treatment option is 
a concern. Therefore, use of other cytokines which may have less toxicity, such as IL-23 or 
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IL-12 and IL-23 has proven useful in treatment of autoimmune diseases(Ding, Xu et al., 
2008;Elson, Cong et al., 2007;Gottlieb, Cooper et al., 2007;Krueger, Langley et al., 2007). 
Treatment with recombinant IL-27 has also proven useful in an in vitro model of arthritis 
(Niedbala, Cai et al., 2008). Together, these points indicate alternative recombinant cytokine 
treatments could be applied in emerging HIV therapeutics. 
3. IL-27 and HIV infection 
IL-27 was first discovered in 2002 by Pflanz et al. as a novel member of the IL-12 family of 
cytokines (Pflanz, Timans et al., 2002). This family is comprised of molecules sharing subunits 
and receptor chain components; therefore, IL-27 and IL-12 have similar functions. IL-27 
engages a heterodimeric receptor composed of gp130 and WSX-1 (Pflanz, Hibbert et al., 2004). 
Numerous immune cells respond to IL-27, as the IL-27 receptor can be found on endothelial 
cells, mast cells, activated B cells, monocytes, Langerhans cells, activated DCs, and polarized 
Th cells (Larousserie, Charlot et al., 2006; Lucas, Ghilardi et al., 2003; Pflanz, Hibbert et al., 
2004;Ruckerl, Hessmann et al., 2006;Wirtz, Tubbe et al., 2006). Functionally, IL-27 exhibits pro- 
and anti-inflammatory properties and, thus, IL-27 can be regarded as an immunomodulatory 
cytokine. Recent evidence has indicated a role for IL-27 in the regulation of 
monocyte/macrophage function (Guzzo, Che Mat et al., 2010; Kalliolias & Ivashkiv, 2008), in 
addition to its well-characterized functions in T cells. IL-27, predominantly produced by 
activated monocytes and dendritic cells, can bridge innate and adaptive immunity by playing 
a key role in the activation of naïve T cells and differentiation to Th1 cells.  
A role for IL-27 in the control of HIV replication was first described in 2007 (Fakruddin, 
Lempicki et al., 2007). This study evaluated the effects of HPV-VLPs (Human Papilloma 
Virus - Virus-Like Particles) on HIV-1 replication in PBMC, CD4 + T cells, and macrophages. 
Using the p24 antigen capture assay to assess viral replication, this study showed treatment 
with HPV-VLPs could suppress replication of both X4 and R5 strains of HIV-1. This 
suppression was independent of any effect on cell surface expression of CD4, CXCR4, or 
CCR5, as analyzed by surface staining and flow cytometry. Upon observing the anti-HIV 
effect of VLP treatment, the authors went on to perform DNA microarray analysis to look at 
gene expression profiles in PBMC and macrophages treated with VLPs. The authors noticed 
induction of interferon (IFN), IFN-stimulated genes (ISIGs),  cytokines like IL-10, IP-10, IL-
15, and most notably, IL-27. Thus, the anti-HIV effects seen with VLP treatment resulted 
from the release of suppressive factors following treatment of cells with HPV-VLPs. VLP-
induced IL-27 expression and production in PBMC and macrophages was further confirmed 
and quantified using RT-PCR and ELISA, respectively. To tease out the specific role of IL-27 
in suppression of HIV replication, the authors immunodepleted IL-27 from VLP-treated cell 
supernatants, and saw a significant reduction in the inhibition of HIV replication, indicating 
IL-27 secretion may be one factor contributing to the suppressive effects seen upon VLP 
treatment of HIV-infected cells. To confirm the direct effect of IL-27 on HIV replication, this 
study went on to treat cells with a recombinant IL-27 (rIL-27) dose response and showed 
increasing suppression of HIV replication in the presence of increasing rIL-27 doses. 
Furthermore, to determine the specificity of IL-27-mediated inhibition of HIV replication, 
the authors performed real-time RT-PCR to examine transcription of HIV RNA in the 
presence of IL-27. Results indicated a 60 – 80% decrease in HIV transcription in the presence 
of IL-27. Lastly, the authors performed DNA microarray analysis on PHA-stimulated CD4 + 
T cells in the presence or absence of IL-27 to compare gene induction profiles. Cells cultured 
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in the presence of IL-27 showed significant upregulation of antiviral genes, including ISIGs, 
myxovirus resistance protein, and 2’-5’-oligoadenylate synthetase. 
Shortly after the initial discovery of the IL-27 anti-HIV functions, the same research group 
examined the mechanisms of IL-27 antiviral activity compared to those of IFN-, another 
key cytokine also known to inhibit HIV replication. In this study the activity and gene 
expression profiles of IL-27 and IFN- were compared in human CD4 + T cells and 
macrophages (Imamichi, Yang et al., 2008). The authors performed a neutralization assay to 
define the role of IFN in IL-27-mediated inhibition of HIV replication. HIV-infected CD4 T 
cells and macrophages were treated with IL-27 in the presence/absence of an antibody 
cocktail containing neutralizing antibodies to each IFN. The antibody treatment did not 
affect HIV inhibition by IL-27, indicating that IFN is not an intermediate in the inhibition of 
HIV replication by IL-27. Of additional note, IL-27, like IFN-, preferentially inhibited HIV 
replication in macrophages compared to CD4 T cells, as lower doses of these cytokines were 
required to get complete inhibition of HIV replication in macrophages compared to T cells. 
Using DNA microarray analysis, this study went on to compare the gene expression profiles 
of IL-27 and IFN- in CD4 T cells and macrophages. From this experiment it was noted that 
both cytokines induced a similar profile of ISIGs and antiviral genes, with greater antiviral 
gene induction in the macrophages compared to CD4 T cells upon IL-27 stimulation. Of 
particular note, IL-27 significantly upregulated antiviral genes like myxovirus resistance 1 
(MX1), oligoadenylate synthetase 2 (OAS2), and RNA-dependent protein kinase–eukaryotic 
initiation factor 2a kinase (PKR/EIF2AK) by greater than 2-fold in the macrophage cells. 
Furthermore, IL-27 also induced expression of apolipoprotein B messenger RNA-editing 
enzyme-catalytic polypeptide-like 3G (APOBEC3G) in macrophages, but not in CD4 T cells. 
The APOBEC proteins are key host cell-derived protective molecules, acting as anti-HIV 
proteins that function as cytidine deaminases to interfere with viral replication (Romani, 
Engelbrecht et al., 2009). Taken together, these results indicate that IL-27, like IFN-, 
significantly induces multiple IFIGs and APOBEC3G in macrophages, resulting in the 
striking anti-HIV functions of these cytokines. 
Subsequent to the initial studies on IL-27 functions in HIV infection, a separate research group 
set out to determine whether IL-27 directly or indirectly regulated expression of the APOBEC 
family of proteins (Greenwell-Wild, Vazquez et al., 2009). Since it had been previously shown 
that IFN- could regulate expression of APOBEC, clinical trials commenced to explore the 
impact of IFN- treatment on induction of APOBEC expression in the setting of HIV infection 
et (Neumann, Polis et al., 2007). However, the many negative side effects of IFN treatment led 
researchers to consider alternative mechanisms to induce APOBEC expression, in particular, 
mechanisms that minimize IFN toxicities associated with direct administration of this 
cytokine. Greenwell-Wild et al. (2009) showed that IL-27 could be a good alternative, as they 
showed IL-27 can induce APOBEC expression to curb HIV replication. This study attributed 
the anti-viral properties of IL-27 to the intermediary IL-27-induced IFN-, which can then, in 
turn, coordinate anti-viral responses. Interestingly, this study investigated whether other IL-12 
cytokine family members, namely IL-12 and IL-23, could suppress HIV replication. No 
significant reduction in HIV replication was observed with IL-12 or IL-23 treatments, 
indicating that the inhibition of HIV replication was selective to IL-27 in the IL-12 family of 
cytokines. This study went on to examine the kinetics of IL-27-induced APOBEC expression 
and found a 24 hour delay in the induction of expression by real-time PCR, suggestive of an 
intermediary in the induction of APOBEC expression. Since it was previously known that IFN-
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treatment of HIV-infected cells. To confirm the direct effect of IL-27 on HIV replication, this 
study went on to treat cells with a recombinant IL-27 (rIL-27) dose response and showed 
increasing suppression of HIV replication in the presence of increasing rIL-27 doses. 
Furthermore, to determine the specificity of IL-27-mediated inhibition of HIV replication, 
the authors performed real-time RT-PCR to examine transcription of HIV RNA in the 
presence of IL-27. Results indicated a 60 – 80% decrease in HIV transcription in the presence 
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The APOBEC proteins are key host cell-derived protective molecules, acting as anti-HIV 
proteins that function as cytidine deaminases to interfere with viral replication (Romani, 
Engelbrecht et al., 2009). Taken together, these results indicate that IL-27, like IFN-, 
significantly induces multiple IFIGs and APOBEC3G in macrophages, resulting in the 
striking anti-HIV functions of these cytokines. 
Subsequent to the initial studies on IL-27 functions in HIV infection, a separate research group 
set out to determine whether IL-27 directly or indirectly regulated expression of the APOBEC 
family of proteins (Greenwell-Wild, Vazquez et al., 2009). Since it had been previously shown 
that IFN- could regulate expression of APOBEC, clinical trials commenced to explore the 
impact of IFN- treatment on induction of APOBEC expression in the setting of HIV infection 
et (Neumann, Polis et al., 2007). However, the many negative side effects of IFN treatment led 
researchers to consider alternative mechanisms to induce APOBEC expression, in particular, 
mechanisms that minimize IFN toxicities associated with direct administration of this 
cytokine. Greenwell-Wild et al. (2009) showed that IL-27 could be a good alternative, as they 
showed IL-27 can induce APOBEC expression to curb HIV replication. This study attributed 
the anti-viral properties of IL-27 to the intermediary IL-27-induced IFN-, which can then, in 
turn, coordinate anti-viral responses. Interestingly, this study investigated whether other IL-12 
cytokine family members, namely IL-12 and IL-23, could suppress HIV replication. No 
significant reduction in HIV replication was observed with IL-12 or IL-23 treatments, 
indicating that the inhibition of HIV replication was selective to IL-27 in the IL-12 family of 
cytokines. This study went on to examine the kinetics of IL-27-induced APOBEC expression 
and found a 24 hour delay in the induction of expression by real-time PCR, suggestive of an 
intermediary in the induction of APOBEC expression. Since it was previously known that IFN-





intermediary molecules mediating IL-27-induced APOBEC expression. Greenwell-Wild et al. 
(2009) went on to show IL-27 can induce expression of both IFN- and –, and that these IFNs 
alone could inhibit HIV replication (p24 assay). Lastly, to confirm that IL-27 induces APOBEC 
expression through IFN, they blocked the IFNreceptor (IFNAR) with neutralizing 
antibody, followed with IL-27 stimulation, and found no induction of APOBEC expression, 
indicating IFN is an intermediate requirement in IL-27-induced APOBEC expression. 
Furthermore, when IFN and IL-27 were added in unison to cell cultures, enhanced inhibition 
of HIV replication was observed, pointing to additional antiviral mechanisms under the 
regulation of these cytokines. Taken together, this study illustrates teamwork between two 
cytokines, IFN and IL-27, in the suppression of HIV. 
So far we have reviewed how IL-27 can suppress HIV replication; however, limited studies 
have described how HIV can affect IL-27. The first study to investigate the impact of HIV 
infection on IL-27 investigated how clinical characteristics such as viral load, hepatitis C 
virus (HCV) co-infection, and CD4 T cell counts were associated with changes in circulating 
levels of IL-27 (Guzzo, Hopman et al., 2010). Guzzo et al. (2010) observed a modest negative 
correlation between IL-27 levels and HIV viral load, suggesting that circulating HIV virus 
may suppress IL-27 expression, a potential pathogenic mechanism for the virus to limit host 
anti-viral responses. Additionally, in this study, when patients were grouped according to 
those receiving HAART therapy and those naïve to HAART, no difference was found in IL-
27 expression, illustrating no impact of HAART on IL-27 expression. Lastly, this study 
investigated if IL-27 expression was associated with changing CD4 T cell counts. A 
consistent trend was observed among patient groups, namely, IL-27 expression peaked with 
moderate declines in CD4 T cell counts (200-350), then decreased in the low CD4 T cell count 
(<200) patients. The study authors hypothesized that the initial boost in IL-27 signified the 
host response to viral insult (declining CD4 T cells), as the host upregulates the anti-HIV 
cytokine as a protective response. However, as HIV disease progresses, dysregulated 
immune responses and increasing viral loads renders the host unable to produce adequate 
IL-27, and the observation of decreased IL-27 with low CD4 T cells counts was observed. 
Overall, this study suggested that HIV viral load, HCV co-infection, and CD4 T cell counts 
are strongly associated with changes in circulating levels IL-27 in the HIV-infected host. This 
research was the first to report how HIV infection might affect expression of IL-27, and to 
date, only one other study has investigated the effect of HIV on IL-27 expression (Palermo, 
Patterson et al., 2011). Palermo et al. (2011) performed alternative AIDS vaccine strategies in 
rhesus macaques followed by viral challenge with adenovirus-expressing HIV-env, SIV-gag, 
or SIV-nef proteins. Following vaccination and viral challenge, global transcriptional 
profiling was performed to characterize any significant alterations in gene expression. At the 
time of peak viremia in the animals, gene expression profiles of the immunized groups were 
different from that of controls. Of particular note was an upregulation of IL-27 expression in 
the immunized group, indicating the protective host response to virus is a boost in the anti-
viral cytokine, IL-27. This study reported significant differences in gene expression of a 
variety of immunological markers between treatment groups, suggesting new potential 
correlates of protection in HIV infection.  
Taking into account the role of IL-27 in driving the differentiation of Th1 cells and keeping 
in mind the ability of IL-27 to inhibit HIV replication, it is clear that further understanding 
of the regulation of IL-27 expression and function during HIV infection is an important area 
of research. It is possible that the use of treatments that upregulate the expression of this 
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cytokine may have a two-pronged beneficial effect: inhibition of virus replication and 
reinstating the Th1 CD4 T cell populations.  
4. IL-23 and HIV infection 
As discussed, the IL-12 family of cytokines regulates CD4 T cell development and immune 
responses. In particular, IL-23 is an IL-12 family member important in regulating the 
differentiation of the proinflammatory, IL-17-producing, Th17 cells. IL-23, a heterodimeric 
cytokine composed of covalently linked IL-12p40 and IL-23p19 subunits was originally 
discovered in 2000 and identified as a member of the IL-12-related cytokine family 
(Oppmann, Lesley et al., 2000). IL-23 is predominantly produced by activated myeloid cells 
such as activated monocytes, antigen-presenting cells, including dendritic cells and 
macrophages, T cells, B cells and endothelial cells (Oppmann, Lesley et al., 2000;Parham, 
Chirica et al., 2002;van Seventer, Nagai et al., 2002). IL-23 shares the IL-12p40 subunit with 
IL-12, and the IL-23-specific subunit, p19, forms a disulphide-linked heterodimer with the 
IL-12p40 subunit(Oppmann, Lesley et al., 2000). The high affinity IL-23 receptor complex is 
comprised of an IL-12Rβ1 (as found in IL-12 receptor) and a unique IL-23Rα subunit 
(Parham, Chirica et al., 2002). As mentioned in the previous section on IL-12, many studies 
have shown the effect of HIV infection on the production of IL-12 and IL-12 receptor 
expression; there is strong evidence suggesting that IL-12 production is impaired in cells 
infected in vitro with HIV and in HIV positive patients (Chehimi, Starr et al., 1994; Marshall, 
Chehimiet al., 1999;Daftarian, Diaz-Mitoma et al., 1995;Boucher, Parato et al., 2010; Buisson, 
Benlahrech et al., 2009). Since IL-12 and IL-23 share the p40 subunit as well as the IL-12R1 
receptor subunit, it is interesting to speculate on the impact of HIV on IL-23 function and the 
involvement of IL-23 in HIV pathogenesis. 
The ability of immune cells to produce IL-23 during HIV infection has not been fully 
studied. Lee and colleagues were the first to demonstrate that spontaneously produced 
IL-23p19 and IFN-γ mRNA from PBMC are reduced in HIV positive patients who 
exhibited increased CD4 T cell counts while on long term HAART (Lee, French, & Price, 
2004). The inability of the cells to produce “normal” levels of these key cytokines may 
compromise the immune response to opportunistic infections. A very recent study 
showed that LPS-induced IL-23 production by monocytes and dendritic cells from HIV 
positive patients was actually increased compared to HIV negative controls (Louis, 
Dutertre et al., 2010). This study included the first longitudinal analysis of IL-23 
production during primary HIV infection. The authors found that the production of IL-23 
was greatly increased and sustained during chronic infection. Interestingly, in response to 
simultaneous LPS and IFN-γ treatment, they also found that IL-23 production, but not IL-
12p70 production correlated strongly with viral loads. This study indicates that HIV 
induces the production of IL-23, and that IL-23 may have an important role in controlling 
viral infection. However, taken together, these studies have conflicting results. In the study 
by Lee et al., mRNA levels of p19 were examined whereas Louis et al. examined secreted 
IL-23, which may partially explain the observed discrepancy. In 2004, a study revealed 
that IL-23 has potent adjuvant effects on induction of epitope-specific cytotoxic T 
lymphocytes (CTLs) (Matsui, Moriya et al., 2004). The authors found that co-
administration of an IL-23 expression plasmid in a prime-boost immunization enhanced 
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IL-23 might offer a new prophylactic and therapeutic strategy for vaccine development 
against infectious pathogens.  
To date, the mechanism of how HIV affects the production of IL-23 is still not clear. 
However, a few studies have been reported on the molecular mechanism of the inhibitory 
action of HIV on IL-12, a related cytokine sharing the IL-12p40 subunit and IL-12R1 
receptor subunit with IL-23. An in vitro study showed that HIV infection of myeloid cells 
was able to disrupt MAP kinase activation and transcription factor binding to the IL-12p40 
promoter(Chambers, Parks et al., 2004). This observation may be explained as a direct effect 
of HIV on the IL-12p40 promoter or may occur as a consequence of altered MAP kinase 
activation. Indeed, the authors demonstrated that the phosphorylation of JNK and p38 
MAPK was impaired and the phosphorylation and degradation of IκBα was suppressed 
after HIV infection (Chambers, Parks, & Angel, 2004). Another in vitro study found that 
intracellular Nef inhibits LPS-induced IL-12p40 transcription by inhibiting the JNK-
activated NF-κB without affecting AP-1 activity (Ma, Mishra et al., 2009). This result 
suggests that intracellular Nef selectively inhibits NF-B activity (apart from other 
transcription factors, such as AP-1), resulting in the inhibition of IL-12p40 expression. 
Similar studies on the molecular mechanism of IL-23p19 regulation in the context of HIV 
infection have yet to be published. 
It is well known that IL-23 is important for the development of a proinflammatory subset of 
T cells, Th17. Little is known about how HIV modulates the function of IL-23 and how HIV 
affects the main downstream functions of this cytokine in the promotion of Th17 cells. If 
HIV infection decreases IL-23 production, Th17 expansion and activation may be 
downregulated. To date, no study has examined the correlation between IL-23 and the IL-
23/Th17 axis in HIV positive patients. Like IL-23, the roles of Th17 and IL-17 in HIV-
replication and immunopathogenesis are not well understood. In the next section we will 
discuss the impact of HIV infection on Th17 cell regulation.  
5. Th17 cells and HIV infection 
The discovery of the Th17 subset has expanded our understanding of T cell mediated 
immunity, leading to a revision of the classical model of T cell populations. Th17 is a 
proinflammatory T cell population that is involved in host immune defense against 
pathogens not adequately handled by Th1 or Th2 cells. The Th17 subset is termed after its 
main effector proinflammatory cytokine, IL-17. The differentiation of Th17 subset is driven 
by the combination of TGF-β and IL-6 which upregulate the transcription factor RORγt 
(McGeachy, Chen et al., 2009). Th17 cells mediate inflammation through upregulation of 
chemokine and inflammatory cytokine expression, and recruitment of macrophages and 
neutrophils (Gaffen, Kramer et al., 2006;Korn, Bettelli et al., 2009). The inflammatory 
response is amplified by the presence of all these factors, resulting in a greater inflammation 
than the response from Th1/Th2 cells. Th17 cells have been demonstrated to be specifically 
involved in immunity against Toxoplasma gondii, Candida albicans, Klebsiella pneumoniae and 
Mycobacterium tuberculosis (Conti, Shen et al., 2009; Gaffen, Kramer, Yu, & Shen, 2006; Korn, 
Bettelli, Oukka, & Kuchroo, 2009). However a role for Th17 cells in the regulation of virus 
infection has been a recent focal area of research, particularly in the case of HIV. 
Mucosal transmission of HIV is the main route of virus entry and site of initial virus infection. 
Th17 cells play important roles in the regulation of mucosal immunity, and they are found in 
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high concentration in the lamina propria of the GI tract (Hunt, 2010). Th17 cells prevent 
microbial translocation across mucosal surfaces by enhancing expression of antimicrobial 
peptides and mobilizing neutrophils to infected sites. At the same time, gut-associated 
lymphoid tissue (GALT) is a major reservoir for CD4 T cells, the source of Th17 cells, and a key 
site of HIV replication and CD4 T cell loss (Brenchley, Schacker et al., 2004;Mehandru, Poles et 
al., 2004). Pathogenic SIV as well as HIV infection results in rapid and significant Th17 loss 
from the GALT which would be expected to have deleterious effects on the regulation of 
microbial translocation (Brenchley, Schacker et al., 2004; Raffatellu, Santos et al., 2008). Indeed, 
HIV infection is correlated with increases in microbial translocation and mucosal inflammation 
(Gori, Tincati et al., 2008). This is supported by studies showing that plasma LPS levels, 
considered as an indication of microbial translocation, in HIV infected individuals are 
remarkably higher than uninfected individuals (Jiang, Lederman et al., 2009;d'Ettorre, 
Paiardini et al., 2011). Interestingly, SIV infected rhesus macaques exhibited Th17 depletion in 
ileal mucosa, resulting in a compromised mucosal barrier and susceptibility to Salmonella 
infection compared to that observed in uninfected macaques (Raffatellu, Santos, et al., 2008). 
Furthermore, in the same study, IL-17R deficient mice also had increased systemic 
dissemination of Salmonella from the gut. Together, this suggests that IL-17 deficiency may 
lead to impaired mucosal barrier function. An interesting report on V1 T cells, T cells present 
in mucosal tissues expressing the T cell receptor, demonstrated that HIV positive 
individuals exhibited an expanded population of these cells that produced both IFN-γ and IL-
17 (Fenoglio, Poggi et al., 2009). This is of interest to mucosal immunity and HIV, as circulating 
Vδ1 T lymphocytes, resident cells in GALT, are increased in HIV-1 infection due to mucosal 
depletion and recirculation (Nilssen, Muller et al., 1996;Fenoglio, Poggi et al., 2009). 
Additionally, Fenoglio et al. (2009) showed that these cells were able to proliferate and 
produce IFN-γ and IL-17 in response to C. albicans and that these cells expressed markers for a 
memory T cell phenotype as well as the Th17 transcription factor RORC. The elevation of this 
subset of T cells in the context of HIV infection may represent a possible mechanism to 
compensate for impaired CD4 T cells, and in particular, that of Th17. 
Studies elucidating the relationship between Th17 cells and HIV infection have yielded 
inconclusive results. The first report that associated HIV with IL-17 showed an increase of 
IL-17 production by CD4 T cells in peripheral blood of HIV patients both in cells left 
untreated or stimulated with PMA/ionomycin (Maek, Buranapraditkun et al., 2007). It was 
later shown that HIV-1 infected children with a plasma viral load of below 50 copies/ml 
(undetectable HIV) had enhanced IL-17 production in contrast to those with detectable HIV, 
which had no observable IL-17 production (Ndhlovu, Chapman et al., 2008). This suggested 
a possible impairment of Th17 cells in patients with detectable HIV levels and decreased IL-
17 levels, and that restoration of Th17 cells could be possible through suppression of 
viremia. In 2008, Macal et al. showed that CD4 T cell restoration (>50%) could be achieved 
regardless of persistent proviral burden and previous HAART (Macal, Sankaran et al., 2008). 
This CD4 T cell restoration was associated with enhanced Th17 CD4 T cell accumulation. 
Additionally, HIV-1 and CMV specific IL-17 producing CD4 T cells are detectable in early 
HIV-1 infection, but are undetectable in chronic and non-progressive HIV-1 infection (Yue, 
Merchant et al., 2008). These experiments together suggest that IL-17 producing T cells are 
associated with viral load and disease progression. They also call into question of what 
impact the restoration of Th17 cells would have on the progression of HIV in the long run. If 
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of the disease towards AIDS, in particular with regard to the function of these cells to 
control possible fungal, parasitic, and bacterial opportunistic infections. 
It is unclear if Th17 cells are preferentially targeted by HIV for infection. One study 
suggested preferential targeting of CCR6+CCR5+ Th17 cells by CCR5 tropic viruses in vivo 
(El Hed, Khaitan et al., 2010). CCR4+ CCR6+ and CXCR3+ CCR6+ T cells express cytokines 
and transcription factors specific for Th17 and Th1/Th17 lineages respectively. These 
markers contribute to gut and lymph node homing potential. These two types of cells are 
highly permissive to HIV replication in that while their frequency is diminished, they can 
recruit more CCR6+ T cells into sites of viral replication (Gosselin, Monteiro et al., 2010). 
Similarly, in SIV infection, α4β7hiCD4 memory T cells were found to harbour most Th17 
cells and were significantly depleted (Kader, Wang et al., 2009). In SIV infected macaques, 
one group found that Th17 loss at mucosal surfaces predicted AIDS progression 
(Cecchinato, Trindade et al., 2008). Furthermore, there was a negative correlation between 
Th17 cell frequencies at mucosal sites and plasma virus level. Altogether these papers found 
that Th17 cells were preferentially depleted within a few weeks in HIV/SIV infection. Other 
reports show that Th17 cells may not be preferentially infected by HIV in vivo. Rather, CD4 
T cell development was shown to be skewed away from the Th17 phenotype toward Th1 
cell maturation in HIV patients (Brenchley, Paiardini et al., 2008) possibly leading to a 
significant loss of Th17 cells in the GI tract of HIV patients.  
Although there is ample evidence to state that Th17 is important in HIV pathogenesis, it is 
still unclear how Th17 cells and IL-17 are regulated during HIV infection. Understanding 
how Th17 cells are dysregulated by HIV infection is crucial to restoring its population and 
function and it is possible that treatments designed to increase Th17 levels may be beneficial 
to HIV infection. This may be particularly important in the protection against opportunistic 
diseases, given that Th17 cells have been well characterized to protect against bacterial, 
parasitic, and fungal infections. 
6. Treg in HIV infection 
Treg cells function to prevent chronic immune activation and act in a suppressive manner to 
control immune activation. These cells are generally defined phenotypically as CD4, CD25+, 
and Foxp3+. It appears that within the setting of HIV infection, the Treg CD4 T cell population 
may be protective to the host by potentially suppressing HIV infection in conventional CD4 T 
cells as well as cytotoxic T cell activity (Moreno-Fernandez, Rueda et al., 2011;Kinter, McNally 
et al., 2007). The Treg population has been demonstrated to coordinate and maintain virus-
specific immune responses (Rouse, Sarangi et al., 2006). Although Tregs have been shown to 
be infected by HIV, this may depend on the strain as well as host and viral properties. Moreno-
Fernandez and colleagues (2009) demonstrated that X4 viruses exhibited a higher level of 
infection in Tregs at early time points compared to R5 viruses in Tregs and X4 viruses in 
effector T cells (Moreno-Fernandez, Zapata et al., 2009). A study which examined viral 
persistence in Treg cells found that these cells are preferentially targeted by HIV, as a greater 
number of Treg cells harboured more HIV DNA than non-Treg cells (Tran, de Goer de Herve 
MG et al., 2008). Of interest, the Foxp3 Treg transcription factor has been shown to enhance 
HIV gene expression via an NF-B dependent mechanism(Holmes, Knudsen et al., 2007). 
Additionally, HIV-specific Treg cells have been detected (Kared, Lelievre et al., 2008;Torheim, 
Ndhlovu et al., 2009). Indeed, HIV has been shown to bind to Treg cells via gp120/CD4 
interactions which has been correlated with increased suppressive activities, extended Treg 
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survival, and upregulated homing receptors for peripheral lymph nodes and mucosal 
lymphoid tissues (Ji & Cloyd, 2009;Nilsson, Boasso et al., 2006). In the same study, it was 
shown that these Treg cells did not exhibit the same homing-induced apoptosis. Taken 
together, this suggests that the HIV-Treg interaction may contribute to upregulated levels of 
Tregs observed in lymphoid and mucosal compartments in HIV positive patients (Mozos, 
Garrido et al., 2007; Ji & Cloyd, 2009; Nilsson, Boasso et al., 2006).  
Absolute numbers of Treg and Treg frequency during HIV infection is an area of contention 
in this field. However, it has been demonstrated that the relative frequency of Treg cells 
within the CD4 T cell population as a whole appears to increase during HIV infection while 
at the same time, the absolute numbers of Tregs decline(Schulze Zur, Thomssen et al., 2011). 
This is supported by several studies which indicated a gradual decline in Treg absolute 
numbers during HIV pathogenesis (Jiao, Fu et al., 2009; Prendergast, Prado et al., 2010; 
Thorborn, Pomeroy et al., 2010; Cao, Jamieson et al., 2009). In particular, in primary HIV 
infection in untreated individuals, HIV-specific Treg cells and suppressive activity 
decreased over a 24 month follow-up period (Kared, Lelievre et al., 2008). Interestingly, a 
recent study by Weis et al. (2010) demonstrated that Treg cells were able to control immune 
activation in patients on ART, however this control was lost during interruption of ART, an 
observation attributed to the decline in absolute Treg numbers(Weiss, Piketty et al., 2010).  
Immune activation during HIV infection has been linked to HIV progression and negative 
outcomes during HIV infection (Douek, 2003; Kassiotis & O'Garra, 2008; Lawn, Butera et al., 
2001; Terzieva, 2008). Tregs could be protective as they can control this immune 
hyperactivation especially during chronic infection (Fazekas de St & Landay, 2008; Belkaid 
& Rouse, 2005). On the other hand, excess Treg activity results in “over” suppression of 
immune responses resulting in too much immune suppression, leading to faster HIV 
progression and negative outcomes (Kinter, Horak et al., 2007). This point is also supported 
by a report showing that recombinant IL-2 treatment in a phase III trial actually enhanced 
Treg populations, possibly explaining why this treatment failed to elicit better clinical 
outcome (Weiss, Letimier et al., 2010). Treg depletion has been associated with an increase in 
immune activation (Eggena, Barugahare et al., 2005) and several important studies have 
demonstrated correlation of Treg proliferation and turnover with lower CD4 counts (Bi, 
Suzuki et al., 2009; Piconi, Trabattoni et al., 2010; Xing, Fu et al., 2010).  
Interestingly, elite controllers, a rare population of individuals that can maintain 
undetectable HIV viral loads in the absence of HAART, demonstrated higher frequencies of 
Treg cells compared to individuals on HAART (Chase, Yang et al., 2008). On the other hand, 
Owen et al., showed that individuals on HAART had higher frequencies of Tregs compared 
to elite controllers (Owen, Heitman et al., 2010). In contrast yet again, more recent studies 
have demonstrated that elite controllers have a lower level of Treg cells compared to viremic 
individuals, but that this “low” level of Tregs is similar to that observed in HIV positive 
individuals with viral load controlled by HAART (Brandt, Benfield et al., 2011). In support 
of this, another group demonstrated that elite controllers had an even lower Treg frequency 
than HIV negative individuals (Hunt, Landay et al., 2011). In view of these studies it seems 
that the Treg frequency in elite controllers may vary according to the patient group 
examined and to which group the comparison is being made.  
7. Th17 versus Treg in HIV infection 
Since the main function of Th17 is to mediate inflammatory responses, and it is involved in 
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to host tissue. Treg development is inexorably associated with Th17 development. IL-2, an 
important growth factor for T cells, is one of several cytokines that mediates the balance 
between Th17 and Tregs. In vitro, levels of Th17 were reduced in the presence of IL-2, while 
Treg numbers increased with IL-2 stimulation (Stockinger, 2007). The same is true with 
respect to HIV infection; a recent study demonstrated that administration of IL-2 to HIV 
patients on ART resulted in enhanced levels of CD4 T cells and Treg cells (Ndhlovu, Sinclair 
et al., 2010b). Overall enhancement of the CD4 T cell count was attributed to enhanced levels 
of naïve T cells. At the same time, this resulted in a decrease in Th17 cell frequency, 
although the absolute numbers of Th17 did not change. These results suggest then that IL-2 
is important for driving the differentiation of CD4 T cells and is selective for Treg 
development while not affecting levels of Th17 cells already present.  
As mentioned before, TGF-β function straddles the border between Treg and Th17 
differentiation depending on the presence of IL-6. It is suggested that TGF-β is constitutively 
produced by the resting immune system to induce Tregs to limit the effect of activated 
memory T cells (Korn, Bettelli, Oukka, & Kuchroo, 2009). However, in the event that the 
immune system is triggered, IL-6 is induced to inhibit the production of Tregs and cause a 
switch towards Th17 development (Korn, Bettelli, Oukka, & Kuchroo, 2009). This supports 
the claim that both TGF-β and IL-6 must be present for Th17 differentiation. The parallel use 
of TGF-β in both Treg and Th17 subsets may be important in mediating the balance between 
the two. It has been suggested that Th17 and Treg share a reciprocal relationship (Bettelli, 
Carrier et al, 2006; Mucida, Park et al., 2007; Zhou, Lopes et al., 2008; Quintana, Basso et al., 
2008). It has been shown that the observed rapid Th17 decline in acute HIV infection is 
predictive of the immune activation later seen in chronic infection. These studies also 
observed a loss of the Th17/Treg balance in pathogenic SIV infection (Lederer, Favre et al., 
2009). More recently, Prendergast et al (2010) demonstrated a profound loss of Th17 cells 
before advanced disease, in contrast to a gradual decline of Treg cells (Prendergast, Prado et 
al,, 2010). In a recent review, B. Kanwar et al. suggest that it is the relative balance of these 
two subsets of T cells that is key to the regulation of progression of HIV/AIDS, as opposed 
to considering only the specific functions of either subset alone(Kanwar, Favre et al., 2010). 
Future work in this regard will be key to furthering our understanding of the impact of this 
virus on our immune system. 
8. The “other” subsets: Th2, Th9, Tfh 
As discussed above, clearly HIV infection impacts the function of Th1, Th17, and Treg cells. 
The antibody response supported by the Th2 T cell subset is critically important to anti-HIV 
immune responses, however the scope of this topic fell outside the realm of this chapter. 
Currently little is known about the impact of HIV infection on the development and 
function of Th9 and Tfh cells. It is interesting to speculate that the differentiation 
programming and functional effects of these cells are disrupted during infection and 
warrant further research in this regard. 
9. Conclusion 
In Figure 2, the overall effect of HIV infection on Th cell subset is illustrated. In actuality, it 
is likely that the mechanisms and impact of the virus on these cells is much more complex 
than portrayed here, however this diagram summarizes the general outcome of CD4 T cell 
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differentiation in terms of Th1, Treg, and Th17 cells during HIV infection. Our immune 
systems consist of many complex processes that are interconnected and the effect of 
inhibiting or upregulating particular cell types will affect not only that particular cell type, 
but a multitude of other cells and cellular processes. As we further our understanding of 
HIV infection and HAART on the regulation of the differentiation of the CD4 T cell 
response, this will enhance our ability to design new treatment therapeutics and potential 
vaccine targets. 
 
Fig. 2. Impact of HIV infection on the IL-12 family of cytokines and their respective effects 
on CD4 T cell development. Shown are the T helper (Th) subsets discussed in detail in this 
chapter. Cytokines that induce their differentiation are shown preceding the cell type, and 
effector cytokines are listed below each cell type. Dark arrows indicate well-defined 
increases (up arrow) or decreases (down arrows) in cytokines (IL-12) or Th cells (Th17 and 
Treg). Large arrows with question marks indicate increases (up arrows) or decreases (down 
arrow) in cytokine and receptor expression that are not well defined. Shown in the top left is 
the ability of IL-27 to inhibit HIV replication.   
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1. Introduction 
The HIV epidemic continues to be a major world-wide health and human problem as 
reflected in the AIDS epidemic updates from the World Health Organization (WHO). 
Highly active antiretroviral therapy (HAART) has improved health management, especially 
in developed countries, since it was first introduced in the mid-1990s. However, access to 
antiretroviral therapy in developing countries has been limited. Developing an effective 
vaccine is an on-going mission, the success of which depends on understanding key aspects 
of the immune response to HIV. Hence, studying the genetic components of the immune 
response to the HIV virus is essential.  
The existence of genetic factors that modulate immune response to infectious diseases was 
described more than 10 years ago (Hill, 1998). We recommend various recent and extensive 
reviews that have focused on the immunobiology of HIV infection (Tripathi and Agrawal, 
2007), the immune response to HIV (Chakrabarti and Simon, 2010; Miyazawa, et al. 2008) 
and specifically the innate response (Borrow and Bhardwaj 2008). Innate and adaptive 
immune responses play a decisive role during the initial stages of HIV infection and will 
also affect the progression of the disease. Definitive evidence that host genetics plays a role 
in the immune response to HIV is the fact that HIV-1 infection does not always progress to 
AIDS. A small percentage (less than 0.2%) of HIV-1 sero-positive patients is able to control 
the infection, meaning that they can maintain a viral load of fewer than 50 copies of HIV-1 
RNA per ml over 10 years. These patients have been given different names: HIV controllers, 
HIV elite controllers, long-term non-progressors (LTNPs) or natural virus suppressors 
(Chakrabarti and Simon, 2010).  
This chapter focuses on the influence exerted on HIV infection by the human major 
histocompatibility complex (MHC) system, also known as the human leukocyte antigen 
(HLA) system. The effect of the MHC system on HIV infection is crucial for development of 
an effective vaccine. We recommend several reviews on this subject that complement the 
present monograph (Carrington and O'Brien, 2003; Stephens, 2005; Miyazawa et al. 2008; 
Kaur and Mehra, 2009; Singh and Spector, 2009). In this chapter, we will first describe the 
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literature on the influence of the MHC on both horizontal and vertical (mother-to-infant) 
transmission. Finally, we highlight the molecular basis of the most important associations 
currently believed to exist between MHC and HIV transmission, with special emphasis on 
recent theories about how the MHC shapes the cytotoxic T cell (CTL) response and its 
relation to the appearance of HIV escape variants.  
2. The human Major Histocompatibility Complex (MHC) 
The MHC is located on the short arm of chromosome 6 and contains a large number of 
genes related to immune system function. Some MHC genes encode proteins that help to 
distinguish self and non-self components. They were first discovered in transplantation 
immunology and the gene products were called antigens. There are 3 major classes: Class I 
molecules are encoded by classical genes (A-C) and non-classical genes (E-G). Class II 
molecules are encoded by classical genes (DP, DQ, DR) and non-classical ones (DM, DOA, 




Fig. 1. Schematic of the Human Major Histocompatibility Complex (MHC). 
2.1 The human MHC class I molecules 
The class I protein comprises a α-polypeptide chain that associates with the invariant β 
chain β2 microglobulin (β2m). MHC class I molecules (A, B, C) present peptides mainly 
from inside the cell; for example, they present viral peptides when these are found in the cell 
cytoplasm. These peptides are produced by the proteasome, which breaks down proteins to 
fragments approximately 9 amino acids (AA) long. Viral, bacterial or self-peptides will be 
displayed in the binding cleft of the MHC molecule on the cell surface, in a process known 
as antigen presentation; the displayed fragments are recognized by CD8+ or cytotoxic T cells 
(CTLs), which destroy infected cells. Each person expresses 3 MHC class I molecules (A, B, 
C) from each chromosome. Most nucleated cells express class I molecules. Many viruses 
reduce the expression of MHC class I molecules to hamper the immune response. This is the 
case of HIV, which down-regulates CD4 and HLA class I expression through its Nef protein 
(Greenberg et al., 1998). Compared to the HLA-A and -B loci, the HLA-C locus shows less 
polymorphism. In addition HLA-C proteins are expressed at lower levels on the cell surface, 
and seem to bind primarily to natural killer immunoglobulin-like receptors (KIRs). 
Class Ia molecules show greater polymorphism and wider tissue distribution than class Ib 
molecules. Of the non-classical HLA class I molecules involved in HIV infection, HLA-G is 
the best studied. Alternative splicing of HLA-G gives rise to 7 isoforms, 4 membrane-bound 
(HLA-G 1-4) and 3 soluble (HLA-G 5-7). G5 and its membrane-bound counterpart G1 are 
proteolytically released from the membrane to give rise to the major soluble forms of HLA-
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G. HLA-G is expressed in placental trophoblast cells as well as in the thymus, pancreas and 
other tissues. Its ectopic expression has been reported under various pathological 
conditions, including viral infections. It is currently accepted that HLA-G molecules exert 
immunosuppressive functions (Fainardi et al., 2011). 
2.2 The human MHC class II molecules 
These are encoded by three classical genes (HLA-DP, -DQ and -DR) and two non-classical 
ones (HLA-DM and -DO) (reviewed by (Handunnetthi et al., 2010)). This region includes 
other genes implicated in antigen processing, such as the genes encoding transporter 
associated with antigen processing protein 1 and 2 (TAP1 and TAP2). Class II molecules 
comprise  andchains. Their expression is restricted mainly to thymic epithelial cells and 
bone marrow-derived antigen-presenting cells. The latter include B cells, macrophages (M) 
and dendritic cells (DCs). Differentiation of B cells into plasma cells, as well as 
differentiation of dendritic cells, is accompanied by down-regulation of MHC class II 
expression. On the contrary activation of T cells up-regulates their expression of class II 
molecules. 
In the HLA-DR sub-region the gene DRA encodes 1 unpolymorphic  chain with only 1 
common and 2 very rare alleles. The  chain is encoded by the very polymorphic DRB1 
gene. There are 3 DRB1 paralogue genes: DRB3, DRB4 and DRB5, however DRB1 is 
expressed at a level five times higher than them. The MHC class II is highly polymorphic. 
For instance, there are over 500 different HLA DRB1 alleles in humans. The DRB loci are 
classified into 5 major haplogroups according to the number of functional genes (DRB1, 3, 4 
and 5) and pseudogenes (DRB2, 6, 7, 8, 9) that are present (Table I).  
 
Halogroup Genes and Pseudogenes 
DR1 DRB1, DRB6 and DRB9 
DR8 DRB1 and DRB9 
DR51 DRB1, DRB5, DRB6 and DRB9 
DR52 DRB1, DRB2, DRB3 and DRB9 
DR53 DRB1M DRB4M DRB7, DRB8 and DRB9 
Families of DRB1 allelic lineage Genes 
DR1 HLA-DRB1*01 and *10 
DR8 HLA-DRB1*08 
DR51 HLA-DRB1*15 and *16 
DR52 HLA-DRB1*03, *11, *13 and *14 
DR53 HLA-DRB1*04, *07 and *09 
Table 1. DRB loci classification in halogroups and DRB1 families. 
Classical class II MHC genes are: 
HLA-DP: α-chain encoded by the HLA-DPA1 locus (16 alleles) and β-chain encoded by the 
HLA-DPB1 locus (118 alleles). 
HLA-DQ: α-chain encoded by the HLA-DQA1 locus (25 alleles) and β-chain encoded by the 
HLA-DQB1 locus (72 alleles).  
HLA-DR: α-chain encoded by the HLA-DRA locus and 4 β-chains encoded by the HLA-
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The expression of MHC class II genes is tightly regulated, primarily at the transcriptional 
level. Their promoter contains regulatory elements collectively called the “SXY module”, to 
which various proteins bind, including regulatory factor X (RFX) and the class II 
transactivator (CIITA) (Handunnetthi et al., 2010). Induction of CIITA and subsequent 
expression of the MHC class II isotype HLA-DR are hallmarks of CD4+ T cell activation 
which, paradoxically, favors HIV replication. Interestingly, CIITA is able to inhibit HIV-1 in 
infected cells by blocking the function of the viral transactivators Tat and Tax (Tosi et al., 
2009). 
A key question about the influence of MHC on infectious disease is whether allele-specific 
sequence variation that affects the level of expression of HLA proteins can lead to class II-
associated diseases. For instance, transcripts in resting peripheral B cells have been reported 
to be more abundant within the DR52 haplogroup than within the DR53 haplogroup. A vast 
number of self-antigens are expressed at high levels in the thymic epithelium. It is 
postulated that a general reduction of self-antigen expression in the thymus could result in 
loss of central tolerance, meaning that thymocytes with excessive reactivity to self-antigens 
escape elimination. Does this increase susceptibility to infectious diseases? In the case of 
HIV, it seems that MHC-II presentation, at least by monocytes/macrophages, is preserved 
during infection (Woc-Colburn et al., 2010).  
Aside from the genes encoding the major antigens, a large number of other genes are located 
in the HLA complex (Fig. 1), many of which are involved in immune function. One 
significant characteristic of the HLA system is its tremendous polymorphism in the human 
population: there are many different alleles for each locus (ImmunoGeneTics HLA database: 
http://www.ebi.ac.uk./imgt/hal/atats.html). This implies that the chance of two unrelated 
individuals having identical HLA molecules on all loci is very low.  
3. Historical perspective: HLA-disease association studies and HIV infection 
The first reviews of HLA association with disease are from the late 1970s (Thomson and 
Bodmer, 1979) and early 1980s (Svejgaard et al., 1983), followed by other studies on HLA 
susceptibility to HIV infection (Scorza Smeraldi et al. ,1986; Just, 1995; Fauci, 1996; Buchacz 
et al. 1998) . 
HLA genes exhibit “linkage disequilibrium”, meaning that they are found together on the 
same chromosome at a higher frequency than expected according to their recombination 
distance. They are defined as a so-called “extended haplotype” or combination of alleles that 
are transmitted together as a unit. As with any gene frequently found in linkage 
disequilibrium with others, it is difficult to identify the specific HLA gene that is responsible 
for a given association observed in a population (Svejgaard et al., 1983). 
Studies of HLA associations with infectious diseases must separate HLA effects from many 
confounding factors, which are other factors that independently affect the risk of 
developing the disease. If the prevalence of these other factors differs between the groups 
being compared, they will distort the observed association. In the case of HLA/HIV 
associations, confounding factors include the ethnicity of the population studied, the 
frequencies of the HLA alleles detected and the resolution of the typing methods used. HLA 
associations are considered to be “consistent” when a similar or equivalent association is 
observed across different ethnic groups (Tripathi and Agrawal, 2007). 
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3.1 HIV associations and ancestral haplotypes 
Initial association analyses focused on ancestral haplotypes. An increased frequency of C4 
null alleles was found in HIV-infected individuals, which could in fact reflect an indirect 
association with a discrete number of ancestral haplotypes (Cameron et al., 1990). At that 
time a series of studies focused on the A1-B8-DR3-DQ2 haplotype, also known as the 8.1 
ancestral haplotype, which has been implicated in disease susceptibility (McNeil et al., 1996; 
Price et al., 1999). In addition, the HLA-B27 allele was found to be related to slow HIV 
disease progression (McNeil et al., 1996). Closer analysis of ancestral haplotypes points to a 
direct role of HLA-B35 in rapid HIV progression, and this allele is thought to be associated 
with disease susceptibility (Flores-Villanueva et al., 2003).  
3.2 HIV infection and HLA frequencies of individual alleles 
The proliferation of studies on associations between HLA frequencies and HIV infection 
made it clear to experts that it would be necessary to establish uniform research standards, 
such as more concrete definitions of HIV disease and its progression (Mann et al., 1992). 
Focusing on particular aspects of the disease, researchers were able to study a cohort of 106 
homosexual men from Amsterdam and correlate certain alleles with different aspects of HIV 
pathogenesis, including skin rash (HLA-B62), rapid decline of CD4+ T lymphocytes to < 
200/microL (HLA-B35), AIDS-related Kaposi's sarcoma (HLA-DR1) and opportunistic 
infections (HLA-DR3 and DQ2) (Klein et al., 1994). HLA disease associations studies were 
performed in different populations, such as in India (Shankarkumar, 2004), south India 
(Selvaraj et al., 2006) and southern Africa (Lombard et al., 2006). 
An important milestone in demonstrating that HIV-1 disease progression is associated with 
MHC genes was the discovery of HLA concordance between hemophilic siblings: pairs that 
shared one or two haplotypes were significantly concordant in CD4+ T cell decline and 
AIDS status within 5 years of seroconversion, while no concordance was found in pairs 
sharing no haplotypes. This is strong evidence that HLA is a determining factor or at least a 
relevant marker of disease progression. 
The expression level of HLA-G during HIV infection was found to be higher in monocytes 
from patients under HAART than from untreated individuals. Similarly, T cells from 
infected individuals express HLA-G. Different HLA-G alleles have been associated with 
protection (G-0105N9) and susceptibility (G-010108) (Fainardi et al. 2011). 
Viral load is an important factor determining the progression of HIV-1 infection. The initial 
peak of infection is followed by a period when the level remains relatively stable; the level 
during this period is called the “viral load set point” (VLS). A recent study addressed the 
influence of genetic factors, including HLA genotype, on the VLS (Saathoff et al., 2010). The 
study population was from Tanzania and was composed of three groups: female bar 
workers and females and males from the general population. HLA alleles were classified as 
protective (A*0205, B*5801, B*8101, B*4201, B*5703), harmful (B*5802, B*4501, B*1801 and 
B*1503) or neutral (all others). The prevalence of elevated viral load was 40% lower among 
individuals with protective alleles than among those with neutral ones. The major 
conclusion from this study is that male gender and possessing harmful HLA alleles are 
associated with higher VLS.  
HLA class II molecules are involved in presenting antigens to CD4+ T cells, which are 
central for establishing helper T responses. The HLA class II allele DRB1*1303 was 





The expression of MHC class II genes is tightly regulated, primarily at the transcriptional 
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expression of the MHC class II isotype HLA-DR are hallmarks of CD4+ T cell activation 
which, paradoxically, favors HIV replication. Interestingly, CIITA is able to inhibit HIV-1 in 
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population: there are many different alleles for each locus (ImmunoGeneTics HLA database: 
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associations are considered to be “consistent” when a similar or equivalent association is 
observed across different ethnic groups (Tripathi and Agrawal, 2007). 
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The expression level of HLA-G during HIV infection was found to be higher in monocytes 
from patients under HAART than from untreated individuals. Similarly, T cells from 
infected individuals express HLA-G. Different HLA-G alleles have been associated with 
protection (G-0105N9) and susceptibility (G-010108) (Fainardi et al. 2011). 
Viral load is an important factor determining the progression of HIV-1 infection. The initial 
peak of infection is followed by a period when the level remains relatively stable; the level 
during this period is called the “viral load set point” (VLS). A recent study addressed the 
influence of genetic factors, including HLA genotype, on the VLS (Saathoff et al., 2010). The 
study population was from Tanzania and was composed of three groups: female bar 
workers and females and males from the general population. HLA alleles were classified as 
protective (A*0205, B*5801, B*8101, B*4201, B*5703), harmful (B*5802, B*4501, B*1801 and 
B*1503) or neutral (all others). The prevalence of elevated viral load was 40% lower among 
individuals with protective alleles than among those with neutral ones. The major 
conclusion from this study is that male gender and possessing harmful HLA alleles are 
associated with higher VLS.  
HLA class II molecules are involved in presenting antigens to CD4+ T cells, which are 
central for establishing helper T responses. The HLA class II allele DRB1*1303 was 





with HIV-1 clade C. This association was confirmed in a larger cohort of 1436 male European 
Americans infected with HIV-1 clade B, demonstrating that the association was independent 
of ethnicity and viral subtype. Whether the protective effect exerted by this allele is due to the 
development of CD4+ T cell responses has yet to be shown (Julg et al., 2010). 
3.3 Advantage of heterozygous individuals 
Heterozygosity of MHC genes has long been thought to confer an advantage in the battle 
against infectious agents, and possessing different alleles at class I and II loci should 
therefore represent a benefit for HIV-infected individuals. Carrington et al. (Carrington et 
al., 1999) corroborated this key immune system dogma by studying HIV infection. They 
found that maximum heterozygosity of HLA-A, -B, and -C genes delayed progression to 
AIDS, while individuals who were homozygous at one or more loci progressed rapidly to 
AIDS. Furthermore, they were able to conclude that B*35 and Cw*04 were consistently 
associated with rapid development of AIDS in Caucasians. This work led to the proposal of 
a “heterozygote advantage and B*35-Cw*04 disadvantage theory" (Carrington et al., 1999). 
In subsequent work, the researchers studied the role of TAP genes and HLA supertypes in 
resistance to HIV infection. They found that the B*35 Px alleles were a risk factor, while the 
presence of alanine at position 665 in TAP2 was associated with resistance. Whether this 
resistance was due to a higher efficiency in transporting peptides, or was a consequence of 
linkage disequilibrium, was not resolved (Liu et al., 2003). Further studies have sought to 
consolidate our understanding of HLA-B35 alleles as risk factors, and have extended the 
findings in Caucasians to other populations (Shankarkumar et al., 2003). 
3.4 HLA supertypes  
Several studies have focused on the analysis of HLA supertypes (Sidney et al., 2008), in 
which HLA alleles are functionally classified according to their peptide-binding specificities 
(MacDonald et al., 2001). An attempt was made to group different HLA-B antigens 
(identified in patients by serology) according to their peptide-anchoring pockets, in order to 
determine whether the abovementioned associations could be explained by differences in 
the peptide repertoire presented by those molecules (Itescu et al., 1995). Later on, it was 
proposed that HIV adapts to the most frequent alleles in the population, implying that the 
expression of rare supertypes confers an advantage (Trachtenberg et al., 2003). 
3.5 Modern theories  
A recent study that, in our opinion, is an important breakthrough in the field, proposed that 
it is not the contribution of only one “relevant” allele that governs disease susceptibility but 
rather the sum of small contributions from several alleles (Leslie et al., 2010). The authors of 
that study justified their reasoning based on the fact that after excluding subjects expressing 
any of the important HLA-B class I alleles that strongly affect HIV control (B*57, B*58, and 
B*18), HLA-B alleles continued to play the dominant role in the observed progression (Leslie 
et al., 2010). If true, this idea would help reconcile some of the disparities reported in the 
literature. 
4. Vertical (mother-to-child) transmission of HIV-1  
Perinatal HIV-1 infection constitutes a significant global health problem and prevention of 
transmission is a high public health priority (Matt and Roger, 2001; Ahmad, 2010; UNAIDS, 
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2010). Much progress has been made in the development and implementation of strategies 
designed to interrupt vertical transmission. Antiretroviral therapy in HIV-infected pregnant 
women has significantly reduced the rate of mother-to-child transmission in developed 
countries down to 1% (Coovadia, 2004). In developing countries, however, many women 
still have limited access to antiretrovirals, and HIV-1 infection in children remains a major 
concern, with approximately 500,000 new HIV-1 infected infants born every year worldwide 
(Ahmad, 2010; UNAIDS, 2010). Prevention of maternal-fetal transmission of HIV-1 is 
therefore a global priority, especially in developing countries. 
Several lines of evidence suggest that host genetic factors are important determinants of 
both susceptibility to vertical transmission of HIV-1 and subsequent progression of AIDS in 
children (Matt and Roger, 2001). The identification of genetic markers linked with 
transmission and disease progression can help to define risk factors associated with vertical 
transmission and provide new insights into HIV-1 pathogenesis that can help in the 
development of an effective HIV-1 vaccine. 
In addition, pediatric HIV infection offers a good opportunity to investigate the influence of 
host genetics on the evolution of HIV, since the virus has first been in contact with the 
mother’s immune system and is then transmitted to a genetically related individual.  
In children with perinatally acquired HIV-1 infection, the expression of clinical and 
immunologic signs of disease seems to follow a bimodal distribution. At the beginning of 
the original HIV epidemic in the 1980s and 1990s, approximately 15–20% of infected infants 
showed an early and severe course of disease and died within the first 2 years of life. The 
remaining children progressed more slowly and had a less severe course, surviving an 
average of 8 years or more (Blanche et al., 1994). Today, children perinatally infected with 
HIV-1 reach adolescence, largely because of advances in treatment over the past 10 years 
(Dollfus et al., 2010). 
4.1 Routes of vertical HIV transmission 
HIV-1 vertical transmission occurs mainly during the following stages (Ahmad, 2010):  
1. prepartum, due to transplacental passage in utero,  
2. intrapartum, due to exposure of infant skin and mucus membranes to maternal blood 
and vaginal secretions during delivery, and  
3. postpartum, due to exposure to contaminated breastmilk during nursing  
In the absence of prophylactic treatment, it is estimated that one-third of children are 
infected in utero (prepartum) and two-thirds are infected intrapartum or postpartum (Kuhn et 
al., 1997). Various factors appear to affect vertical transmission throughout the gestation 
period and it seems probable that an interplay of all factors occurs, with some factors more 
determinant than others during specific periods. For instance, factors protecting against in 
utero infection may be less efficient against delivery or breast-feeding transmission. A 
general and global strategy concerning all known factors must be used to prevent vertical 
transmission (Bongertz, 2001). A greater understanding of the role played by various risk 
factors for HIV-1 infection is crucial to designing new preventive and therapeutic strategies. 
The risk of prepartum transmission depends on exposure of the fetus in utero to free virus or 
to HIV-infected maternal cells (Mittleman and Shearer, 1996), the risk of which is likely to be 
very high (Matt and Roger, 2001). Relatively few maternal cells are thought to enter the fetal 
circulation during gestation under normal circumstances. However, HIV-1 is known to 
infect cells within the placenta (Kesson et al., 1993). Intrauterine infection has therefore been 
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associated with rapid development of AIDS in Caucasians. This work led to the proposal of 
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resistance was due to a higher efficiency in transporting peptides, or was a consequence of 
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(identified in patients by serology) according to their peptide-anchoring pockets, in order to 
determine whether the abovementioned associations could be explained by differences in 
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expression of rare supertypes confers an advantage (Trachtenberg et al., 2003). 
3.5 Modern theories  
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that study justified their reasoning based on the fact that after excluding subjects expressing 
any of the important HLA-B class I alleles that strongly affect HIV control (B*57, B*58, and 
B*18), HLA-B alleles continued to play the dominant role in the observed progression (Leslie 
et al., 2010). If true, this idea would help reconcile some of the disparities reported in the 
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4. Vertical (mother-to-child) transmission of HIV-1  
Perinatal HIV-1 infection constitutes a significant global health problem and prevention of 
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2010). Much progress has been made in the development and implementation of strategies 
designed to interrupt vertical transmission. Antiretroviral therapy in HIV-infected pregnant 
women has significantly reduced the rate of mother-to-child transmission in developed 
countries down to 1% (Coovadia, 2004). In developing countries, however, many women 
still have limited access to antiretrovirals, and HIV-1 infection in children remains a major 
concern, with approximately 500,000 new HIV-1 infected infants born every year worldwide 
(Ahmad, 2010; UNAIDS, 2010). Prevention of maternal-fetal transmission of HIV-1 is 
therefore a global priority, especially in developing countries. 
Several lines of evidence suggest that host genetic factors are important determinants of 
both susceptibility to vertical transmission of HIV-1 and subsequent progression of AIDS in 
children (Matt and Roger, 2001). The identification of genetic markers linked with 
transmission and disease progression can help to define risk factors associated with vertical 
transmission and provide new insights into HIV-1 pathogenesis that can help in the 
development of an effective HIV-1 vaccine. 
In addition, pediatric HIV infection offers a good opportunity to investigate the influence of 
host genetics on the evolution of HIV, since the virus has first been in contact with the 
mother’s immune system and is then transmitted to a genetically related individual.  
In children with perinatally acquired HIV-1 infection, the expression of clinical and 
immunologic signs of disease seems to follow a bimodal distribution. At the beginning of 
the original HIV epidemic in the 1980s and 1990s, approximately 15–20% of infected infants 
showed an early and severe course of disease and died within the first 2 years of life. The 
remaining children progressed more slowly and had a less severe course, surviving an 
average of 8 years or more (Blanche et al., 1994). Today, children perinatally infected with 
HIV-1 reach adolescence, largely because of advances in treatment over the past 10 years 
(Dollfus et al., 2010). 
4.1 Routes of vertical HIV transmission 
HIV-1 vertical transmission occurs mainly during the following stages (Ahmad, 2010):  
1. prepartum, due to transplacental passage in utero,  
2. intrapartum, due to exposure of infant skin and mucus membranes to maternal blood 
and vaginal secretions during delivery, and  
3. postpartum, due to exposure to contaminated breastmilk during nursing  
In the absence of prophylactic treatment, it is estimated that one-third of children are 
infected in utero (prepartum) and two-thirds are infected intrapartum or postpartum (Kuhn et 
al., 1997). Various factors appear to affect vertical transmission throughout the gestation 
period and it seems probable that an interplay of all factors occurs, with some factors more 
determinant than others during specific periods. For instance, factors protecting against in 
utero infection may be less efficient against delivery or breast-feeding transmission. A 
general and global strategy concerning all known factors must be used to prevent vertical 
transmission (Bongertz, 2001). A greater understanding of the role played by various risk 
factors for HIV-1 infection is crucial to designing new preventive and therapeutic strategies. 
The risk of prepartum transmission depends on exposure of the fetus in utero to free virus or 
to HIV-infected maternal cells (Mittleman and Shearer, 1996), the risk of which is likely to be 
very high (Matt and Roger, 2001). Relatively few maternal cells are thought to enter the fetal 
circulation during gestation under normal circumstances. However, HIV-1 is known to 
infect cells within the placenta (Kesson et al., 1993). Intrauterine infection has therefore been 





Certain conditions of delivery such as premature birth, low birth weight, early placental 
rupture or placental membrane inflammation seem to be related to increased risk of vertical 
transmission (Bongertz, 2001). Cesarean delivery is associated with a significant decrease in 
perinatal HIV transmission, from 55% to 80% (Welles et al., 2000). This result is likely to 
hold only for women with a sufficiently high viral load, since the transmission rate for 
women with undetectable viral loads is already low.  
To avoid postpartum transmission, breastfeeding by HIV-infected women is not 
recommended because it is associated with an additional 15-20% risk of transmission of 
HIV-1 (Nduati et al., 2000).  
In conclusion, it is now clear that the risk for vertical transmission and subsequent immune 
suppression depends on multiple factors in both the virus and the host (Singh and Spector, 
2009). Several factors have been proposed to influence the risk of mother-to-child 
transmission and disease progression in children infected with HIV. These include high 
maternal viral load at birth (Shearer et al., 1997) and viral phenotype (De Rossi et al., 1997).  
4.2 Maternal viral load and vertical HIV transmission 
Higher maternal virus load is associated with an increase in the vertical HIV transmission 
rate (Cao et al., 1997; Rogers and Shaffer, 1999), although the correlation is modest. Treating 
HIV-infected pregnant women with the antiretroviral drug zidovudine was associated with 
a reduced rate of transmission (Connor et al., 1994), though the drug may not produce this 
effect by reducing viral load: a recent study found that zidovudine reduced vertical 
transmission despite a minimal effect on viral load (Melvin et al., 1997; Newberry and 
Kelsey, 2003). Whatever the mechanism of zidovudine, it remains generally true that risk of 
vertical transmission can be minimized if therapies known to reduce the patient's serum and 
vaginal viral loads are continued during pregnancy. Indeed, even if the risk of mother-to-
child transmission is very low in women with low viral load, vertical transmission has been 
reported in women with all viral load levels (Newberry and Kelsey, 2003).  
4.3 Viral phenotype and vertical HIV transmission 
Viral phenotype is also a risk factor for vertical transmission. Genetic variability within HIV-
1 is generated by reverse transcriptase during replication of the viral genome. The enzyme 
lacks 3’ proofreading ability. Consequently, rapid replication result in a high degree of virus 
polymorphism (Wei et al., 1995). This variability among virus phenotypes may allow the 
appearance of viral escape forms, so-called because they can escape the immune response 
(Pillay and Phillips, 2005), as well as allow the emergence of viral strains resistant to 
antiretroviral therapy (Biggar et al., 2002). Both of these viral forms may then be transmitted 
to the child. Viral phenotype is also a risk factor independent of reverse transcriptase: the 
frequency of appearance of resistance mutations depends on the HIV subtype (A, C and D) 
(Kantor et al., 2002).  
4.4 Cytotoxic T lymphocytes (CTLs) and vertical HIV transmission 
Various components of the immune system affect viral replication and therefore may 
participate in vertical transmission. Induction of suppressor and cytotoxic T lymphocytes 
(CTLs) and neutralizing antibodies (NAbs) are considered fundamental for a protective 
immune response against HIV (see Section 6) and have also been implicated in protection 
against vertical transmission (Bongertz, 2001).  
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Class I-restricted CTLs exert significant immune pressure on HIV-1 and may be an 
important factor in mother-to-child transmission (Pillay and Phillips, 2005). Recognition of 
peptide-MHC complexes by CTL receptor triggers a response that ends in the recognition 
and lysis of HIV-infected cells by CTLs, which blocks the propagation of HIV-1. There is an 
inverse correlation between plasma RNA viral load and levels of HIV-specific CTLs in 
patients infected by HIV-1 (Ogg et al., 1998). CTLs detect viral antigens that have been 
processed intracellularly. Peptides are cleaved and presented on the cell surface by MHC I 
molecules. Recognition of the peptide-MHC complex triggers a response that results in lysis 
of the infected cell. HIV-1-specific CTLs seem to contribute to the control of HIV-1, as do 
certain HLA class I alleles that encode the MHC molecules required for the presentation of 
these peptide fragments to CTLs. In particular, HLA-B27 and HLA-B57 are predicted to be 
involved in the control of both HIV infection and AIDS progression, while HLA-B35 is 
associated with rapid disease progression (Kaslow et al., 1996; Carrington et al., 1999).  
The impact of CTL responses on vertical transmission in HIV-infected pregnant women has 
been investigated since the 1990s (Matt and Roger, 2001). CTL activity in the maternal 
peripheral circulation is similar to that in the non-pregnant state and CTLs can appear early 
in infants, where their presence correlates with slow progressive HIV disease (Pillay and 
Phillips, 2005). Consequently, an indirect role for CTLs in mother-to-child transmission has 
been proposed (Polycarpou et al., 2002). Moreover, levels of CTL precursor frequencies 
specific for pol and nef HIV variants were more frequently found during pregnancy in non-
transmitting mothers than in transmitting ones (Jin et al., 1998). Because nef is transcribed 
early during the replication of HIV, a strong nef-specific CTL response may be important for 
the clearance of HIV soon after viral protein expression, thereby limiting further viral 
transmission. Interestingly, a nef-specific CTL response has also been observed in uninfected 
children born to HIV-positive women (De Maria et al., 1994). Importantly, CD4+ T cells are 
critical in maintaining CTL activity against HIV-1 (Kalams and Walker, 1998), and their 
importance in vertical transmission has also been demonstrated (Plaeger et al., 1999).  
Although it induces the CTL response, the virus cannot always be completely controlled. 
This is often due to mutations in viral peptides that allow virus to escape CTL recognition 
via MHC class I molecules (Pillay and Phillips, 2005). Vertical transmission of HIV-1 may 
imply that the transmitted virus is a CTL escape form; such forms have indeed been 
detected in infants (Pillay and Phillips, 2005). Mothers share at least 50% of their HLA alleles 
with their children but children may still respond differently than their mothers, depending 
on their HLA and their concordance with the mother’s alleles. For example, if the mother 
and the child share the protective HLA-B27, transmission of virus to the child will be 
effective: since the virus is adapted to escape B27 recognition, the allele will not confer 
protection from HIV-1 on the child (Goulder et al., 2001). In contrast, if the child inherits the 
HLA B27 allele from the father, the child will be able to generate a strong response to viral 
epitopes. The viral escape mutation can be maintained in the HIV-1 population if it does not 
imply a fitness cost; if it does, the mutation will revert in the absence of immune pressure 
(see Section 6) (Allen et al., 2004).  
4.5 Neutralizing antibodies (NAbs) and vertical HIV transmission 
Although the CTL response is an important mediator of protective immunity and has been 
implicated in controlling virus load, the maternal CTL response is insufficient to determine 
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transmission (Bongertz, 2001). Cesarean delivery is associated with a significant decrease in 
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women with undetectable viral loads is already low.  
To avoid postpartum transmission, breastfeeding by HIV-infected women is not 
recommended because it is associated with an additional 15-20% risk of transmission of 
HIV-1 (Nduati et al., 2000).  
In conclusion, it is now clear that the risk for vertical transmission and subsequent immune 
suppression depends on multiple factors in both the virus and the host (Singh and Spector, 
2009). Several factors have been proposed to influence the risk of mother-to-child 
transmission and disease progression in children infected with HIV. These include high 
maternal viral load at birth (Shearer et al., 1997) and viral phenotype (De Rossi et al., 1997).  
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Higher maternal virus load is associated with an increase in the vertical HIV transmission 
rate (Cao et al., 1997; Rogers and Shaffer, 1999), although the correlation is modest. Treating 
HIV-infected pregnant women with the antiretroviral drug zidovudine was associated with 
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Class I-restricted CTLs exert significant immune pressure on HIV-1 and may be an 
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inverse correlation between plasma RNA viral load and levels of HIV-specific CTLs in 
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processed intracellularly. Peptides are cleaved and presented on the cell surface by MHC I 
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Although the CTL response is an important mediator of protective immunity and has been 
implicated in controlling virus load, the maternal CTL response is insufficient to determine 





important, including the ability of the mother to generate antibodies, particularly 
neutralizing antibodies (NAbs) that are able to block viral replication. In individuals 
infected with HIV-1, high levels of antibodies against the envelope viral proteins gp120 and 
gp41 are synthesized (Fig. 2). However, these antibodies do not seem to be very effective 
against HIV since they are not able to neutralize it in vitro. This is probably due to the high 
degree of glycosylation of these proteins (Reitter et al., 1998; Wyatt et al., 1998; Rudd et al., 
2001). Nevertheless, there are other Nabs that can be generated rapidly in primary HIV 
infection (Richman et al., 2003). NAbs are thought to protect against vertical transmission, 
since they can pass through the placental barrier, they have been detected in mother’s milk, 
and they are believed to be present during delivery (Bongertz, 2001). In general the presence 
of high amounts of NAbs is correlated with chronic, non-progressive disease (Pillay and 
Phillips, 2005).  
High levels of NAbs are detected during pregnancy. Nevertheless, whether maternal NAbs 
and maternal humoral immunity in general play a role in vertical HIV transmission remains 
controversial. Several early reports indicated an association between maternal NAbs and 
protection against vertical transmission (Rossi et al., 1989; Devash et al., 1990; 
Louisirirotchanakul et al., 1999), but these observations were not confirmed (Bal et al., 1996; 
Hengel et al., 1998). Since selection for escape HIV-1 variants occurs during transmission, it 
is possible that non-neutralized variants are transmitted to the infant (Okamoto et al., 1997). 
Moreover it appears that the timing and mechanism of NAb activity during vertical 
transmission is important. A strong local NAb response is probably effective at controlling 
HIV multiplicity during pregnancy, but ineffective at blocking transmission of HIV-1-
infected cells (Bongertz, 2001).  
4.6 HIV coreceptors and vertical HIV transmission 
In this section of the chapter, we will briefly describe non-MHC genetic factors that 
influence vertical transmission and then we will focus on the association between HLA 
polymorphism and vertical transmission. 
In addition to CD4, HIV-1 uses other coreceptors to enter the T cell, and these have been 
identified as chemokine receptors (Cairns and D'Souza, 1998). The CCR5 chemokine 
receptor is mainly used by non-syncytium-inducing (NSI) HIV-1 strains, whereas 
syncytium-inducing strains use the SDF1 chemokine receptor CXCR4. Some strains also use 
additional chemokine receptors such as CCR2 and CX3R1 (Cairns and D'Souza, 1998; Singh 
and Spector, 2009). A mutant CCR5 allele carrying a 32-bp deletion (CCR5-Δ32) was 
identified independently by several groups, and found to cause the loss of coreceptor 
activity (Dean et al., 1996; Liu et al., 1996; Samson et al., 1996). This allele has been identified 
as a natural polymorphism that reduces the risk of acquiring HIV-1 infection (McNicholl et 
al., 1997). Nevertheless, several studies about the role of this allele in mother-to-child 
transmission showed that CCR5-Δ32 heterozygosity alone does not protect against vertical 
transmission (Matt and Roger, 2001). Conversely, another genetic polymorphism, CCR5-
59356-T, was strongly associated with a higher rate of vertical transmission of HIV-1 among 
black infants (Kostrikis et al., 1999).  
The CCR2-64-I allele was shown to confer long-term protection in adults (Smith et al., 1997), 
but it was not associated with mother-to-child transmission (Mangano et al., 2000). A genetic 
polymorphism in the untranslated region of the SDF-1 gene in mothers was associated with 
increased risk of vertical transmission of HIV-1, mainly through breastfeeding (John et al., 
2000).  
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4.7 MHC and vertical HIV transmission 
Although vertical transmission of HIV-1 has been correlated with a wide range of viral and 
maternal features, the factors affecting this transmission have yet to be definitively 
identified (Matt and Roger, 2001). Efforts to explain why only a proportion of children born 
to HIV-infected mothers become infected have led to the discovery of important host genetic 
and delivery variables. One of the most relevant genetic factors is the MHC system, which, 
as mentioned above, plays a critical role in HIV transmission in both horizontal and vertical 
transmission. Since the 1990s, it has been known that certain HLA types are more 
susceptible or resistant to HIV-1 infection. In principle, HLA genotype may influence 
disease susceptibility in utero by affecting CTL response or other immune responses. HLA 
association with mother-to-child transmission has been found with class I, class II, and non-
classical HLA alleles. A serologic HLA typing study of Scottish infants by Kilpatrick et al. 
(Kilpatrick et al., 1991) found that specific HLA haplotypes were associated either with 
protection or increased susceptibility to HIV-1 vertical transmission. In particular, the HLA-
A3-B7-DR2 haplotype was associated with protection against HIV-1 infection, whereas the 
HLA-A1-B8-DR3 haplotype was associated with HIV-infected children. RFLP HLA-DRB1 
analysis performed by Greggio et al. showed that certain DRB1-13 allele subtypes were 
associated with protection against vertical transmission of HIV-1 (Greggio et al., 1993). 
These findings were subsequently confirmed using molecular HLA typing methods. The 
HLA-DR2 allele (DRB1*1501) was not associated with mother-to-child transmission of HIV-
1, while the HLA-DR3 (DRB1*03011) allele was positively associated with the occurrence of 
HIV-1 infection among American Caucasian infants (Winchester et al., 1995).  
Among infected infants, MHC alleles can influence disease progression. For instance, the 
HLA DR3 haplotype (DRB1*0301-DQA*0501-DQB1*0201) was associated with the 
development of severe clinical manifestations and death in African-Americans, DPB1*0101 
was associated with survival to at least two years of age, and DQB1*0604 was related with 
increased risk of infection (Just et al., 1995a). A study with Spanish children in Catalonia 
confirmed the association between the DQB1*0201 allele and severe clinical outcomes, but 
found that the DRB1*0301 allele showed a tendency to protect against disease progression 
(Just et al., 1996). The differences observed between these studies may be explained by 
ethnic differences among the children studied (Winchester et al., 1995; Just et al., 1996). 
Indeed, ethnicity appears to be an important variable for interpreting the effect of HLA 
alleles. For instance, the DRB1*13011 allele is significantly associated with a diminution in 
vertically transmitted HIV-1 infection in African-American children but not in American 
Caucasian children. Moreover, other HLA DR13 alleles (DRB1*1301, *1302, *1303) are 
associated with protection against HIV-1 transmission in African-American but not in 
Caucasian children (Winchester et al., 1995).  
Altogether, these data suggest that the HLA DR3 haplotype is associated with both 
increased risk of vertical transmission of HIV-1 and pediatric disease progression (Just et al., 
1995b; Winchester et al., 1995), while the HLA DR13 allele is associated with protection 
against HIV-1 infection (Winchester et al., 1995). However, the HLA DR3 (DRB1*03011) and 
HLA-A2 alleles show discordant effects between African-American and Caucasian ethnic 
groups. 
These observations suggest that variations in the transport of virally encoded peptides to, or 
presentation by, MHC molecules may significantly influence the host response to HIV 
infection and mother-to-child transmission. However, the identity of the HLA alleles by 
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discordance of HLA alleles between mother and child seems to be a key factor for vertical 
transmission.  
HLA-G is a non-classical HLA molecule from MHC class Ib with a limited distribution in 
tissues, and it is selectively expressed in placental trophoblast cells in the maternal-fetal 
interphase (Kovats et al., 1990). HLA-G has been identified as a molecule involved in 
immune tolerance, and its main function appears to be to protect the fetus from maternal 
CTLs and natural killer (NK) cells (Hunt, Petroff et al. 2000). Because of its presence in the 
placenta, it is logical to suggest that HLA-G helps to determine vertical transmission of HIV-
1, and that certain allelic mutations in the HLA-G gene increase or decrease protection of 
infants against in utero transmission. Indeed, a correlation between HLA-G variants and 
mother-to-child transmission was found in a study by Aikhionbare et al. (Aikhionbare et al., 
2001). Discordance between mother and child for a mutation in exon 2 of HLA-G was 
significantly more common among non-transmitting than transmitting mother-child pairs. 
This suggests that mother-child pairs in which both carry the same mutation in HLA-G exon 
2 may be at higher risk of vertical transmission of HIV-1. Nevertheless, another study with a 
bigger cohort of mother-child pairs in Zimbabwe did not find any relation between mother-
child HLA-G concordance/discordance and either intrauterine or peripartum transmission 
(Matte et al., 2002). Moreover, the mutation in exon 2 of HLA-G (at codon 57) does not 
change the amino acid composition of the protein (silent mutation), so it is difficult to 
envisage how a silent mutation could have a direct influence on mother-child transmission 
of HIV-1. The significant association reported in the first study (Aikhionbare et al., 2001) 
may be attributed to their relatively small sample size. However, in more recent work, 
Aikhionbare et al. argued that the differences between the studies may be due to the 
homogeneous population in the Zimbabwe study, where 90% of the mother-child pairs 
belonged to the Shona ethnicity. They suggested that in such a homogeneous group, certain 
mutations may not play a role in disease protection, whereas they do in mixed populations. 
In addition, they identified several polymorphisms in HLA-G that may be associated with 
decreased risk of vertical transmission of HIV-1 (Aikhionbare et al., 2006).  
An important milestone is the so-called “pattern of inheritance theory,” based on the 
premise that HLA concordance between a mother and her infant can be a determinant of 
vertical transmission. A study showed that HLA class I antigen concordance between a 
mother and her child is associated with an increased risk of intrauterine HIV-1 transmission, 
whereas maternal-child HLA discordance results in protection against vertical transmission 
(MacDonald et al., 1998). This was confirmed in another study showing the association with 
HLA class I concordance, but not with HLA class II (Polycarpou et al., 2002). This was also 
shown in other studies where children who inherited one or more alleles associated with 
short-term disease progression progressed more rapidly to AIDS if they inherited the alleles 
from their fathers, but not if they inherited them from their mothers. The opposite situation 
also occurs: a protective allele may be effective in children only when it comes from the 
father and not from the mother (Kuhn et al., 2004). It has been proposed that fetal 
alloimmune responses directed against maternal HIV-infected cells or free virus bearing 
maternal MHC determinants may account for protection in some children (Mittleman and 
Shearer, 1996). Maternally derived cells carry HLA molecules on their surface, as well as 
infectious viral particles. Fetal cord blood leukocytes are able to recognize foreign maternal 
HLA and mount a strong immune response. Nevertheless, in cases in which maternal HLA 
antigens are similar or identical to fetal HLA, the fetal immune response is probably less 
potent or nonexistent (Mittleman and Shearer, 1996). This may explain why HLA 
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concordance between a mother and her child is associated with an increased risk of 
intrauterine HIV transmission. A recent study of mother-child pairs in Spain suggests that 
HLA-B35 increases transmission risk, a finding that is also consistent with the pattern of 
inheritance theory (Arnaiz-Villena et al., 2009). 
5. Other MHC-related factors that influence HIV transmission 
5.1 Innate immune response 
Although the innate immune response is an essential part of anti-viral responses, its role in 
HIV infection remains obscure (Biasin et al., 2010). Viruses are recognized by the immune 
system through receptors named “pattern recognition receptors" (PRRs) that bind to 
“pathogen-associated molecular patterns” (PAMPs), which are small pieces of the virus with 
a conserved “viral tag” that host cells identify as foreign. Viral proteins are recognized by 
Toll-like receptors (TLR) 2 and 4 in the plasma membrane, while viral nucleic acids are 
recognized by TLR 3, 7, 8 and 9, which are located in endosomal membranes. In this latter 
group, TLR7 and 8 recognize single-stranded viral RNA (v-ssRNA) from HIV. Studies on 
TLR signalling during HIV infection are scarce, even though it has been proposed that 
exposed but non-infected individuals mount stronger responses through TLR-initiated 
signalling (Biasin et al., 2010).  
There are also cytoplasmic receptors such as RIG-I-like (RLR) and nucleotide-binding 
domain, leucine-rich receptors (NIRs) that have been implicated in the recognition of 
viruses. Signals from these receptors activate the cells that express them and initiate the 
production of interferons and inflammatory cytokines, including IL-1B and IL-18, which 
determine important aspects of the adaptive immune response, such as the CTL response. 
HIV is able to disrupt both TLR and RIG-1 signalling by depleting IRF3 interferon 
regulatory factor 3 (IRF-3) (Doehle et al., 2009). Type I interferons (IFN ) are especially 
crucial in early stages of viral infections. They promote an “antiviral state” by inducing the 
expression of hundreds of target genes, so-called interferon-stimulated genes (ISGs) (Baum 
and Garcia-Sastre, 2010). Plasmacitoid dendritic cells (pDCs) are the main natural INF 
producers in vivo. This subpopulation appears to be depleted in chronic HIV infection 
(Soumelis et al., 2001).  
5.2 NK responses 
NKs are CD3+ lymphocytes and they are divided into two major subgroups, NK regulatory 
or NK effector cells, depending on the levels of expression of CD56 and CD16. These cells 
play a prominent role during viral infections because they mediate early, non-adaptive 
responses against virus, and they modulate the activity of other effector cells of the innate 
and adaptive immune system. NKs exhibit cytolytic activity against cells infected with 
viruses and they secrete anti-viral products. Their cytolytic activity appears to involve 
receptors that bind MHC class I molecules. HIV-exposed but uninfected subjects have been 
reported to have enhanced NK functions and increased IFN- and TNF- levels. During 
chronic HIV infection, NK cell cytotoxicity is reduced (Ahmad et al., 2001). 
The ability of NKs to kill virally infected cells depends on a fine balance in the relative 
expression of inactivating and activating NK receptors (NKRs). Several studies have 
addressed the relationship between NK receptors that bind to MHC molecules, and viral 
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HLA-B molecules can be classified according to the presence of the mutually exclusive 
public epitopes Bw4 or Bw6 that are shared by various MHC molecules. However, only Bw4 
is a ligand for KIRs, which are type I integral membrane glycoproteins. To date, 14 distinct 
KIR genes have been described (http://www.ebi.ac.uk.kir) (Paximadis et al., 2011). KIRs 
can have either activating or inhibitory functions. It has been shown that suppression of 
HIV-1 viremia is associated with homozygosity for HLA-Bw4. Furthermore, the Bw4-80I 
group, which has isoleucine at position 80, includes two alleles (B*57 and B*27) that are 
considered protective, as previously mentioned. KIR allele KIR3DS1, which is an activating 
receptor, binds HLA-B Bw4-80I molecules, and this binding was shown to delay progression 
to AIDS. Furthermore, coexpression of both alleles in the same individual reduces the risk of 
both infection and progression (Lopez-Vazquez et al., 2005; Boulet and Bernard 2008; Boulet 
et al., 2008).  
The involvement of HLA-B Bw4/6 epitopes in transmission from infected men to their 
female sex partners was analyzed. Compared with men who were homozygous for Bw6, 
men who carried Bw4 were about half as likely to transmit HIV-1 to their female partner 
(Welzel et al., 2007). However, a more recent study that compared men homozygous for 
HLA-Cw1 or HLA-Cw2 attributed functional differences in human NK cell activity to 
distinct KIR/HLA genotypes, independently of KIR3DL1/HLA-Bw4 interactions 
(Ahlenstiel et al., 2008). It turns out that HLA-E and HLA-G are also important in the 
regulation of NK cell responses (Tripathi and Agrawal, 2007). 
The simultaneous presence of the HLA-Bw4 epitope and both the HLA-B*57 and HLA-
Cw*18 alleles correlated with low levels of viremia in 147 HIV-infected individuals in Brazil. 
The protective effect of HLA-Bw4 depended on the presence of HLA-B*57. In contrast to 
previous studies, the HLA-Bw4 epitope bearing isoleucine at position 80 did not confer a 
protective effect in the presence of the activating KIR3DS1 allele (Da Silva et al., 2011). 
The associations most consistently observed between KIRs and HIV progression involves 
KIR3DS1 and KIR3DL. KIR and HLA class I alleles were studied in 224 South African 
mothers and their 222 infants, of whom 72 were infected and 150 uninfected (Paximadis et 
al., 2011). The frequencies of KIR2DL1 and KIR2DL3 were lower in intrapartum-
transmitting (IP-T) mothers than in non-transmitting (NT) mothers. Homozygosity for 
KIR2DL3, alone or in combination with HLA-C heterozygosity (Cw1/Cw2), was more 
frequent in IP-T mothers than in NT ones. The combination of the KIR2DL3 allele and its 
ligand, HLA-Cw1 occurred less frequently in infected infants, as did homozygosity for 
KIR2DL3 in combination with HLA-Cw1/Cw2. It is noteworthy that these effects of 
genotype were more readily detectable after stratifying the sample based on low or high 
maternal viral load. 
5.3 Chemokines 
Since the discovery of CCR5 as an HIV entry cofactor (Dean et al., 1996), researchers have 
focused on chemokines as possible restriction/susceptibility factors (Alkhatib et al., 1996). 
Thus variants or haplotypes of CCL5, CCL2-CCL7-CCL1 and CCL3 have been consistently 
associated with differential susceptibility to infection or transmission (Telenti and McLaren, 
2010). Polymorphism of chemokine receptors has, in turn, been linked to specific HLA 
alleles, such as CCR2 and HLA-B58; the latter is present in long-term survival women from 
Nairobi (Fang et al., 2004) 
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5.4 Other factors 
CTL-associated antigen 4 (CTLA4) is a member of the immunoglobulin superfamily, and is 
expressed mainly on helper and regulatory T cells. After ligand binding it transmits an 
inhibitory signal to the cell. Single-nucleotide polymorphisms in the promoter region of the 
CTLA4 gene were analyzed in relationship to viral load and time to AIDS, but no clear 
association was established (Shao et al., 2006). 
6. Contribution of HLA selection of CTL responses to HIV susceptibility or 
protection  
Here we provide an overview of an important subject that is central to the struggle to 
develop a successful CTL-based HIV vaccine (Bangham et al., 2009). CTLs, also known as 
CD8+ T cells, eliminate HIV-infected cells through the recognition of antigenic peptides 
displayed by HLA class I molecules on the infected cell surface. HIV can evade T cell 
responses by mutating epitopes that are recognized by CTLs (Phillips et al., 1991) and then 
those HIV variants or “escape mutations” are selected if they maintain the fitness of the 
virus. This is called “fixation” of the mutation and it implies that the mutation confers some 
advantage for the virus against the CTL response. Significant efforts have been made to 
obtain a complete map of HIV epitopes recognized by CTLs and antibody-producing cells 
(http://www.hiv.lanl.gov), since this mapping is essential for vaccine development.  
In general it is thought that most mutations occur in the initial phase of the infection when 
the virus is rapidly replicating and therefore is more likely to mutate. However, it appears 
that the mutations in some delayed escape variants occur later in the viral life cycle. One of 
the best documented examples of an HIV escape variant is a “gag epitope” recognized by 
the HLA-B27 molecule. Patients with HLA-B27 progress more slowly to AIDS than does the 
general HIV-infected population. Peptides that bind HLA-B27 very frequently have an 
arginine (R) at the second position. The HIV gag epitope263-272 contains such arginine that 
when mutated, is no longer recognized by T cells. This escape mutation occurs in 
approximately 50% of HLA-B27-infected individuals after several years of infection. Why 
does it not appear at the beginning of the infection? Because the escape mutation R264K 
must be preceded by a first mutation, and then it subsequently appears together with a 
third. The mutation R264K has a fitness cost and thus the mutant virus tends to revert to the 
wild-type (WT) sequence in the absence of selection (i.e. HLA-B27). This was demonstrated 
by studying HLA-B27-negative babies born to HLA-B27-positive mothers infected with 
virus carrying the R264K mutation (Goulder et al., 2001); this study found that “HLA-
mediated selective pressures on the virus in a transmitting mother-infant pair may 
undermine future HLA-mediated viral control in the child”. Later the fitness cost was 
shown to be compensated by a third mutation in a position that binds an inhibitory receptor 
on dendritic cells (DCs). This example illustrates that escape mutations can be very 
complicated events, which may explain their late appearance in the course of the infection 
(McMichael et al., 2007). 
There are well established examples of associations between expression of an HLA class I 
molecule and deviation from the consensus HIV sequence (“escape mutations”). The 
converse situation also exists, namely, association of certain HLAs with the WT or 
“preserved” sequence (Leslie et al., 2005). Therefore it was proposed that HIV-1 is adapting 
to HLA-restricted responses as a consequence of selection pressure (Moore et al., 2002; John 
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lacking the selecting MHC alleles have been identified. The obvious implication of these 
data is that some CTL responses can be evaded only by escape mutations that paradoxically 
reduce the replicative fitness of the virus (Leslie and Goulder, 2006). Study of the impact of 
HLA on HIV molecular evolution is further complicated by the “founder effect” of HIV 
strains (Bhattacharya et al., 2007; Klenerman and McMichael, 2007). 
The question at the moment is to what extent is HIV adapting to HLA class I molecules? 
This issue was directly addressed in an international multi-cohort study, in which nine 
cohorts from 5 different continents were pooled, allowing the analysis of more than 2,800 
subjects. They studied the HLA-B*51-restricted epitope TAFTIPSI, corresponding to 
residues 128-135 of reverse transcriptase, and they showed a strong correlation between the 
frequency of the escape mutation I135X and HLA-B*51 prevalence. Similarly, the 
frequencies of other well-defined CD8+ T-cell epitopes restricted by HLA-B*57 and HLA-
B*27 correlated with the prevalence of the restricting HLA allele in the different cohorts, 
demonstrating strong evidence of HIV adaptation to HLA at the population level 
(Kawashima et al., 2009).  
7. Summary: HLA molecules confer protection or susceptibility to HIV 
infection  
The best way to identify protection or susceptibility factors is to study exposed but 
seronegative (ESN) individuals and HIV-infected LTNPs (Miyazawa et al., 2009). There are 
several possible factors that may determine how HLA molecules condition the anti-HIV 
immune response (Fig. 2). One obvious factor is the differences in peptide-binding 
repertoires among HLA molecules, which is the logic behind grouping the alleles in clusters 
or supertypes. Another factor is that HLA-DR polymorphism affects interaction with CD4 
(Fleury et al., 1995), which implies that some HLA-DR molecules bind CD4+ lymphocytes 
more than others. Similarly, particular HLA molecules, such as HLA-B*27, HLA-B57, HLA-
B*5701 (in Caucasians) and HLA-B*5703 (in Africans), are more likely to mediate successful 
control of HIV infection by activating CTL responses (den Uyl et al., 2004). HLA B*5701 was 
found to be a clear protective factor, but the protection could not be attributed to any 
quantitative differences in the total HIV-specific CD8+ T cell response (Migueles et al., 2000). 
In the case of HLA-B27, there are reports of CTL-protective response against p24 HIV 
protein, which has a relatively low rate of mutation (den Uyl et al., 2004). HIV-infected 
chimpanzees do not develop AIDS and therefore they have been used as a model to 
understand the influence of MHC on HIV disease. The peptide-binding groove of frequent 
chimpanzee MHC class I molecules, similarly to HLA-B*27/B*57, target similar conserved 
areas of HIV-1/SIV(cpz) (de Groot et al., 2010). Interestingly HLA-B*5701 is one of the major 
alleles responsible for hypersensitivity to the reverse transcriptase inhibitor abacavir (Mallal 
et al., 2002). 
Various factors, including HLA that might confer protection or susceptibility, have been 
studied in a cohort of 30 LTNPs from Spain (Salgado et al., 2011b). For example, these 
investigators studied CCR5 and the CCL3L1 gene, which encodes the MIP1a protein, an 
inhibitory CCR5 ligand. They found the B27 and B58 supertypes, as well as certain class I 
alleles, to be protective; the B7 supertype and other class I alleles were non-protective. No 
significant association with CCR5-Delta32 was found, probably because this mutation is rare 
among Spaniards. Similarly, CCL3K1 copy number did not influence the rate of progression. 
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Protective HLA-B and -C alleles were more frequent in LTNPs, though such an association 
was not observed with HLA-A alleles. In addition to HLA-B*5701 and -B*2705, the 
investigators found HLA-Cw0102, -Cw0602 and -Cw1203. The presence of allele 
combinations such as HLA B*5701-Cw0602, HLA B*2705-Cw0102, and HLA B*3801-Cw1203 
showed the strongest association with non-progression. 
 
 
Fig. 2. Points where genetics influences HIV infection and its progression.  
Although chimpanzees are susceptible to infection with HIV-1, they do not develop AIDS. A 
similar situation occurs when they are infected with the chimpanzee simian 
immunodeficiency virus (SIVcpz). Chimpanzee class I molecules are designated Patr-A, -B 
and –C, and like those of humans, they are polymorphic. However it has been proposed that 
their repertoire has been skewed by strong selective pressure exerted by HIV or an ancestral 
retrovirus of HIV. Therefore the chimpanzee has been used as a model system to 
understand resistance to progression to AIDS. Thus, the Patr peptide-binding repertoire has 
been analyzed and compared to the binding repertoire of human HLA-B*27 and B*57, two 
HLA molecules correlated with resistance in humans (Groot et al., 2010). This work showed 
that at least one Patr molecule in the study population recognizes conserved areas of the 
Gag protein that are also recognized by B*27 and B*57. 
The mechanism of the protective effect exerted by HLA-B*58:01 was studied in South 
African individuals infected with HIV subtype-C (Chopera et al., 2011). One of the major 
conclusions of this work is that HLA-B*58:01 patients whose CTLs target the TW10 in the 
p24Gag viral epitope maintain higher CD4+ T cell numbers than those whose CTLs do not 
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weeks after infection. In addition, the escape mutations were accompanied in some cases by 
compensatory mutations that may limit the protective effect of the HLA-B*58:01 allele. 
A correlation was found between the HLA peptide-binding affinities of 95 HLA class I 
alleles and sequence conservation of targeted viral regions in 52 human viruses, including 
HIV (Hertz et al., 2011). This analysis indicates that HLA-A alleles and those HLA-B alleles 
most closely related to chimpanzee alleles preferentially target peptides from DNA viruses, 
while other HLA-B alleles generally target peptides derived from RNA viruses. This is an 
important conclusion that may at least partially explain why it is primarily HLA-B alleles 
that determine susceptibility and progression of HIV infection. 
7.1 Susceptibility conferred by HLA-B35 alleles 
Individuals positive for HLA-B35 have a greater chance of becoming infected and show 
accelerated HIV-1 disease progression. In the late 1990s, numerous HIV mutations in HLA-
B35-restricted epitopes were found (Kawana et al., 1999). Hence initial studies of 
susceptibility conferred by HLA-B35 focused on CTL responses (Jin et al., 2002). Later work 
showed that the increased risk was associated with the subset of HLA-B35 alleles known as 
B*35-Px molecules (Jin et al., 2002). Interestingly, some alleles in the alternative set of B*35 
subtypes, B*35-PY, present HIV-1 epitopes identical to those of B*35-Px molecules, yet have 
no detectable impact on HIV-1 disease outcomes. In other words, both HLA-B35 subtypes 
recognize the same HIV epitopes, implying a similar CTL response. If that is true, how can 
we explain the differences in responses in these two HLA-B35 subsets? Differences in innate 
immunity could be the underlying cause: the B*35-PY molecule B*3501 and the B*35-Px 
molecule B*3503 differ by only one amino acid and present identical HIV-1 epitopes, yet the 
B*35-Px molecule binds with greater affinity to immunoglobulin-like transcript 4 (ILT4), an 
inhibitory MHC class I receptor expressed on DCs. This binding to ILT4 is associated with 
significantly stronger DC dysfunction during in vitro functional assays (Huang et al., 2009). 
That study concludes that differential interactions between HLA class I allele subtypes and 
immune regulatory MHC class I receptors on DCs is an important determinant of the 
immune response to the HIV virus. 
Lazaryan et al. (2011) compared the effects of class I alleles in African-Americans infected 
with subtype B with those in Africans infected with subtype C. Among African-Americans, 
HLA alleles A*32, A*74, B*14 and B*45 were strongly associated with control of HIV 
infection. Furthermore, infrequent HLA-B alleles were associated with better disease 
outcome. This was consistent with a previous study by the same investigators, in which they 
found that relatively infrequent supertypes in African-Americans correlated with a better 
immunological profile. When the researchers took into account the known linkage 
disequilibrium among A, B and C alleles in their cohort, they detected that HLA-A*32 and 
A*74 were associated with favourable outcome. The protective effect of HLA-B*57 was also 
confirmed in this population, while B35 and B53 alleles were associated with poor outcome. 
These results are inconsistent with the previously described PX/PY theory (Huang et al., 
2009) (section 7.1). Lazaryan et al. (2011) found that both B*5301 (PX) and B*3501 (PY), the 
most frequent alleles in their groups, were equally disadvantageous. 
8. Hypersensitivity to anti-HIV drug treatment  
The occurrence of hypersensitivity reactions to drugs used to treat HIV infection has 
complicated HIV treatment management. Antiretroviral drugs are currently grouped into 6 
major classes:  
Genetic Factors that Influence HIV Infection:  
The Role of the Major Histocompatibility Complex System 
 
223 
- Nucleoside reverse transcriptase inhibitors (NRTIs) 
- Non-nucleoside reverse transcriptase inhibitors (NNRTIs) 
- Protease inhibitors (PIs) 
- Entry inhibitors, further subdivided into fusion inhibitors and CCR5 inhibitors 
- Integrase inhibitors 
Most HIV patients receive therapy that combines various drugs, known as HAART. This 
complicates the diagnosis of drug hypersensitivity. In addition, allergic reactions to anti-
HIV drugs usually occur with a delay of 1 to 6 weeks. Skin reactions are the most common 
manifestations, and they can vary from exanthema to systemic symptoms or syndromes that 
have received various names, such as drug-induced hypersensitivity syndrome (DIHS). 
Most of the drugs used to treat HIV infection produce hypersensitivity in a percentage of 
patients. We recommend to our readers an excellent recent review on the subject (Chaponda 
et al., 2011). 
Genetic factors have been shown to play a role in some of the adverse effects of these drugs, 
especially in the case of abacavir. This NRTI induces hypersensitivity that is strongly 
associated with the MHC class I HLA*5701 allele (Mallal et al., 2002), implying a significant 
genetic component. Screening for HLAB*5701 has now become part of HIV treatment 
involving abacavir and has helped prevent adverse reactions.  
9. New technologies 
Historically, studies of HLA association with HIV infection have evolved in parallel with 
advances in technology. Initially HLA determinations were performed by serology, which 
has gradually been replaced by molecular techniques. We are now in the so-called "-omics" 
era: genomics and proteomic technologies, including microarrays, next-generation DNA 
sequencing and mass spectrometry, are important for identifying molecular markers in 
complex traits (Sharon et al., 2010), such as in HIV infection. The genetics of HIV 
susceptibility will most probably include frequent and rare variants, with each type of 
variant making different contributions to the specific aspect of the disease analyzed. This 
implies that the design of the study itself is a key factor that affects the consistency of the 
results. Therefore a large number of subjects is recommended in some instances (1000 
patients and 1000 controls) (Telenti and McLaren, 2010). 
A whole-genome association study (WGAS) was performed to uncover the genetic factors 
that govern variations in viral load among individuals during the asymptomatic period of 
infection. Two polymorphisms were found, one located in an endogenous retroviral element 
occurring within the HLA-B57*01 allele, and another near the HLA-C gene (Fellay et al., 
2007). More recently, a WGAS of a cohort of 2,554 HIV-infected Caucasian individuals 
excluded a role for any gene polymorphism outside the MHC complex, including the 
chemokine receptor gene cluster on chromosome 3 (Fellay et al., 2011). Viral control was 
associated with genetic variants that map near the HLA-B and -C loci, though variants also 
exist in the MHC region. The study detected in this cohort two previously described SNPs 
(Fellay et al., 2007) and found them to be associated with HLA-B*5701 and HLA-C (Fellay et 
al., 2011). 
In a study of the association of HLA-C with HIV control, Kulkarni et al., (2011) reexamined 
the SNP -35, which lies 35 kb upstream of HLA-C (Fellay et al., 2007). This SNP was found 
to be in fact a marker of another polymorphism in the 3’-untranslated region (3'-UTR) of 
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the 3'-UTR. This binding results in relatively low surface expression of HLA-C. MicroRNAs 
are RNAs that bind to the 3'-UTR to cause post-transcriptional repression, cleavage or 
destabilization. Even more, the 3'-UTR polymorphism of HLA-C that regulates binding by 
has-miR-148 is associated with HIV control.  
Recently, the International HIV Controllers Study Group (Pereyra et al., 2010) analyzed a 
large cohort from multiple populations, comprising 974 controllers and 2,648 progressors. 
The study yielded 1,384,048 single-nucleotide polymorphisms (SNPs). In the largest group 
of 1,712 individuals of European ancestry, all SNPs that reached statistical significance were 
located in the MHC region, around class I genes. A similar clustering of SNPs occurred in 
other ethnic groups and across the entire sample population. When the HLA typing and the 
SNPs were considered together, through a process of "imputation" in which HLA type was 
inferred from a previous WGAS on diabetes, HLA B*57:01, B*27:05, B*14/Cw*08:02, B*52, 
and A*25 were identified as protective alleles, and B*35 and Cw*07 as risk alleles. These 
results are consistent with previous HLA association studies. The HIV Controllers study 
went a step further and analyzed whether the observed associations might be explained by 
the presence of specific AAs within the polymorphic positions on HLA molecules. Among a 
total of 372 polymorphic AA positions in class I and II, 286 were biallelic, accommodating 
two possible AAs, while the remaining 86 could accommodate more than two AAs. 
Interestingly position 97 was detected as the most polymorphic, with 6 alternatives. In fact, 
position 97 in HLA-B was more significant than any single SNP, and positions 67, 70 and 97, 
located in the binding groove, were better markers than any single classical HLA allele. 
Position 97 is located at the base of the binding groove and has an important contribution to 
peptide binding. Arginine is present at position 97 in HLA-B*35, a “risk molecule”, while 
protective HLA molecules, such as B*5701, B*27:05 and B*14 possess valine, asparagine and 
tryptophan, respectively. A similar analysis performed on HLA-A showed a small but 
significant contribution of position 77, while for HLA-C the results were more difficult to 
interpret. This WGAS corroborated the importance of HLA-B peptide presentation for HIV 
susceptibility (Pereyra et al., 2010).  
Novel genetic factors influencing plasma levels of HIV-RNA and cellular HIV-DNA in 605 
HIV-1-infected individuals were investigated. Most of the SNPs were located in the 6p21 
MHC region, near class I and II genes, except for two outside this region. One of them was 
located within the syndecan 2 gene (Dalmasso et al., 2008). Intriguingly, increased 
expression of syndecan isoform 1 -but not of isoform 2- has been implicated in microbial 
translocation in the gut that is associated with chronic stimulation of the immune system 
(Smith et al., 2010).  
DNA microarrays were used to analyze gene expression patterns in CD3+ T cells from 
LTNPs and controls. They found that most up-regulated genes in rapid progressors 
localized to cellular organelles and were implicated in the regulation of DNA replication, 
cell cycle progression and DNA damage response. In contrast, most genes up-regulated in 
LTNPs were located at the plasma membrane and were involved in cytokine-cytokine 
receptor interaction, negative control of apoptosis and regulation of the actin cytoskeleton. 
This suggests that progressors mainly up-regulate markers of viral replication, while non-
progressors do not (Salgado et al., 2010a).  
Proteomics is now also being used to study host genetic factors in HIV response, though 
mostly in relation to specific aspects of the disease, such as neurological damage (reviewed 
by (Zhang et al., 2010)).  
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We would like to end this chapter by mentioning new trends in research on the genetics of 
HIV disease by mentioning the role of autophagy (Blanchet et al., 2010), and the cell skeleton 
or cytoskeleton (Harmon et al., 2010) during HIV infection and replication within the cells. 
A very recent and interesting report showed that a known tumour suppressor protein, the 
cyclin-dependent kinase inhibitor p21, has an important role in inhibiting various steps of 
HIV transcription in CD4+ T cells. Elite controllers showed increased expression of p21, 
which should effectively down-regulate HIV replication. Future studies should determine 
whether individuals expressing protective alleles such as HLA-B*57 express high levels of 
p21. These studies are necessary in light of the fact that the locus of the CDKN1A gene, 
which encodes p21, is located near the MHC class I genes (Chen et al., 2010). We are certain 
that genetic factors involved in these processes will be identified as susceptibility or 
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Long survival in women in Nairobi. 
Protection against HIV infection. CTL 
responses 
Fang et al., 2004 ; Chopera et 
al., 2011 
Bw4 
Protection in infection and disease 
progression. Suppression of viremia in 
homozygosis. Receptor for KIR (NK cells) 
Lopez-Vazquez et al., 2005; 
Welzel et al., 2007; Boulet & 
Bernard, 2008; Boulet et al., 
2008 
HLA-C 
Variation of viral load during asymptomatic 
period. Polymorphism at 3’UT region that 
binds microRNA decreasing its level of 
expression 
Fellay et al., 2007; Kulkarni 
et al., 2011 
Cw*04 Disease progression in Caucasian Carrington et al., 1999 
Cw*07 Risk of progression Pereyra et al., 2010 
DQB1*0201 Severe clinical outcome in children Just et al., 1996 
DR1 Kaposi’s sarcoma Klein et al., 1994 
DR3, DRB1*0301 Opportunistic infections. Risk of infection in American Caucasian children. 
Klein et al., 1994; 




Protection in vertical transmission. 
DRB1*1303 associates with reduced viral 
loads 
Greggio et al., 1993; 
Winchester et al., 1995; Julg 
et al., 2010 
HLA-E Implicated in NK cells responses Tripathi & Agrawal, 2007 
HLA-G 
Discordance between mother and child for 
mutation in exon 2 has a higher frequency 
among non-transmitting mother-child pairs. 
Controversial role in vertical transmission. 
Implicated in NK cells responses 
Aikhionbare et al., 2001; 
Matte et al., 2002; 
Aikhionbare et al., 2006; 
Tripathi et al., 2007; Fainardi 
et al., 2011 
A3-B7-DR2 Protection in vertical transmission Kilpatrick et al., 1991 
A1-B8-DR3 Increased risk of vertical transmission Kilpatrick et al., 1991 
KIR2DL1, KIR2 
DL3 
Lower frequencies in intrapartum-
transmitting (IP-T) mothers than in non-
transmitting (NT) mothers 
Paximadis et al., 2011 
CCR5 (delta32), 
CCR2-64I 
Correceptor for HIV, reduced risk of 
infection. CCR2-64-I allele was shown to 
confer long-term protection in adults 
Dean et al., 1996; Liu et al., 
1996; Samson et al., 1996 ; 
McNicholl et al., 1997; Smith 
et al., 1997 
Table 2. Major factors associated with HIV infection and progression. 
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Table 2. Major factors associated with HIV infection and progression. 
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1. Introduction 
According to widely held current paradigms of cellular infection and transmission of HIV-1 
the virus first binds to a membrane receptor on a target cell, such as CD4 and a chemokine 
receptor (CCR5 or CXCR4) that serve as co-receptors. After penetration of the plasma 
membrane of the cell by the virus via receptor-mediated fusion, followed by insertion of the 
viral RNA and intracellular replication, the newly assembled virion buds from the host cell 
into the extracellular environment where it becomes a cell-free infectious virion. In 
accordance with this, it is widely believed that prior to infecting new target cells HIV-1 in 
blood exists mainly as cell-free infectious virions (Ho et al., 1989; Pan et al., 1993). Upon 
encountering a new target cell a new cycle leads to entry and infection of the new cell. In 
this chapter, we will review an alternative concept that HIV-1 can bind to human 
erythrocytes, and that erythrocyte-bound HIV-1 remains infectious and promotes trans 
infection of CD4(+) T cells. We further propose the general concept that is likely that 
virtually all infectious HIV-1 particles in blood are bound to circulating cells in vivo, rather 
than existing as cell-free circulating virus. We will review various mechanisms that might be 
involved in binding of infectious HIV-1 to erythrocytes, and the implications that trans 
infection by erythrocyte-bound HIV-1 might have for pathogenesis of HIV-1 and for vaccine 
development. 
2. Binding of HIV-1 to erythrocytes: In vitro studies 
Several studies have addressed the adherence of HIV-1 to erythrocytes in vitro. Olinger et al. 
(2000) suggested that HIV-1 binding to the surface of CD4(-) cells might be an important 
route for infection of T cells based on the ability of HIV-1 strain MN (T-cell line-adapted) 
and X4 and R5 primary isolates to bind to various cell types. Virus apparently bound in vitro 
both to isolated CD4(+) and CD4(-) cells, including peripheral blood mononuclear cells 
(PBMC), neutrophils, tonsillar mononuclear cells, platelets, and erythrocytes. Virus that had 
bound to CD4(-) cells was up to 17 times more infectious for T cells in co-cultures than was 
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cells was not due to stimulatory signals provided by CD4(-) cells or infection of CD4(-) cells, 
and it was proposed that virus bound to the surface of CD4(-) cells was efficiently passed to 
CD4(+) T cells during cell-cell adhesion. Although the study by Olinger et al. (2000) did not 
investigate the mechanism of HIV-1 binding or the binding site on the CD4(-) cells, it was 
suggested that HIV-1 binds at relatively high levels to CD4(-) cells, including erythrocytes, 
and that cell-bound HIV-1 is highly infectious for T cells. 
 
 
Fig. 1. Binding of a HIV-1 isolate to erythrocytes.  
(A) Increasing amounts of HIV-1 isolate 90US_873 (as quantified by p24) were incubated with 5x107 
erythrocytes and binding of p24 to the cells was determined. (B) Dose-dependent binding of the HIV-1 
isolate (8,486 pg p24) with increasing numbers of erythrocytes. The experiment shown is representative 
of 3 separate experiments. In each experiment HIV-1 was bound to erythrocytes in triplicate, washed, 
and the triplicates were pooled for p24 determination. From Beck et al. (2009). 
The binding of HIV-1 at 4°C in vitro to normal erythrocytes from 30 different individual 
donors was subsequently confirmed and found to be calcium dependent by Beck et al. 
(2009), and further confirmed by Garcia et al. (2011). As shown in Fig. 1A, the binding of p24 
to 5 x 107 erythrocytes obtained from a selected individual donor exhibited a dose-response 
up to 8,486 pg of added p24 (the maximum amount of p24 in the HIV-1 stock that could be 
used in the assay); however when this latter amount of p24 was then incubated with 
increased numbers of erythrocytes, to a level of 20 x 107 (the maximum number of 
erythrocytes that could be used because of viscosity restraints in the assay), a further three-
fold increase of p24 binding was observed (Fig. 1B) (Beck et al., 2009). At the highest ratio of 
erythrocytes/p24 there was no clear plateau in the amount of p24 binding, but it did appear 
likely that the binding pattern was in the form of a wide and relatively shallow sigmoid 
curve that might be approaching a plateau. 
When the erythrocytes from 30 donors were examined, a mean of only 2.4% of the total 
added HIV-1 p24 was bound to the erythrocytes, but additional experiments further 
demonstrated that adsorption of the original HIV-1 preparation with erythrocytes removed 
essentially all (up to 97%) of the infectivity of HIV-1 for trans infection of CD4(+) PBMC 
(Beck et al., 2009). It was thus demonstrated that only a small fraction of the originally 
added p24 became bound to the erythrocytes, but this amount comprised virtually all of the 
infectious HIV-1 particles in the original preparation added to the cells.  
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From the data shown in Fig. 1 it seems clear that either the binding affinity of infectious 
HIV-1 particles for erythrocytes is extremely low, or the number of cells in the erythrocyte 
population that actually bind infectious HIV-1 particles is a very small number of the total 
cells present. However, because the binding to the cells survived several relatively vigorous 
washing techniques resulting in a p24-free supernatant, it would appear unlikely that the 
binding affinity to the cells was low. To estimate the approximate fraction of cells in the 
erythrocyte population that had the capacity to bind infectious HIV-1 particles, the 
following theoretical calculations can be considered. If one assumes that: (A) one infectious 
virion contains ~5,000 molecules of gag p24 (Briggs et al., 2004); and (B) the molecular 
weight of p24 is 24,000, then there are ~5,000 viruses per pg of p24. If one further assumes 
(C) that all of the infectious virions that were added to the erythrocytes were contained 
within 320 pg of p24 that were attached to 20 x 107 erythrocytes (Fig. 1B), then the 
calculation suggests that only approximately 1 infectious virion was bound per 125 
erythrocytes. The data thus suggested that the binding of infectious HIV-1 particles to cells 
in the erythrocyte preparation was a relatively rare event, and perhaps fewer than 1% of the 
cells that were present in the erythrocyte pool had the capacity to bind HIV-1. However, it 
was also likely that binding to erythrocytes per se did occur because substantial binding was 
observed with erythrocyte ghosts prepared after the initial binding event was completed. 
Furthermore, binding was also observed directly with fresh erythrocyte ghosts (Beck et al., 
2009). 
2.1 Contaminating cell types as potential targets for binding of HIV-1 in erythrocyte 
preparations 
Because <1% of the cells in the erythrocyte population appeared to bind the HIV-1, several 
possible circulating cell types could be suggested as candidates that might contain the 
observed HIV-1 binding site, including: myeloid-derived multipotent progenitor cells and 
long-lived hematopoietic stem cells (Carter et al., 2010; Carter et al., 2011); young 
erythrocytes or direct precursors of erythrocytes (such as reticulocytes); damaged but still 
circulating mature erythrocytes; aged erythrocytes near or at the end of their circulating life-
span; and CD4(-) nucleated cells that were not removed during the preparation of the 
erythrocytes. 
It is notable that platelets contain two C-type lectins, C-type lectin-like receptor 2 (CLEC-2) 
and dendritic cell-specific, ICAM-3 grabbing, nonintegrin (DC-SIGN), that are each surface-
expressed proteins that exhibit calcium-dependent binding of infectious HIV-1 particles 
(Boukour et al., 2006; Chaipan et al., 2006; Flaujac et al., 2010). Although it has been 
suggested that platelets might represent a circulating reservoir for HIV-1, it has also been 
reported that internalization of HIV-1 by platelets might cause disrupt viral integrity 
(Boukour et al., 2006; Flaujac et al., 2010). Because platelets are notoriously sticky, it is 
possible that clumps of platelets might become bound as contaminants on a small number of 
erythrocytes either in vitro or in vivo, and because of the ability of platelets to bind HIV-1 
these erythrocyte-platelet combinations might then serve as platforms for trans infection by 
attached HIV-1. 
Hemolysis of the erythrocytes after the initial binding of HIV-1, followed by centrifugation 
to remove nucleated cells, revealed that a substantial amount of binding of p24 was found 
not only on the erythrocyte ghosts, but also on the small number of nucleated cells that 
contaminated the erythrocyte pool (Beck et al., 2009). Flow cytometry analysis of the 
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hemolyzed) cells [0.07% CD4(+) and 0.33% CD4(-) cells]. However, based on the small 
numbers of nucleated cells in the erythrocyte population but the relatively high level of p24 
binding to cells other than erythrocytes, it appeared that the binding of HIV-1 to leukocytes 
was stronger than binding of the HIV-1 to erythrocytes. Despite this, it was further 
demonstrated that when the initial incubation temperature of 4°C that was used for binding 
to erythrocytes was subsequently raised to 37°C, no detectable internalization of virus 
occurred over a period of 4 hours. Binding of p24 at 4°C, or even after 4 hours at 37°C, was 
substantially eliminated by treatment of the erythrocytes with EDTA. It was thus concluded 
that binding of the virus to sites on contaminating cells in the erythrocyte population that 
could be infected by HIV-1 did not account for any of the observed binding of HIV-1 (Beck 
et al., 2009). 
3. Candidate binding sites on erythrocytes 
The binding site (or sites) for infectious HIV-1 on erythrocytes, whether protein, 
carbohydrate, or lipid (including glycolipid or phospholipid), or combinations of these, have 
not yet been completely determined. In considering this problem, there is also the 
theoretical and practical difficulty of differentiating the binding of whole infectious virions 
from binding of defective virus particles or degradation products such as free p24.  
The external cell membrane contains numerous proteins with many functions, and the 
literature on red cell proteins and their functions has been extensively reviewed (Anstee, 
2011; Daniels, 2007; Denomme, 2004; Mohandas & Narla, 2005; Reid & Mohandas, 2004; 
Telen, 2005). At least 60 different erythrocytic surface proteins that could be candidates for 
binding of HIV-1 are classifiable into at least six categories based on their functions, namely: 
enzymes; membrane transporters; receptors; adhesion molecules; blood group antigens; and 
structural proteins. The functions of some of these proteins are known; in others their 
function can be assumed from the protein structure or from limited experimental evidence. 
Some of the proteins carry out only one specific function and some have more than one. 
Some might be evolutionary relics and may no longer have significant functions. Several 
membrane transporter glycoproteins are polymorphic, and are blood group antigens (such 
as Kidd, Gill, Rh, etc.). However other receptors and adhesion molecules have blood group 
function as well (Duffy, Lu, LW). 
In pondering the possible binding sites, it is useful to remember that the complement-
independent in vitro binding described above (section 2) required calcium, and many integrins 
or adhesion factors, including molecules in the C-type lectin-like domain superfamily such as 
DC-SIGN on dendritic cells and platelets, require calcium for binding to carbohydrates 
(Zelensky & Gready, 2005). The gp41 protein of HIV-1 contains a binding site for calcium that 
co-locates with a binding site for a glycosphingolipid (Ebenbichler et al., 1996; Yu et al., 2008). 
It is well-known that erythrocytes contain numerous glycosphingolipids, such as ganglioside 
GM3 (hematoside) and ceramide trihexoside (CTH or Gb3, also known as Pk blood group 
antigen) (Suzuki, 2009), and that binding of HIV-1 to these molecules, and to other glycolipids, 
can occur (Fantini et al., 2002; Alving, et al., 2006; Lund et al., 2009). 
The above glycosphingolipids are possible candidate binding sites for HIV-1 on 
erythrocytes. However, binding to GM3 or Gb, or other glycosphingolipids, might initially 
seem unlikely because they are relatively small molecules and are hidden under overlying 
proteins in normal erythrocytes. Because of steric hindrance by overlying proteins they 
cannot even bind to specific antibodies (Alving, 2006). However, binding of antibodies to 
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erythrocytic glycosphingolipids readily occurs when the erythrocytes have been damaged 
by proteolytic enzymes that remove some of the overlying proteins to unmask the 
underlying glycosphingolipid (Koscielak et al. 1968; Alving, 2006). In view of the 
observation that <1% of the cells in the in vitro erythrocyte population bound HIV-1 (see 
section 2), it is conceivable that the binding of HIV-1 to erythrocytes occurs to 
glycosphingolipids that are exposed on the small number of cells that are damaged, or that 
are at a critical point during the evolution from the reticulocyte stage to mature 
erythrocytes, or perhaps HIV-1 binds to erythrocytes that are senescent and are about to be 
removed from circulation. 
3.1 Duffy blood group antigen on erythrocytes 
The Duffy blood group antigen system was originally described in 1950 based on discovery 
of an alloantibody against an antigen denoted as Fy(a) in a patient with hemophilia who had 
received multiple transfusions (Cutbush et al., 1950). The Duffy antigen system consists of 
multimeric erythrocytic membrane surface proteins composed of different subunits in 
which glycoprotein D is the major subunit that carries the antigenic determinants as defined 
by anti-Fy(a), anti-Fy(b) antibodies (Tournamille et al., 1997). The Duffy antigen system 
achieved considerable prominence when it was discovered that it comprised the 
erythrocytic receptor site for binding and entry of merozoites of Plasmodium vivax and 
Plasmodium knowlesi into erythrocytes (Langhi & Bordin, 2006; Miller et al., 1976). 
Individuals lacking the Duffy phenotype were also found to be resistant to infection by 
strains of malaria that bind to Duffy antigen on erythrocytes, thus explaining the remarkable 
resistance to P. vivax malaria that occurs in large areas of West Africa. Because of the 
subsequent discovery that the Duffy antigen also binds to chemokines, resulting in the 
binding of cytokines to erythrocytes and endothelial cells and perhaps causing regulation of 
plasma cytokine levels, this blood group antigen family is now commonly known as the 
Duffy Antigen Receptor for Chemokines (DARC) (Smolarek et al., 2010). DARC belongs to a 
family of erythrocyte chemokine receptors that bind to interleukin 8 (IL-8), monocyte 
chemoattractant protein 1 (MCP-1), and RANTES, but that do not bind macrophage 
inflammatory protein 1α (MIP-1α) or MIP-1β. 
In 1998, it was reported that HIV-1 could bind to DARC on erythrocytes in vitro and that 
erythrocyte-bound DARC could cause infection in trans of CD4(+) PBMC (Lachgar et al., 
1998). In confirmation of this, based on an in vitro experimental study with erythrocytes 
containing or lacking the DARC phenotype, He et al. proposed that HIV-1 specifically binds 
to DARC on the surface of erythrocytes at 37°, and that this binding results in the trans 
infection of CD4(+) target cells by transfer of infectious HIV-1 to target cells from 
erythrocytes (He et al., 2008). Binding of HIV-1 particles to erythrocytes was inhibited by 
recombinant chemokines such as RANTES, but not by recombinant MIP-1α prior to 
incubation of the cells with HIV-1. It was suggested that RBCs may function as a reservoir 
for HIV-1 and it was postulated that DARC might be a receptor for HIV-1 on CD4(-) cell 
subsets such as neurons or endothelial cells. Although neither of these studies directly 
measured the binding of HIV-1 to DARC on erythrocytes, they provided evidence of 
increased infection of CD4(+) target cells when the CD4(+) target cells were co-incubated in 
the presence of DARC(+) erythrocytes, or co-incubated in the presence of DARC(+) 
erythrocytes that had been previously incubated with HIV-1 and then washed free of 
unbound HIV-1. Because this was not observed after co-incubation of HIV-1 with DARC(-) 
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further reported that the HIV-1 strain MN gp120 envelope protein might exhibit sequence 
similarity to the binding domain of Duffy-binding protein of P. vivax (Bolton & Garry, 2011). 
The experimental conditions used for the reported binding of HIV-1 to DARC by He et al. 
(2008) differed from those used by Beck et al. (2009) in at least two ways: the HIV-1 
preparation was incubated by He et al. with 107 erythrocytes (20-fold fewer than used by 
Beck et al. (2009)) and the initial incubation with HIV-1 was performed at 37° rather than 4°. 
He et al. (2008) reported that the DARC(+) erythrocytes caused infection in trans with 5- to 
12-fold greater efficiency than DARC(−) erythrocytes. The larger number of erythrocytes 
employed by Beck et al. (2009) might therefore explain the binding of HIV-1 observed in the 
latter study with erythrocytes that were obtained from all donors, including both DARC(-) 
and DARC(+) erythrocytes. Although the preponderance of the above indirect evidence for 
HIV-1 binding to DARC supports the suggestion that DARC might enhance the binding of 
HIV-1 to erythrocytes, it does not negate other reports that adherence of infectious HIV-1 to 
erythrocytes can also occur through mechanisms that do not involve binding to DARC. 
After the above laboratory demonstration of apparent DARC-dependent transfer of 
infectious HIV-1 from erythrocytes to CD4(+) target cells, He et al. (2008) further provided a 
detailed epidemiological survey, and a summary, of previously published genetic 
distributions of DARC(+) phenotype in different racial groups. Based on this survey, and 
based on a follow-on natural history study of HIV-1 infection (Kulkarni et al., 2009; Nibbs, 
2009), they proposed that increased susceptibility to HIV-1 infection may be related to 
genetic occurrence of the DARC(+) phenotype, with a survival advantage to absence of the 
DARC phenotype, among Africans and African-Americans. They further concluded that 
after Duffy(+) individuals become infected with HIV-1 they had a decreased risk of disease 
progression (see editorial by Walton & Rowland-Jones, 2008). 
The epidemiological conclusions that suggested racial predispositions to increased HIV-1 
infection or decreased HIV-1 susceptibility among Africans and African-Americans were 
based on extrapolation from in vitro studies, and they caused considerable dissent from 
these concepts from numerous scientists engaged in large HIV research programs in which 
infectious patterns among Africans and African-Americans were being examined in detail 
(Horne et al., 2009; Julg et al., 2009; Walley et al., 2009; Winkler et al., 2009). This controversy 
relating to epidemiology of HIV-1 infection is interesting and still ongoing, but it is beyond 
the scope of the present discussion of the occurrence of binding of infectious HIV-1 particles 
to erythrocytes. At this time, the relative epidemiological importance from a practical 
standpoint of HIV-1 binding to erythrocytes having DARC(+)phenotypes is still not clear. 
3.2 Complement receptors on erythrocytes 
Circulating immune complexes (IC) are normally removed from blood through activation of 
the complement (C) cascade (Hebert, 1991; Schifferli et al., 1986). When the C cascade is 
activated by IC the production of C4 and C3b results in the binding of the IC to the C4/C3b 
receptor, also known as complement receptor type 1 (CR1 or CD35), that is present on the 
surface of the erythrocytes. The erythrocytes then transport the IC to fixed macrophages in 
the liver and spleen for removal from the circulation. 
Complement-mediated binding of pathogen IC to erythrocytes is also well known, and the 
same mechanisms for removal of the pathogens take place. In the course of HIV-1 infection 
circulating IC inevitably appear that consist of induced antibodies that are bound to 
infectious HIV-1 particles (Morrow et al., 1986). Many authors have analyzed the role of C in 
HIV-1 infection (Aasa-Chapman et al., 2005; Beck et al., 2008; Gras et al., 1997; Huber & 
Interactions of Infectious HIV-1 Virions 
with Erythrocytes: Implications for HIV-1 Pathogenesis and Infectivity 
 
245 
Trkola, 2007; Legendre et al., 1996; Moir et al., 2000; Montefiori, 1997; Stoiber et al., 1997) and 
direct in vitro binding of HIV-1-erythrocyte IC to CR1 on erythrocytes, and even to 
recombinant CR1, has been demonstrated (Montefiori et al., 1994; Stoiber et al., 2008; Zhou 
& Montefiori, 1996) 
To illustrate C-dependent binding of HIV-1-IC to erythrocytes, Horakova et al (2004). used 
radiolabeled HIV-1, and also prepared preformed HIV-1/anti-HIV-1 immune complexes 
(HIV-IC) that were opsonized in various human sera. The HIV-IC were purified using 
sucrose density gradient ultracentrifugation, and incubated with human erythrocytes. They 
observed immune adherence of the complexes to erythrocytes, and adherence was abolished 
when C was blocked. C-deficient sera indicated that both the classical and alternative 
pathways of C activation played a role. No adherence was seen in C1q-deficient serum, and 
the adherence of HIV-1 was reduced when the alternative pathway was blocked using anti-
factor D Abs. The adherence could be inhibited by a mAb against CR1. At 
supraphysiological concentrations, purified C1q mediated the binding of a small fraction of 
HIV-1 and HIV-IC to erythrocytes. 
4. Implications of binding of HIV-1 to erythrocytes for HIV-1 pathogenesis and 
vaccine development 
The immune system serves as the primary defense against infection by pathogenic 
microorganisms. In the quest for development of an HIV-1 vaccine it is believed that 
neutralizing antibodies may be a useful, or even vital, requirement (Mascola & Montefiori, 
2010). In addition, innate functions initiated by antibodies, including antibody-dependent 
complement activation, and Fc-receptor mediated antibody-dependent cell-mediated 
cytotoxicity (ADCC) or antibody-dependent cell-mediated viral inhibition (ADCVI) may 
also be mobilized, even by non-neutralizing antibodies (Asmal et al., 2011; Forthal & Moog, 
2009). In the present context, the question arises whether erythrocytes may serve as an 
immunologically protected site for infectious HIV-1 virions that can cause HIV-1 infection of 
infection of HIV-1-susceptible cells in trans. To address the above question, Beck et al. (2011) 
studied the ability of two well-known broadly neutralizing human monoclonal IgG 
antibodies (mAbs), 4E10 and b12, to prevent trans infection of CD4(+) PBMC by erythrocyte-
bound HIV-1 both in the presence and absence of complement (Fig. 2). 
In the absence of C both of the mAbs neutralized trans infection of erythrocyte-bound virus 
less effectively than neutralization of cell-free virus, and at a low concentration 4E10 even 
caused enhanced trans infection, perhaps because of Fc-receptor mediated uptake of the 
virus by the PBMC. However, when cell-free HIV-1 was incubated with the 4E10 mAb in the 
presence of C, followed by incubation with erythrocytes, significant enhancement of trans 
infection occurred (Fig. 2). In contrast, if the HIV-1 was first pre-incubated with 
erythrocytes, and the 4E10 mAb and C were then added later, significant inhibition of trans 
infection was observed (Fig. 2). 
The explanation for these different effects of C was explained by Beck et al. (2011) as being 
determined by different binding sites for HIV-1 on the erythrocyte. As illustrated in Fig. 3B, 
when cell-free HIV-1 was exposed to 4E10 and C, partial activation of the C cascade 
occurred and C3b was generated, as a result of which the viable infectious HIV-1 became 
bound to CR1 on the erythrocytes, leading to trans infection of PBMC. In contrast, as shown 
in Fig. 3A, when the HIV-1 was pre-attached to erythrocytes (presumably to a site other than 
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generation of membrane attack complexes and killing of the HIV-1. Interestingly, the b12 
mAb exhibited no C-dependent effects on erythrocyte-bound HIV-1, an observation that 
was compatible with previous absence of observed C effects in attempts to use b12 to inhibit 







Fig. 2. Effects of antibody-dependent C activation on the trans infection of PBMC by 
erythrocyte-bound HIV-1-mAb complexes.  
(A) Data with 4E10 are the mean±SEM of 8 experiments. (B) Data with b12 are the mean ± 
SEM of 6 experiments . The baselines represent the values obtained in the absence of C, heat-
inactivated C (HI-C), or C inactivated by treatment with zymosan. (Zy-C). The dashed lines 
indicate the levels of 50% or−50%, defined as positive cutoffs for inhibition or enhancement 
of virus growth, respectively. In each case, 4E10 had been pre-incubated with the cell-bound 
or cell-free HIV-1, followed by addition of C, HI-C, or Zy-C, as indicated. From Beck et al. 
(2011). 
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Fig. 3. Schematic representation of C-dependent neutralization of erythrocyte-bound virus, 
and C-dependent enhancement of infection of PBMC by cell-free virus.  
(A) After antibody-independent and C-independent binding of HIV-1 to erythrocytes (Beck et al., 2009), 
binding of 4E10 (Fig. 4A), but not b12 (Fig. 4B), to the erythrocyte-bound HIV-1 results in C-dependent 
neutralization. (B) Binding of 4E10 (Fig. 4A), but not b12 (Fig. 4B), to cell-free HIV-1 results in C-
dependent binding to CR1 on erythrocytes or B cells, or CR2 on B cells, with enhanced infection of 
PBMC through trans infection of PBMC by erythrocyte-bound or B cell-bound HIV-1. From Beck et al. 
(2011).  
The conclusions by Beck et al. (2011) were that antibodies and C each represents a two-
edged sword. Under certain circumstances, and depending on the individual antibody, 
inhibition or enhancement of trans infection of PBMC can be caused either by the antibody 
itself or by innate mediators such as Fc receptor binding or activation of C. 
5. Does HIV-1 bind to erythrocytes in vivo? 
In view of the considerable in vitro evidence that HIV-1 can bind to erythrocytes, the 
question naturally arises whether HIV-1 actually binds to erythrocytes in vivo. Three reports 
have examined whether HIV-1, or markers of the presence of HIV-1, can be detected on 
erythrocytes obtained from infected individuals. In the first study, Hess and colleagues 
reported that infectious HIV-1 was bound to erythrocytes via immune complexes (Hess et 
al., 2002; Levy, 2002). Hess et al. showed that HIV-1 RNA and infectious virus was bound to 
erythrocytes circulating in blood of HIV-1-infected patients. Even in infected individuals 
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question naturally arises whether HIV-1 actually binds to erythrocytes in vivo. Three reports 
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erythrocytes obtained from infected individuals. In the first study, Hess and colleagues 
reported that infectious HIV-1 was bound to erythrocytes via immune complexes (Hess et 
al., 2002; Levy, 2002). Hess et al. showed that HIV-1 RNA and infectious virus was bound to 
erythrocytes circulating in blood of HIV-1-infected patients. Even in infected individuals 





detected. They concluded that viral RNA was bound to immune complexes with a short 
half-life. 
In a second study more highly purified erythrocytes were used from 13 HIV-1 infected but 
aviremic patients, 11 of whom were receiving ART and 2 of whom were “long-term 
nonprogressors” who were not receiving ART (Fierer et al., 2007). In this study, that used 
PCR detection techniques, the previous conclusions of Hess et al. (2002) were disputed in 
that virus was not detected on the purified erythrocytes (Fierer et al., 2007). Although the 
reason for the discrepancy with the previous study is unclear, Fierer et al. (2007) suggested 
that the previously studied cell population of Hess et al. (2002) might have contained a 
higher level of contaminating CD4(+) lymphocytes that were removed by Fierer et al by 
using more stringent purification techniques. 
In a third recent study, the presence of p24-antigen bound to highly purified erythrocytes 
from HIV-1-positive individuals was reported (Garcia et al., 2011). In this study 51 out of the 
71 patients with detectable plasma viral loads (pVL) showed erythrocyte-associated p24-
antigen (Ag-E) whereas 13 showed p24-antigen in plasma (Ag-P). Twenty-two out of the 51 
patients with Ag-E showed high pVL and undetectable Ag-P. The amount of erythrocyte-
associated p24-antigen was not related to p24-antigen in plasma or pVL levels. Among the 
41 patients with prior undetectable pVL, eight presented detectable pVL and erythrocyte-
associated p24-antigen at the moment of the study. The other 33 showed undetectable pVL 
and 5 of these presented erythrocyte-associated p24-antigen. A positive relationship was 
found between the presence of erythrocyte-associated p24-antigen and the detectable pVL. 
This study thus confirmed the presence of erythrocyte-associated p24-antigen in HIV-1-
infected individuals. Since erythrocyte-associated p24-antigen is not always related to pVL 
or p24-antigen in plasma, erythrocyte associated p24-antigen showed viral expression not 
represented in plasma. 
Although the above three studies suggest that some degree of controversy exists, the 
preponderance of data now indicates that HIV-1 does bind to erythrocytes in vivo. In view of 
this it is reasonable to speculate whether such binding might result in hematologic 
abnormalities in HIV-1-infected patients. Changes in erythrocyte and lymphocyte 
membrane properties have been associated with infection, including changes in calcium 
signaling, decreased membrane fluidity, decreased acetylcholinesterase activity, and 
decreased intracellular calcium concentration (Martins-Silva et al., 2006). It was concluded 
that the observed changes were consistent with the hypothesis that erythrocytes were being 
maintained as a circulating in vivo reservoir of infectious virus and that this was causing 
adverse physical changes in the erythrocytes. Regardless of the exact mechanism(s) involved 
in causing these effects, it is apparent that anemia might be a potential sequel. 
Anemia is reportedly the most common hematologic manifestation of HIV-1 infection 
(Claster, 2002). However, there can be multiple causes of anemia, including reduced 
erythrocyte production. As noted earlier (section 2.1), HIV-1 infects multipotent progenitor 
cells in the bone marrow that might affect reticulocyte production (Carter, et al., 2010). 
Anemia might also be secondary to a variety of causes such as drug-related anemia, 
parvovirus infection, and nutritional deficiencies, in addition to increased erythrocyte 
destruction. Clearly, appropriate therapies can address the various correctable causes of the 
clinical course of anemia. However, it should be noted that regardless of the underlying 
cause, anemia has been cited as an independent predictor of mortality and progress of 
disease among HIV-1-infected women in Tanzania (O’Brien et al., 2005). 
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From the above three studies it is evident that the question of HIV-1 binding to erythrocytes 
in vivo has generated some degree of controversy. Although the reasons for the failure of 
Fierer et al. (2007) to detect erythrocyte-bound HIV-1 are unknown, in view of the study by 
Hess et al., 2002 and the confirmatory results of Garcia et al. (2011), and when this it taken in 
the context of the several studies that have demonstrated binding of HIV-1 to erythrocytes 
in vitro, it seems likely that infectious HIV-1 virions are present on circulating erythrocytes 
in HIV-1 infected persons. In view of the recent in vitro evidence by Beck et al. (2011) that 
erythrocyte-bound HIV-1 may sometimes be more difficult to neutralize with antibodies 
than cell-free HIV-1, and that both inhibition and enhancement can occur with antibody-
mediated innate immunity in the presence of C, it also seems likely that circulating 
erythrocytes may represent an attachment site for infectious HIV-1 that is relatively 
protected from attack by antibodies and C. It is possible that further research will identify 
means to induce antibodies that block trans infection by erythrocyte-bound HIV-1. A 
corollary of this is that development of a trans infection neutralization assay may also be 
useful as an in vitro correlate of protective immunity in addition to neutralization assays in 
which cell-free virus is the infecting agent. 
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1.1 Latency and reactivation of HIV-1 
Since the discovery of human immunodeficiency virus type 1 (HIV-1), there has been a great 
deal of interest in identifying cofactors that might accelerate the stages of development 
associated with acquired immunodeficiency syndrome (AIDS). Many environmental agents, 
namely inherent factors such as ethnicity and geographical location, were first implicated as 
risk factors in the study of HIV infection. However, speculation that infectious diseases may 
act as cofactors in HIV infection began to be studied soon thereafter. These speculations led 
to one of the early opinions that HIV plays a correlary role in AIDS, but not a causative role 
(Duesberg, 1989). AIDS patients have a history of both circumstantial serological and 
microbial evidence of increased exposure to a number of common and opportunistic 
infectious agents. It is difficult to ascertain, however, whether these various coinfections 
contribute anything to the progressive decline of the immune system (Pedersen et al., 1990). 
In vivo, infection with HIV-1 is followed by a long disease-free period, during which a low 
number of CD4+ mononuclear leukocytes (CCR5 coreceptor positive monocytes and CXCR4 
coreceptor positive lymphocytes) containing transcriptionally silent integrated provirus can 
be found. HIV-1 replication can be demonstrated in only a small population of T cells 
without inducing clinical manifestations. This state of latency is partly due to low 
transcriptional activity of the integrated provirus in resting cells. Activation of CD4+ cells by 
antigens, mitogens (Tobiume et al., 1998) or superinfection by other viruses interacting with 
HIV-1 via viral and/or cellular transacting factors may terminate HIV-1 latency, leading to a 
productive HIV-1 infection. Transactivation of the HIV-1 long terminal repeat (LTR) in turn 
will induce gene expression, including the synthesis of the HIV-1 transactivator protein 
(TAT) (Arya et al., 1985). TAT will then independently amplify HIV-1 gene expression, 
ultimately leading to a high level of virus replication and death of infected cells. Onset and 
progression of AIDS correlates with augmented production of infectious virions parallel to a 
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shift in their tropism from CCR5 towards the CXCR4 coreceptor. The number and ratio of 
infected cells, mainly CD4+ T lymphocytes, increases 100-1000-fold during this period 
(Ensoli et al., 1989). 
Initiation and augmentation of transcription by HIV relies not only on the simultaneous 
binding of virus-encoded TAT polypeptide to TAR, but the normal cellular transcriptional 
factors (NF-, Sp1, and other regions of the 3’ HIV-1 mRNA start site) also anchor into 
specific binding sites of the proviral LTR. The production of such factors are augmented 
after mitogen treatment followed by signal transduction from cell surface receptors and 
through several parallel pathways including secondary messenger systems (Martin et al., 
1991; Mosca et al., 1987a, 1987b; Nabel & Baltimore, 1987; Siekievitz et al., 1987). The basal 
level promoter activity does not require binding of NF-B or other nuclear factors (Wang et 
al., 1994).  
1.2 The role of heterologous viruses in HIV-1 activation 
Two alternative ways exist for HIV transactivation by heterologous viruses. First, two (or 
more) viruses can simultaneously infect the same immune cell if the appropiate receptors 
are expressed on its surface. Several DNA viruses have been suggested as potential cofactors 
in AIDS due to their capability to transactivate in vitro the HIV-1 LTR-directed gene 
expression by a tat-independent mechanism. For example, herpes simplex virus type 1 
(HSV-1) immediate early gene products ICP0 and ICP4 act via NF-B and Sp1 (Mosca et al., 
1987a, 1987b). Stimulating effects vary by cell type, indicating that the cellular environment 
plays an important role in viral transactivation (Albrecht et al.,1989). HSV-2 can coinfect, 
simultaneously replicate and transactivate HIV-1 (Kucera et al., 1990). Human 
cytomegalovirus (HCMV) IE genes activate via Sp1 and NF-B sites (Davis et al., 1987; 
Ghazal & Nelson, 1993). HCMV also transactivates HIV-2 LTR (Duclos et al., 1989). Epstein-
Barr virus (EBV) EBNA2, BRLF1 and LMP gene products act through NF-B and Sp1 
(Hammarskjöld et al., 1992; Kenney et al., 1988; Quinlivan et al., 1990). The IE protein of 
pseudorabies virus induces the overproduction of Sp1 (Yuan et al., 1989). Papovaviruses (JC, 
BK) transactivate through Sp1 (Gendelman et al., 1986), adenovirus (AdV) E1A 13S protein 
exerts activation on the TATA box and Sp1 sites (Nabel et al., 1988; Rice & Mathews, 1988). 
Vaccinia virus (Stellrecht et al., 1992), hepatitis B virus (HBV) X protein (Seto et al., 1988), 
and a retrovirus named human T lymphotropic virus type I (HTLV-I) tax polypeptide 
(Siekievitz et al., 1987) transactivate HIV-1. Lymphoid cells chronically infected with HTLV-
I are more susceptible to infection in vitro with HIV-1, and coinfected cells produce higher 
levels of HIV-1 (De Rossi et al., 1986, Ongrádi et al., 2000b). It is likely that the activation of 
HIV-1 by heterologous viruses in dually infected cells results from the cumulative effects of 
various gene promoters. None of these viruses infects CD4+ T cells as their primary target. 
Their gene products do not bind directly to the HIV LTR sequences, and there is no 
apparent molecular link between these products and cellular transcriptional factors. 
Intracellular transactivation is mediated by those transcriptional factors that are upregulated 
upon external stimuli. They may act in a paracrine manner, whereby altering mediator 
production affects the producer cell or neighbouring cells. It has been established that tumor 
necrosis factor (TNF)-α via NF-B activation acts in tandem with HSV-1 in augmenting HIV-
1 in different CD4+ cells such as T lymphocytes, monocytes, and leukemic cell lines (Popik 
& Pitha, 1994). Thus, the relevance of these viruses to direct HIV-1 activation in vivo is still 
waiting for unequivocal confirmation. Simultaneous infection in a single cell is a relatively 
rare event, and as such the biological effects of an event of this nature could be minimal. On 
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the contrary, cross-talk between immune cells carrying different viruses is more common, 
especially in lymph nodes where they are in the vicinity of one another. Heterologous 
viruses can infect many other types of cells which are not targets of HIV, but release several 
immunomodulating mediators. This transcellular transactivation can last a lifetime, and its 
intensity may vary on an individual basis, as well as on the synergistic or antagonistic 
effects of several factors including the heterologous viruses themselves. This category of 
interaction seems to have a more significant biological and clinical impact on HIV 
replication and AIDS progression. Expression of the early and/or immediate early genes of 
several heterologous viruses exert very strong modifying effects on the normal mediator 
pattern, which consequently alters HIV replication. HIV infected individuals carrying other 
viruses, therefore, may be at a greater risk for early onset and rapid progression of AIDS. 
2. Human herpesvirus 6 as a broad-range virus transactivator 
2.1 Characterization and genetic structure of HHV-6  
Among heterologous viruses, human herpesvirus 6 (HHV-6, Herpesviridae family, 
Betaherpesvirinae subfamily, Roseolovirus genus) seems to be one of the most important HIV-1 
transactivator. HHV-6 is predominantly a T cell tropic virus, and its unique 
immunomodulatory characteristics have made it a widely studied in vitro and in vivo model. 
HHV-6 has two variants, which differ on the basis of distinct genetic, immunological and 
biological characteristics.; Variant A (HHV-6A) was originally obtained from the peripheral 
blood mononuclear cells (PBMC’s) of patients with HIV infection and other 
lymphoproliferative disorders (Salahuddin et al., 1986), while HHV-6B was originally 
obtained from the PBMC’s of children suffering from exanthema subitum. Isolates were 
later grouped according to prototypes (e.g. GS and U1102 for HHV-6A, Z29 and HST for 
HHV-6B) (Ablashi et al., 1991). The viral genome is 160-162 kbp in size and is formed by a 
central unique (U) region (143-145 kbp) flanked at both ends by terminal direct repeats (DR, 
each 8-9 kbp long). The DR’s contain a tandem repetitive sequence that is also present in 
human telomeres (Thomson et al., 1994a). The genome of HHV-6B contains 119 open 
reading frames (ORFs) encoded by 97 genes, 9 of which are absent in HHV-6A: DR4, DR5, 
DR8, U1, U61, U78, U88, U92, U93 (Dominguez et al., 1999; Gompels et al., 1995). Several 
conserved genes organized into 7 blocks are present in the genome of all herpesviruses. One 
additional block comprises 17 genes conserved in all Roseoloviruses (U20-21, U23-24, U26, 
U85, U100). Two genes are unique to HHV-6 and present in both variants: U83, which 
encodes chemokines (Dewin et al., 2006), and U94, which encodes for a homologue of the 
human adeno-associated virus type 2 (AAV-2) rep gene (Thomson et al., 1994b). The latter is 
transcribed in latently infected lymphocytes, suggesting it likely contributes to the 
maintenance of latency (Rotola et al., 1999). The overall nucleotide sequence identity 
between HHV-6A and –B variants is 90%, but the genes of DR, U86-U93, and U95-U100 
show the highest degree of sequence divergence, reaching 72%. Increased divergence in 
consequent amino acid sequences explains the biological and pathogenic differences 
between variants A and B. Differences in the U100 gene products, designated gQ, determine 
differences in cell tropism between variants (Mori et al., 2003). The variants also differ in 
temporal regulation and splicing patterns of U91 transcripts in T cell lines (Mirandola et al., 
1998). The products of U90 and U95 genes are hypothesized to play a role in the 
establishment of variant–specific niches within the host. The degree of heterogeneity 
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isolates obtained from immunocompetent persons no genetic gradients and recombinants 
between HHV-6A and HHV-6B have been detected, making it clear that the two variants 
have independent biological niches and meet the criteria for classification into distinct 
species (Dominguez et al., 1999).  
2.1.1 Molecular interactions between HHV-6 and the immune system 
2.1.1.1 Modulation of surface receptor expression, cytokine and chemokine pattern 
CD46 has been demonstrated as a cellular receptor for both HHV-6A and HHV-6B (Santoro 
et al., 1999). This glycoprotein is a complement regulator, and is expressed on the surface of 
all nucleated cells. Binding of HHV-6A gH structural polypeptides, but not HHV-6B gB 
structural polypeptides, to CD46 cell surface receptors induces the downregulation of IL-12 
and CD46 with consequent disturbances in the complement system (Santoro et al., 1999), cell 
fusion, and CD4+ T lymphocyte depletion (Mori et al., 2002). Through CD46, HHV-6 has the 
ability to infect a wide variety of cell types including neuronal cells (references in De Bolle et 
al., 2005), but both variants express a non-naive phenotype and replicate most efficiently in 
CD4+ T lymphocytes (Ablashi et al., 1991; Grivel et al., 2003). This phenotype introduces a 
unique relationship to the immune system with profound implications on 
immunomodulation. They also infect monocyte/macrophages (Kondo et al., 1991) and 
dendritic cells (Kakimoto et al., 2002) to further establish their latent infection. HHV-6A 
efficiently infects CD8+ T cells (Lusso et al., 1991), γδ lymphocytes (Lusso et al., 1995), and 
natural killer (NK) cells (Lusso et al., 1993). This leads to the induction of CD4 expression on 
infected cells, which in turn potentially increases the range of cells susceptible to HIV 
infection. The genes responsible for transactivation of the CD4 promoter include U86 and 
U89 (Flamand et al., 1998). HHV-6A and HHV-6B viral envelope proteins inhibit T 
lymphocyte proliferation induced by phytohemagglutinin (PHA), IL-2 or antigens (Horvat 
et al., 1993). Not only do the infected cells experience programmed cell death (apoptosis), 
but adjacent healthy lymphocytes die as well due to high concentrations of both TNF-α and 
-β released from nearby infected cells (Inoue et al., 1997). Both variants inhibit the 
expression of CD3/T cell receptor (TCR) complex (Lusso et al., 1991), the lectin-like receptor 
DC-SIGN on dendritic cells (Niiya et al., 2004), CD14, CD64 and HLA-DR on antigen 
presenting cells (Janelle & Flamand, 2006). 
HHV-6 profoundly modifies the bodily pattern of cytokine and chemokine production as 
well, which in turn significantly affects the functionality of effective immune responses. 
HHV-6A strongly inhibits IL-12 and IFN-γ production, consequently lowering the output of 
uninfected T lymphocytes (Arena et al., 1999). IL-12 production by macrophages (Smith et 
al., 2003), IL-2 production by CD4+ lymphocytes (Flamand et al., 1995), IL-2, IFN-γ 
production by HSB-2 cultures (Ongrádi et al., 1990), IL-10 and IL-14 production in SupT1 
cultures is inhibited (Mayne et al., 2001). On the contrary, HHV-6A upregulates the 
production of IL-1β, IFN-α, TNF-α, IL-10 synthesis in PBMC’s, TNF-α production in HSB-2 
cultures, IL-10, IL-12 production in monocytes, and IL-15 production in both monocytes and 
NK cells (Arena et al., 1997, 1999, 2000; Flamand et al., 1990, 1991, 1996; Kikuta et al., 1990; 
Mayne et al., 2001; Li et al., 1997; Ongrádi et al., 1990). HHV-6A induces GM-CSF in the 
peripheral blood lymphocytes and the ensuing increase in macrophages consequently 
enhances differentiation of bone marrow progenitor cells, further sensitizing them to HIV 
infection (Furlini et al., 1996). All these changes result in a Th1 to Th2 shift in cytokine 
pattern, an impairment of cellular immunity and maintenance of persistent viral infections.  
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Similar to HHV-6A, HHV-6B increases expression of IL-18, IL-2 receptor and members of 
TNF-α superfamily receptors (Mayne et al., 2001). HHV-6B increases the production of IFN-
α in PBMC’s (Kikuta et al., 1990), IL-8 release from HepG2 human hepatoma cell lines 
without altering IL-1β expression (Inagi et al., 1996), and downregulates IL-12 production 
(Smith et al., 2001). Upon HHV-6B infection, the cytokine pattern produced by MOLT-3 
CD4+ lymphoid cells drastically changes as compared to mock-infected cultures in 
synergism with IL-2, while the concentration of IL-3, IL-4, IL-10, IL-15, GM-CSF, TNF-α and 
-β decreases. These changes result in the suppression of innate, humoral and cellular 
immunity in vivo (Ongrádi et al., 2006). 
It seems that the global effect of HHV-6 on human immune functionality differs by variant. 
HHV-6A targets the suppression of cellular immunity above all, while HHV-6B primarily 
weakens humoral immunity. The consequence of variant-specific immunomodulation is the 
onset of different clinical entities and provision of helper function for other viral diseases. 
These studies have suggested that HHV-6A induced chronic immune alterations contribute 
to HIV pathogenesis and AIDS progression as causative factors, while recurrent HHV-6B 
infection acts as a secondary contributor by aggravating and accentuating other 
immuncompromised conditions. 
2.1.1.2 HHV-6 encoded chemokines and chemokine receptors 
During co-evolution with animals, HHV-6 seems to have obtained genes from them via 
molecular piracy. The products of these genes may play important roles in pathogenesis and 
immune evasion. U83 of HHV-6B encodes for a functional β-chemokine (Zou et al., 1999). 
This protein is produced by infected cells, and as a highly active CCR2 agonist attracts 
CCR2-expressing cells such as monocytes/macrophages the virus establishes new infection, 
thus facilitating the spread of the virus. U83 of HHV-6A encodes for two different forms of 
β-chemokines. The full-length form acts as an agonist while the spliced form acts as an 
antagonist that interacts with other chemokine receptors, i.e. CCR1, CCR4, CCR5, CCR6 and 
CCR8, and is expressed on T cells, monocytes/macrophages, and dendritic cells (Dewin et 
al., 2006). Gene U22 also codes for yet another chemokine (French et al., 1999). Counterparts 
of U12 and U51 genes have been shown in the betaherpesviruses and they code for G-
protein coupled receptor homologs: U12 protein of both variants acts as a β-chemokine 
(RANTES, macrophage inflammatory protein /MIP/-1α and -1β, monocyte chemoattractant 
protein /MCP/-1) binding receptor related to CCR1, CCR3, and CCR5. It is expressed at the 
late stage of infection of monocyte/macrophages and cord blood mononuclear cells. Its 
expression is activated by the above cytokines elicited on the effect of other factors, i.e. 
viruses, but not by the α-chemokine IL-8 (Isegawa et al., 1998, Kondo et al., 2002). While 
expressed on human epithelial cells, U51 protein specifically binds and down-regulates 
RANTES (Caruso et al., 2003; Milne et al., 2000) by mimicking receptors typically expressed 
on the surface of activated T cells (Menotti et al., 1999). Down-regulation of RANTES may 
consequentially compromise the ability of T-lymphocytes, monocytes and eosinophils to 
gather at sites of inflammation. The gene product of U51 may act as a positive regulator of 
viral replication, possibly promoting membrane fusion and facilitating cell-to-cell spread 
(Zhen et al., 2005).  
The main task of the production of HHV-6 specific chemokines and chemokine receptors is 
to ensure the efficient dissemination of virus throughout the organism either by way of 
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2.2 Clinical manifestations and transactivating potential of HHV-6A 
The exact mode of transmission and pathomechanism of HHV-6A have not been 
established. In developed countries, HHV-6A does not or very rarely infects children, but 
from adolescence onward its prevalence increases. In several countries of the developing 
world, especially in Sub-Saharan and South Africa, as much as one quarter of children 
below the age of 18 months already carries this variant in both HIV-1 positive and negative 
groups. This suggests that early infections have a different exposure profile compared to 
North America and Europe (Kasolo et al., 1999). In a recent study of genotyping, variant A 
was identified in 85% of HHV-6 infections of asymptomatic African infants, and HHV-6B 
was largely detected as a co-infection alongside HHV-6A (Bates et al., 2009). In such cases, 
unusual recombinants between HHV-6A and HHV-6B were shown (Gompels & Kasolo, 
2006; Kasolo et al., 1997). This is reminescent of the peculiar adenovirus recombinants found 
in the intestines of AIDS patients (Hierholzer et al., 1988). The molecular mechanisms are 
known in neither case, but each raise the idea of a common effect exerted by HIV-1. Saliva 
and breast milk contained neither HHV-6A virions nor viral DNA. It was found in 54% of 
the lungs of healthy adults (Cone et al., 1996). In the blood of children born to HIV 
seropositive mothers living in Africa, a high-quantity load of HHV-6A can be detected. 
HHV-6 DNA has been found in the semen of two thirds of healthy males, and although its 
variant specificity has not been established, epidemiological circumstances raise the 
possibility of sexual spread. Transmission is also suspected to occur from mother to child 
(Bates et al., 2009). The symptoms of acute infection are unknown, but in some well-
documented cases febrile conditions in children were observed. Primary adult infections 
have been associated with severe inflammatory or neurological disease with increased 
neurotropism (Alvarez-Lafuente et al., 2007; Hall et al., 1998; Portolani et al., 2005). 
Persistent HHV-6A infection in the brain may also contribute to AIDS-associated dementia. 
Primary HHV-6A infection later in life may trigger the onset of multiple sclerosis (MS) 
(Akhyani et al., 2000; Alvarez-Lafuente et al., 2006; Ongrádi et al., 1999). HHV-6A also 
establishes life-long latency in CD4+ immune cells, and is usually reactivated in 
immunocompromised patients after bone marrow or organ transplantation along with 
HHV-6B, HHV-7 and HCMV (Griffiths et al., 1999). HHV-6A might be a cofactor in the 
progression of several tumors. The simultaneous detection of HHV-6A and human 
papilloma virus type 16 (HPV-16) in cervical carcinoma cells (Chen et al., 1994b) and the 
ability of HHV-6A U16 and U30 gene products to transactivate E6 and E7 of HPV-16 in 
cervical epithelial cells (Chen et al., 1994a) have prompted investigation of its role in the 
pathogenesis of cervical carcinoma. In a large clinical study, it was concluded that although 
HHV-6A is not the causative agent of cervical carcinoma, it can contribute to multistage 
carcinogenesis and the progression of cervical cancer (Di Paolo et al., 1994). It is of note that 
cervical cancer is one of the AIDS criteria. Furthermore, due to their high prevalence in the 
lymphoid tissues, HHV-6 and EBV are frequently detected simultaneously (Bertram et al., 
1991). HHV-6A infection has been shown to activate EBV replication from latency by a 
mechanism of transactivation that targets a cyclic AMP response element with the EBV 
Zebra promoter (Flamand & Menezes, 1996) to increase expression of EBV early genes 
(Cuomo et al., 1995) and to enhance the transformative capacity of EBV (Cuomo et al., 1998). 
In return, the presence of EBV renders B cells susceptible to HHV-6 infection. EBV has been 
detected in all brain lymphomas and frequent detection occurs in other lymphomas of AIDS 
patients as well (Cuomo et al., 1995). HHV-6A has been shown to enhance the progression 
of lymphomagenesis. As mentioned earlier, the HHV-6A U94 gene product, known as the 
 
In Vitro and In Vivo Transactivation of HIV-1 by Human Herpesvirus 6 
 
263 
RepH6 polypeptide, is able to complement replication of a rep-deficient AAV-2 genome 
(Thomson et al., 1994b). Contrary to HIV LTR activation by HHV-6, HHV-6 cannot 
transactivate latent infection by human T lymphotropic virus type I (HTLV-I) or 
subsequently affect the expression of its tax transactivator gene (Cao & Sullivan, 1992). 
Mediators released from actively replicating HHV-6A or carrier cells transactivate the 
human endogenous retrovirus (HERV) K18 and induce expression of HERV K18-encoded 
superantigen (Tai et al., 2009). HHV-6B also induces HERV K18-encoded superantigen 
expression (Turcanova et al., 2009).  
In rare clinical manifestations of HHV-6A infection (e.g. hepatitis) or transmission by organ 
transplantation in Europe, North-America and Japan (Portolani et al., 2005; Potenza et al., 
2008) where HHV-6B predominates, HHV-6A strains may be considered emergent 
infectious diseases. These cases will require careful genotyping as well as viral load and 
gene expression studies to further characterize the infection (Bates et al., 2009).  
2.3 Epidemiology and biological effects of HHV-6B 
Although both HHV-6 variants infect CD4+ immune cells, and despite their high molecular 
homology they profoundly differ in epidemiology and pathogenesis. Lack of reliable 
serological testing has hindered their differentiation in pathological conditions for several 
decades, but variant specific polymerase chain reaction (PCR) and other PCR based 
quantitative methods have yielded satisfactory data on their role played in acute and 
chronic diseases. The mode of transmission and pathomechanism of HHV-6B has sine been 
well-characterized, and evidence seems to indicate that humans are the only know 
reserviors of HHV-6B. The salivary gland serves as a reservoir for symptomless shedding, 
and the saliva of the caregivers of small children has been shown to transmit infection via 
droplets (Fox et al., 1990). By age 2, almost all children have become seropositive (references 
in Ongrádi et al., 1999d). The majority of infections are symptomless, but approximately 
15% of infected children develop exanthema subitum (Yamanishi et al., 1988). Although 
HHV-6B DNA sequences were found in the genital tract of 20% of pregnant women, 
perinatal transmission is unlikely (Okuno et al., 1995). HHV-6B establishes life-long latency 
in CD4+ immune cells. HHV-6B is frequently reactivated in immunocompromised 
conditions, e.g. after transplantation of bone marrow, liver, kidney or pancreas. High fever, 
graft rejection and other lethal complications are not uncommon. HHV-6B reactivation is 
followed by HHV-7 and HCMV reactivation in a temporal pattern, aggravating clinical 
symptoms (Herbein et al., 1996). HHV-6B might also act as a cofactor in the pathogenesis of 
several chronic debilitating immunological or neurological diseases such as Hodgkin’s 
lymphomas, multiple sclerosis, mesial temporal lobe epilepsy, chronic fatigue syndrome 
and drug induced hypersensitivity syndrome (references in Caselli & Di Luca 2007 and De 
Bolle et al., 2005). HHV-6B DNA is commonly detected in the brain of deceased AIDS 
patients and HHV-6B proteins are often located in the demyelinated areas, suggesting an 
active role in persistent infection and neurological complications in AIDS patients (Drobyski 
et al., 1994). No vaccination against HHV-6B exists, but for chemoprevention and treatment 
in severe conditions ganciclovir, valaciclovir, foscarnet and cidofovir have been used 
(references in Caselli & Di Luca, 2007 and De Bolle et al., 2005). 
2.4 Chromosomally integrated HHV-6 
It has recently been demonstrated that both variants of HHV-6 can integrate specifically into 
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graft rejection and other lethal complications are not uncommon. HHV-6B reactivation is 
followed by HHV-7 and HCMV reactivation in a temporal pattern, aggravating clinical 
symptoms (Herbein et al., 1996). HHV-6B might also act as a cofactor in the pathogenesis of 
several chronic debilitating immunological or neurological diseases such as Hodgkin’s 
lymphomas, multiple sclerosis, mesial temporal lobe epilepsy, chronic fatigue syndrome 
and drug induced hypersensitivity syndrome (references in Caselli & Di Luca 2007 and De 
Bolle et al., 2005). HHV-6B DNA is commonly detected in the brain of deceased AIDS 
patients and HHV-6B proteins are often located in the demyelinated areas, suggesting an 
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2.4 Chromosomally integrated HHV-6 
It has recently been demonstrated that both variants of HHV-6 can integrate specifically into 





vitro (Luppi et al., 1993; Morrisette & Flamand, 2010; Torelli et al., 1995). This behavior is 
unique among human herpesviruses. The presence of human telomeric-like repeat 
sequences at the HHV-6 genome termini (Gompels & Macaulay, 1995) and the HHV-6 U94 
gene product (RepH6) might mediate the site-specific viral DNA integration within human 
cells (Surosky et al., 1997). Chromosomally integrated HHV-6 (CIHHV-6) can be passed 
through the germ line. Recent evidence from studies in the USA, UK, and Japan have shown 
that approximately 0.2-0.85% of infants experience vertical transmission of HHV-6 through 
the germ line, accounting for almost all HHV-6 congenital infections with no significant 
differences between distribution of variants (Hall et al., 2008; Tanaka-Taya et al., 1996; Ward 
et al., 2006). Cells containing CIHHV-6 copies do not have closed circular viral DNA 
(episomes), but produce a high viral load in the blood (106-107 copies per ml). A person with 
CIHHV-6 will never be negative by PCR in serum or whole blood (Ward et al., 206). While 
some individuals with CIHHV-6 are asymptomatic, the integrated virus appears to be 
capable of reactivating. Members of these families carry identical HHV-6 strains, and some 
of them suffer from severe neurological symptoms. It has been demonstrated that CIHHV-6 
can be made to reactivate by chemically stimulating the integrated cells (Arbuckle et al., 
2010). Several case reports have shown that CIHHV-6 patients with neurological problems 
responded to antivirals (Troy et al., 2008; Wittekind et al., 2010). 
3. Transactivation of HIV by human herpesvirus 6 variant A and B 
3.1 In vitro studies on the intracellular transactivation of HIV by HHV-6 variants  
The fact that HHV-6 and HIV-1 infect overlapping subsets of CD4+ lymphocytes (Lusso & 
Gallo, 1995) and lytic HHV-6 infection may contribute to the decline of this cell population 
in HIV-infected individuals, has lead to the hypothesis that there is specific interaction 
between these viruses. To substantiate this claim, several arguments were initially raised 
based on in vitro data rather than on clinical observations. In the first logical investigation, 
freshly isolated and activated PBMC’s containing CD4+ immune cells were simultaneously 
infected with HIV-1 and HHV-6A (GS). It was demonstrated that HHV-6A and HIV-1 could 
productively coinfect individual CD+ T cells, resulting in accelerated HIV-1 gene expression 
and enhanced cell death through apoptosis (Lusso et al., 1989). Infection of the ACH-2 
leukemic T cells carrying latent HIV-1 with HHV-6A resulted in HIV-1 antigen co-
expression with early-late HHV-6 products, suggesting that more IE gene products are 
involved in the activation of latent HIV-1 (Isegawa et al., 2007). Superinfection of U1 
promonocytic cells latently carrying HIV-1 occurred by introducing HHV-6A (GS) and 
treating with TNF- induced massive HIV-1 replication, whereas none of the clinical isolates 
of HHV-6B were able to break latency of HIV-1. It is of interest that HIV-1 upregulation 
elicited by HHV-6 was not inhibited by anti-TNF-α antibodies (Knox & Carrigan, 1996). 
Cloned fragments of HHV-6 and HIV-1 LTR were cotransfected into different cells, and the 
transactivating potential of HHV-6 infection on HIV-1 LTR was reported (Ensoli et al., 1989). 
Since then, transactivating functions have been assigned to an increasing number of 
individual HHV-6 genes. The protein encoded by HHV-6A (U1102) DR7 gene, expressed 
from 18h postinfection has been shown to transactivate HIV-1 LTR promoter and increase 
HIV-1 replication (Kashanchi et al., 1994, Thompson et al., 1994). Its oncogenic potential in 
NIH 3T3 fibroblast cells relates to its capacity for binding and intiating the tumor suppressor 
protein p53 (Kashanchi et al., 1997). The U3-encoded protein was found to transactivate the 
HIV-1 LTR promoter in money kidney CV-1 cells (Mori et al., 1998). The U16 to U19 genes 
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encode transactivators that upregulate viral and cellular transcription. The immediate early 
(IE) expressed spliced gene products of U16/U17 and the IE U18- and U19-encoded proteins 
have all been shown to independently transactivate the HIV-1 LTR promoter in vitro 
(Flebbe-Rehwaldt et al., 2000; Geng et al., 1992; Nicholas & Martin, 1994). The DNA 
polymerase processing factor, encoded by the HHV-6 (U1102) U27 gene, was shown to 
transactivate the HIV-1 LTR in CV-1 cells. The presence of NF-B binding sites was 
mandatory for the response to pU27 (Zhou et al., 1994). The HHV-6 IE-A locus encodes two 
proteins, IE1 and IE2, corresponding to the ORFs U89 and U86-87, respectively. Both are 
expressed from spliced mRNAs, and each contains an exon derived from the U90 gene 
(Nikolaou et al., 2003). IE1 of HHV-6A was shown capable of transactivating heterologous 
promoters. Compared to the IE1 protein of HHV-6A, the HHV-6B IE1 protein was found to 
exhibit much lower transactivating potential on HIV-1 LTR (Gravel et al., 2002). IE2 activates 
multiple promoters that have no regulatory element in common, such as the complex HIV-1 
LTR promoter, or simple promoters containing zero or only one response element (NF-B, 
CRE, or NF-AT (Gravel et al., 2003). It also transactivates the CD4 promoter (Flamand et al., 
1998). HHV-6A (U1102) U94-encoded RepH6 acts as a transactivator by binding to a 
transcription factor, human TATA binding protein (Mori et al., 2000). RepH6 by itself 
possesses single-stranded DNA binding capacity, which is enhanced by cellular nuclear 
factors (Dhepakson et al., 2002), and is known to activate the HIV-1 LTR promoter in 
fibroblast cells (Thomson et al., 1994b). 
HHV-6 encoded proteins with HIV-1 LTR transactivating potential not only stimulate HIV-1 
expression (Ensoli et al., 1989; McCarthy et al., 1998), but these proteins (e.g. IE1) and the 
HIV-1 transactivating protein TAT have been shown to interact synergistically in this 
respect as early as 6.5 hours after HHV-6 infection (Di Luca et al., 1991, Garzino-Demo et al., 
1996). HIV-1 TAT enhances HHV-6A titers and protein synthesis in cord blood lymphocytes 
and continuous CD4+ JJHAN T cells (Sieczkowski et al., 1995), but no activation was 
detected in Jurkat cells (Di Luca et al., 1991). More products of genes and cloned gene 
fragments of HHV-6A (U1102), namely SalI L, EcoRI (encoding p41) genomic fragments and 
HHV-6A (GS) pZVB70 and pZVB10 transactivate HIV-1 LTR at the NF-B site, while 
pZVH14 acts through the Sp1 site in African green monkey kidney cells (CV-1) and human 
T cells (Geng et al., 1992), although in other experiments all three fragments have been 
shown to activate NF-B. HHV-6A is able to activate HIV LTR in both stimulated and 
resting T lymphocytes, while HHV-6B (Z29) can carry out HIV LTR activation in T cells only 
(Horvat et al., 1991). 
Patients and clinically normal individuals are frequently infected with multiple viruses. It is 
therefore important to understand the implications of simultaneous infection by multiple 
viruses. Coinfections with HIV, HHV-6A and hepatitis C virus (HCV) are frequently seen in 
the same individual. In a recent study, human lymphoid cells were simultaneously infected 
with all three viruses. Individual cells were able to support replication of all three viruses 
without dominance of one virus. All these viruses are highly cytolytic, and therefore triply-
infected cells were short lived (Salahuddin et al., 2007).  
There are several reports concerning the inhibitory effect of HHV-6 on HIV-1 in cell 
cultures. Peripheral blood lymphocytes, macrophages, and dendritic cells were coinfected. 
Unfortunately, in the majority of these studies, two different HHV-6 strains belonging to 
variant B were used: either strain Z29 (Asada et al., 1999; Carrigan & Knox, 1990; Spira et al., 
1990) or SF (Levy et al., 1990b). Their further studies on cytokines produced by HHV-6 B 
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this way, consecutive generations of viruses induced different cytokines at very different or 
overlapping time points. 
3.2 In vitro studies on the transcellular transactivation of HIV by HHV-6 A and B 
Next, to study the possible transcellular transactivation of HIV by HHV-6A, Ongrádi et al. 
infected HSB-2 CD4+ T lymphocytes with HHV-6A (GS). Supernatants of the infected cells 
contained a myriad of mediators and newly produced virions, similarly to the serum of 
patients. At regular time intervals, supernatant samples were removed and filtered until 
virus-free. Meanwhile CEM-ss cells were infected with HIV-1 (IIIB) at different multiplicities 
of infection (moi) and then mixed with HHV-6A-free supernatant samples. Next, HIV-1 
production was quantitated by syncytia formation, reverse transcriptase (RT) activity and 
p24 antigen production. Supernatants obtained at 24 and 48 hours post-infection exerted the 
strongest HIV-1 activation. The smaller the HIV-1 inocula were, the higher activating effect 
was observed. This timing coincides with the expression of early HHV-6A genes. Elevated 
TNF-, but suppressed IFN- production was exhibited, and IL-2 was found to have no role. 
Late supernatant samples obtained at the time of virion production showed slightly 
inhibited HIV production. Distinct cytokines and chemokines are produced in a sequential 
manner by the same cell. Their ratio continuously changes, and they furthermore exert 
pleiotropic effects. HIV-1 activation (and/or inhibition) via HHV-6 induced cytokine and 
chemokine production is the net effect of many soluble factors. This is the only known 
experiment in the literature describing that HHV-6 infected--but virus-free--media obtained 
from one type of CD4+ lymphoid culture modifies HIV-1 production in another lymphoid 
culture (Ongrádi et al., 1990, 1999c). Similarly, separated human peripheral blood 
monocytes were exposed to different viral antigens, and aliquots of the media of these 
monocytes were mixed to ACH-2 and U1 cells latently infected by HIV-1. Conditioned 
media obtained from HCMV and EBV antigen exposed monocyte cultures augmented HIV-
1 replication, whereas others, such as HSV-1, HSV-2, VZV, HHV-6A failed to stimulate HIV-
1 replication (Clouse et al., 1989). These suggest that HIV-1 is under several synergistic or 
antagonistic effects in vivo. Several studies have also shown that certain proinflammatory 
cytokines induced by HHV-6A infection--such as TNF-, IL-1 and IL-6 enhance in vitro 
expression of HIV-1(Flamand et al.., 1991). The major mode of transcellular transactivation 
between HHV-6A (GS) infected and HIV-1 carrier lymphocytes is mediated by TNF- and 
consequent NF-B induction followed by its increased binding to LTR sequences. In vivo, 
HHV-6A induces the T helper cell profile to shift from Th1 to Th2 by upregulating IL-10 and 
downregulating IL-12 in infected PBMC’s (Arena et al., 1999), which might act with the 
similar effects of HIV-1 to accelerate AIDS progression.  
4. Epidemiological studies on the HIV transactivating and AIDS promoting 
potential of HHV-6 
4.1 Cross sectional molecular studies 
In vivo transactivation of HIV-1 by HHV-6 has been postulated on the basis of several in vitro 
experiments. Following the discovery of HHV-6A, it was frequently isolated from HIV-1 
infected patients worldwide (Dowling et al., 1987; Levy et al.., 1990a; Lopez et al.., 1988; 
Tedder et al., 1987) although no opportunistic diseases had been associated with HHV-6A at 
that time. Concomitant infection by HHV-6A, HTLV-I and HIV-2 has also been described 
(Agout et al., 1988). Widespread HHV-6A infection was documented in patients with AIDS 
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at post-mortem examination (Carrigan & Knox, 1994). HHV-6A infected cells--usually lung 
macrophages--were observed in all patients, whereas HHV-6A infected lymphocytes and 
epithelial cells were seen in approximately two thirds of patients. The kidneys and liver also 
showed wide-spread infection of lymphocytes in inflammatory infiltrates. In the lymph 
nodes, HHV-6A concentrated in lymphocytes in the medullary region. Lymphoid organs are 
important reservoirs of HIV infection, and progression from HIV-1 infection to AIDS is 
associated with the involution of these tissues. Cell destruction is synergistically enhanced 
leading to early disintegration of the lymphoid environment with higher viral load. HIV 
proviral viral load was higher in tissues taken at autopsy if the organ also harbored HHV-6, 
which could suggest upregulation of the former by the latter (Corbellino et al., 1993; Knox & 
Carrigan, 1994a, 1996). HHV-6B levels in the lymph nodes and in different organs of 
deceased patients also were found elevated alongside increased HIV-1 loads. It has been 
postulated that neighbouring cells exert mutual effects by altered cytokine milieu (Emery et 
al., 1999). Excretion of HHV-6B in the saliva of patients in successive stages of the disease 
was not significantly different (Gautheret et al.., 1995).  
Ongrádi et al. also tested several groups of patients for double virus infection. In the first 
series of cross-sectional studies, patients in consecutive stages of HIV-1 infection with 
declining CD4+ cell number (symptomless, full blown and terminal AIDS, permanent HIV 
seronegative sexual partners, and control individuals) were screened for HHV-6A 
antibodies by immunofluorescence. As compared to controls, the mean level of IgM in the 
sexual partners raised 30-fold, that of IgG increased 10-fold, and 80% of individuals had low 
avidity IgG suggesting fresh HHV-6A infection. As compared to controls, the mean titer of 
IgM to HHV-6A remained elevated 10-fold in each group of HIV positive subjects. The 
highest level was found in the HIV seronegative partner group. The IgG level was 6-fold 
increased in asymptomatic HIV carriers, 4-fold in early and 5-fold in terminal AIDS patients. 
In the rapid progressors of AIDS patients HHV-6A IgG was higher, whereas in the 
subgroup of rapid progressors of terminal AIDS patients HHV-6A IgG was significantly 
lower compared to slow progressors. More than one quarter of AIDS patients had low 
avidity IgG to HHV-6A. These data suggest that, parallel to the decline of CD4+ T cell 
number and disease progression, HHV-6A maintains a chronic persistent infection in a 
significant number of HIV infected persons, and repeated HHV-6A infection furthermore 
occurs in the sexual partners of HIV-1 carriers. In the case of rapid progression, HHV-6A 
IgG production ceases (Maródi et al., 1998; Ongrádi et al., 1999b, 1999e), and as a result 
HHV-6A can become widely distributed by inflitrating the lymphocytes of several organs 
without specific tissue damaging effects (Knox & Carrigan, 1996). 
Restricted expression of the same immediately early and early genes without the complete 
replication cycle, of several viruses can alter cellular machinery, resulting in malignant 
transformation and altering cytokine/chemokine production and subsequent HIV 
transactivation. The question then became whether simultaneous carriage of HIV-1 and 
HHV-6, or expression of viral genes reflecting active virus replication can influence 
depletion of CD4+ T cells and disease progression in different risk patients such as 
hemophiliacs and intravenous drug abusers (IVDA) compared to blood donors. DNA was 
extracted from plasma and peripheral blood lymphocytes (PBL’s), while RNA was only 
extracted from PBL’s. Carriage of both viruses was detected by PCR, and their expression by 
RT-PCR: PCR specific for HIV-1 env gene and nested PCR specific for HHV-6 ZVH14 
fragment, was carried out. RT-PCR was carried out on complementer (c) DNA under the 
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at post-mortem examination (Carrigan & Knox, 1994). HHV-6A infected cells--usually lung 
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(Ceccherini-Nelli et al., Ongrádi et al. detected HHV-6A active replication more frequently 
in IVDA, 107/135, 79%), than in hemophiliacs (11/35, 31%, p<0.001) and blood donors 
(26/145, 18%, p<0.001). 81% of IVDA was positive by HIV-1 DNA PCR and, in spite of 
specific retroviral therapy, expressed HIV in 54% of cases. Furthermore, 43% (58/135) of 
these persons also expressed HHV-6 sequences evidently able to transactivate HIV-1. 
Expression of HHV-6 in HIV-1 seropositive patients is found to be 6.1 times more frequent 
than in HIV-1 seronegative counterparts. Simultaneous virus expression was shown to 
enhance CD4+ cell depletion. HHV-6 expression was found to enhance mortality of AIDS 
patients by approx. 35% in a two year period. These data prove that in the majority of 
patients HIV-1 expression is associated with active HHV-6A replication, but not with the 
latent state of HHV-6A. Among HIV-1 transactivating cofactors, HHV-6A seems to be 
relatively frequent. These data also suggest that the route of HHV-6A dispersal throughout 



















1 17 147.9 + + - - C3 
2 29 501.8 - - - - C3 
3 59 32.66 - - - - B3 
4 79 72.57 - + - - B3 
5 97 190.06 + + - - C3 
6 139 388.4 + + - - C3 
7 197 10.9 - - + + C3 
8 217 117.46 - - - - A2 
9 240 negative - - - + A2 
10 280 negative - - + + A2 
11 321 18.9 - - - - A2 
12 346 51.53 - - + + A2 
13 429 13.04 - + + + A2 
14 432 13.77 - + + + C2 
15 453 12.52 - - - + A2 
16 504 11.48 + + + + A1 
17 598 28.1 - - - + A1 
18 735 negative - + + + A1 
Table 1. Clinical, virological and immunological data of HIV-1 seropositive patients 
As outlined in Section V, HHV-7 shows a marked reciprocal interference with HIV-1 in vitro. 
To investigate in vivo interactions of HHV-6, HHV-7 and HIV-1, another cross-sectional 
study comprising 18 HIV-1 seropositive patients and 33 blood donors has been recently 
described (Barsanti et al., submitted). Presence of HHV-6 was established as above, and 
nested PCR for HHV-7 on DNA extracted from PBLs was carried out using a set of specific 
primers and probe designed from the KHR strain of HHV-7 as described (Okuno et al., 
1995). HIV-1 load was quantitated by branched DNA signal amplification. Although no 
significant difference in HHV-6 prevalence was found between patients and controls (22 and 
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33%, respectively), all 4 HHV-6 positive patients belonged to variant A, whereas among 
controls with HHV-6 DNA positivity had variant A and 4 had variant B, confirming that 
HHV-6A is predominantly associated with immunocompromised patients (Table 1). The 
percentage of HHV-7 positivity in HIV-1 seropositive patients (39%) is significantly lower 
than that of blood donors (82%, p<0.01, χ2 test). HHV-7 positivity significantly correlated 
with a low level of HIV-1 (p<0.01, Mann-Whitney’s test) as compared to HHV-7 negative 
HIV-1 positive patients. Interestingly, while the presence of HHV-6A was detected in 
patients with all consecutive stages of HIV-1 infection, distributed evenly, HHV-7 positivity 
was found more frequently in patients with earlier stages of HIV-1 infection: namely stages 
A1- 3/3, A2-5/7, C2-1/1, B3-0/2, and C3-1/3. Although the number of patients in each 
group is very small, the trend is clear: independent or synergistic destruction of CD4+ T 
cells by HHV-7 and HIV-1 lead to their rapid declination. Another possibility is that rapid 
declination of CD4+ cells by HIV-1 prevents the replication of HHV-7 in the later stages of 
HIV-1 infection, but the low level of HIV-1 load argues against this hypothesis. Irrespective 
of interpretation, these results raise the idea that HHV-7 may not be such a harmless virus in 
HIV-1 infected patients. Further in vivo studies on the interaction between HIV-1 and HHV-
7 are warranted (Barsanti et al., submitted). 
4.2 Longitudinal, serological and molecular studies 
Follow-up studies could be done only in a limited number of double infected patients, and 
methodology was the same as described above. The first study of HHV-6 infection was 
carried out in two HIV-1 seropositive patients to provide in vivo evidence of HHV-6 
reactivation. Concomitant with a significant rise of anti-HHV-6 IgG detected by IFA, a 
transient increase in HHV-6 viral load was shown in PBL’s via PCR. During HHV-6 
reactivation it was identified either as cell-free HHV-6 by PCR in plasma or by IgM antibody 
titers. HHV-6 reactivation was followed by a temporary decrease in CD4+ count and by a 
progressive dramatic loss of CD4+ cells during the 18 months post-reactivation. HHV-6 
strain characterization by PCR demonstrated that the first patient (a woman with 232 CD4+ 
cell/mm3 at the beginning, 34 CD4+/mm3 with full-blown AIDS 16 months later) initially 
carried the B variant followed by reactivation and persistence of the A variant, while in the 
second patient (a man with 248 CD4+ at the beginning, then 14 CD4+/mm3, Pneumocystis 
carinii pneumonia and esophageal candidiasis 13 months later) only the A variant was 
detected. The evidence of HHV-6A reactivation presented suggests its involvement in a 
mechanism of immunologic damage underlying the disease by either direct destruction of 
lymphoid cells or altering cytokine pattern (Iuliano et al., 1997). In another longitudinal 
follow-up of two AIDS patients from active HHV-6A infection evidence was demonstrated 
but the profile of infection in the two patients varied. One patient demonstrated the 
appearance and disappearance of HHV-6A indicating viral reactivation, whereas the other 
patient exhibited chronic or persistent HHV-6A infection (Ablashi et al., 1997). In another 
cohort, serum samples and PBMC’s collected over a period of four years. IgG antibodies to 
HHV-6 gp110 late antigen did not differentiate between HIV-1 infected and control subjects, 
but IgG and IgM antibodies to p41/38 early antigens showed a significantly higher 
prevalence in HIV-1 infected individuals than in healthy donors, suggesting viral activation. 
HHV-6A was also shown in doubly infected PBL’s of T lineage (CD2+, CD4+, CD38+) 
(Ablashi et al., 1998b). As Ceccherini-Nelli et al., Ongrádi et al. demonstrated, others have 
also shown that HHV-6A is frequently reactivated in early asymptomatic HIV-1 infected 
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33%, respectively), all 4 HHV-6 positive patients belonged to variant A, whereas among 
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also shown that HHV-6A is frequently reactivated in early asymptomatic HIV-1 infected 





acquired HIV-1 and early acquisition of HHV-6A infection (Kositanont et al., 1999). Periodic 
reactivation or sustained persistence seem to be general phenomena among doubly infected 
persons. Additionally, high HHV-6 antibody titers were demonstrated in patients with 
consistently increasing HIV-1 load (Lenette et al., 2005).  
HHV-6A upregulates CD4 expression, competitively inhibits binding of CCR5-trop HIV 
particles through RANTES overproduction, and ensures selective advantage of CXCR4-trop 
particles to infect T lymphocytes. HHV-6A persistence seems to sensitize the organism to 
HIV-1 infection. In the early phases of HIV infection, reactivated HHV-6A -especially in 
children- speeds up the disintegration of lymph nodes, as well as the onset and progression 
of AIDS in a vicious cycle. During the terminal phase of AIDS, a large amount of reactivated 
HHV-6A particles invade the whole body. In rapid AIDS progressors, both prevalence of 
HHV-6A virions and the titer of anti-HHV-6A antibodies are higher than in slow 
progressors. In AIDS-associated retinitis, HHV-6A proviral DNA, RNA and polypeptides 
are frequently shown beside HCMV (Qavi et al., 1989). In AIDS patients, HHV-6A might 
aggravate pneumonitis (Knox & Carrigan, 1994), Regarding the neuropathogenesis of HIV-1 
infected children, HHV-6A is extensively disseminated in neural cells of the brain. It was 
reported that adult patients with AIDS had large areas of demyelination in their brain tissue 
at time of death (Knox & Carrigan, 1995).  
5. Human herpesvirus 7 as a negative competitor of HIV infection 
HHV-7 was isolated from the activated T lymphocytes of a healthy blood donor (Frenkel et 
al., 1990). HHV-6 and HHV-7 share similar genetic, biologic and immunologic features. 
HHV-7 also belongs to the Roseolovirus genus. The viral DNA is completely sequenced 
(Nicholas, 1996), it is formed by a unique segment of 133 kbp flanked by 6 to 10 kbp DR 
sequences, so that the genome length ranges between 145 and 153 kbp. Similar to HHV-6, 
the HHV-7 viral genome contains herpesvirus conserved genes arranged in 7 boxes. Nucleic 
acid sequence identity ranges from 20.7 to 75.7% in various genes, while amino acid 
sequence identity is between 41 and 75%. The coding ability of HHV-7 comprises 84 
different ORFs (Megaw et al., 1998), only one gene (U55B) is HHV-7 specific, and there is no 
homologue to the HHV-6 U94 gene. It has been shown that HHV-7 gB attaches to CD4 
molecules as a receptor (Lusso et al., 1994). It is likely that other molecules can act as 
receptors, and it is known that HHV-7 can infect cells that do not express CD4, e.g. 
lymphocytes, monocytes, epithelial cells, and fibroblasts. CD4 alone is not sufficient for a 
productive infection (Kempf et al., 1998). HHV-7 also establishes latent infection in CD4+ 
lymphocytes and macrophages, persistent infection occurs in salivary gland tissues as well, 
as shown by specific PCR (Sada et al., 1996). In vitro, only the CD4+ immature T cell line 
(SupT1) supports HHV-7 growth (Ablashi et al., 1998a). Due to CD4 affinity, HHV-7 
competes for the shared receptor with HIV-1 (Lisco et al., 2007). Blockade of the CD4 
molecule with anti-CD4 monoclonal antibodies (mAbs) or HIV-1 gp120 (which bind to CD4), 
inhibits HHV-7 infection of T cells. Exposure of terminally differentiated CD4+ 
macrophages derived from peripheral blood monocytes to intact or UV-inactivated HHV-7 
prior to HIV-1 infection reduced the average level of HIV-1 p24 antigen production in cell 
culture supernatants by 91%, indicating that the mechanism of interference depends directly 
on the competition for CD4. It was suggested that this antagonistic effect be exploited to 
devise therapeutic approaches to AIDS. However, in prospective in vivo studies, HHV-7 was  
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detected in only 3% of HIV-1 infected patients and 12% of controls. It was suggested that 
this low level of detection resulted from HIV-1 out-competing HHV-7 for infection of CD4+ 
cells. There was no association between HHV-7 viral load in PBL and progressson of HIV-1 
disease (Crowley et al., 1996). HHV-7 has a strong down-regulation on CD4 mRNA and 
transcriptional activity in cord blood lymphocytes and SupT1 cell (Furukawa et al., 1994). 
The HHV-7 U21 open reading frame codes for an immunoevasin that inhibits the transport 
of class I MHC and CD4 molecules to the surface, thus infected cells are more difficulty 
recognizable by CD8+ cytotoxic T lymphocytes (Hudson et al., 2003). Expression of Kaposi’s 
sarcoma herpesvirus (HHV-8), K5 protein (MIR2) (Paulson et al., 2001) and adenovirus 
E3/19K protein (Lippé et al., 1991) also restrict surface expression of MHC class I molecules. 
HIV Nef polypeptide down-regulates both MHC class I and CD4 molecules (Mangasarian et 
al., 1999). In patients carrying several viruses simultaneously, the concerted action of HIV 
Nef and immunoevasins of heterologous viruses dramatically diminishes cytotoxic immune 
cell activism, resulting in the survival of virus-producing cells and consequently increasing 
bodily viral load. HHV-7 down-modulates CXCR4 surface molecule independently of CD4 
in infected cells (Secchiero et al., 1998), which inhibit HIV-1 spread through the body. 
Differently than HHV-6A, HHV-7 does not down-regulate CD3, and has no effect on CD1, 
CD2, CD44 and CD49 T cell adhesion molecules (Yasukawa et al., 1993). In addition, HHV-7 
decreases CD38 levels, and slightly increases CD5 and CD57 on the surface of infected both 
SupT1 cells (Kirn et al., 1997). During the late stage of infection, HHV-7 increases the 
expression of CD46 at both the transcriptional and translational levels, as well as on the 
surface of SupT1 cells and primary CD4+ T cells. Together with CD59 overexpression, 
HHV-7 infected cells become more resistant to complement-dependent cytotoxicity than 
uninfected cells. CD46 overexpression facilitates infection of these immune cells by several 
heterologous viruses, among them HHV-6 and some adenovirus types, which are known to 
transactivate HIV-1 (Takemoto et al., 2007). Unlike with HHV-6, a generalized increase in 
host cell protein synthesis is observed in HHV-7 infected lymphocytes. Host genes whose 
expression is upregulated by HHV-7 infection include the lymphocyte specific G-protein 
coupled receptor EBI I, GADD45 (Kirn et al., 1997), GM-CSF and IL-15 (Atedzoé et al., 1997). 
Infection of PBMC’s obtained from seronegative individuals (mimicking primary infection) 
increases the level of intracellular mRNA and secreted polypeptides of TNF-, TGF-, IFN-, 
but decreases the production of IL-2 from mitogen (bacterial endotoxin polysaccharide, LPS 
and OKT3 mAb) activated PBMC. On the other hand, HHV-7 does not affect IL-4 and IL-6 
synthesis (Atedzoé et al., 1999). In PBMC’s of seropositive persons (mimicking secondary 
infection), HHV-7 infection results in diminished IL-2 and IFN- production with or without 
mitogen activation. HHV-7 induces early IL-10 production, which is known to inhibit 
cytokine release from CD4+ helper lymphocytes. After a primary infection, HHV-7 causes 
significant inhibition of lymphocyte proliferation and overall the cellular immununity, but 
in repeated infections the overall effect of HHV-7 on cytokine production by infected cells is 
balanced.This might contribute to the moderate immunosuppression upon reactivation 
(Ongrádi et al., 1999a). HHV-7 also encodes two functional chemokine receptors, U12 and 
U51, which are counterparts of human CCR4 and CCR7. And whose natural ligands are 
CCL22 and CCL19, respectively. These receptors are expressed on T and B lymphocytes, 
and promote their translocation from the blood to the lymph nodes. Overexpression of these 
receptors facilitate the dissemination of infected lymphocytes throughout the body 
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HHV-7 is ubiquitous worldwide. Approximately 70% of children are infected and 
seroconvert before 4 years of age,usually following HHV-6B infection, but 30% of the 
population acquires infection later in life. In children, HHV-7 can induce exanthema 
subitum directly or, through activation of HHV-6B, may induce febrile convulsions or 
hepatitis. HHV-7 is reactivated in some patients 4 to 6 weeks after liver, kidney, bone 
marrow or stem cell transplantation, and may exacerbate human cytomegalovirus (HCMV) 
induced immunosuppression. HHV-7 can also reactivate HHV-6B in vitro (Katsafanas et al., 
1996). In seronegative adults, HHV-7 can induce pityriasis rosea (PR) as presence of 
infective viruses, viral DNA and rising antibody as is indicated by increasing levels of IFN-
and - in the serum (Drago et al., 1997; Vág et al.., 2004a). Although rare, cases of PR have 
been described in patients with HIV-1 infection. Several types of papulosquamosus 
disorders might occur also in AIDS patients (Duvic et al., 1991). The lack of herald patch 
typical of genuine HHV-7 induced PR supports proper differential diagnosis. Due to some 
common immune pathways of HHV-7 and HIV-1 (e.g. alteration of cytokine pattern in the 
skin), PR might be mimicked in AIDS patients (Sadick et al., 1990). Interaction of HHV-6B or 
HHV-7 with human parvovirus B19 induces papular-purpuric gloves-and-socks syndrome 
(PPGSS, Ongrádi et al., 2000a; Vág et al., 2004b). HHV-7 is transmitted via saliva (Wyatt & 
Frenkel, 1992) and breast milk (Fujusaki et al., 1998). HHV-7 has been detected at the same 
ratio, more frequently, at higher viral loads, or in decreased quantitiy in saliva from HIV+ 
individuals with clinical symptoms of immunodeficiency than from controls by PCR in 
different studies (Di Luca et al., 1995; Lucht et al.., 1998; Gautheret-Dejean et al., 1997). There 
is no evidence for congenital infection, although 2.7% of cervical samples obtained from 
pregnant women during the third trimester are PCR positive (Hall et al., 2008). Viral DNA is 
sporadically detected in the urine of healthy individuals, and in 6.5% of the cellular fraction 
of urine samples from HIV-1 positive patients with low CD4+ cell count (Gautheret-Dejean 
et al., 1997), but no infectious virus has been obtained from cervical and urine samples 
simultaneously. The HHV-7 pp85 protein was detected in 9 of 32 HIV-associated cases, and 
in one of 7 classic sporadic Kaposi’s sarcoma lesions, which was localized to the cytoplasm 
of CD4-CD68+ cells of the monocyte/macrophage lineage. Dually infected HHV-6B and 
HHV-7 CD4-CD68+ cells were detected in 9% of these lesions. The cytokine-rich 
environment of Kaposi’s sarcoma might activate HHV-7 and subsequently HHV-6B (Kempf 
et al., 1997). These data suggest that HHV-7 also interacts with different viruses, among 
them HHV-6B, but does not activate HIV-1 directly and does not activate HIV-1 through 
HHV-6A activation. On the other hand, its immunomodulatory effects can be additive to 
immune suppression induced by HIV-1 in vivo.  
6. Animal models to study transactivation by heterologous viruses 
6.1 Simian AIDS model  
A major hindrance to elucidating the in vivo role played by HHV-6A in AIDS has been the 
lack of a reliable animal model system (Lusso et al., 2007). Although simian (SIV) and feline 
(FIV) immunodeficiency viruses in their natural hosts provide appropriate models, the lack 
of known counterparts of Roseolovirus isolates from these animals impedes studies on the 
effect of simultaneous infection in AIDS progression. Peripheral blood lymphocytes of adult 
chimpanzees, pig-tailed macaques (Macaca nemestrina) and African green monkeys were 
found as susceptible to HHV-6A (Lusso et al., 1990, 1994) and HHV-6B (Levy et al., 1990) 
infections as were human PBL’s. Although HHV-6A infected PBL cultures of chimpanzees 
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exhibited CPE similar to that seen in human PBL and produced infectious virus (Lusso et al., 
1990), this model is practically unavailable. The availability of pig-tailed macaques whose T 
cells are highly susceptible to HHV-6A infection is an ideal experimental model (Lusso et 
al., 1994). It has been established that in vivo coinfection with HHV-6A accelerates the course 
of SIV disease in pig-tailed macaques (Lusso et al., 2007). Three groups of young adult 
animals were infected by intravenous inoculation with either SIVsmE660 alone, HHV-6AGS 
alone, or both SIV and HHV-6A. Dually infected animals were first inoculated with SIV and 
then superinfected with HHV-6A 14 days later. None of the animals had detectable 
antibodies to HHV-6A and SIV before inoculation. Animals were observed for 32 months. 
HHV-6A infected animals developed clinical manifestations of mild to moderate intensity 
such as fever, splenomegaly, and generalized lymphadenopathy. Anti-HHV-6A 
seroconversion appeared after a mean of 3±1.4 and 2.2±0.5 weeks in HHV-6A and dually 
infected animals, respectively. SIV infection resulted in plasma viremia, and SIVp27Gag 
antigenemia at two weeks post-inoculation in both groups. Clinical signs included fever, 
generalized lymphadenopathy and splenomegaly, while the fever was higher and longer in 
duration in animals coinfected with SIV and HHV-6A. A transient loss of circulating CD4+ 
T lymphocytes was detected in singly and coinfected macaques. During the follow-up, no 
long term clinical or hematological alterations were seen in animals singly infected with 
HHV-6A, and their CD4+ and CD8+ T cell counts remained stably with the normal range. 
By contrast, a progressive loss of circulating CD4+ and CD8+ T cells was seen in 
coinfected animals. SIV superinfection of animals carrying HHV-6B for 13 to 21 months 
resulted in a very rapid decline of CD4+ and CD8+ T cells, and these animals developed 
AIDS-related conditions after 69 and 15 weeks of SIV superinfection (Lusso et al., 2007). 
Interestingly, the longer the duration of HHV-6A latency was, the shorter of AIDS-related 
conditions developed. This means that even latent HHV-6A infection induces irreversible 
changes in the immune system. Unlike the immunological parameters, the levels of SIV 
plasma viremia and antigenemia during the follow up were not significantly different 
between singly or dually infected macaques. Interestingly, disease progression in dually 
infected animals was accompanied by frequent episodes of HHV-6A reactivation, 
suggesting that SIV infection exerted a boosting effect on HHV-6A replication. Dually 
infected animals also showed a significantly expedited decrease in anti-HHV-6A antibody 
reactivity over time demonstrating exhaustion of humoral immunity. Lymph node biopsy 
one month post-inoculation showed follicular hyperplasia in all animals. However, in 
macaques singly infected with SIV or HHV-6A the nodal architecture was conserved, 
whereas in dually infected monkeys it exhibited a florid follicular hyperplasia with 
confluent germinal centers. Coinfected lymph nodes showed higher levels of SIV RNA 
deposited on the surface of follicular dendritic cells and HHV-6A mRNA expression in the 
extrafollicular area. Thus, HHV-6A and SIV could simultaneously replicate in coinfected 
lymph nodes. In biopsies obtained 6 months after inoculation, lymph nodes of dually 
infected animals showed significant atrophy of germinal centers. During the 32 months of 
the study, AIDS-defining clinical conditions developed in all coinfected macaques, but in 
only one of 4 infected with SIV.  
It was also shown that reisolated SIV obtained from HHV-6A coinfected macaques after one 
year of infection had acquired resistance to RANTES (regulated upon activation normal T 
cell expressed and secreted). RANTES is a CCR5 binding chemokine that blocks the entry of 
SIV into cells, since SIV depends on CCR5 for infection. As has been previously discussed, 
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coinfected macaques, SIV subsequently evolved toward RANTES resistance, most likely 
under the selective pressure of elevated RANTES levels. Resistance to RANTES is 
increasingly recognized as a key virulence factor in HIV infection (Grivel et al., 2003), which 
may allow the virus to replicate in the high-RANTES milieu. One of the possible 
mechanisms whereby HHV-6A may foster the progression to AIDS is by facilitating an early 
acquisition of RANTES resistance (Lusso et al., 2007). In a recent study, SIV were reisolated 
from singly and HHV-6A-coinfected macaques. Surgically removed human tonsils in the 
presence of RANTES and PBMC from randomly selected healthy donors or from a 
homozygous CCR5-32 +/+ donor were infected with SIV reisolates. All SIV isolates were 
able to replicate in human lymphoid tissue. Inoculation of different cell lines expressing 
several coreceptors (CCR2b, CCR3, CCR4, CCR6, CCR8, CX3CR1, and CXCR4) were not able 
to support SIV infection. The majority of SIV isolates from HHV-6A coinfected macaques 
were not able to replicate in CCR5-32 +/+ PBMC’s showing that SIV variants, despite 
maintaining exclusive CCR5 coreceptor sensitivity, become resistant to HHV-6A and 
RANTES receptor competition. Cytokine polypeptide production in PBMC’s obtained from 
healthy donors was induced by infection using either SIV from singly infected animals or 
SIV from HHV-6 coinfected animals. IL-2 production was significantly down-regulated 
while IFN- production was significantly upregulated in cultures infected with SIV derived 
from coinfected macaques as compared to the cytokine-inducing ability of SIV obtained 
after a single infection. For other Th1 and Th2 cytokines (IL-1 and -, IL-4, IL-7, IL-12, IL-
15, IL-16, and TNF-), chemokines (MIP-1 and –), other mediators (GM-CSF, IP10, MIG, 
and SDF-1) no significant differences between lymphoid tissue infected with the two 
groups of SIV isolates were recorded. These results also indicate that SIV isolates obtained 
from HHV-6A-coinfected animals undergo a biological evolution in vivo, with the 
emergence of viral strains containing a reduced sensitivity to RANTES-mediated inhibition, 
thus, bypassing an important mechanism of virus control. It has been learned from clinical 
studies, that progression toward full-blown AIDS is often associated with the evolution of 
HIV-1 toward increased virulence. HIV-1 acquires the ability to use CXCR4 as a coreceptor, 
becoming resistant to the inhibitory effects of endogenous CCR5-binding chemokines. This 
phenotypic switch is typically accompanied by an accelerated loss of CD4+ T cells and 
suppression of Th1 polarized responses that play an essential role in the clearance of viral 
infections. These results are conclusive in vivo evidence that HHV-6A accelerates the 
progression of SIV toward full-blown AIDS (Biancotto et al., 2009), and excellently support 
human clinical and experimental data on the interaction of HHV-6A and HIV-1. 
6.2 Feline AIDS as an ideal small animal model to study the interaction between 
retroviruses and different heterologous viruses 
Although SIV infection is very close to the human analog monkeys are not available for the 
majority of research groups due to short supply and ethical considerations. Specific 
pathogen-free populations are nonexistent. Feline immunodeficiency virus (FIV), another 
member of the family Retroviridae has a pathogenesis similar to that of HIV infection, and 
because cats are both plentiful and available in specific pathogen free (SPF) status, they 
might prove to be an ideal model for AIDS cofactor studies. FIV shares many genetic, 
structural and biological characteristics with HIV. Although FIV shows tropism for CD4+ 
cells, its receptor is CD134 (Shimojima et al., 2004), and it requires further interaction with 
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chemokine coreceptors (CCR5 and CXCR4) for entry (de Parseval et al., 2006). RANTES 
inhibits FIV infection of feline PBMC’s, while antibodies against CXCR4, CCR5 and CCR3 
reduce FIV infection. CD4+ and CD8+ T cells monocytes/macrophages are the major targets 
of FIV, in which it might establish latent infection. Upon virus activation, cells die of 
apoptosis (references in Bendinelli et al., 1995 and Burkhard & Dean, 2003). FIV diverges 
from other lentiviruses throughout the genome. Beside gag, pol, env and other small ORFs 
encoding regulatory proteins, the provirus contains two LTR elements, one at each end, 
which accommodate multiple regulatory elements. FIV LTRs appear to be strong basal 
promoters and poorly active in transactivation (Sparger et al., 1992). Regulatory sequences 
include one or two TATA boxes, and a variety of enhancer or promoter protein-binding sites 
(AP-1, NF-B, etc). FIV transactivation is significantly different than that seen for HIV 
because FIV lacks TAT and the transactivating response (TAR) element (Sparger et al., 1992). 
Instead, FIV contains Orf-2 (also designated as Orf-A), a tat-like gene encoding a viral 
transactivator necessary for productive FIV replication in primary T lymphocytes as well as 
feline T cell lines (de Parseval & Elder, 1999). Unlike other lentiviral transactivators, FIV Orf-
2 requires additional LTR elements for transactivation (Chatterji et al., 2002). Infection with 
FIV is usually associated with direct inoculation of the virus into the body via bites, and 
there is a distinct transient initial stage of infection that follows exposure by several weeks. 
After recovery from this initial disease, afflicted cats enter into a long asymptomatic stage of 
the infection that lasts for months or years before other signs appear. CD4+ T lymphocyte 
decline and inversion of the CD4/CD8 ratio are hallmarks of FIV infection, especially in 
neonates (Diehl et al., 1996) due to apoptosis induced by TNF-overproduction (Ohno et 
al., 1993). Serum levels of IL-1, IL-6 and TNF- increase in parallel with viral replication 
(Kraus et al., 1996). After in vitro treatment of separated PBMC in experimentally infected 
cats CD4+ lymphocytes produce TNF-, IFN-, IL-2, IL-4 and IL-8, while CD8+ T 
lymphocytes express TNF-, IFN-, and IL-2. Monocytes/macrophages are the source of IL-
1, IL-6, TNF-, IL-10 and IL-12p40 (Ritchey et al., 2001). The terminal AIDS stage of FIV 
infection is associated with a number of chronic common and opportunistic-type infections. 
Like HIV infection of humans, other infectious diseases may interact with FIV infection in 
the field to cause a more severe disease syndrome. 
Retroviruses and herpesviruses are associated with a variety of diseases in animals. It has 
been suspected for long time that their interaction may result in synergistic induction of 
diseases (Bacon et al., 1989). A possible interaction of feline herpesvirus type 1 (FHV-1, 
subfamily Alphaherpesvirinae) with FIV has been studied in vivo and in vitro. FHV-1 is a 
significant pathogen of family Felidae, causing an upper respiratory tract disease in cats. In 
dually infected animals it induces several immunological abnormalities (Reubel et al., 1992, 
1994). FHV-1 also infects T lymphocytes. Productive coinfection of individual T 
lymphocytes has been detected (Kawaguchi et al., 1991). FHV-1 ICP4 was shown to 
modulate FIV LTR activity (Kawaguchi et al., 1994, 1995). 
Among other AIDS-promoting DNA viruses, adenoviruses (AdV) are known to cause fatal 
enteritis among terminal AIDS patients. The only feline adenovirus isolate (FeAdV) was 
obtained (Ongrádi, 1999) from a PCR positive fecal sample (Lakatos et al., 1997) of a cat with 
unknown FIV status. In Europe, 10 to 20% of free roaming cats are seropositive (Lakatos et 
al., 1996, 2000). FeAdV DNA has been detected in fecal samples of a child and her cat in 
Japan (Phan et al., 2006), and in a Brazilian child with upper respiratory tract infection (Luiz 
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chemokine coreceptors (CCR5 and CXCR4) for entry (de Parseval et al., 2006). RANTES 
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Among other AIDS-promoting DNA viruses, adenoviruses (AdV) are known to cause fatal 
enteritis among terminal AIDS patients. The only feline adenovirus isolate (FeAdV) was 
obtained (Ongrádi, 1999) from a PCR positive fecal sample (Lakatos et al., 1997) of a cat with 
unknown FIV status. In Europe, 10 to 20% of free roaming cats are seropositive (Lakatos et 
al., 1996, 2000). FeAdV DNA has been detected in fecal samples of a child and her cat in 
Japan (Phan et al., 2006), and in a Brazilian child with upper respiratory tract infection (Luiz 





AY512566) and fiber (Pring-Akerblom & Ongrádi, GenBank Accession No. AY518270) 
suggest that FeAdV is related to human AdV type 1. It would be ideal to explore its 
interrelationship with both HIV and FIV, especially with respect to the role of AdVs in the 
intestinal complications of AIDS.  
Another common interaction in nature is between FIV infection and feline leukemia virus 
(FeLV). About 10 to 15% of the cats clinically ill with FIV infection are coinfected with FeLV 
worldwide (Hosie et al., 1989; Ishida et al., 1989; Yamamoto et al., 1989). FeLV can also 
induce immunodeficiency (Rojko & Olsen, 1984). In dually infected cats, the CD4+/CD8+ T 
lymphocyte ratio becomes rapidly inverted (Pedersen et al., 1990). FeLV induced tumors are 
a source of frequent and anticipated feline death (Shelton et al., 1990). This interrelationship 
is similar to what has been described for HIV and HTLV-I (Levy, 1993). 
Besides viruses, other opportunistic infections can enhance the progression of feline AIDS. 
Both Toxoplasma gondii (Levy et al., 1998) and Listeria monocytogenes (Dean et al., 1998; Dean 
& Pedersen, 1998; Levy et al., 1998) disrupt the synergistic production of normal Th1 type 
cytokines, causing a loss of cellular immunity in FIV positive animals.  
These different systems clearly show that the progression of feline AIDS is facilitated by a 
wide array of microbes. Further studies are warranted to better delineate the role of other 
putative cofactors among the Roseoloviruses in FIV infection as an ideal small animal model 
for human AIDS.  
7. Importance of rapid viral diagnosis, treatment and prevention of HIV-1 and 
HHV-6 simultaneous infections  
Several transactivating herpesviruses cause severe, long-lasting, and unusual opportunistic 
infections in HIV-1 infected and AIDS patients. Heterologous viruses frequently show 
unusual resistance to antiviral drugs. The potential to transactivate HIV and cause 
opportunistic infection shows an intimate mutual relationship between these viruses and 
their relationship within the immune system. Prevention and suppression of both 
phenomena ought to be a continuous clinical tasks while treating and improving the quality 
of life of these patients. 
There are excellent laboratory methods available to diagnose HIV-1 and 2 antibodies, and to 
determine the actual viral load in the serum of patients. Determination of their resistance to 
antiviral drugs is also routinely analyzed during treatment. Unfortunately, no serological 
tests are routinelyavailable for the differential diagnosis of HHV-6 variants A and B. 
Immunfluorescent and ELISA methods determine the total quantity of anti-HHV-6 
antibodies due to cross reactions, however the level of detectable serology can be insensitive 
when diagnosing immunocompromised populations. Several multiplex and real-time PCR 
assays are available for the simultaneous detection and quantification of HHV-6A, HHV-6B 
and HHV-7 specimens in patients (Safronetz et al., 2003). Recently, the success of highly 
active antiretroviral therapy (HAART) in controlling HIV-induced immunosuppression has 
resulted in the disappearance of HHV-6 opportunistic infections, according to the trend 
already described for HCMV (Martinez et al., 2007; Salzberger et al., 2005). HHV-6 variants 
are sensitive to ganciclovir, foscarnet, cidofovir, IFN- and IFN-, and all of them have 
already been used in a small number of patients with different immunocompromised 
conditions. Some HHV-6A strains can carry mutations in the U69 gene responsible for 
phosphotransferase activity, consequently displaying resistance to treatment with 
ganciclovir (De Clercq & Naesens, 2006).  
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8. Future dimensions 
Future research efforts could be directed toward hot topics such as the following: 
First, it has not been established that cytokines and other mediators excreted from HHV-6 
infected cells are structurally normal or have altered chemical structure (e.g. 
glycosylation, phosphorylation). It is also conceivable that HHV-6 carrier cells produce 
one or more unique soluble mediators that strongly transactivate HIV-1. Such aspects 
ought to be explored.  
Second, results strongly suggest that persistent HHV-6 gene expression and replication 
sensitizes to HIV infection and rapid progression. Rapid progressors might carry integrated 
HHV-6, or may be progressing due to other potential yet presently unknown genetic 
immunological defects. Available samples of former and recent patients ought to be retested 
with this goal in mind. More attention must also be payed to these HIV-1 infected, HHV-6 
carrier patients concerning anti-HHV-6 therapy. Gene therapy to suppress HHV-6 
expression would be ideal to treat patients carrying integrated HHV-6. 
Finally, further studies on the in vivo interrelationship between FIV and feline roseolovirus 
are necessary to understand the clinical aspects of dual infections of this nature. A feline 
counterpart of HHV-6 ought to be discovered and characterized. 
9. Conclusions 
HIV-1 infection is followed by a long disease-free period due to low transcriptional activity 
of the integrated provirus in resting CD4+ immune cells. Activation of CD4+ cells by 
mitogens, altered cytokine/chemokine milieu, or superinfection by heterologous viruses 
upregulate cellular, nuclear transcriptional factors, which in turn upregulate HIV-1 LTR 
directed gene expression by a tat-independent mechanism leading to augmented HIV-1 
production. HHV-6 variant A possesses several alternative ways to upregulate HIV-1 
infection and promote AIDS progression. Co-infection of HIV-1 carrier CD4+ cells results in 
enhanced cell death through apoptosis in vitro and in vivo, especially in the lymph nodes. 
Infection of immune cells leads to a a shift in cytokine pattern from Th1 to Th2. 
Overproduction of TNF-, IL-1 and IL-6 strongly transactivates HIV-1 via secondary 
messengers and the same nuclear transcriptional factors. Elevated levels of RANTES 
facilitate the change of CCR5-trop HIV-1 population towards the strongly cytopathic CXCR4 
mutants. In the body, synergistic effects of immune evasion result in either a continuous or 
alternating presence of high level viremia, dissemination of the virus to all organs of the 
body which contributes to their failure and the consequentially premature death of AIDS 
patients. HHV-6A primarily damages cellular immunity, whereas HHV-6B predominantly 
suppresses the activity of humoral immune function. While HHV-6B infects CD+ immune 
cells, it hardly contributes to the activation of HIV-1, due to a differently modified 
cytokine/chemokine pattern. HHV-7 binds directly to CD4 molecules, therefore directly 
competing for this receptor with HIV-1. It is regarded as a harmless virus, but in successive 
stages of HIV-1 infection contributes to the gradual loss of CD4+ cells. There are molecular 
techniques for the simultaneous and rapid detection of these herpesviruses in vivo. Since the 
introduction of HAART, severe complications by HHV-6 have become rare, but if necessary 
ganciclovir and foscarnet can be used to inhibit these herpesviruses to improve the quality 
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1. Introduction 
Human immunodeficiency virus (HIV) infection is a pandemic that affects all parts of the 
globe. Current treatments fail to cure disease and for this reason there is significant interest 
in producing a vaccine to prevent HIV transmission, but clinical trials have proved 
disappointing. For this reason it is important to consider alternative measures to control 
incidence and prevalence of the disease. 
Trichomonas vaginalis is a highly prevalent and under-diagnosed sexually transmitted 
infection that facilitates transmission of and susceptibility to HIV infection (McClelland et 
al., 2007; Mavedzenge et al., 2010). Although current treatment is effective the disease is still 
poorly controlled and there are concerns about increasing levels of drug resistance (Upcroft 
& Upcroft, 2001). Efforts to research disease mechanisms and immune response with 
consideration to a rational vaccine design approach should be investigated as a potential 
method to reduce global incidence of T. vaginalis infection. 
A reliable murine model of T. vaginalis infection has been established with symptoms in 
female mice mimicking those seen in women (from vaginitis/vulvitis and discharge to 
asymptomatic but culture-positive for infection). Using this model it has been shown that 
vaccinating mice (by injection of trichomonad cells with adjuvant) protects the animals from 
subsequent vaginal infection (Abraham et al., 1996). By studying immune responses in mice, 
factors that are critical for immunological protection can be elucidated to create a 
“blueprint” for an effective human vaccine. 
Herein we provide an overview of the current understanding of T. vaginalis infection and 
epidemiology, methods of diagnosis and treatment, and implications of animal models for 
understanding disease mechanisms . We discuss how and why current T. vaginalis treatment 
protocols fail to control infection incidence with consideration as to how a T. vaginalis 
vaccine could overcome these obstacles and reduce disease burden. The association between 
T. vaginalis and HIV is examined and the potential for reducing HIV infection rates by 
lowering T. vaginalis incidence is elucidated.  
A vaccine against T. vaginalis would provide long term protection that could be more 
successful than treatment in controlling the spread of this very common disease. As T. 
vaginalis infection is a clear risk factor for HIV acquisition, it is our belief that this approach 
would also be effective in ameliorating HIV incidence and prevalence, especially in areas 
such as South and Southeast Asia and sub-Saharan Africa where HIV and T. vaginalis are 
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2. Trichomonas vaginalis 
2.1 Morphology 
The basic structure of T. vaginalis as reviewed in Petrin et al. (1998) and Heine & McGregor 
(1993) is best described as a 10-20 μm ovoid organism with four free-moving flagella located 
at the anterior portion, and one recumbent flagellum attached to the body of the cell by a 
membrane that forms an axostyle running longitudinally from the anterior portion to the 
posterior forming a pointed tip. The flagella and undulating membrane contribute to the 
organism’s characteristic jerky movements visualized under a common laboratory light 
microscope. Within the protozoan resides a nucleus with six chromosomes, a developed 
Golgi complex, but is devoid of mitochondria, peroxisomes or glycosomes, so instead 
contains hydrogenosomes typical of anaerobic protozoa and fungi. With respect to 
metabolic processes the parasitic nature of T. vaginalis owes to its inability to synthesize 
many nutrients and thus implicates a significant contribution of scavenged nutrients from 
hosts to survive (Heine & McGregor, 1993). 
2.2 Genetics 
Recently a draft genome sequence has been completed (Carlton et al., 2007) revealing a 
genome of approximately 160 Mb containing a core set of roughly 60,000 genes although it is 
suggested 39 Mb is repetitive genomic information as a result of enormous gene expansions. 
Important information will be derived from this data especially since gene regulation is not 
well understood and even now novel core promoter elements are being identified (Gomez et 
al., 2010; Smith et al., 2011) as well as hypothetical surface proteins from proteome analysis 
(de Miguel et al., 2010). Hypothetical surface proteins are of particular interest for 
extracellular parasites functioning to establish and maintain infection, and may shed light 
on current issues of classifying phenotypic differences for variable clinical presentation 
between hosts (Smith et al., 2011).  
2.3 Epidemiology 
T. vaginalis is an extracellular, anaerobic, parasitic protozoan that is the cause of 
trichomoniasis, the most common non-viral, curable STI with global incidence of at least 174 
million cases per year (WHO, 2001), likely an immense underestimation of actual incidence. 
Nevertheless, to put this number into relative terms of other curable STI the global incidence 
of syphilis, chlamydia and gonorrhoea as reported by WHO (2001) were 12 million, 92 
million and 62 million, respectively. The majority of cases are localized in regions of low 
income or lack of resources, especially health care. Other risk factors include Neisseria 
gonorrhoeae infection, Chlamydia trachomatis infection, risky sexual behaviours, older male 
partners (in terms of heterosexual couples), potential for non-sexual transmission by cultural 
habits such as shared bathing water, new or multiple sex partners, a history of STI, exchange 
of sex for payment, and drug use (Crucitti et al., 2011; Krashin et al., 2010; Sutton et al., 2007; 
Workowski & Berman, 2010). 
2.4 Trichomoniasis 
T. vaginalis resides in the squamous epithelium of the genital tract of both females and males 
with prevalence primarily within the reproductive years. General areas of infection in males 
include the urethra, external genitalia, prostate and epididymis. The vagina is the area most 
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commonly infected for females though it should be noted that other areas of infection 
include the Bartholin’s, Skene’s and periurethral glands, bladder and cervix (Heine & 
McGregor, 1993; Petrin et al., 1998). The infection is followed by an incubation period prior 
to onset of symptoms, if any at all, with persistent infection commonly occurring in females 
whereas eventual resolution occurs in males whom mostly serve as carriers and spread the 
infection to other partners (Petrin et al., 1998; Van Der Pol et al, 2005). 
A plethora of possible symptoms surrounds T. vaginalis infection. Rarely are all symptoms 
present nor are typical symptoms easily distinguishable from other urogenital infections. 
Additionally up to 50% of infected females and greater numbers in males are asymptomatic 
(Fouts & Kraus, 1980, as cited in Cudmore et al., 2004; Pastorek et al., 1996). While men and 
women usually present with malodorous discharge from the infected areas the most 
significant burden is found in women who may present with any of the following; high 
vaginal pH, bloody mucus, colpitis macularis, and vulvitis. Infection is associated with pelvic 
inflammatory disease, birth complications including premature rupture of the placental 
membrane, premature labour, low average birth-weight, and infertility, and increased 
transmission and contraction of HIV (Cotch et al, 1997; Mavedzenge et al., 2010; McClelland et 
al., 2008; Moodley et al., 2002; Pastorek et al., 1996; Wølner-Hanssen et al., 1989).  
2.4.1 Treatment of trichmoniasis 
Lossik (1990) describes the basics of metronidazole, a chemically modified form of the 
natural Streptomyces product azomycin from the family of nitroimidazoles, first synthesized 
in 1957 and finally marketed in 1960. Metronidazole is effectively administered as a single 2 
g dose or 500 mg twice daily for seven days with average cure rates of 96% and 92%, 
respectively. Side effects are minimal and more adverse effects are the result of  very high 
dosage and longer duration (Lossik, 1990). Upon diagnosis and treatment – typically 
females are diagnosed as male partners are less likely to observe or report symptoms – it is 
encouraged that sexual partners be tested and treated in concert as often these individuals 
are infected as well (up to 70% of male partners are also infected as reported by PCR testing 
in Seña et al., 2007). The treatment of trichomoniasis with this drug is highly effective 
although 5-10% of T. vaginalis isolates exhibit some degree of resistance as assayed in vitro 
(Upcroft & Upcroft, 2001).  
Five years after the discovery of metronidazole the first metronidazole-refractory case of T. 
vaginalis isolated from a female patient was reported by Robinson (1962, as cited in Lossick, 
1990). To avoid future difficulties with metronidazole resistance clinical and laboratory 
generated drug resistant isolates are under study to determine the mechanisms of resistance 
that can arise or have arisen (Upcroft & Upcroft, 2001). Alternatively, a T. vaginalis vaccine 
would sidestep the necessity to discover potential drug replacements in the event of 
epidemic resistance. 
2.5 Phenotypic variance of clinical disease 
In an attempt to define the phenotypic differences between clinical isolates causing 
symptomatic disease versus asymptomatic disease a number of areas are under 
investigation regarding host immune response and parasite-host interactions.  
2.5.1 Host immune response 
Scott et al. (2005) demonstrated that a symptomatic isolate of T. vaginalis induced only an IL-10 
response in dendritic cells while a more diverse IL-12, IL-10 and IFN-α repertoire was 
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produced in response to selected infectious mucosal bacteria. Within the findings a potential 
relationship is noted between an IL-10 only response and chronicity of infection. IL-10 alone 
contributes to inhibition of T helper type 1 (Th1) immunity and favours a Th2 response 
(Banchereau et al., 2000, as cited in Scott et al., 2005). Similar results of a lack of IL-12 induction 
in macrophages were previously reported by Chang et al. (2004). On the other hand, cytokines 
related to Th1 type response (IL-2 and IFN-gamma) have been noted to be more prevalent in 
the sera of mice infected with asymptomatic isolates than symptomatic isolates (Malla et al., 
2007; Paintlia et al., 2002). Similar results have been found in other protozoal disease cytokine 
studies suggesting that in these cases Th1 mediated response may regulate disease and 
prevent overt clinical symptoms but not abolish infection (Agarwal et al., 1999,  Bayraktar et 
al., 2005 and Campbell & Chadee, 1997, all as cited in Malla et al., 2007). 
Yadav et al. (2005) investigated immunoglobulin kinetics of intravaginal trichomoniasis in a 
mouse model with asymptomatic and symptomatic clinical isolates. IgM, IgG (subclasses 1, 
2a, 2b and 3) and IgA were measured in serum and from vaginal washes from mice infected 
with asymptomatic and symptomatic isolates. Titers of IgG, IgG1 and IgM of vaginal wash 
and serum samples were significantly greater in symptomatic infected mice than 
asymptomatic mice, while IgA responses were not statistically different for serum or vaginal 
washes of either asymptomatic or symptomatic isolates. These results are mostly in line with 
vaginal wash data from symptomatic infections in women showing IgG and IgA at 
detectable levels versus undetectable levels in asymptomatic women (Alderete, 1984, as 
cited in Yadav et al., 2005). Data from Paintlia et al. (2002) found greater IgA levels in both 
vaginal wash and serum samples of asymptomatic isolates infected in mice contradicting the 
aforementioned findings. These results may indicate complications with the model of study 
or are simply the intricacies of trichomonal infection. Thus, some antibodies may provide a 
method of predicting the  severity of infection. Whether these findings are host dependent 
or mediated by phenotypic variance of T. vaginalis is yet to be elucidated. 
2.5.2 Parasite-host interactions 
Contact-independent mechanisms of damage correlated to symptomatic states of infection 
involve soluble factors shed from T. vaginalis including cell detaching factor (CDF), cysteine 
proteases and a haemolytic factor that is reliant on specific elevated vaginal pH in the range 
typically observed in clinical disease (Alderete & Garza, 1984; Fiori et al., 1996; Garber & 
Lemchuk-Favel, 1990). 
Gene regulation is influenced by contact with epithelial cells (Kucknoor et al., 2005) and 
cytoadherence has been noted as a better predictor of in vivo pathogenicity than cytotoxicity 
by soluble factors (Escario et al., 1995). Unfortunately the pathogenic role of adhesion 
proteins such as AP65, AP51, AP33 and AP23 that have been associated with epithelial cell 
binding of T. vaginalis (Alderete & Garza, 1984; Arroyo et al., 1992) have not conclusively 
been elucidated. Midlej & Benchimol (2010) suggests that adherence may aid phagocytic 
capability and disruption of monolayers in which T. vaginalis literally mechanically 
disassembles and phagocytoses membranes of epithelial monolayers in vitro similar to 
previous findings in amoebae and macrophages during ingestion of tumour cells (Chambers 
& Weiser, 1969, as cited in Midlej & Benchimol, 2010; Martinez-Paolmo et al., 1985, as cited 
in Midlej & Benchimol, 2010). Particularly, whole, viable cells are not phagocytosed yet 
destruction of epithelial cell layers is observed suggesting necrotizing ability of T. vaginalis. 
Interestingly within Midlej & Benchimol’s study (2010) an actin polymerization inhibitor 
significantly abrogated adherence while cytotoxicity remained relatively unaffected. 
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Another mechanism of interest is the availability of iron and its role in regulating immune 
evasion, and expression of adhesins and cysteine proteases (Lehker et al., 1991; Lehker & 
Alderete, 1992). Alternative pathway complement lysis allows destruction of trichomonads 
under low iron conditions assessed by Alderete et al. (1995). Upon supplementation of 
media with high levels of iron a cysteine proteinase capable of removing surface bound C3 
is upregulated. Still not all cysteine proteases are upregulated as found in Kummer et al. 
(2008). Herein, the data provides an inverse correlation of iron abundance and presence of 
CP2, CP3, CP4 and CPT (collectively referred to as CP30) which are involved in apoptosis of 
human vaginal epithelial cells. Kummer et al. (2008) suggests this particular apoptotic 
mechanism may play a role in iron acquisition and is self-regulating upon iron uptake. 
Alvarez-Sánchez et al. (2007) also provide a negatively regulated soluble factor, CP65, under 
high iron conditions. 
Understanding phenotypic variance will aid in understanding of the disease and elucidation 
of possibly novel mechanisms of regulation, as well as contribute to the strategies employed 
for development of a vaccine, a goal of ongoing research that will be discussed later. 
2.6 Diagnosis 
Before assessing the current diagnostic techniques available it is imperative to emphasize 
the difficulties of arriving at the diagnostic stage. Using a clinical syndromic approach a 
significant number of asymptomatic cases are missed. By not testing for nor treating 
asymptomatic infected individuals this enables the spread of disease and the lack of 
diagnosis results in underreported statistics of infection worldwide (Yin et al., 2008). 
Furthermore, in a prospective study Wiesenfeld & Macio (1999) found the available 
diagnostic tools such as simple wet mount microscopy, pH test or whiff test were often not 
used even under clinical suspicion of trichomoniasis. Ignoring the latter issue yet another 
problem arises. Diagnosis of cases investigated from clinical suspicion of trichomoniasis are 
at mercy of low sensitivity of current diagnostic standards as recent evaluations over the 
past decade have come to find (Lusk et al., 2010; Roth et al., 2011; Seña et al., 2007; Van Der 
Pol, 2007; Wendel et al., 2002). The most prevalent and most promising techniques will be 
reviewed below while a more detailed overview of guidelines for laboratory diagnosis and 
the methodology can be found in Domeika et al. (2010). 
2.6.1 Culture and wet mount microscopy 
Culture is considered the gold standard for diagnosis of T. vaginalis. Culture liquid is 
supplemented with antibiotics and samples are obtained from various locations such as 
vaginal/urethral discharge and swabs of known areas of infection. This technique requires 
as little as 102 trichomonads/mL (Garber, 2005). Unfortunately bacterial contamination 
remains an issue as well as lag growth phases of T. vaginalis. Additionally, this method is 
expensive and time consuming (Domeika et al., 2010) despite the availability of commercial 
culture systems (InPouch TV system: BioMed Diagnostics). Studies have found sensitivities 
ranging between 75-83% and specificity near 100% (Huppert et al., 2007; Nye et al., 2009; 
Wendel et al., 2002). 
Wet mount is an attractive diagnostic tool due to its simplicity and cost effectiveness, and is 
consequently the most widely used (Huppert et al., 2007). This technique requires that 
samples are placed in physiological sterile saline and kept warm for immediate viewing 
under a common laboratory microscope. Positive detection is assessed by visualization of 
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trichomonads exhibiting characteristic jerky movements (Domeika et al., 2010). Due to the 
requirement of at least 104 trichomonads/mL (Garber, 2005) this technique is not viable for 
urethral swab samples from males who typically yield low organism counts. Moreover, 
incorrect temperature or too much time elapsing between sampling and assessment results 
in loss of movement creating difficulty of differentiation from lymphocytes or nuclei of 
vaginal epithelial cells present in the sample (Garber, 2005). Sensitivities range from 52-
61.5% and specificity near 100% (Huppert et al., 2007; Nye et al., 2009; Van Der Pol et al, 
2006; Wendel et al., 2002). 
2.6.2 Nucleic acid amplification test and transcription mediated amplification 
Nucleic acid amplification testing (NAAT) and transcription mediated amplification (TMA) 
are recent, fairly labour intensive, highly sensitive but non-FDA approved diagnostic tools 
for detecting T. vaginalis which have been based on modifications of previous NAAT and 
TMA tests for infections such as chlamydia or gonorrhoea (Domeika et al., 2010; Van Der Pol 
et al, 2006). These tests may be conducted years after sample collection depending on proper 
storage conditions unlike wet mount which results in much less sensitivity unless 
maintained under strict time and temperature conditions (Van Der Pol et al, 2006). Despite 
high sensitivity for both male and female samples (Seña et al., 2007), greater than wet mount 
and culture (Crucitti et al., 2003; Lusk et al., 2010; Roth et al., 2011), in the range of 70-98% 
and specificity from 94-100% (Huppert et al., 2007; Nye et al., 2009; Seña et al., 2007; Wendel 
et al., 2002) this method is problematic as it is not point of care and remains unconfirmed for 
use in clinical settings. 
2.6.3 Rapid antigen testing 
Rapid antigen testing presents as probably the most promising technique despite requiring 
adequate technical skills and slightly less sensitivity than NAAT or TMA since it is 
inexpensive and can be employed at point of care (Domeika et al., 2010; Huppert et al., 
2007). Also, this diagnostic tool is more sensitive than wet mount and culture microscopy. 
The rapid antigen test employed in Huppert (2007) obtained a sensitivity of 90% and 
specificity of 100%. 
3. Murine model of infection and vaccination 
An effective model for the study of T. vaginalis is pertinent not only to understand the 
disease in context of the findings discussed so far, which only skim the surface of the actual 
breadth of scientific knowledge for each topic, but also to encourage development of vaccine 
strategies especially given the underestimated prevalence of the disease, the largely 
asymptomatic population group that remains untreated and the lack of available drug 
treatment in low resource settings. Within this frame of mind a mouse model modified to its 
current state by our lab holds important implications for study of T. vaginalis pathogenicity 
and also serves as a vaccination model. 
The murine model has been in development for some time coming to fruition as successfully 
demonstrating inducible protection upon vaccination against intravaginal challenge of T. 
vaginalis in BALB/c mice (Abraham et al., 1996).  
First, estrogenization studies in rats appear to affect APC presentation in vaginal cells and 
uterine stromal cells negatively while increasing antigen presentation in the uterine 
epithelial cells through mechanisms not thoroughly understood (Wira et al., 2000). 
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Nevertheless estrogenization is pivotal for increasing experimental infection rates in mice. It 
is hypothesized estrogenization may induce a state of estrus that is more permissive to 
infection (Meysick & Garber, 1992). This hypothesis is in line with results also within 
Meysick & Garber (1992) that infection rates were increased, but duration was unaffected, 
thus a factor at timepoint zero of infection likely mediates the findings. Additionally, in the 
same study the vaginal flora of the mouse remained unaffected by treatment, an important 
factor as we will see in other studies. Interestingly as a side note estrogenization in mice 
affects CDF, a soluble cytotoxicity element secreted by T. vaginalis (Garber et al., 1991). This 
may complicate findings when used as a disease model. 
Next, particular elements of the human vaginal environment have been thought to play a 
role in infection as noted by a decrease of Lactobacillus species levels and an associated 
increase of pH. Thus, through experimental inoculation of Lactobacillus acidophilus the mice 
would reflect more appropriately the human vaginal environment in terms of presence of 
lactobacilli and an associated pH decrease produced by products excreted by L. acidophilus 
(McGrory & Garber, 1992). With low percentages of natural incidence of lactobacilli in mice 
vaginas, an elevated pH and the disruption of these variables observed in human vaginas 
(Meysick & Garber, 1992) this factor of colonization was investigated. McGrory & Garber 
(1992) showed a significant increase in duration of trichomonal infection at day 24 post 
infection – 63-75% infected lactobacillus inoculated versus 0-25% infected controls. This 
suggests lactobacilli facilitate prolonged T. vaginalis infection. 
Finally, the vaccination model (see Abraham et al., 1996) utilizes subcutaneous whole cell 
vaccination emulsified in adjuvant. While unfortunately the current adjuvants used 
(Freund’s complete adjuvant and Freund’s incomplete adjuvant) are not safe for human use, 
current preliminary work with human-safe FDA approved adjuvant aluminum hydroxide 
(Alhydrogel) has shown induction of serum immunoglobulin responses significantly greater 
than natural infection (unpublished observations). While this result is not entirely surprising 
it simply adds to validation for use of the current mouse model as a candidate for 
experimental vaccine development. Furthermore these mice when infected fall into 
categories of asymptomatic and symptomatic infection. Of the latter, typical symptoms 
include vulvitis, vaginitis and vaginal discharge. 
Another similarity to human infection within the mouse model is that drug treatment 
resolution of infection and rechallenge does not confer any level of immune protection in 
mice as seen in humans (Abraham et al., 1996). On the other hand healthy skepticism is 
warranted in use of this current mouse model as suggested by Corbeil (1995). The actual 
pathogenic interactions of the murine vaginal epithelial cells with T. vaginalis are not 
characterized and similar protein binding adhesins mechanisms have not been 
demonstrated (Corbeil, 1995) which as previously noted was a significant correlate to 
symptomatic disease. Instead Corbeil suggests the use of a Tritrichomonas foetus bovine 
model.  
4. Vaccinating against trichomonads 
4.1 Bovine vaccine against T. foetus 
The T. foetus bovine model cattle are a natural host to the parasite and infection occurs 
through natural means. In addition to its well characterized disease states a commercial 
vaccine is already available (Fort Dodge Laboratories, Fort Dodge, Iowa) based on previous 
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trichomonads exhibiting characteristic jerky movements (Domeika et al., 2010). Due to the 
requirement of at least 104 trichomonads/mL (Garber, 2005) this technique is not viable for 
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incorrect temperature or too much time elapsing between sampling and assessment results 
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vaginal epithelial cells present in the sample (Garber, 2005). Sensitivities range from 52-
61.5% and specificity near 100% (Huppert et al., 2007; Nye et al., 2009; Van Der Pol et al, 
2006; Wendel et al., 2002). 
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Nucleic acid amplification testing (NAAT) and transcription mediated amplification (TMA) 
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for detecting T. vaginalis which have been based on modifications of previous NAAT and 
TMA tests for infections such as chlamydia or gonorrhoea (Domeika et al., 2010; Van Der Pol 
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treatment in low resource settings. Within this frame of mind a mouse model modified to its 
current state by our lab holds important implications for study of T. vaginalis pathogenicity 
and also serves as a vaccination model. 
The murine model has been in development for some time coming to fruition as successfully 
demonstrating inducible protection upon vaccination against intravaginal challenge of T. 
vaginalis in BALB/c mice (Abraham et al., 1996).  
First, estrogenization studies in rats appear to affect APC presentation in vaginal cells and 
uterine stromal cells negatively while increasing antigen presentation in the uterine 
epithelial cells through mechanisms not thoroughly understood (Wira et al., 2000). 
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Next, particular elements of the human vaginal environment have been thought to play a 
role in infection as noted by a decrease of Lactobacillus species levels and an associated 
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infection – 63-75% infected lactobacillus inoculated versus 0-25% infected controls. This 
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(Freund’s complete adjuvant and Freund’s incomplete adjuvant) are not safe for human use, 
current preliminary work with human-safe FDA approved adjuvant aluminum hydroxide 
(Alhydrogel) has shown induction of serum immunoglobulin responses significantly greater 
than natural infection (unpublished observations). While this result is not entirely surprising 
it simply adds to validation for use of the current mouse model as a candidate for 
experimental vaccine development. Furthermore these mice when infected fall into 
categories of asymptomatic and symptomatic infection. Of the latter, typical symptoms 
include vulvitis, vaginitis and vaginal discharge. 
Another similarity to human infection within the mouse model is that drug treatment 
resolution of infection and rechallenge does not confer any level of immune protection in 
mice as seen in humans (Abraham et al., 1996). On the other hand healthy skepticism is 
warranted in use of this current mouse model as suggested by Corbeil (1995). The actual 
pathogenic interactions of the murine vaginal epithelial cells with T. vaginalis are not 
characterized and similar protein binding adhesins mechanisms have not been 
demonstrated (Corbeil, 1995) which as previously noted was a significant correlate to 
symptomatic disease. Instead Corbeil suggests the use of a Tritrichomonas foetus bovine 
model.  
4. Vaccinating against trichomonads 
4.1 Bovine vaccine against T. foetus 
The T. foetus bovine model cattle are a natural host to the parasite and infection occurs 
through natural means. In addition to its well characterized disease states a commercial 
vaccine is already available (Fort Dodge Laboratories, Fort Dodge, Iowa) based on previous 
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work of immunization of bulls with whole cell or membrane fraction in oil adjuvant (Clark 
et al., 1983, as cited in Corbeil, 1995; Clark et al., 1984, as cited in Corbeil, 1995) and partial 
immunity in cows (Herr et al., as cited in Corbeil, 1995; Kvasnicka et al., 1989; Kvasnicka et 
al., 1992, as cited in Corbeil, 1995). The vaccines are not 100% protective, but significantly 
reduce transmission and infection rates among herds (Corbeil, 1995). Still this model may 
not be as attractive due to costs associated with purchase and husbandry of these animals 
whereas large sample numbers are obtainable, handling is easier and costs are within 
regular laboratory budgets to maintain mice. Also, while the host may be natural differences 
exist between T. vaginalis and T. foetus such as their ability to specifically induce lysis of 
human vascular endothelial cells and bovine vascular endothelial cells, respectively (Singh 
et al., 2004). As a last ironic note of difference it is the females that generally clear infection 
and the males that are asymptomatic carriers of T. foetus infection (Corbeil, 1995). 
4.2 Developing a human vaccine against T. vaginalis 
T. vaginalis presents an interesting challenge for providing immunity. It requires both 
mucosal immunity and consideration of mechanisms surrounding chronicity. Notably a 
vaccine obstacle is the surface heterogeneity of T. vaginalis inadvertently downregulating 
potent immunogenic proteins or glycoproteins (Alderete et al., 1986). Between phenotypic 
expression differences and strain differences between asymptomatic and symptomatic 
isolates an immunogen will be required to elicit robust immune response against a variable 
spectrum of antigens upon infectious challenge. The immunological activation necessarily 
must be sufficient enough to provide resolution without drug treatment especially in 
females. 
Theoretically speaking the approach may seem easy such as vaccinating against a protein 
involved in sequestering resources given the parasitic nature of the infection. Even if a 
recombinant immunogenic protein can be purified and produced consistently the delivery 
method is problematic as many routes of vaccination exist. While some routes are more 
desirable than others, depending on the adjuvant of choice the options to produce an 
appropriate response via a given route become far and few between. While applying our 
expanding knowledge of adjuvant mechanisms and adjuvant-mediated immune response 
skew (O’Hagan & De Gregorio, 2009) may seem an obvious path, it neglects to consider the 
importance of understanding of the infection processes that mediate immune evasion or are 
the reason natural immunity fails in the first place. This gap emphasizes our need for a 
consistent laboratory model for study of pathogenesis and the mechanisms of function to 
facilitate adjuvant selection and even antigen selection as a subunit vaccine alone may not 
work. Lastly, in design of a vaccine we must consider the target demographic. In this case 
there is a strong need to service low resource communities especially those sub-Saharan 
Africa areas with high incidence and prevalence of both T. vaginalis and HIV infection 
(World Health Organization, 2001). 
Progress in development of a bovine vaccine rather than a human vaccine has been strongly 
driven by economical factors of commercial farming involving loss of calves in utero 
(Kvasnicka et al., 1989). If it is commercial revenue or cost associated with the disease that 
drives funding for research then one must consider the 1.52-2.05 fold increased risk of HIV-1 
acquisition (Mavedzenge et al., 2010; McClelland et al., 2008) and the costs associated with 
drug therapy of both trichomoniasis and HIV.  
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5. Rationale for a human T. vaginalis vaccine 
5.1 Failure to control T. vaginalis with current treatment 
The current treatment for trichomoniasis is oral metronidazole or tinidazole, either as a 
single 2g dose, or 500mg twice a day for 5 to 7 days (WHO, 2003). Treatment of a patient's 
current sexual partners has often been recommended but there is some question as to the 
efficacy of partner therapy. The Centers for Disease Control and Prevention (CDC) do not 
recommend patient delivered partner treatment (PDPT) for trichomoniasis as they have not 
found sufficient evidence that PDPT significantly impacts rates of T. vaginalis infection 
(Centers for Disease Control and Prevention, 2006). Additionally, there are barriers 
associated with PDPT. Having multiple partners or a new partner are predictors for 
trichomoniasis (Peterman et al., 2006), so PDPT may be ineffective as it may be difficult or 
undesirable to provide multiple partners with treatment, and a partner obtained after 
treatment has been completed obviously could not have been the source of initial infection 
and therefore will not receive treatment. Additionally, a study of HIV positive women who 
were provided with PDPT showed that 25% did not deliver treatment to their partners. 
Reasons for not delivering medication included being unable to contact a partner, not 
wanting to see a partner again, and being afraid of a partner's reaction. Fear of a partner's 
reaction was not limited to revealing T. vaginalis infection, but was also associated with 
having a partner who was unaware of the woman's HIV infection status (Gatski et al., 2010). 
This is particularly disturbing in light of the fact that the presence of T. vaginalis can lead to 
an increased risk of the partner contracting HIV, while at the same time ignorance about 
HIVpositive status may mean that the partner is more willing to engage in unprotected sex.  
Because trichomoniasis is endemic in resource-limited settings, diagnosis is generally made 
purely on the basis of symptoms without any clinical testing. Syndromic treatment then is 
prescribed based on the most likely cause of illness. Because the symptoms of T. vaginalis 
infection are similar to other non-ulcerative STIs (urethritis in men, vaginitis and discharge 
in women) (Petrin et al., 1998) the disease is frequently misdiagnosed and the inappropriate 
drug is prescribed. Despite of the fact that WHO guidelines indicate metronidazole or 
tinidazole therapy is recommended in all cases of vaginal discharge (WHO, 2003), 
trichomoniasis is still under-diagnosed and under-treated.  
A study in India showed that using the relatively inexpensive InPouch culture kit to test for 
T. vaginalis at the point of care increased would have increased the correct treatment of 
trichomoniasis from 51% (syndromic treatment, no testing performed) to 82% (based on 
InPouch results) (Madhivanan et al., 2009). Unfortunately, culture testing requires 3 to 7 
days of incubation to confirm the presence or absence of trichomonads, and this time frame 
may not be acceptable to patients who need to travel to reach medical facilities. 
Another problem with syndromic management of trichomoniasis is that treatment 
guidelines are clear for women only. In India, a country where metronidazole treatment for 
vaginal discharge is part of syndromic management, high rates of T. vaginalis infection were 
still found in women, and also in many men. Current guidelines recommend treating for 
trichomoniasis in men only if symptoms of urethritis persist after treatment for gonorrhoea 
and chlamydia (WHO, 2003). Introducing metronidazole as a part of syndromic treatment 
for men presenting with non-ulcerative genital infection has been recommended (Becker et 
al., 2010), however this will still not address the problem of asymptomatic carriers. 
Poor control of trichomoniasis is not solely a problem in developing countries. A study in 
the United States showed that the prevalence of T. vaginalis infection is approximately 3% in 
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work of immunization of bulls with whole cell or membrane fraction in oil adjuvant (Clark 
et al., 1983, as cited in Corbeil, 1995; Clark et al., 1984, as cited in Corbeil, 1995) and partial 
immunity in cows (Herr et al., as cited in Corbeil, 1995; Kvasnicka et al., 1989; Kvasnicka et 
al., 1992, as cited in Corbeil, 1995). The vaccines are not 100% protective, but significantly 
reduce transmission and infection rates among herds (Corbeil, 1995). Still this model may 
not be as attractive due to costs associated with purchase and husbandry of these animals 
whereas large sample numbers are obtainable, handling is easier and costs are within 
regular laboratory budgets to maintain mice. Also, while the host may be natural differences 
exist between T. vaginalis and T. foetus such as their ability to specifically induce lysis of 
human vascular endothelial cells and bovine vascular endothelial cells, respectively (Singh 
et al., 2004). As a last ironic note of difference it is the females that generally clear infection 
and the males that are asymptomatic carriers of T. foetus infection (Corbeil, 1995). 
4.2 Developing a human vaccine against T. vaginalis 
T. vaginalis presents an interesting challenge for providing immunity. It requires both 
mucosal immunity and consideration of mechanisms surrounding chronicity. Notably a 
vaccine obstacle is the surface heterogeneity of T. vaginalis inadvertently downregulating 
potent immunogenic proteins or glycoproteins (Alderete et al., 1986). Between phenotypic 
expression differences and strain differences between asymptomatic and symptomatic 
isolates an immunogen will be required to elicit robust immune response against a variable 
spectrum of antigens upon infectious challenge. The immunological activation necessarily 
must be sufficient enough to provide resolution without drug treatment especially in 
females. 
Theoretically speaking the approach may seem easy such as vaccinating against a protein 
involved in sequestering resources given the parasitic nature of the infection. Even if a 
recombinant immunogenic protein can be purified and produced consistently the delivery 
method is problematic as many routes of vaccination exist. While some routes are more 
desirable than others, depending on the adjuvant of choice the options to produce an 
appropriate response via a given route become far and few between. While applying our 
expanding knowledge of adjuvant mechanisms and adjuvant-mediated immune response 
skew (O’Hagan & De Gregorio, 2009) may seem an obvious path, it neglects to consider the 
importance of understanding of the infection processes that mediate immune evasion or are 
the reason natural immunity fails in the first place. This gap emphasizes our need for a 
consistent laboratory model for study of pathogenesis and the mechanisms of function to 
facilitate adjuvant selection and even antigen selection as a subunit vaccine alone may not 
work. Lastly, in design of a vaccine we must consider the target demographic. In this case 
there is a strong need to service low resource communities especially those sub-Saharan 
Africa areas with high incidence and prevalence of both T. vaginalis and HIV infection 
(World Health Organization, 2001). 
Progress in development of a bovine vaccine rather than a human vaccine has been strongly 
driven by economical factors of commercial farming involving loss of calves in utero 
(Kvasnicka et al., 1989). If it is commercial revenue or cost associated with the disease that 
drives funding for research then one must consider the 1.52-2.05 fold increased risk of HIV-1 
acquisition (Mavedzenge et al., 2010; McClelland et al., 2008) and the costs associated with 
drug therapy of both trichomoniasis and HIV.  
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The current treatment for trichomoniasis is oral metronidazole or tinidazole, either as a 
single 2g dose, or 500mg twice a day for 5 to 7 days (WHO, 2003). Treatment of a patient's 
current sexual partners has often been recommended but there is some question as to the 
efficacy of partner therapy. The Centers for Disease Control and Prevention (CDC) do not 
recommend patient delivered partner treatment (PDPT) for trichomoniasis as they have not 
found sufficient evidence that PDPT significantly impacts rates of T. vaginalis infection 
(Centers for Disease Control and Prevention, 2006). Additionally, there are barriers 
associated with PDPT. Having multiple partners or a new partner are predictors for 
trichomoniasis (Peterman et al., 2006), so PDPT may be ineffective as it may be difficult or 
undesirable to provide multiple partners with treatment, and a partner obtained after 
treatment has been completed obviously could not have been the source of initial infection 
and therefore will not receive treatment. Additionally, a study of HIV positive women who 
were provided with PDPT showed that 25% did not deliver treatment to their partners. 
Reasons for not delivering medication included being unable to contact a partner, not 
wanting to see a partner again, and being afraid of a partner's reaction. Fear of a partner's 
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This is particularly disturbing in light of the fact that the presence of T. vaginalis can lead to 
an increased risk of the partner contracting HIV, while at the same time ignorance about 
HIVpositive status may mean that the partner is more willing to engage in unprotected sex.  
Because trichomoniasis is endemic in resource-limited settings, diagnosis is generally made 
purely on the basis of symptoms without any clinical testing. Syndromic treatment then is 
prescribed based on the most likely cause of illness. Because the symptoms of T. vaginalis 
infection are similar to other non-ulcerative STIs (urethritis in men, vaginitis and discharge 
in women) (Petrin et al., 1998) the disease is frequently misdiagnosed and the inappropriate 
drug is prescribed. Despite of the fact that WHO guidelines indicate metronidazole or 
tinidazole therapy is recommended in all cases of vaginal discharge (WHO, 2003), 
trichomoniasis is still under-diagnosed and under-treated.  
A study in India showed that using the relatively inexpensive InPouch culture kit to test for 
T. vaginalis at the point of care increased would have increased the correct treatment of 
trichomoniasis from 51% (syndromic treatment, no testing performed) to 82% (based on 
InPouch results) (Madhivanan et al., 2009). Unfortunately, culture testing requires 3 to 7 
days of incubation to confirm the presence or absence of trichomonads, and this time frame 
may not be acceptable to patients who need to travel to reach medical facilities. 
Another problem with syndromic management of trichomoniasis is that treatment 
guidelines are clear for women only. In India, a country where metronidazole treatment for 
vaginal discharge is part of syndromic management, high rates of T. vaginalis infection were 
still found in women, and also in many men. Current guidelines recommend treating for 
trichomoniasis in men only if symptoms of urethritis persist after treatment for gonorrhoea 
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for men presenting with non-ulcerative genital infection has been recommended (Becker et 
al., 2010), however this will still not address the problem of asymptomatic carriers. 
Poor control of trichomoniasis is not solely a problem in developing countries. A study in 
the United States showed that the prevalence of T. vaginalis infection is approximately 3% in 
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women between the ages of 14 and 49. This infection rate doubles in the poorly educated 
and economically disadvantaged, and nearly quadruples in black women (Allsworth et al., 
2009). Additionally persistent, subclinical T. vaginalis infections have been reported even 
after seemingly successful treatment. A study on HIV positive women diagnosed with 
trichomoniasis showed that despite reported compliance with metronidazole treatment 
regimen and putative successful cure (negative InPouch culture), a number of women tested 
positive for T. vaginalis infection 3-6 months later, despite reporting no sexual contact in the 
intervening time (Gatski & Kissinger, 2010).  
Drug resistance to nitroimidazoles such as metronidazole and tinidazole has also been 
reported in 5-10% of clinical specimens (Upcroft & Upcroft, 2001). As there are currently no 
effective non-nitroimidazole treatments for trichomoniasis, drug resistant T. vaginalis must 
be treated by increasing medication dosages, which often leads to increased adverse effects. 
If these adverse reactions become severe enough to force cessation of therapy, 
trichomoniasis can become a chronic condition (Cudmore et al. 2004). 
5.2 Other issues with treatment to control T. vaginalis 
Sexually transmitted infections such as trichomoniasis are societal as well as medical 
problems. In order to successfully control the disease the personal, social, and cultural 
barriers associated with dealing with STI need to be addressed. 
5.2.1 The education risk factor 
Accurate and useful information on STI can be difficult to obtain. A study done with 
students (aged 13-16, male and female) in the United Kingdom showed that STI were 
recognized as a serious health problem. However, many of the teenagers were ill- or 
misinformed about the names of common STI, how to identify a possible infection, where to 
seek treatment, etc. (Garside et al., 2001). Lack of education has clearly been shown to be a 
risk factor for acquiring STI. Unfortunately education programs are not available in many 
areas where HIV and trichomoniasis are endemic due to reasons such as lack of finance and 
resources, geography, and cultural or personal discomfort about discussing sexuality and 
STI. As such, the importance of protecting those with little opportunity to access 
information about STI cannot be underestimated. 
Lack of information and awareness regarding STI has been shown to lead to delays in 
seeking treatment for medical issues involving the genitals. Participants in a study in rural 
Zimbabwe had little awareness that having an STI could increase their risk of contracting 
HIV. Men were more aware of the link between STI and HIV (18% of men vs 5 % of women) 
and this knowledge was associated with seeking treatment more promptly upon noticing 
symptoms of genital disease. However many men (36%) and the majority of women (70%) 
ignored symptoms of urethral/vaginal discharge or discomfort, or lower abdominal pain 
for a week or more before seeking treatment (Gregson et al., 2001). Given the fact that 
trichomoniasis and other STI have been linked to sequelae such as infertility and adverse 
pregnancy outcomes, delays in seeking treatment puts reproductive health at risk. 
Education about STI in the general population is not the only issue, part of the problem can 
stem from the lack of healthcare workers specialized in dealing with sexual issues and 
diseases. In many parts of the world specialist physicians are rare and general practitioners 
may not have sufficient background, or simply not be comfortable discussing "intimate" 
issues, especially with the opposite sex. Women are often more comfortable dealing with 
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other women when discussing sexual issues, but a study in Bangladesh found that  female 
healthcare workers were often uncomfortable discussing sexuality or performing genital 
exams (Gibney et al., 1999). Because of the embarrassment, social implications, etc. often 
attached to the subject of STI, an open discussion between a patient and healthcare provider 
can be difficult when medical personel are clearly uncomfortable with the subject. Patients 
may be less forthcoming about their symptoms and less likely to seek treatment if healthcare 
workers appear to be judgemental or reluctant to provide information and care. 
5.2.2 Cultural barriers 
There is a nearly universal stigma attached to having an STI. Sex and sexuality are generally 
considered to be very personal issues and seeking treatment for genital disease involves 
speaking about private matters. In addition reluctance to seek treatment can stem from fear 
of being associated with promiscuity and negative social behaviours, which are often linked 
with STI. A study of pregnant women in India showed that although the majority of women 
stated they were willing to be tested for HIV, they were also highly concerned about the 
reactions of their husbands, families, and community should it be found that they were 
seropositive. Additionally, not breastfeeding (recommended to prevent maternal-child HIV 
transmission) was widely believed to be a sign that a woman was a bad mother or had been 
unfaithful to her husband (Rogers et al., 2006). 
Women in particular are often reluctant to speak about genital health issues, one study cites 
"shyness" as the single biggest barrier in seeking STI treatment (Gibney et al., 1999). A study 
of pregnant women in Nairobi found that over a quarter of women refused to answer 
portions of a health questionnaire related to vaginal discharge. Of the women who did 
respond, only 6% complained of discharge, but 51% were found were found to have 
abnormal vaginal discharge on clinical examination (Marx et al., 2010). Another study, also 
in pregnant women, found that although many of the women questioned recognized a 
variety of symptoms (including vaginal discharge/itching, dysuria, and genital ulcers or 
swelling) only 9% sought treatment (Blankhart et al., 1999). This statistic is particularly 
disturbing in view of the adverse outcomes associated with having an STI during 
pregnancy. Reluctance to seek STI treatment for fear of negative reactions from family 
and/or community is putting both child and maternal health at risk. 
5.2.3 Sexual inequality and risk 
Sexual risk behaviour in women has been found to significantly influence their likelihood of 
contracting trichomoniasis, but not HIV. Conversely high risk (male) partner behaviour 
significantly increased the female partner's risk of acquiring HIV, but was not associated 
with increased incidence of trichomoniasis (Mavedzenge et al., 2010). This issue of male 
sexual risk behaviour contributing to a female partner's risk of acquiring an STI, especially 
HIV, is important because many women do not have complete control of their sexual 
activities. A study of 481 pregnant young women in the Central African Republic showed 
that 72% reported voluntarily engaging in their first sexual intercourse, 18% were pressured 
their first intercourse, and 11% reported their first sexual intercourse was a rape. With 
respect to their pregnancies, 52% reported their pregnancy was planned and desired, 32% 
reported unplanned but accepted, and 16% reported that they did not desire the pregnancy 
(Blankhart et al., 1999).  
A study on risk factors for HIV acquisition in Africa found that women's sexual choices are 
often limited or dictated by their male partners. Some women reported that they were 
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women between the ages of 14 and 49. This infection rate doubles in the poorly educated 
and economically disadvantaged, and nearly quadruples in black women (Allsworth et al., 
2009). Additionally persistent, subclinical T. vaginalis infections have been reported even 
after seemingly successful treatment. A study on HIV positive women diagnosed with 
trichomoniasis showed that despite reported compliance with metronidazole treatment 
regimen and putative successful cure (negative InPouch culture), a number of women tested 
positive for T. vaginalis infection 3-6 months later, despite reporting no sexual contact in the 
intervening time (Gatski & Kissinger, 2010).  
Drug resistance to nitroimidazoles such as metronidazole and tinidazole has also been 
reported in 5-10% of clinical specimens (Upcroft & Upcroft, 2001). As there are currently no 
effective non-nitroimidazole treatments for trichomoniasis, drug resistant T. vaginalis must 
be treated by increasing medication dosages, which often leads to increased adverse effects. 
If these adverse reactions become severe enough to force cessation of therapy, 
trichomoniasis can become a chronic condition (Cudmore et al. 2004). 
5.2 Other issues with treatment to control T. vaginalis 
Sexually transmitted infections such as trichomoniasis are societal as well as medical 
problems. In order to successfully control the disease the personal, social, and cultural 
barriers associated with dealing with STI need to be addressed. 
5.2.1 The education risk factor 
Accurate and useful information on STI can be difficult to obtain. A study done with 
students (aged 13-16, male and female) in the United Kingdom showed that STI were 
recognized as a serious health problem. However, many of the teenagers were ill- or 
misinformed about the names of common STI, how to identify a possible infection, where to 
seek treatment, etc. (Garside et al., 2001). Lack of education has clearly been shown to be a 
risk factor for acquiring STI. Unfortunately education programs are not available in many 
areas where HIV and trichomoniasis are endemic due to reasons such as lack of finance and 
resources, geography, and cultural or personal discomfort about discussing sexuality and 
STI. As such, the importance of protecting those with little opportunity to access 
information about STI cannot be underestimated. 
Lack of information and awareness regarding STI has been shown to lead to delays in 
seeking treatment for medical issues involving the genitals. Participants in a study in rural 
Zimbabwe had little awareness that having an STI could increase their risk of contracting 
HIV. Men were more aware of the link between STI and HIV (18% of men vs 5 % of women) 
and this knowledge was associated with seeking treatment more promptly upon noticing 
symptoms of genital disease. However many men (36%) and the majority of women (70%) 
ignored symptoms of urethral/vaginal discharge or discomfort, or lower abdominal pain 
for a week or more before seeking treatment (Gregson et al., 2001). Given the fact that 
trichomoniasis and other STI have been linked to sequelae such as infertility and adverse 
pregnancy outcomes, delays in seeking treatment puts reproductive health at risk. 
Education about STI in the general population is not the only issue, part of the problem can 
stem from the lack of healthcare workers specialized in dealing with sexual issues and 
diseases. In many parts of the world specialist physicians are rare and general practitioners 
may not have sufficient background, or simply not be comfortable discussing "intimate" 
issues, especially with the opposite sex. Women are often more comfortable dealing with 
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other women when discussing sexual issues, but a study in Bangladesh found that  female 
healthcare workers were often uncomfortable discussing sexuality or performing genital 
exams (Gibney et al., 1999). Because of the embarrassment, social implications, etc. often 
attached to the subject of STI, an open discussion between a patient and healthcare provider 
can be difficult when medical personel are clearly uncomfortable with the subject. Patients 
may be less forthcoming about their symptoms and less likely to seek treatment if healthcare 
workers appear to be judgemental or reluctant to provide information and care. 
5.2.2 Cultural barriers 
There is a nearly universal stigma attached to having an STI. Sex and sexuality are generally 
considered to be very personal issues and seeking treatment for genital disease involves 
speaking about private matters. In addition reluctance to seek treatment can stem from fear 
of being associated with promiscuity and negative social behaviours, which are often linked 
with STI. A study of pregnant women in India showed that although the majority of women 
stated they were willing to be tested for HIV, they were also highly concerned about the 
reactions of their husbands, families, and community should it be found that they were 
seropositive. Additionally, not breastfeeding (recommended to prevent maternal-child HIV 
transmission) was widely believed to be a sign that a woman was a bad mother or had been 
unfaithful to her husband (Rogers et al., 2006). 
Women in particular are often reluctant to speak about genital health issues, one study cites 
"shyness" as the single biggest barrier in seeking STI treatment (Gibney et al., 1999). A study 
of pregnant women in Nairobi found that over a quarter of women refused to answer 
portions of a health questionnaire related to vaginal discharge. Of the women who did 
respond, only 6% complained of discharge, but 51% were found were found to have 
abnormal vaginal discharge on clinical examination (Marx et al., 2010). Another study, also 
in pregnant women, found that although many of the women questioned recognized a 
variety of symptoms (including vaginal discharge/itching, dysuria, and genital ulcers or 
swelling) only 9% sought treatment (Blankhart et al., 1999). This statistic is particularly 
disturbing in view of the adverse outcomes associated with having an STI during 
pregnancy. Reluctance to seek STI treatment for fear of negative reactions from family 
and/or community is putting both child and maternal health at risk. 
5.2.3 Sexual inequality and risk 
Sexual risk behaviour in women has been found to significantly influence their likelihood of 
contracting trichomoniasis, but not HIV. Conversely high risk (male) partner behaviour 
significantly increased the female partner's risk of acquiring HIV, but was not associated 
with increased incidence of trichomoniasis (Mavedzenge et al., 2010). This issue of male 
sexual risk behaviour contributing to a female partner's risk of acquiring an STI, especially 
HIV, is important because many women do not have complete control of their sexual 
activities. A study of 481 pregnant young women in the Central African Republic showed 
that 72% reported voluntarily engaging in their first sexual intercourse, 18% were pressured 
their first intercourse, and 11% reported their first sexual intercourse was a rape. With 
respect to their pregnancies, 52% reported their pregnancy was planned and desired, 32% 
reported unplanned but accepted, and 16% reported that they did not desire the pregnancy 
(Blankhart et al., 1999).  
A study on risk factors for HIV acquisition in Africa found that women's sexual choices are 
often limited or dictated by their male partners. Some women reported that they were 
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forced into a sexual relationship as it was their only means to obtain food, shelter, or money 
for education. Others stated that they required their partner's permission to obtain medical 
care (including HIV testing) and to protect themselves (ie. use condoms). Marital standards 
are also unbalanced as while married women are expected to remain faithful to their 
husbands, men are not necessarily expected to maintain complete fidelity, especially if they 
are away from their wives (Chersich & Rees, 2008).  
In many rural areas labourers must migrate to different locations or into cities to find work. 
This can result in significant periods of spousal separation and can result in one or both 
partners seeking extra-marital sexual intercourse. A study in Zimbabwe showed that while 
both partners may visit "beer halls" women are at statistically significant increased risk of 
HIV acquisition, while only a small non-significant increase in risk was seen for men 
(Gregson et al., 2001). In China, a study of migrant workers of both sexes found that they 
often engaged high risk sexual behaviours much more than the general population. In 
particular women were more likely to sell sex for money and men more likely to pay for sex. 
Interestingly, this increased involvement with the sex trade increased the prevalence of STI 
and HIV in women, but no statistically significant increase seen in men (Wang et al., 2007). 
5.2.4 Marginalized populations 
Female sex workers (FSW) are unsurprisingly at a high risk for STI. They can also act as a 
reservoir for STI that can be difficult to deal with using treatment alone as they can be 
sexually active on a daily basis. Additionally studies like one in Indonesia have shown that 
STI rates are highest in FSW in the lowest socioecomonic class, who charge the lowest prices 
per sex act and as such need to see more clients, increasing their risk for STI. These women 
are also more likely to have little ability to negotiate condom use, and have minimal money 
to spend on medical care and medication (Joesoef et al., 1997). 
Even when healthcare initiatives aimed at FSW are in place, education and medical care are 
still not necessarily easily available to all. This is especially true for FSW who are non-
residents or illegal immigrants in the country in which they are working. A study in Sydney, 
Australia showed an impressively low rate of STI amongst "local" FSW (women who were 
native Australian or had been in the country a significant period, and English-speaking) 
after partial legalization of the sex trade and an aggressive education campaign. However 
"international" FSW (women born outside of Australia whose first language was not 
English) showed high rates of STI. Language barriers, lack of access to the same medical 
programs as residents, and concerns about drawing attention to themselves by accessing 
medical care meant that these women remained at high risk despite there being a system in 
place to help protect them (O'Connor et al., 1996). 
Sex trade workers are clearly an excellent target population for a vaccine that could provide 
long term, consistent protection from T. vaginalis infection and offer a reduced risk of HIV 
acquisition. They are part of a "core" group that acts as a reservoir for STI, and reducing the 
burden of infection in this population can be a community benefit.  
5.3 Advantages of a vaccine for prevention of T. vaginalis infection 
Trichomoniasis can be treated relatively easily and inexpensively, yet the disease is poorly 
controlled. Diverse factors lead to both a failure to recognize T. vaginalis infection and 
inability or unwillingness to seek or access treatment. A vaccine could provide long term 
protection eliminating the need for repeated doctor visits and treatments, the risk of 
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misdiagnosis, and address the needs of high risk populations. In addition, given the link 
between trichomoniasis and other genital infection, especially HIV, a vaccine capable of 
preventing T. vaginalis infections has the potential to impact global STI burden. 
6. T. vaginalis and HIV 
6.1 Incidence and prevalence of trichomoniasis and HIV 
It is estimated that approximately 33.3 million people are currently infected with HIV-1. 
About two-thirds of these (22.5 million) are living in sub-Saharan Africa and 4.1 million live 
in South and Southeast Asia (UN, 2009). Both these areas also have the highest rates of T. 
vaginalis infection, with about 32 million cases in sub-Saharan Africa and 76.5 million in 
South and Southeast Asia every year (WHO, 2001). Global rates of trichomoniasis and HIV 
tend to follow similar patterns in different areas of the world (ie. the higher the incidence of 
T. vaginalis infection, the higher the prevalence of HIV) with two exceptions. As stated 
above, sub-Saharan Africa has the highest prevalence of HIV and the second highest 
incidence of trichomoniasis, while the opposite is true for south and Southeast Asia. The 
other exception is North America, which has a fairly high prevalence of HIV (1.5 million 
cases) (UN, 2009) relative to a low incidence of T. vaginalis infection (8 million annually) 
(WHO, 2001). 
Rates of co-infection with HIV and T. vaginalis in women have been reported to range from 
16% to almost 30% (Allsworth et al., 2009; Gatski et al., 2010; Månsson et al., 2010; Marx et 
al., 2010). It is difficult to reliably estimate co-infection rates in men as trichomoniasis is 
generally asymptomatic and not usually considered a significant STI in males. 
6.2 T. vaginalis and increased risk of HIV transmission 
Trichomoniasis has been associated with a 1.52 to 2.05 times greater risk of seroconversion 
upon exposure to HIV (McClelland et al., 2007, Mavedzenge et al., 2010). A longitudinal 
study of almost 5000 women in South Africa and Zimbabwe showed that the link between 
HIV and T. vaginalis appears to be bi-directional. Compared to uninfected women, those 
with trichomoniasis were more likely to test positive for HIV at their next study visit, and 
HIV positive women were more likely to have acquired T. vaginalis infection by their 
following study visit (odds ratios were >2 for both cases, after adjusting for confounders 
such as age, other STIs, and sexual risk behaviours) (Mavedzenge et al., 2010). This leads to 
an increased risk of both T. vaginalis and HIV infection if both diseases are present in any 
combination between sexual partners. 
6.2.1 Disruption of genital mucosa 
As previously mentioned, T. vaginalis is capable of both contact dependent and contact 
independent disruption of cell layers (see section 2.5.2). This disruption can provide portals 
of entry that allow HIV access past the epithelium into tissue, can sometimes lead to the 
formation of punctuate mucosal hemorrhages (strawberry cervix) women. 
Without co-factors such as STI co-infection or trauma to the genital mucosa, the odds of a 
woman acquiring HIV through sexual exposure are estimated to be 0.08%. The odds of 
female to male transmission are 0.04% per exposure. Healthy, intact genital mucosa is 
considered to be a significant barrier to HIV infection (Thurman & Doncel, 2011). Because 
trichomoniasis can disrupt the integrity of mucosal tissue this primary barrier against 
infection is breached and HIV transmission risk is increased. 
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forced into a sexual relationship as it was their only means to obtain food, shelter, or money 
for education. Others stated that they required their partner's permission to obtain medical 
care (including HIV testing) and to protect themselves (ie. use condoms). Marital standards 
are also unbalanced as while married women are expected to remain faithful to their 
husbands, men are not necessarily expected to maintain complete fidelity, especially if they 
are away from their wives (Chersich & Rees, 2008).  
In many rural areas labourers must migrate to different locations or into cities to find work. 
This can result in significant periods of spousal separation and can result in one or both 
partners seeking extra-marital sexual intercourse. A study in Zimbabwe showed that while 
both partners may visit "beer halls" women are at statistically significant increased risk of 
HIV acquisition, while only a small non-significant increase in risk was seen for men 
(Gregson et al., 2001). In China, a study of migrant workers of both sexes found that they 
often engaged high risk sexual behaviours much more than the general population. In 
particular women were more likely to sell sex for money and men more likely to pay for sex. 
Interestingly, this increased involvement with the sex trade increased the prevalence of STI 
and HIV in women, but no statistically significant increase seen in men (Wang et al., 2007). 
5.2.4 Marginalized populations 
Female sex workers (FSW) are unsurprisingly at a high risk for STI. They can also act as a 
reservoir for STI that can be difficult to deal with using treatment alone as they can be 
sexually active on a daily basis. Additionally studies like one in Indonesia have shown that 
STI rates are highest in FSW in the lowest socioecomonic class, who charge the lowest prices 
per sex act and as such need to see more clients, increasing their risk for STI. These women 
are also more likely to have little ability to negotiate condom use, and have minimal money 
to spend on medical care and medication (Joesoef et al., 1997). 
Even when healthcare initiatives aimed at FSW are in place, education and medical care are 
still not necessarily easily available to all. This is especially true for FSW who are non-
residents or illegal immigrants in the country in which they are working. A study in Sydney, 
Australia showed an impressively low rate of STI amongst "local" FSW (women who were 
native Australian or had been in the country a significant period, and English-speaking) 
after partial legalization of the sex trade and an aggressive education campaign. However 
"international" FSW (women born outside of Australia whose first language was not 
English) showed high rates of STI. Language barriers, lack of access to the same medical 
programs as residents, and concerns about drawing attention to themselves by accessing 
medical care meant that these women remained at high risk despite there being a system in 
place to help protect them (O'Connor et al., 1996). 
Sex trade workers are clearly an excellent target population for a vaccine that could provide 
long term, consistent protection from T. vaginalis infection and offer a reduced risk of HIV 
acquisition. They are part of a "core" group that acts as a reservoir for STI, and reducing the 
burden of infection in this population can be a community benefit.  
5.3 Advantages of a vaccine for prevention of T. vaginalis infection 
Trichomoniasis can be treated relatively easily and inexpensively, yet the disease is poorly 
controlled. Diverse factors lead to both a failure to recognize T. vaginalis infection and 
inability or unwillingness to seek or access treatment. A vaccine could provide long term 
protection eliminating the need for repeated doctor visits and treatments, the risk of 
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misdiagnosis, and address the needs of high risk populations. In addition, given the link 
between trichomoniasis and other genital infection, especially HIV, a vaccine capable of 
preventing T. vaginalis infections has the potential to impact global STI burden. 
6. T. vaginalis and HIV 
6.1 Incidence and prevalence of trichomoniasis and HIV 
It is estimated that approximately 33.3 million people are currently infected with HIV-1. 
About two-thirds of these (22.5 million) are living in sub-Saharan Africa and 4.1 million live 
in South and Southeast Asia (UN, 2009). Both these areas also have the highest rates of T. 
vaginalis infection, with about 32 million cases in sub-Saharan Africa and 76.5 million in 
South and Southeast Asia every year (WHO, 2001). Global rates of trichomoniasis and HIV 
tend to follow similar patterns in different areas of the world (ie. the higher the incidence of 
T. vaginalis infection, the higher the prevalence of HIV) with two exceptions. As stated 
above, sub-Saharan Africa has the highest prevalence of HIV and the second highest 
incidence of trichomoniasis, while the opposite is true for south and Southeast Asia. The 
other exception is North America, which has a fairly high prevalence of HIV (1.5 million 
cases) (UN, 2009) relative to a low incidence of T. vaginalis infection (8 million annually) 
(WHO, 2001). 
Rates of co-infection with HIV and T. vaginalis in women have been reported to range from 
16% to almost 30% (Allsworth et al., 2009; Gatski et al., 2010; Månsson et al., 2010; Marx et 
al., 2010). It is difficult to reliably estimate co-infection rates in men as trichomoniasis is 
generally asymptomatic and not usually considered a significant STI in males. 
6.2 T. vaginalis and increased risk of HIV transmission 
Trichomoniasis has been associated with a 1.52 to 2.05 times greater risk of seroconversion 
upon exposure to HIV (McClelland et al., 2007, Mavedzenge et al., 2010). A longitudinal 
study of almost 5000 women in South Africa and Zimbabwe showed that the link between 
HIV and T. vaginalis appears to be bi-directional. Compared to uninfected women, those 
with trichomoniasis were more likely to test positive for HIV at their next study visit, and 
HIV positive women were more likely to have acquired T. vaginalis infection by their 
following study visit (odds ratios were >2 for both cases, after adjusting for confounders 
such as age, other STIs, and sexual risk behaviours) (Mavedzenge et al., 2010). This leads to 
an increased risk of both T. vaginalis and HIV infection if both diseases are present in any 
combination between sexual partners. 
6.2.1 Disruption of genital mucosa 
As previously mentioned, T. vaginalis is capable of both contact dependent and contact 
independent disruption of cell layers (see section 2.5.2). This disruption can provide portals 
of entry that allow HIV access past the epithelium into tissue, can sometimes lead to the 
formation of punctuate mucosal hemorrhages (strawberry cervix) women. 
Without co-factors such as STI co-infection or trauma to the genital mucosa, the odds of a 
woman acquiring HIV through sexual exposure are estimated to be 0.08%. The odds of 
female to male transmission are 0.04% per exposure. Healthy, intact genital mucosa is 
considered to be a significant barrier to HIV infection (Thurman & Doncel, 2011). Because 
trichomoniasis can disrupt the integrity of mucosal tissue this primary barrier against 
infection is breached and HIV transmission risk is increased. 
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The degree of epithelial disruption has been found in vitro to vary between different isolates 
of T. vaginalis. A study examining four different T. vaginalis clinical isolates (two from 
asymptomatic patients and two from symptomatic patients presenting with cervicitis and 
vaginal discharge) found that the symptomatic isolates rapidly disrupted cell monolayers, 
but the asymptomatic isolates had a much more limited effect on monolayer integrity. The 
potential impact of monolayer disruption on the ability of HIV to enter tissue was examined 
by adding HIV and T. vaginalis to the apical surface of stratified monolayers growing on 
transwell plates, then measuring the amount of virus present in the basolateral supernatant. 
The degree of monolayer disruption was found to correlate with the amount of HIV released 
into the basolateral supernatant. Symptomatic isolates (disrupted monolayers) caused a 
four- to five-fold increase in HIV released into supernatant, whereas asymptomatic isolates 
(intact monolayers) showed HIV supernatant levels similar to background (no trichomonads 
on monolayers) (Guenthner et al., 2005). Although only four isolates were used, this 
experiment suggests that not all isolates of T. vaginalis may have equal impact on the risk of 
acquiring HIV infection. This is an intriguing possibility that could potentially offer some 
explanation as to why the high incidence of trichomoniasis in South and Southeast Asia is 
not matched by an equally high prevalence of HIV. 
6.2.2 Changes to vaginal flora 
Both trichomoniasis and HIV transmission have been linked to disrupted or abnormal 
vaginal flora. A study examining the link between T. vaginalis infection and bacterial 
vaginosis (BV) showed that 61% of HIV positive women also had BV and 80% had abnormal 
vaginal flora (defined as Nugent scores of 7-10 and 4-10, respectively). In comparison HIV 
negative women with trichomoniasis showed 47.3% incidence of BV co-infection, and 58.9% 
had abnormal vaginal flora (Gatski et al., 2010). However, since co-infection with 
trichomoniasis and BV is relatively common, it is difficult to tell which, if either, infection 
acts as the primary risk factor. 
Both trichomoniasis and BV are associated with an increase in vaginal pH and decreased or 
absent vaginal Lactobacillus species (Petrin et al., 1998 (trichomoniasis) and Sha et al., 2005 
(BV)). Lactobacilli produce lactic acid which maintains the low pH of the (healthy) vagina. 
Lactic acid has been shown in vitro to inactivate HIV, as has H2O2 which is produced by 
some, but not all, lactobacilli (Klebanoff et al., 1991). Lactobacilli therefore contribute 
maintaining a vaginal milieu that is not permissive to infectious agents, and loss of 
Lactobacillus species can lead to increased chances of STI. Low vaginal pH and H2O2 can also 
inhibit activation and proliferation of vaginal lymphocytes, particularly CD4+ T cells (Hill & 
Anderson, 1992). This means that disruption of the vaginal environment by T. vaginalis can 
lead to greater risk of HIV infection due to an increase of activated CD4+ T cells that can be 
infected by the virus. 
6.2.3 Inflammatory response 
Infection with T. vaginalis leads to a local inflammatory response that includes 
chemoattractant (IL-8) and acute pro-inflammatory (TNF-α ,IL-1β, and IL-6) cytokines that 
are responsible for initiating immune response to infection and recruiting immune cells. 
Symptomatic infection is the result of a more vigorous immune response in which there is 
an increased amount of inflammation and cell recruitment. For example, in women vaginal 
discharge often contains neutrophils that respond to the presence of IL-8 (Thurman & 
Doncel, 2010). However immune response may fail to clear T. vaginalis, and does not 
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provide long term immunological memory to prevent subsequent infections. Additionally 
immune response to trichomoniasis can attract lymphocytes that are the targets of HIV 
infection. 
A powerful chemoattractant, IL-8 recruits immune cells to where they are needed to 
eliminate infection. However, it has also been shown that this cytokine can increase the 
susceptibility of monocytes, macrophages, and CD4+ T cells to HIV infection. IL-8 can also 
enhance HIV replication in infected immune cells (Narimatsu et al., 2005). 
A study using cervicovaginal lavage samples from HIV positive women who were also 
infected with T. vaginalis showed elevated levels of IL-1β. Levels of IL-1β could be 
significantly different between visits, but clearly correlated with HIV viral load (Mitchell et 
al., 2011). 
An in vitro study using HIV-infected peripheral blood mononuclear cells (PBMC) cultured 
with T. vaginalis resulted in increased replication of HIV compared to PBMCs alone. Unlike 
epithelial cell disruption, different isolates (symptomatic or asymptomatic) seemed to 
induce similar levels of increase in HIV replication. It was found that TNF-α levels were 
elevated in the supernatant of cultures containing T. vaginalis compared to controls and the 
addition of anti-TNF-α antibody could attenuate the increase in HIV replication (Guenthner 
et al., 2005). 
The relationship between IL-6 and HIV is interesting in that they seem to be capable of 
upregulating each other in an apparent positive feedback loop. Examination of ectocervical 
tissue from HIV positive women found higher levels of IL-6 than in uninfected controls. 
Because the ectocervix was an area where high levels of HIV replication had been detected, 
recombinant IL-6 was applied to tissue explants and a greater than 300-fold increase in HIV 
transcription was seen (Asin et al., 2009). HIV appears to be capable of not only infecting 
immune cells, but of using immune response to its own advantage to enhance its replication.  
6.2.4 Increased viral load 
Inflammatory response to T. vaginalis infection leads to an influx of susceptible lymphocytes 
and the release of cytokines that can upregulate the rate of HIV replication. This in turn can 
increase HIV viral load and lead to a higher risk of spreading the infection to unprotected 
partners. A study looking at HIV positive men with genital ulcers found HIV RNA 
increased in ulcers caused by herpes simplex virus type 2 (HSV-2) only if HSV-2 was 
present in the ulcer. However, co-infection with T. vaginalis increased HIV viral load in 
ulcers regardless of the presence of HSV-2 indicating that trichomoniasis leads to increased 
shedding of HIV regardless of (or perhaps even in synergy with) other STI (Paz-Bailey et al., 
2010).  
While trichomoniasis does increase the amount of HIV viral shedding, elimination of T. 
vaginalis infection returns HIV RNA levels in the genitals to lower levels. A study in Africa 
of HIV positive women with trichomoniasis measured viral RNA at the time of trichomonal 
infection, and then 2 weeks later after treatment when infection had been resolved. There 
was a 4.2 fold decrease in the amount of HIV shed (Wang et al., 2001). Another study in 
New Orleans examined vaginal viral shedding in HIV positive women with and without 
trichomoniasis. Women with T. vaginalis infection were almost twice as likely as women 
without trichomoniasis to have detectable HIV RNA in their vaginal secretions at baseline 
(36.2% vs 19.6%). One month following successful treatment for trichomoniasis, the number 
of women shedding HIV was reduced (although it remained significantly higher than in 
women previously uninfected by T. vaginalis). At followup visits three months after initial 
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lead to greater risk of HIV infection due to an increase of activated CD4+ T cells that can be 
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Infection with T. vaginalis leads to a local inflammatory response that includes 
chemoattractant (IL-8) and acute pro-inflammatory (TNF-α ,IL-1β, and IL-6) cytokines that 
are responsible for initiating immune response to infection and recruiting immune cells. 
Symptomatic infection is the result of a more vigorous immune response in which there is 
an increased amount of inflammation and cell recruitment. For example, in women vaginal 
discharge often contains neutrophils that respond to the presence of IL-8 (Thurman & 
Doncel, 2010). However immune response may fail to clear T. vaginalis, and does not 
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provide long term immunological memory to prevent subsequent infections. Additionally 
immune response to trichomoniasis can attract lymphocytes that are the targets of HIV 
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A powerful chemoattractant, IL-8 recruits immune cells to where they are needed to 
eliminate infection. However, it has also been shown that this cytokine can increase the 
susceptibility of monocytes, macrophages, and CD4+ T cells to HIV infection. IL-8 can also 
enhance HIV replication in infected immune cells (Narimatsu et al., 2005). 
A study using cervicovaginal lavage samples from HIV positive women who were also 
infected with T. vaginalis showed elevated levels of IL-1β. Levels of IL-1β could be 
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An in vitro study using HIV-infected peripheral blood mononuclear cells (PBMC) cultured 
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immune cells, but of using immune response to its own advantage to enhance its replication.  
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partners. A study looking at HIV positive men with genital ulcers found HIV RNA 
increased in ulcers caused by herpes simplex virus type 2 (HSV-2) only if HSV-2 was 
present in the ulcer. However, co-infection with T. vaginalis increased HIV viral load in 
ulcers regardless of the presence of HSV-2 indicating that trichomoniasis leads to increased 
shedding of HIV regardless of (or perhaps even in synergy with) other STI (Paz-Bailey et al., 
2010).  
While trichomoniasis does increase the amount of HIV viral shedding, elimination of T. 
vaginalis infection returns HIV RNA levels in the genitals to lower levels. A study in Africa 
of HIV positive women with trichomoniasis measured viral RNA at the time of trichomonal 
infection, and then 2 weeks later after treatment when infection had been resolved. There 
was a 4.2 fold decrease in the amount of HIV shed (Wang et al., 2001). Another study in 
New Orleans examined vaginal viral shedding in HIV positive women with and without 
trichomoniasis. Women with T. vaginalis infection were almost twice as likely as women 
without trichomoniasis to have detectable HIV RNA in their vaginal secretions at baseline 
(36.2% vs 19.6%). One month following successful treatment for trichomoniasis, the number 
of women shedding HIV was reduced (although it remained significantly higher than in 
women previously uninfected by T. vaginalis). At followup visits three months after initial 
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interviews there was no significant difference in the number of women shedding vaginal 
HIV between the two groups (Kissinger et al., 2009), indicating that elimination of the 
parasite removes the enhanced HIV risks associated with trichomoniasis. As T. vaginalis 
clearly has a significant impact on HIV infection, reducing incidence of trichomoniasis has 
the potential to help control the incidence and prevalence of HIV. 
6.3 Reducing T. vaginalis as a method of HIV prevention 
Trichomoniasis is clearly associated with HIV risk, the question is can reducing T. vaginalis 
infections have an impact on the incidence of HIV? A study in Tanzania showed that a 
decrease in HIV prevalence in women was accompanied by a significant decrease in 
multiple STI, particularly trichomoniasis which dropped from 21.2% to 5% incidence over 
the 3-5 year cross-sectional study. This reduction in disease burden was attributed mainly to 
changes in sexual behaviour as a result of a multi-pronged sexual health awareness 
campaign. Interestingly very little change was seen in condom use or age of first sexual 
intercourse, but a dramatic decline was seen in women reporting having engaged in casual 
sex (Msuya et al., 2007). As a women's sexual risk behaviour is correlated with the risk of 
trichomonal infection, this study suggests that protecting women from T. vaginalis could 
contribute to protecting them from HIV. Since treatment has proved to be an ineffective 
method of reducing trichomoniasis, a vaccine could provide long term for protection to 
those who are both most at risk and least able to protect themselves. 
A vaccine would also be helpful in targeting specific at risk populations. For example, black 
women have consistently been shown to have a higher incidence of trichomoniasis than 
women of other races (Shafir et al., 2009). This may be the result of sample bias, as many 
studies take place in inner-city clinics and in sub-Saharan Africa where other risk factors 
such as poverty and lack of education are also present. It could also be the result of certain 
common practices (eg. vaginal cleaning/douching), unknown biological factors, or a 
combination of factors that act synergistically to increase susceptibility to T. vaginalis 
infection. The availability of a vaccine could target protection to those with increased risk, 
while avoiding stigmatizing a specific population. As this population has also been found to 
have an increased risk of HIV infection, an single effective vaccine could potentially have a 
significant impact on the incidence of both diseases. 
HIV and the spectrum of medical issues that arise from infection are complicated issues that 
are often not well understood by either the HIV positive or the HIV negative. For example, 
many people believe if an HIV-positive person has an undetectable viral load, that they 
cannot infect anyone else. However, it has been shown that up to 33% of women with 
undetectable serum viral load continue to shed the virus in cervicovaginal secretions (Neely 
et al., 2007). Due to high rates of co-infection with T. vaginalis it is likely that a number of 
these women have or will acquire trichomoniasis. A T. vaginalis vaccine could reduce the 
burden of disease in HIV positive individuals who are at high risk to acquire trichomoniasis, 
and protect their partners from the elevated risk associated with co-infection. 
7. Conclusions 
Current methods for reducing the incidence of HIV include education and public health 
programs (providing condoms and encouraging condom use, needle exchange, etc.) and 
antiretorviral therapy (ART) to reduce HIV viral titers and minimize the risk of 
transmission. However, HIV is endemic in developing countries where obtaining resources 
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(financial, personal, etc.) and accessing (may need to travel from rural areas to cities) 
education and health programs can be difficult, potentially limiting positive impact. 
Providing ART also poses a problem in resource limited settings as it is an expensive multi-
drug cocktail and therapy is often complicated by drug interactions and toxicity, and 
adverse patient reactions. Additionally, ART is usually prescribed based on CD4+ T cell 
count, and monitoring can be difficult if patients must travel to reach a medical facility 
capable of testing (WHO, 2006). Finding simple, inexpensive alternative methods to reduce 
the transmission of HIV could help reduce dependence on ART as a means of controlling 
HIV incidence.  
Treatment of STI can be difficult for reasons beyond drug availability and efficacy and 
access to healthcare. Cultural barriers and personal beliefs can affect an individual's 
acceptance of their diagnosis and willingness to seek treatment. Limited control over one's 
sexual activity can lead to an inability to protect oneself and control sexual risk. In addition, 
some populations (eg. FSW) are at a persistently higher risk for STI and while treatment 
eliminates disease, it does not protect against subsequent infection thus will have minimal 
impact on STI incidence. The development of a T. vaginalis vaccine that could be offered as 
part of routine medical care for high risk groups could eliminate the need to seek treatment, 
reduce risk, and lower the incidence of trichomoniasis. 
T. vaginalis infection has been shown to facilitate both transmission and acquisition of HIV 
through multiple mechanisms. Many of these mechanisms have been described in vitro, but 
their exact correlation to infection is not clearly defined. The existence of a mouse model of 
T. vaginalis infection provides a powerful and relatively inexpensive tool to elucidate the 
disease mechanisms of trichomoniasis in vivo. The model also allows for the evaluation of 
immune responses to T. vaginalis infection and vaccination as a part of an approach to 
rational vaccine design. 
The actual increase in risk of acquiring HIV or infecting a sexual partner due to 
trichomoniasis is unknown. However, given that the high incidence of T. vaginalis infection 
(174 million cases annually), the fact that it is globally distributed in similar patterns to those 
of HIV, and that some populations have been found to have co-infection rates as high as 
almost 30% (Allsworth et al., 2009), even a small percentage of T. vaginalis infections leading 
to seroconversion could significantly impact the incidence of HIV. Vaccination against T. 
vaginalis offered to "core" groups that act as reservoirs of STI could have the potential to 
reduce community incidence of both trichomoniasis and HIV. Pregnant women are also 
often at increased risk of trichomoniasis due to hormonal changes. Vaccinating against T. 
vaginalis would not only prevent adverse birth outcomes associated with trichomoniasis, but 
could potentially protect against an HIV infection that could lead to maternal-child 
transmission of the virus. Thus, we suggest vaccination against T. vaginalis as an alternative 
approach to HIV control as well as for prevention of this highly prevalent STI. 
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1. Introduction 
The use of animal models in the study of human diseases is obviously important. 
Fundamental properties of the disease can be investigated analytically and thoroughly by 
this approach, contributing much to the progress of basic science as well as clinical medicine 
(Nomaguchi & Adachi, 2010). Researchers in various specialties, therefore, have made every 
effort to establish animal models for human diseases including those caused by infectious 
agents. Acquired immunodeficiency syndrome (AIDS) of humans has long been one of the 
major targets for the model study in appropriate animals. However, human 
immunodeficiency virus type 1 (HIV-1) itself, the predominant causative virus of human 
AIDS, can not be used due to its very narrow host range. Because HIV-1 has adapted itself 
dexterously from the ancestral virus to replicate, persist and spread strictly in humans, it is 
very unique among various primate immunodeficiency viruses and no good counterparts 
are available in nature (Desrosiers, 2007; Kirchhoff, 2009; Sauter et al., 2009). Therefore, it 
can be concluded that practical and meaningful animal systems of non-alternative nature for 
HIV-1 study do not exist at all to date, although there are pre-existing animal models of 
some significance. 
HIV-1 does not replicate in animal species except for chimpanzees and humans (Nomaguchi 
et al., 2008a). Animals frequently used for our experiments on virology, such as rodents and 
nonhuman primates, are not exceptions to this barrier. However, if we are to search for, 
develop and establish a fruitful animal model system for HIV-1 research, nonhuman 
primates are considered to be most suited, for HIV-1 is best fitted with humans and some 
apes. Ever since the discovery of HIV-1 (Barre-Sinoussi et al., 1983), many prominent 
researchers keen on understanding its biology and molecular biology have done 
investigations extensively to elucidate the bases underlying the species-specificity unique to 
HIV-1. These studies have highlighted the presence of potent anti-HIV-1 factors in 
nonhuman cells that efficiently restrict or even abolish the replication of HIV-1 and 
successfully raised an epoch-making notion of the intrinsic immunity (Andrew & Strebel, 
2010; Arhel & Kirchhoff, 2010; Ayinde et al., 2010; Bergamaschi & Pancino, 2010; Douglas et 
al., 2010; Fujita et al., 2010; Huthoff & Towers, 2008; Kirchhoff, 2010; Luban, 2007; Malim & 
Emerman, 2008; Nakayama & Shioda, 2010; Nomaguchi et al., 2008a, 2008b; Planelles & 
Barker, 2010; Sauter et al., 2010; Strebel et al., 2009; Towers, 2007). Cellular factors shoulder 
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this intrinsic immunity known to date are cyclophilin A (CypA) (Franke et al., 1994; Thali et 
al., 1994), apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G 
(APOBEC3G)/APOBEC3F (Sheehy et al., 2002), tripartite motif protein 5 (TRIM5) 
(Stremlau et al., 2004), TRIMCyp (Nisole et al., 2004; Sayah et al., 2004), and tetherin 
(alternatively called BST-2) (Neil et al., 2008; Van Damme et al., 2008). Because HIV-1 can 
indeed counteract human orthologs of these restriction factors effectively, it is well 
anticipated that HIV-1 in turn can be genetically engineered to replicate efficiently in 
nonhuman primates such as macaques. Nonetheless, most likely due to the lack of extensive 
and appropriate biological studies, we are still forced to use macaque-derived simian 
immunodeficiency virus (SIVmac) or SIVmac chimeric with a small portion of HIV-1 (SHIV) 
as an input virus for in vivo model studies in macaques. SIVmac and SHIV are genetically 
and biologically distinct from HIV-1 in a number of critical points, albeit they are quite 
similar to HIV-1 in the genome organization and pathogenic potentials (Desrosiers, 2007; 
Freed & Martin, 2007). They might not be used for future model studies aimed at 
understanding the biology of HIV-1 as a highly replicable/mutable, persistent, and 
pathogenic virus. We must go behind the outward form to grasp the inner meaning of the 
phenomenon, i.e., the species-specificity. 
On the collective basis of molecular and biochemical studies performed by us and others so 
far, we recently have constructed a series of HIV-1 derivative clones tropic for macaque cells 
and/or macaques (Hatcho et al., 2008; Igarashi et al., 2007; Kamada et al., 2006, 2009; 
Kuroishi et al., 2009; Nomaguchi et al., 2008a; Saito et al., 2011; Yamashita et al., 2008), and 
are currently further modifying them for in vivo studies (our unpublished results). The 
viruses we have generated carry a minimal sequence of SIVmac, and overcome at least some 
species barriers. Importantly, these viruses are regarded to be genetically HIV-1, since they 
have less than 10% SIVmac genetic content (Igarashi et al., 2007). While we firmly believe 
that HIV-1 derivative viruses already constructed in our laboratory are useful for a variety 
of studies on HIV-1 infection in individuals, further improvement of the viruses by 
deliberating the evolutional process of SIV/HIV would surely add more scientific 
significance to basic and applied research fields. Needless to say, our goal is to generate a 
macaque-tropic HIV-1 (HIV-1mt) that replicates efficiently and is pathogenic for macaques 
as a standard pathogenic SIVmac clone such as SIVmac239 (Kestler et al., 1990). Through 
construction and biochemical/biological characterization of the ideal HIV-1mt clone with 
ability to induce AIDS at least in some species of macaques, we would be able to clarify the 
detailed molecular mechanisms for the narrow host range (species-tropism) of HIV-1. Viral 
Gag-capsid (CA) and accessory proteins (Vif, Vpx, Vpr, Vpu and Nef) are targets for those 
studies as a matter of course. Moreover, by using this persistent and pathogenic HIV-1mt 
clone as a seed virus for macaque infection experiments, we can trace and analyze its 
mutation, adaptation, evolutional direction to generate viral quasi-species, and finally 
pathogenesis in the context of immunological interaction. In addition, we can evaluate and 
develop the anti-HIV-1 drugs/vaccines by this HIV-1mt/macaque system. 
In this chapter, we first outline the early and current studies on HIV-1, SIVmac and SHIV to 
emphasize and address the unique characteristics of HIV-1 and scientific issues to resolve. 
We then describe viral and cellular factors that are responsible for or potentially associated 
with restriction of viral replication. We finally focus on our recent studies on the strategies 
to obtain HIV-1mt clones and on the biology/molecular biology of HIV-1mt clones. Main 
parts of this chapter consist of: (i) Overview of the biology and molecular biology of HIV-1, 
SIVmac and SHIV; (ii) Determinants for HIV-1 species-tropism; (iii) Generation and 
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characterization of various HIV-1mt clones. The primary mission of we basic virologists is to 
understand viral replication and viral pathogenesis in vivo by multilateral approaches 
(Nomaguchi & Adachi, 2010). We then take over our new important findings to functional 
parties in related fields, thus promoting further progress in virology.  
2. Overview of the biology and molecular biology of HIV-1, SIVmac and SHIV 
Numerous immunodeficiency viruses of distinct groups have been isolated from humans 
and a wide variety of African nonhuman primates (Desrosiers, 2007; Freed & Martin, 2007). 
These viruses infect the immune system of primates, kill cells that are critical for effective 
immune responses, and eventually cause AIDS in some hosts (Desrosiers, 2007; Kuritzkes & 
Walker, 2007). Soon after the discovery in 1983 (Barre-Sinoussi et al., 1983; Barre-Sinoussi, 
2010; Montagnier, 2010), HIV-1 was demonstrated to belong to a lentiviral genus of the 
retrovirus family, and expected to exhibit the properties characteristic of the family (Goff, 
2007). In 1986, another human immunodeficiency virus was identified and designated HIV-
2 (Clavel et al., 1986; Montagnier, 2010). Among these primate lentiviruses, HIV-1, HIV-2 
and its close relative SIVmac are most well-studied through biological, biochemical and 
medical approaches, and many findings crucial for the biological and medical sciences have 
been generated (Ho & Bieniasz, 2008). 
Basically, HIV/SIV exhibit a virological phenotype common to the retroviruses. Viral 
proteins are synthesized from viral DNA genome integrated into host chromosomal DNA, 
and progeny viral particles (virions) are produced from cells in a typical manner. However, 
HIV/SIV are unique, as primate lentiviruses, in the genome and virion composition among 
the retroviruses (Fig. 1). They all have additional genes relative to a standard retrovirus. 
Importantly, these extra genes encode, in addition to structural Gag, Pol and Env proteins 
common to all retroviruses, viral regulatory (Tat and Rev) and accessory proteins that are 
essential for the specific and unique characteristics of HIV/SIV. HIV/SIV virions, therefore, 
contain some viral proteins not found in the other retroviral virions. The common and 
unique properties are also applicable to their replication cycle. HIV/SIV replicate in their 
target cells essentially in the same way with the other retroviruses. Retroviral replication 
cycle consists of early and late phases. The early phase (Fig. 2) begins with the virion entry 
step into cells, and proceeds to the reverse transcription of viral RNA genome, uncoating, 
nuclear import of viral DNA genome, and integration of viral DNA genome into host DNA 
to generate proviral DNA. The late phase (Fig. 3) then starts with the proviral transcription, 
and proceeds to the viral RNA export to cytoplasm, translation into viral proteins, assembly 
of the viral RNA/proteins at cell surface, budding/release from cells, and maturation into 
infectious virions.  
Of viral proteins unique to HIV/SIV, Tat and Rev are essential for virus replication as is the 
case for structural proteins Gag, Pol, and Env, and act as regulators for expression of the 
other viral proteins (Freed & Martin, 2007). Tat is a potent trans-activator of transcription, 
and is the primary switch of viral gene expression. Rev is responsible for the viral RNA 
export process, and required for expression of viral structural proteins and most of the 
accessory proteins except for Nef. Thus, Rev can be considered to be the second expression 
switch. In contrast to the two regulatory proteins, accessory proteins are not always 
necessary for viral replication in cells (Freed & Martin, 2007). Early studies indicated that 
these proteins are unnecessary or dispensable for virus replication in the established cell 
lines. However, it was soon noticed that, in the primary natural target cells such as CD4-
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proteins are essential or important for virus replication. These findings have led to the 
identification of innate anti-viral factors APOBEC proteins (Sheehy et al., 2002) and tetherin 
as described above (Neil et al., 2008; Van Damme et al., 2008), and to the search for an anti-
viral macrophage factor(s) (Fujita et al., 2010). Although some aspects of the accessory 
proteins are becoming more organized and much clearer than before as summarized in 
Table 1, detailed mechanisms for their activity remain to be elucidated. In particular, much 
is still unknown about structurally related Vpr and Vpx proteins. Moreover, functional 
studies in animals on HIV-1 and HIV-2 accessory proteins have not yet been performed. 
 
 
Fig. 1. Genome and virion characteristics of HIV/SIV. Upper: Proviral genome structure is 
schematically shown. Blue, orange, pink areas (boxes) indicate the structural, regulatory and 
accessory genes, respectively. Accessory genes unique to HIV-1 (vpu) and HIV-2/SIVmac 
(vpx) are indicated by yellow and purple, respectively. LTR, long terminal repeat. Lower: A 
schema of viral particle (virion). Viral proteins reported to be present in virion are 
illustrated. CA, capsid; IN, integrase; MA, matrix; NC, nucleocapsid; PR, protease; RT, 
reverse transcriptase; SU, surface; TM, transmembrane. 
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Fig. 2. The early phase of HIV/SIV replication cycle in target cells. Viral replication steps 
from the binding to generation of provirus are shown. Viral and cellular proteins 
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is still unknown about structurally related Vpr and Vpx proteins. Moreover, functional 
studies in animals on HIV-1 and HIV-2 accessory proteins have not yet been performed. 
 
 
Fig. 1. Genome and virion characteristics of HIV/SIV. Upper: Proviral genome structure is 
schematically shown. Blue, orange, pink areas (boxes) indicate the structural, regulatory and 
accessory genes, respectively. Accessory genes unique to HIV-1 (vpu) and HIV-2/SIVmac 
(vpx) are indicated by yellow and purple, respectively. LTR, long terminal repeat. Lower: A 
schema of viral particle (virion). Viral proteins reported to be present in virion are 
illustrated. CA, capsid; IN, integrase; MA, matrix; NC, nucleocapsid; PR, protease; RT, 
reverse transcriptase; SU, surface; TM, transmembrane. 
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Fig. 2. The early phase of HIV/SIV replication cycle in target cells. Viral replication steps 
from the binding to generation of provirus are shown. Viral and cellular proteins 







Fig. 3. The late phase of HIV/SIV replication cycle in target cells. Viral replication steps from 
the transcription of proviral genome to maturation are shown. Viral and cellular proteins 
particularly important in this chapter are highlighted. For details, see the reference (Freed & 
Martin, 2007). 
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Degradation of tetherin 
Degradation of newly synthesized CD4 
in ER 
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Down-regulation of cell surface 
molecules (CD4, MHC-I etc.) 
Enhancement of viral infectivity 
Kirchhoff et al., 2008 
Kirchhoff, 2009 
Jere et al., 2009 
Table 1. Multi-functional activity of HIV/SIVmac accessory proteins. Major functions or 
activities are listed. For details, refer to the articles shown. ER, endoplasmic reticulum; 
MHC, major histocompatibility complex. 
One of the most outstanding biological properties of HIV-1 is its especially narrow host 
range. It was recognized soon after the virus isolation that HIV-1 can not infect macaque 
cells and macaques, animals frequently used for experimental infection. We, therefore, 
pioneered the work to determine viral determinants for this species-tropism by construction 
and characterization of chimeric viruses between SIVmac and HIV-1 (Nomaguchi et al., 
2008; Sakuragi et al., 1992; Shibata et al., 1991, 1995; Shibata & Adachi, 1992). SIVmac has a 
wider host range relative to HIV-1, and can efficiently replicate both in macaque and human 
cells. The chimeric viruses (Fig. 4), later called SHIV, were useful to localize the viral genetic 
area responsible for the tropism. Among NM-1, NM-3, and NM-8 in Fig.4, only NM-3 was 
shown to display infectivity to macaque cells. In addition, Gag-CA region was suggested to 
be important for the tropism by a similar analysis of chimeric viruses (Dorfman & 
Gottlinger, 1996). Totally, these SHIV studies revealed that Gag-CA plus some viral 
protein(s) encoded by the central viral genomic region may determine the HIV-1 species-
tropism.  
As for input viruses of model infection studies in macaques, SIVmac and SHIVs have been 
widely and frequently used (Ambrose et al., 2007; Nomaguchi et al., 2008). SIVmac is 
thought to emerge by a cross-species infection of rhesus macaques with SIVsmm naturally 
occurring in African sooty mangabeys (Fultz et al., 1986; Murphey-Corb et al., 1986). It 
targets CD4-positive cells such as T-lymphocytes and macrophages, persists, and finally 
cause AIDS in rhesus macaques. Pathogenic SHIVs have been obtained from the original 
prototype SHIV by serial animal passages, and were used for infection experiments in 
rhesus macaques. An SIVmac derivative that has reverse transcriptase (RT) of HIV-1 (RT-
SHIV) (Fig. 4) was also constructed to test the effect of anti-RT drugs on virus replication 
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including the assessment of immune response, evaluation of anti-viral drugs, analysis of 
drug-resistance, and establishing the strategy for vaccine development, there are some 
intrinsic differences among important virological properties of HIV-1, SIVmac and SHIVs as 
summalized in Table 2. These should be seriously considered for the future model studies. 
To underscore the essential need for the suitable primate model research to answer basic 
questions about HIV-1 in vivo, we wish to mention here, as an example, that the trials to 
develop anti-viral vaccines have been unsuccessful due to the lack of appropriate models 
(Hayden, 2008; Watkins et al., 2008).  
 
 
Fig. 4. Genome organization of HIV/SIV and representative SHIVs. Proviral genome 
structure is schematically shown. White and blue areas (boxes) indicate the genes and LTR 
of HIV-1 NL4-3 (Adachi et al., 1986) and SIVmac MA239 (Shibata et al., 1991), respectively. 
Areas without gene names indicate that the genes there are inactivated by genetic 
manipulations. 
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3. Determinants for HIV-1 species-tropism 
Our early studies on systematic analysis of HIV-1 proviral mutants by site-directed 
mutagenesis have clearly demonstrated the cell-dependent functionality of some viral 
proteins (Gag-CA, Vif, Vpu, and Vpx) and the cell-dependent viral replication (Adachi et al., 
1999; Kawamura et al., 1994b, 1998; Sakai et al., 1993, 1995; Sakuragi et al., 1995). These 
results have strongly suggested the presence of specific intracellular factors, other than 
receptor molecules for viruses, responsible for viral cellular tropism. Importantly, restriction 
factors against HIV-1 (APOBEC3/Vif, TRIM5/Gag-CA, and tetherin/Vpu) have been 
recently identified and molecularly cloned (Neil et al., 2008; Sheehy et al., 2002; Stremlau et 
al., 2004; Van Damme et al., 2008). Furthermore, a new restriction factor functional in 
macrophages and antagonized by Vpx has been proposed (Fujita et al., 2008; Fujita et al., 
2010; Sharova et al., 2008; Srivastava et al., 2008). Taken altogether, these findings have 
prompted active researchers to examine whether these cellular proteins are associated with 
the HIV-1 species-tropism. As results of a series of comparative biological and biochemical 
studies on the interaction between HIV/SIV and human/monkey restriction factors, it has 
been revealed that various species-specific cellular proteins in Table 3 determine or 
modulate the species-tropism of HIV-1. As can be understood in Table 3, viral accessory 
proteins Vif, Vpu, Vpx (and/or Vpr), and Nef (in the case of some SIVs) play significant 
roles (Tables 1 and 2) against the restriction factors present in host cells (Malim & Emerman,  
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Suppression of uncoating / 
reverse transcription 
Table 3. Restriction factors against HIV-1. Cellular anti-HIV-1 factors identified and one of 
potential anti-viral factors are listed. As for the details of restriction factors of these two 
categories, see the text. 
2008). It is well-predicted that primate immunodeficiency viruses now have evolved by 
acquiring the appropriate accessory genes through numerous mutations and recombinations 
(Kirchhoff, 2009, 2010; Sauter et al., 2009, 2010). Among viral structural proteins, only Gag-
CA, which constitutes a major virion component, appears to be deeply involved in the 
species-tropism of HIV-1. By adapting Gag-CA and accessory proteins to the hostile 
environment, HIV/SIV could spread, persist, and survive. In this regard, HIV-1 has 
developed its specific characteristics from the progenitor form, and may be still uniquely 
altering its virological property through multiple rounds of the infection cycle in human 
populations.  
3.1 Vif and APOBEC3G/F 
Accessory protein Vif (Table 1) is essential for HIV/SIV replication in certain cell types such as 
natural target cells (T-lymphocytes and macrophages) that express APOBEC3G/APOBEC3F. 
APOBEC3G/F are members of a polynucleotide cytidine deaminase family that displays 
Macaque-Tropic HIV-1 Derivatives: 
A Novel Experimental Approach to Understand Viral Replication and Evolution In Vivo 
 
335 
diverse functions (Holmes et al., 2007), and are potent inhibitors of viral replication 
counteracted by Vif. Vif degrades APOBEC3G/F via the ubiquitin-proteasome pathway (Table 
1 and Fig. 3). In the absence of Vif, APOBEC3G/F are incorporated into virions, and cause 
lethal mutations in viral genome during the reverse transcription process in a new infection 
cycle (Table 3). There are two functional domains in Vif, that is, N-terminal binding region to 
APOBEC proteins and C-terminal region for degradation (Strebel et al., 2009). Noteworthy, 
HIV-1 Vif does not degrade APOBEC3Gs of the rhesus macaque and African green monkey 
probably due to its inability to binding to them. In contrast, SIVmac Vif can inactivate both 
human and simian APOBEC3Gs. Thus, the interaction of Vif and APOBEC3G/F is critically 
important for the unique species-tropism of HIV-1. In our experience, APOBEC3G/F is the 
strongest determinant for this tropism among the restriction factors listed in Table 3. Whether 
another activity of Vif to induce G2 cell cycle arrest (Izumi, T., 2010) (Table 1) is involved in the 
species-tropism is presently unknown. 
3.2 Gag-CA and its interacting cellular proteins (CypA, TRIM5 and TRIMCyp) 
Early studies have already indicated that Gag-CA is responsible for the HIV-1 species-
tropism as described above (Shibata et al., 1991; Dorfman & Gottlinger, 1996). Recent works 
have focused on the interaction of Gag-CA and its counterpart (CypA, TRIM5 and a 
TRIM5/CypA fusion protein, TRIMCyp). It is well-established now that CypA, TRIM5 
and TRIMCyp act as an inhibitor of HIV-1 replication in a species-specific manner (Lim et 
al., 2010; Luban, 2007; Nakayama & Shioda, 2010; Price et al., 2009; Towers, 2007; Ylinen, 
2010). These cellular proteins exert their anti-viral powers on the incoming virion core in a 
poorly defined way (Table 3 and Fig. 2). Of note, CypA positively and negatively regulates 
HIV-1 replication in human and macaque cells, respectively. Importantly, rhesus TRIM5, 
cynomolgus TRIM5 and cynomolgus TRIMCyp effectively inhibit HIV-1 replication, but 
not rhesus TRIMCyp. Therefore, CypA, TRIM5 and TRIMCyp can determine the unique 
species-tropism of HIV-1. We estimate that Gag-CA is the second strongest determinant for 
the tropism. It should be stressed here that the polymorphism observed in TRIM5 alleles 
affects the sensitivity of hosts to virus infection.  
3.3 Vpu and tetherin 
Accessory protein Vpu (Table 1) is required for optimal replication of HIV-1 in certain cell 
types that express tetherin. Tetherin specifically inhibits the virion release from cells (Table 
3) and is countered by Vpu (Nomaguchi et al. 2008b; Strebel et al., 2009). Vpu degrades 
cellular tetherin and CD4 effectively. It is generally accepted that Vpu enhances virion 
release from the cell surface by down-regulation of tetherin (Table1, Table 2 and Fig.3), and 
thereby promote viral replication. However, Vpu proteins of HIV-1 and some SIVs can not 
efficiently antagonize simian tetherin molecules relative to those of SIVs with a high ability 
(Sauter et al, 2009). In fact, HIV-1 NL4-3 scarcely suppressed the anti-viral activity of the 
rhesus tetherin. Based on this finding, it can be concluded that tetherin is associated with the 
species-tropism of HIV-1. However, in our experience, the positive effect of Vpu on viral 
replication is much smaller than those of Vif and Gag-CA. Moreover, another functional 
activity of Vpu to degrade cellular CD4 is considered to be irrelevant to the HIV-1 species-
tropism. Whether Vpu is associated with the HIV-1 pathogenesis is an important question to 
address. Interestingly and importantly, Env of some HIV-2 isolates and Nef of some SIVs 
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3.4 Potential determinants for HIV-1 species-tropism 
It has been recently reported that HIV-2/SIVmac Vpx is necessary for the post-entry step of 
viral replication, such as uncoating/reverse transcription, in monocyte-derived dendritic 
cells and macrophages (Fujita et al., 2008; Goujon et al., 2007; Srivastava et al., 2008). Vpx is 
supposed to counter an unidentified anti-retroviral factor(s) present in cells of this lineage 
(Tables 1-3 and Fig. 2). Because Vpx can also up-regulate the HIV-1 replication, the 
unidentified macrophage factor appears to be commonly important for HIV/SIV replication. 
To substantiate the macrophage entity as a restriction factor against HIV/SIV and/or the 
other retroviruses, its identification is urgently required.  
During a systemic characterization of HIV-1mt CA mutants, we have noticed a TRIM5-
independent enhancement of viral infectivity in macaque cells (Nomaguchi et al., 
manuscript in preparation). This result suggests the presence of unknown anti-viral factor 
that interact with HIV-1 Gag-CA. We also have found a mutation in the Env-SU region that 
confers the mutant a significant affinity to macaque CD4, considerably promoting virus 
replication (Nomaguchi et al., manuscript in preparation). These observations may be 
relevant to the HIV-1 species-tropism.  
4. Generation and characterization of various HIV-1mt clones 
To obtain a novel class of HIV-1 that infects, replicates and finally causes AIDS in macaques, 
we and a research group in USA have independently initiated the work on HIV-1mt and 
have done macaque model studies (Hatcho et al., 2008; Hatziioannou, 2006, 2009; Igarashi et 
al., 2007; Kamada et al., 2006, 2009; Kuroishi et al., 2009; Nomaguchi et al., 2008a; Saito et al., 
2011; Yamashita et al., 2008). Another group has published a report on HIV-1mt derivatives 
very recently (Thippeshappa et al., 2011). We now are actively and thoroughly amending 
the HIV-1mt genome by computer-assisted and structure-guided mutagenesis.  
Our prototype HIV-1mt designated NL-DT5R (Kamada et al., 2006) contains a 21-nucleotide 
SIVmac Gag-CA element (corresponding to the HIV-1 CypA-binding loop) and the entire 
SIVmac vif gene inserted into the genetic background of HIV-1 NL4-3 (Adachi et al., 1986). 
From this clone, we have systemically generated a series of HIV-1mt clones as shown in Fig. 
5. Because CCR5-tropic (R5) viruses of HIV-1 are thought to be clinically more important 
than CXCR4-tropic (X4) viruses, we have constructed two sets of HIV-1mt clones. Our 
strategy for generation of HIV-1mt clones pathogenic for macaques are as follows: (i) 
Adaptation of viruses in macaque cells. Targets for infection are cynomolgus and rhesus 
macaque lymphocyte cell lines immortalized by Herpesvirus saimiri (HVS) (Table 4).; (ii) In 
vitro mutagenesis of the clones based on bioinformatics. With the aid of the computational 
sciences, new viral genome sequences are designed.; (iii) Selection of appropriate clones by 
their replication kinetics in macaque lymphocyte cell lines in Table 4. Viruses which 
replicates similarly with or more robustly than SIVmac239 in cynomolgus and rhesus 
peripheral blood mononuclear cells are then chosen. On the basis of this strategy, we have 
successfully obtained a number of new generations with increasing ability to replicate from 
the original prototype NL-DT5R (see below). However, so far, none of the HIV-1mt clones 
tested are pathogenic for macaques (pig-tailed and cynomolgus) (Igarashi et al., 2007; 
Nomaguchi et al., manuscript in preparation; Saito et al., 2011), although they all can 
replicate in the monkeys. The newest clones in Fig. 5 (MN4Rh-3V and MN5Rh-3V), which 
replicate best in macaque cells among our HIV-1mt clones, have not yet been examined for 
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their pathogenicity. It should be mentioned here that the replication potentials of the HIV-




Fig. 5. Genome organization of HIV/SIV and various clones of HIV-1mt. Proviral genome 
structure is schematically shown. Blue, white and pink areas (boxes) indicate the genes and 
LTR of SIVmac MA239 (Shibata et al., 1991), X4-tropic HIV-1 NL4-3 (Adachi et al., 1986) and 
R5-tropic HIV-1 NF462 (Kawamura et al., 1994a), respectively. HIV-1mt clones on the left 
and right are X4 and R5 viruses, respectively. Arrows indicate the site of each single/double 
nucleotide-mutation introduced (Nomaguchi et al., manuscripts in preparation). There are 
several single-nucleotide mutations in the green area of Gag-CA (Nomaguchi et al., 
unpublished). h6/7L, Loop between helices 6 and 7.  
In parallel with the generation and characterization of a series of HIV-1 mt clones, we have 
searched for and established macaque cell lines suitable for our projects. Table 4 lists the cell 
lines we routinely use now. Since the lymphocyte cell lines immortalized by HVS do not 
lose their original characteristics as primary lymphocytes in most cases and are readily 
maintained for experiments, to biologically characterize viruses like HIV-1, it is quite 
important for laboratory researchers to have HVS-immortalized cell lines. In our laboratory, 
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replicate best in macaque cells among our HIV-1mt clones, have not yet been examined for 
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their pathogenicity. It should be mentioned here that the replication potentials of the HIV-




Fig. 5. Genome organization of HIV/SIV and various clones of HIV-1mt. Proviral genome 
structure is schematically shown. Blue, white and pink areas (boxes) indicate the genes and 
LTR of SIVmac MA239 (Shibata et al., 1991), X4-tropic HIV-1 NL4-3 (Adachi et al., 1986) and 
R5-tropic HIV-1 NF462 (Kawamura et al., 1994a), respectively. HIV-1mt clones on the left 
and right are X4 and R5 viruses, respectively. Arrows indicate the site of each single/double 
nucleotide-mutation introduced (Nomaguchi et al., manuscripts in preparation). There are 
several single-nucleotide mutations in the green area of Gag-CA (Nomaguchi et al., 
unpublished). h6/7L, Loop between helices 6 and 7.  
In parallel with the generation and characterization of a series of HIV-1 mt clones, we have 
searched for and established macaque cell lines suitable for our projects. Table 4 lists the cell 
lines we routinely use now. Since the lymphocyte cell lines immortalized by HVS do not 
lose their original characteristics as primary lymphocytes in most cases and are readily 
maintained for experiments, to biologically characterize viruses like HIV-1, it is quite 
important for laboratory researchers to have HVS-immortalized cell lines. In our laboratory, 





cell lines are chosen as targets for virus infection, and frequently used. HSC-F cells are very 
sensitive to HIV-1mt and SIVmac clones, and produce a large amount of progeny viruses 
after infection. M1.3S cells are quite resistant to HIV-1mt and SIVmac clones, and are 
appropriate for selection of highly replicable and potentially pathogenic viruses. Because we 
are interested in analyzing the species-tropism of HIV-1, we need to have various target cell 
lines of human and simian origins with a unique property. Monolayer cell lines of 
cynomolgus MK.P3 (F) and rhesus LLC-MK2 are easily used for transfection experiments 
and for monitoring the single-cycle viral infectivity assays. In fact, we have differentially 
and successfully used the cell lines in Table 4 depending on the purpose of each project.  
 
Macaques Cell lines Origins TRIM5 alleles 
Cynomolgus HSC-F lymphocyte TRIM5 and TRIMCyp
 MK.P3 (F) kidney TRIM5 and TRIMCyp
Rhesus HSR1.4 lymphocyte Mamu-3 and Mamu-4
 HSR5.4 lymphocyte Mamu-7 
 M1.3S lymphocyte Mamu-1 and Mamu-3
 LLC-MK2 kidney Mamu-1 and Mamu-7
Table 4. Cell lines for virological evaluation of HIV-1mt. TRIM5 alleles of the cell lines listed 
have been determined in our laboratory (Doi et al., 2010; our unpublished results). For the 
polymorphism of TRIM5 alleles, see the references (Newman et al., 2006; Virgen et al., 2008; 
Wilson et al., 2008). 
We have repeatedly examined the replication kinetics of HIV-1mt clones in various macaque 
cell lines. Fig. 6 shows the typical kinetics (a schema) based on the results from our 
numerous infection experiments. In highly sensitive HSC-F cells, all the viruses do replicate 
to distinct extents. As is clear, MN4Rh-3V and MN5Rh-3V replicate most robustly among 
HIV-1mt clones. In relatively resistant M1.3S cells, three clones do replicate but the others 
do not. In both cell lines, SIVmac239 (MA239N) (Doi et al., 2010) displays the best potential 
to replicate. These results indicate that we still need to improve MN4Rh-3V and MN5Rh-3V 
to obtain the ideal clone, the pathogenic HIV-1mt. In this situation, there are two directions. 
These are the selection of host macaques susceptible to the currently available clones and the 
further efforts to obtain the desired clones. First, pig-tailed and/or the other macaque 
species sensitive to the viruses can be selected by their TRIM5 alleles (Newman et al., 2006; 
Virgen et al., 2008; Wilson et al., 2008), and used for infection. Indeed, American research 
groups have adopted this strategy using the pig-tailed macaques/variants of simian-tropic 
(st) HIV-1 with a vif-substitution only (Hatziioannou et al., 2009; Thippeshappa et al., 2011). 
However, we very much prefer to take the second possibility. Through this approach, we 
would be able to better understand the molecular mechanism underlying various events 
between the pathogen and host. Furthermore, if one is interested in the studies to analyze 
the mutations, adaptations, and evolution of the pathogen, the pressure-giving environment 
(Malim & Emerman, 2008), i.e., natural hosts having a wide variety of restriction factors, 
would be much better. Of a particular note, pig-tailed monkeys infected with various st 
HIV-1s have not yet develop AIDS (Igarashi et al., 2007; Hatziioannou et al., 2009; 
Thippeshappa et al., 2011). 
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Fig. 6. Schematic representation of replication kinetics of various viral clones. A schema of 
replication kinetics is illustrated. Molecular proviral clones for study are shown on the right. 
Routinely, cell-free virus samples are prepared by transfection of proviral clones into 293T 
cells (Kamada et al., 2006), and viruses produced in cells of equal RT units are inoculated 
into HSC-F and M1.3S cells (Table 4). After infection, viral replication is monitored at 
intervals by RT activity in the culture supernatants. 
5. Conclusion 
We have described the generation of CXCR4-tropic and CCR5-tropic HIV-1 clones with 
macaque cell-tropism (HIV-1mt) in this chapter. The best X4 and R5 viruses we have now 
replicate comparably with a standard SIVmac clone in macaque cells, although their 
pathogenicity for macaques needs to be determined. The genomes of these HIV-1 mt clones 
contain the entire vif gene of SIVmac, some nucleotide substitutions in the gag gene to give a 
small number of mutated amino acids, two adaptive mutations in the pol gene, and one 
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For the moment, our goal is to have the HIV-1mt clones pathogenic for cynomolgus and/or 
rhesus macaques with the aid of computational sciences. The clones are expected to have the 
HIV-1-derived or closely related accessory genes except for the vif gene. With these ideal 
HIV-1mt clones, we would be able to authentically investigate the HIV-1/host interaction 
including: (i) viral replication in individuals; (ii) viral pathogenesis; (iii) viral 
mutations/adaptations/evolution. Once these clones are available, a wide variety of basic 
and clinical studies would be initiated otherwise impossible. 
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1. Introduction 
Development of a small animal model to study human immunodeficiency virus type-1 
(HIV-1) infection began with the discovery of the disease itself. Such a model would 
significantly facilitate studies of disease pathogenesis, vaccine and anti-viral drug 
development and testing. However, HIV-1 replication is subject to a number of species-
specific restrictions at the level of cellular entry and/or post-entry. Although many attempts 
to develop a model that can overcome these cellular restrictions have been attempted, no 
satisfactory small animal model for HIV-1 infection has been identified to date.  
The cotton rat has been a superb model for human infectious diseases. This “new world” 
wild rodent, that is now highly inbred, was shown to be susceptible to an extraordinary 
spectrum of human pathogens, particularly viruses. Importantly, it was shown by two 
different laboratories that cotton rats can be infected with the Human Immunodeficiency 
Virus (HIV-1), and that virus can be detected long after infection and antibodies are 
generated against viral proteins. In more recent studies, cotton rat cells were made 
permissive to HIV infection by engineering the expression of human co-receptors for HIV-1, 
supporting HIV-1 infection, DNA integration, and more importantly, production of infective 
HIV particles.  
Importantly, the cotton rat is susceptible to other two pathogens that are extraordinarily 
associated with HIV-AIDS, Mycobacterium tuberculosis (TB) and herpes simplex virus (HSV). 
We will review previous attempts to develop a small animal model for HIV infection and 
explore the scientific and commercial significance of developing such a model. We will 
describe the cotton rat model of HIV, TB, HSV as they stand today. Finally, we will describe 
recent advances in the production of transgenic cotton rats that express HIV receptor 
molecules. 
2. Animal models for HIV-1 
The total number of Human Immunodeficiency Virus (HIV)-infected people worldwide is 
estimated at 40 million (and 600 new infections per hour). Preventive vaccine and 
prophylactic therapies against HIV infection and more efficient drugs for AIDS are not only 
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translational HIV research rests in the absence of inexpensive and efficient pre-clinical trial 
models. 
Several animal models for HIV-1 infection have been useful, adding complementary 
information for specific aspects of HIV-1 disease in humans. Limitations of the current 
models include the limited availability and high cost (non-human primates), absence of or 
delay in an acquired immunodeficiency syndrome (AIDS), lack of viremia, and 
permissiveness only to related retroviruses. These models include human HIV-1 in 
chimpanzees, macaques, mice, rats, rabbits, and Simian HIV in several species of monkeys 
(Cohen, 2001; Nath, Schumann, and Boyer, 2000; van Maanen and Sutton, 2003). 
HIV-1 replication is subject to a series of species-specific restrictions in cells of non-primate 
species. Binding of HIV-1 envelope protein (Env) to both CD4 and the appropriate member 
of the seven-transmembrane G-protein-coupled receptor superfamily are necessary for 
efficient entry of HIV-1 (Berger, Murphy, and Farber, 1999; Deng et al., 1996). Several 
different chemokine receptors (CCR2b, CCR3, CCR5, or CXCR4) or orphan chemokine 
receptor-like molecules (STRL33, GPR1, GPR15, V28, APJ) may participate in HIV-1 entry, 
but hCXCR4 and hCCR5 are the principal co-receptors for X4 (T-cell line-tropic) or R5 
(macrophage-tropic) isolates, respectively. Blocking and down-regulation of these two 
cytokine receptors are ways by which their physiological ligands or modified analogues can 
reduce HIV-1 entry (Stantchev and Broder, 2001). 
One approach for developing animal models in laboratory rodents has been to identify and 
then overcome specie-specific barriers that HIV encounters during its replication. The 
ultimate goal is to use the knowledge to develop an immunocompetent transgenic small 
animal model that is fully permissive to HIV replication. The barriers that stall replication in 
mouse and rat cells have been studied. Mice that express hCD4 and hCCR5 or hCXCR4 were 
first developed (Browning et al., 1997; Sawada et al., 1998). Preliminary results with these 
mice were initially exciting because the expression of the transgenes promoted viral entry, 
but were ultimately disappointing because the mice did not support viral replication 
(Browning et al., 1997). These results were partly explained by differences between the 
human and the mouse cyclin T1 (CycT1), which is an important cellular component of the p-
TEFb transcription factor complex that is responsible for transcription from the viral long 
terminal repeat (HIV-LTR) (Garber et al., 1998; Wei et al., 1998). Recent studies indicate 
additional restrictions in mouse cells. Transgenic mice expressing human cyclin T1, human 
CD4, and the human chemokine receptor failed to produce high levels of HIV (Garber et al., 
1998; Mariani et al., 2001) and other downstream elements like the maturation of the gag 
protein to produce p24 were also shown to be compromised in mouse cells (Mariani et al., 
2001). These post-transcriptional defects result in a dramatically reduced yield of infectious 
virus (up to 10,000-fold) in a single cycle of HIV replication, as compared to human cells 
(Bieniasz and Cullen, 2000).  
In 2001, Goldsmith and co-workers made improvements in the rat model for HIV. They first 
demonstrated that rat cells are more efficient for replication of HIV than mouse cells 
(Keppler et al., 2001), producing substantial levels of viral p24gag. Based on these results, 
they engineered rats transgenic for the hCD4 and the hCCR5 that expressed the genes in 
CD4+ T lymphocytes, macrophages, and microglia (Keppler et al., 2002). They found that 
these cells could be productively infected by various recombinant and primary R5 strains of 
HIV-1 ex vivo, although the animals do not support viremia during infection.  
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The laboratory rabbit appears to be susceptible to HIV, but requires large inocula and viral 
replication does not spread (Dunn et al., 1995; Filice, Cereda, and Varnier, 1988). Rabbit cell 
lines expressing hCD4 and hCCR5 demonstrated an increase in infection and replication of 
CCR5 dependent strain of HIV (JR-CSF and YU-2)(Speck et al., 1998). Recently, new studies 
support the previous evidence for the susceptibility of rabbit cells, especially T cells, to HIV 
infection and suggest that in addition to the receptor complex transgenesis, modifications in 
gag and possibly vif of the HIV-1 might render the rabbit model fully permissive to infection 
by HIV-1 (Tervo and Keppler, 2010). 
Recently, a small animal model of HIV transmission was developed by transplanting human 
bone marrow, liver, and thymus (BLT) into severe combined immunodeficient mice (Melkus 
et al., 2006). Consequently, human APCs and lymphocytes populate the mucosal surfaces, 
and the model can be used to assess some strategies to prevent vaginal HIV transmission 
(Denton et al., 2008). Further, once infected, the BLT mice generate humoral and cellular 
HIV-specific immune responses (Brainard et al., 2009). Some of these models allow 
transmission of HIV via the vaginal and rectal mucosa and display high-level viremia and 
CD4 T cell depletion. Unfortunately, these models are technically challenging, time-
consuming, and not amenable to widespread use. Moreover, HIV-1 infected, xenotransplant 
mice mount low or dysfunctional adaptive immune responses to HIV infection, limiting 
these studies of natural immune control and vaccine testing. 
3. The cotton rat 
The cotton rat is a common New World rodent ranging in distribution from the southern 
United States through Mexico, Central America, Colombia and Venezuela. Eight species are 
recognized, with a karyotype ranging from 22 to 52 chromosomes. The most recent 
classification is to the Subfamily Sigmodentinae of the family Cricetidae, which includes New 
World mice, rats, voles, lemmings and muskrat. Sigmodon hispidus is the most commonly 
used cotton rat in biomedical research, but some investigators have also utilized laboratory-
bred S. fulviventer (Piazza et al., 1992; Porter et al., 1991). 
In the 1930's, it was discovered that inoculation of the cotton rat with poliovirus induced a 
paralytic disease, while other laboratory rodents did not develop disease (Armstrong, 1939). 
For over a decade, S. hispidus remained the prime animal model for polio until supplanted 
by monkeys and mice, with mice requiring extensive adaptation of virus. Since then, the 
cotton rat has been extensively used as a model to study different aspects of infection by 
respiratory syncytial virus (Li et al., 2000; Malley et al., 1998; Prince et al., 2001; Prince et al., 
1978; Prince et al., 1999; Rodriguez et al., 1997; Tang et al., 2001), influenza A and B 
(Sadowski et al., 1987), parainfluenza viruses types 1, 2, and 3 (Ottolini et al., 2000; Porter et 
al., 1991; Prince et al., 2001; Sadowski et al., 1987), herpes simplex virus type 1 (HSV-1) 
(Lewandowski et al., 2002), HSV-2 (Yim et al., 2005), measles virus (Niewiesk, 2001; 
Niewiesk et al., 1997; Wyde et al., 1999), as well as several serotypes of adenovirus (Brunori 
et al., 2001; Ginsberg et al., 1989; Ginsberg, Moldawer, and Prince, 1999; Rojas-Martinez et 
al., 1998; Tsubota et al., 1998; Wildner and Morris, 2002). Finally, cotton rats are also natural 
reservoirs of several viruses of importance as emerging human pathogens. These include 
Venezuelan equine encephalitis (Wang et al., 2001), Guaranito and Pirital viruses (Fulhorst 
et al., 1999); and several species of hantavirus (Fulhorst et al., 1997; Glass et al., 1998; 
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S. hispidus and S. fulviventer are fully inbred and both species are available from the 
Sigmovir Biosystems Inc. colony, a USDA licensed dealer for cotton rats. 
4. HIV infection in cotton rat 
Infection by HIV is defined as the replication of detectable virus in the host and the 
development of antibodies against HIV-1 proteins. Previously, one laboratory in the U.S. 
(Langley, Prince, and Ginsberg, 1998) and another in Russia (Rytik et al., 1995; Rytik et al., 
2004) demonstrated that HIV-1 was detected in tissues of cotton rats previously infected 
with HIV-1. In the U.S. study (Langley, Prince, and Ginsberg, 1998), cotton rats were 
infected with HIV-1 and proviral DNA was detected in peripheral blood mononuclear cells 
(PBMCs) and tissues including spleen, thymus, and bone marrow from infected animals. 
Virus stimulated a strong, specific, and long-lasting immune response (in some animals 
included neutralizing antibodies and antibodies recognizing major HIV antigens) that was 
maintained up to 1 year post-infection. Although not demonstrable by direct culture of 
PBMCs or tissues from infected animals, infectious virus replicated at a low level in PBMCs 
of these animal because its presence was detected in animals that received three serial 
passages of blood from the original infected cotton rats.  
In addition, Rytik and collaborators have also described the permissiveness of the cotton rat 
to HIV-1 infection by detection of viral DNA in spleen and brain (100% of the animals after 6 
month), increase in mortality (17%), and morphological changes in cells of the central 
nervous system (CNS). These data strongly indicate that non-transgenic cotton rats are semi-
permissive to HIV-1 replication. These findings imply that a productive infection may occur 
in cotton rats. The cotton rat offers several advantages for the development of an animal 
model, including small size, convenience of breeding, and the increasing availability of 
reagents to study the immunological and pathological aspects of HIV-1 disease (R&D 
Systems Inc).  
4.1 Cotton rat primary macrophages support HIV-1 gene expression 
Recently, the ability of cotton rat cells to support HIV-1 transcription was assessed by our 
laboratory using macrophages from two different cotton rat species (S. hispidus and S. 
fulviventer), from BALB/c mice, and from humans. Macrophages were transfected with a 
luciferase reporter gene encoding pNL4 env-R+, which provides a quantitative marker of 
HIV-1 gene expression. Macrophages from S. hispidus and S. fulviventer supported 
transcription of the HIV-1 derived backbone as indicated by enhanced luciferase activity 
compared with that of cells transfected with the control promotor-less luciferase construct 
(Fig. 1). The levels of transcription found in cotton rat macrophages were comparable to that 
measured in human macrophages, and all were significantly greater in comparison to 
mouse macrophages transfected with the HIV-1 reporter plasmid. Interestingly, the levels of 
transcription in macrophages of S. hispidus was at least 10 folds higher than the activity 
recorded in macrophages of humans or S. fulviventer. Although the nature of this high 
transcription efficiency of the LTR in S. hispidus is unknown, it could be related to the lift of 
a particular blockage or to an increase RNA/protein stability of luciferase. Transfection 
efficiencies measured by the expression of a CMV promoter-driven -galactosidase activity 
were equivalent in cells of all species. These data indicate that cotton rat macrophages 
support transcription from the HIV-1-LTR and apparently lack the transcriptional blocks 
found in mouse cells.  
 




Fig. 1. Macrophages from S. hispidus and S. fulviventer supported transcription of the HIV-1 
derived backbone. Mouse, human, S.hispidus and S. fulviventer macrophages were 
transfected with a control plasmid (pGL3-basic, Promega) or a plasmid containing a HIV-1 
NL-4-E-R+. Human macrophages were prepared by differentiating elutriated monocytes 
(from the NIH Blood Bank) for 14 days in high‐cell density cultures of D‐MEM media 
supplemented with 10% human AB serum, 2 mM L‐glutamine and antibiotics in 100 mm 
square Petri. Cotton rat peritoneal macrophages from S. hispidus and S. fulviventer were 
prepared by injecting 3‐month‐old rats intraperitoneally with 8 ml of thioglycollate broth. 
Mouse macrophages were obtained in similar fashion injecting 3 ml of thioglycollate broth 
into the peritoneal cavity of Balb/c mice. Four days post injection, animals were sacrificed 
by CO2 inhalation and the peritoneal cavity was washed twice with cold saline solution. 
Cells obtained were seeded in culture plates as indicated for human macrophages. For 
transfection of human, mouse, and cotton rat macrophages the ratio of transfection reagent 
in μl (FuGENE 6, Roche Molecular Biochemical) to NL4‐3 derived backbone plasmid in μg 
was 4 to 1, where the total of 4.5 μg of plasmid DNA were used for each 106 macrophages. 
Transfection was carried out overnight at 37°C and the next day macrophages were washed 
and incubated for an additional 48 h before lysis and quantification of luciferase activity. 
The results represent luciferase activity obtained from transfected cells in triplicate wells 
from a representative experiment. 
4.2 Cotton rat cell lines expressing the HIV-1 receptor complex are susceptible to HIV-
1 infection 
Two different cotton rat cells lines, CCRT (an osteosarcoma) and VCRT (an undifferentiated 
spindle cell sarcoma), that were selected for expression of hCD4/hCXCR4 and 
hCD4/hCCR5, were tested for infection with three well characterized isolates of HIV-1 
virus: the MN isolate (a T-tropic HIV isolate that infects T cell lines and peripheral T cells, 
but not monocytes, and uses hCXCR4 as co-receptor), and the BAL and US1 isolates (M-
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levels of p24gag in the supernatant of cotton rat cells expressing the HIV receptor complex 
were significantly higher than in control, untransfected cell cultures, with a peak of p24gag 
production evidenced on day 6 post-infection (Blanco et al., 2009). Fully mature, infectious 
HIV-1 particles were efficiently synthesized and assembled in HIV-1-infected cotton rat cells 
since PHA-activated PBMCs (pool of human PBMC from negative donors) or H9 cells 
incubated with the derived supernatants from cotton rat cells produced detectable amounts 
of p24gag (~200pg/ml) as early as day 3 post-transfer of all cotton rat-derived stocks. 
Furthermore, proviral DNA was detected in infected cotton rat cells, and subsequent direct 
cloning demonstrated that HIV-1 DNA integrates into the genome of infected cells (Blanco 
et al., 2009). The sequence of one of the integrated fragments (~ 1.6 kb) revealed the presence 
of 650 bp corresponding to sequence of the 5’ LTR of HIV-MN attached to 950 bp of a cotton 
rat genomic DNA sequence (GenBank acc# AY703985), and further demonstrates that cotton 
rat cells are able to support integration of viral DNA in their genome (Blanco et al., 2009). 
5. The cotton rat model of tuberculosis 
HIV fuels the TB epidemic in many ways. HIV promotes progression to active TB in both 
categories, that is, people with recently acquired TB and those with latent Mycobacterium 
tuberculosis infection (LTBI). HIV is the most powerful known risk factor for reactivation of 
LTBI to active disease. HIV also appears to increase the risk of pediatric TB, which is itself 
difficult to diagnose. A small animal model that is susceptible to infection with both 
pathogens could lead to development of treatments and vaccines that can target more 
efficiently this unparalleled problem for the population of third world countries.  
The natural history of TB infection in S. hispidus and S. fulviventer has been studied (Elwood 
et al., 2007). The relatively short life span of the cotton rat (12-18 months) makes it possible 
to study TB infections throughout the entire life span of the animal. The studies 
demonstrated that young cotton rats experience a primary tuberculous pulmonary infection 
characterized by typical granuloma formation. There were differences in response to 
infection between the two species, with S. fulviventer demonstrating greater mortality than S. 
hispidus. Gross inspection of TB-infected cotton rat lungs show whitish nodular lesions and 
large numbers of TB (1 X 105-7 cfu) were cultured from granulomas, spleen, and occasionally 
in smaller numbers from liver and bone marrow. Tuberculous lesions may also be seen in 
the adrenal glands (other organs remain to be examined) (Elwood et al., 2007). Established 
granulomas in some cases underwent central necrosis and calcification and cytokine genes 
are more highly expressed in the granuloma than in the unaffected areas of the lung. A 
minority of animals, about 20-30% with primary infection, develop serious progressive TB 
pulmonary disease, wasting, and succumb to infection. The remaining animals control or 
clear their infection by two to four months after challenged. Later, about half of these 
otherwise well appearing animals continue to have small numbers of TB recovered from 
lungs (1 X 102-3 cfu) despite no microscopic evidence of inflammation or clinical disease. 
However, 50% of immunocompetent animals surviving past 9 months demonstrated 
positive lung tissue cultures for TB without histological evidence of disease. These findings 
are consistent with the development of LTBI. Furthermore, reactivation of disease occurs in 
the surviving animals after immunosuppression with cyclophosphamide (Elwood et al., 
2009), indicating that a model of HIV-1 infection in the cotton rat more likely will parallel 
the course of TB disease seen in co-infected individual.  
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6. The cotton rat model of HSV infection 
Genital herpes is one of the most prevalent sexually transmitted diseases (STD) worldwide 
and is the most common cause of genital ulcers. In the US, 17% of the population is 
seropositive for herpes simplex virus type 2 (HSV-2) and 58% for HSV-1, which is emerging 
as a major cause of genital herpes infections in developed countries (Roberts, 2005; Roberts, 
Pfister, and Spear, 2003; Xu et al., 2006). The HSV-2 seroprevalence rates are much higher in 
some populations, reaching 90-95% among HIV-infected subjects and female sex workers in 
developing countries where HSV-2 remains the dominant cause of genital ulcerative disease 
(Nagot et al., 2007). Implications of genital herpes infection include the risk of transmission 
to sexual partners and offspring as well as an increased risk of acquiring and transmitting 
HIV. Epidemiological studies consistently demonstrate that mucosal HIV-1 shedding is 
more frequent and in greater amounts during mucosal and subclinical reactivations (Corey 
et al., 2004; Nagot et al., 2007; Watson-Jones et al., 2008). HSV-2 can be detected in swabs 
obtained from the cervix from seropositive subjects by culture on 3% of days and by 
sensitive DNA PCR on about 20% of days, illustrating the high frequency of asymptomatic 
shedding (Wald et al., 2000). Being sero-positive for HSV-2 is associated with a 3- to 10-fold 
increased risk of HIV-1 acquisition in women, based on longitudinal cohort studies showing 
HSV-2 infection preceding HIV-1 acquisition and adjusted for sexual behavior (Celum et al., 
2004; Celum, 2004; Freeman et al., 2006). In sub-Saharan Africa, more than a quarter of 
incident HIV infections may be attributed directly to HSV-2 (Abu-Raddad et al., 2008). A 
recently completed Phase IIb study, CAPRISA 004, found that 1% Tenofovir (TFV) vaginal 
gel was effective in reducing HIV transmission to high risk, seronegative, sexually active 
women (Abdool Karim et al., 2010). An unanticipated finding in these trials was that TFV 
gel provided 51% protection against HSV-2 (Q. Abdool Karim, unpublished data). Together, 
these results highlight the importance of the development of a preclinical model for testing 
combined therapies against HIV and HSV. 
Female cotton rats (S. hispidus) are susceptible to genital HSV infection and do not require 
hormonal treatment to become infected (Yim et al., 2005). After HSV inoculation, animals 
develop lesions by day 12, without mortality. This contrasts significantly with the murine 
model, where medroxyprogesterone treatment is required for consistent infection, a higher 
inoculum is typically required, and mice develop hind limb paralysis and must be euthanized 
(Parr et al., 1994; Parr and Parr, 2003). In humans, primary genital herpes infections may be 
associated with constitutional symptoms, aseptic meningitis, and clinically asymptomatic 
spread of the virus to liver, lungs, and kidneys. In cotton rats, viral DNA was readily detected 
in vaginal swabs on days 3, 5, and 7 post-infection and could also be detected in the liver, lung, 
kidney, lumbosacral cord, and brain on the same days. Viral DNA was detected 100 days post-
infection in lumbosacral cord, but not the brain, suggesting a state of latency in cotton rat 
dorsal root ganglia. Following healing of the primary lesions, 15-20% of female cotton rats 
display clinical signs of spontaneous reactivation with lesion formation at any given time (Yim 
et al., 2005). The lesions associated with reactivation are generally smaller than primary 
lesions, similar to human disease. Spontaneous recurrences are often preceded by virus being 
detected in vaginal swabs by PCR or culture, again similar to the human situation. 
Reactivation can be enhanced experimentally by dexamethasone treatment, increasing the rate 
to two- to three-fold higher than the rate of spontaneous reactivation. 
Clinically silent reactivation of HSV is much more common than previously recognized and 
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6. The cotton rat model of HSV infection 
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study of shedding in HSV-2 seropositive subjects who self-collected swabs 4 times daily for 
60 days, HSV-2 was detected by PCR on 19% of days with a median duration of 13 h (Mark 
et al., 2008). Intermittent spontaneous viral shedding was observed in the absence of clinical 
lesions and was also detected by PCR and culture prior to the onset of clinical recurrences 
(Yim et al., 2005); these findings are consistent with those observed with human HSV 
infection and set up a potential valuable model of HSV and HIV co-infection and treatment. 
7. Progress toward the development of a cotton rat model of HIV infection 
Mammalian transgenic experiments have contributed tremendously to our understanding 
of numerous complex biological processes. While other laboratory animals have been used 
to produce transgenic lines, genetic manipulation has never been attempted in cotton rats. 
Development of transgenic cotton rat that is permissive to infection with HIV-1 was 
considered a project of sufficient importance to justify the development of the transgenic 
technique in this relatively new animal model. Since cotton rat stem cells are not available, 
pronuclear microinjection of DNA and subsequent embryonic transfer is required. To do 
that, an entire characterization of the reproductive habits of the cotton rat S. hispidus (52 
chromosomes, inbred for more than 70 generations) including understanding the anatomy 
of its reproductive system, mating, and mothering habits, hormone stimulation, and 
fertilized egg recovery was required to optimize specific parameters for the production of 
transgenic cotton rats.  
Female cotton rats maintained in 12-hour light-dark cycle (lights off from 6 PM to 6 AM) 
ovulate approximately every 9 days. Superovulation by hormone injection has been used in 
mice and rats to increase the number of one-celled fertilized eggs to use for microinjection. 
This is achieved by a course of treatment with pregnant mare serum gonadotrophin (PMS), 
followed by human chorionic gonadotrophin (HCG). The optimal age for hormone 
treatment of female cotton rats was 12 weeks, with the treatment consisting of 30 IU of PMS, 
followed with the same amount of HCG, 4 days later. Following these pretreatment 
conditions, matings were successful 65% of the time (i.e., 65% of females exhibit a copulatory 
plug) producing an average of 6 fertilized eggs per female (Fig. 2).  
Two hours after coitus, fertilized eggs can be retrieved from the oviduct (Fig. 3A). The shape 
and size of the cotton rat fertilized eggs resemble those of mice (Fig. 3B) with a 
distinguishable male and female pronucleus (FIG. 3C). Microinjection is performed using 
standard procedures by injecting 1 pl of purified and linearized DNA into the male pro-
nucleus (Fig. 3D). Pseudopregnant recipients are used as surrogate mothers to nurture 
microinjected eggs to birth. These are young female cotton rats that are set for mating with 
vasectomized males. First, young female cotton rats at the peak of oestrus are identified and 
placed with vasectomized males at the beginning of the dark cycle. The mating rate of the 
young females with the vasectomized males is ~30%.  
There is a very different anatomy of the cotton rat female reproductive system when 
compared to the mouse or laboratory rats, e.g., the mouse and the rat have an evident 
ampulla where the fertilized eggs are located and where the transfer of embryos take place 
through the infundibulum. However, we could not find any evidence of the existence of an 
ampulla in the cotton rat. The infundibulum, however, is located inside the bursal sac as in 
the mouse. In contrast to the mouse that has the infundibulum free and accessible into the 
bursa to transfer the eggs, the cotton rat infundibulum is associated with the wall of the 
bursal sac. Eggs are implanted in the part of the oviduct that is proximal to the bursal sac 
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(were the ampulla is anatomically located), and where the eggs are located at 20 hr post-
coitum in the superovulated females (Fig. 3A).  
 
 
Fig. 2. Schematized protocol for the isolation of cotton rat fertilized eggs (egg donors, left side), 
and for the preparation of recipient pseudo-pregnant females (egg recipients, right side). 
Super-ovulation of female cotton rats is achieved by course of treatment of PMS followed by 
HCG before caging them with males for mating. In addition, female cotton rats in estrous are 
identified and set in mating pairs with vacectomized males. On day 0, females that have 
copulatory plugs are identified; eggs are isolated from oviducts of super-ovulated females, 
microinjected with DNA, and transferred to oviducts of pseudo-pregnant recipient females. 
 
 
Fig. 3. Development of the transgenic technique in cotton rats. (A) H&E staining of cotton 
rat oviduct showing the location of the eggs. (B).Cotton rat fertilized eggs isolated from a 
super-ovulated cotton rat. (C) Fertilized cotton rat egg in which the male pro-nucleus, where 
DNA microinjection takes place, is depicted. (D) Microinjection of DNA in a fertilized egg. 
Insert shows viable eggs in culture after DNA microinjection. (E).Exposure of the oviduct of 
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8. Generation of transgenic cotton rats 
The original genomic constructs for human CD4, CCR5 and CycT1 that were previously 
used in the mouse and rats (Keppler et al., 2002; Sawada et al., 1998), and that expressed 
their products in a tissue-specific manner (kindly provided by Dr. Dan R. Littman, M.D., 
Ph.D., Director of the Molecular Pathogenesis at Skirball Institute of Biomolecular Medicine) 
were purified to homogeneity for pronuclear microinjections. In the first set of 
microinjections and embryo transfer experiments, a set of three founders (2 females and one 
male) were obtained. After crossing, the F1 generation was genotyped for human CD4 and 
CCR5. Several animals in the F1 generation were positive by PCR and Southern blot 
genotyping for hCD4 and CCR5, indicating the production of transgenic cotton rats (Fig. 4). 
None of the animal genotyped were found to be transgenic for both transgenes. We are 
currently in process of determining expression of these genes in the transgenic cotton rats in 
order to produce double transgenics and subsequently initiate infection experiments to 
determine the degree of susceptibility to HIV-1 infection achieved.  
 
 
Fig. 4. Genotyping the F2 generation of cotton rats harboring transgenic hCD4 (upper panel) 
and transgenic hCCR5 (lower panel) by RT-PCR followed by Southern blot. PCR 
amplifications using DNA from the original transgenic constructs (+), and from wild-type 
cotton rats (wt) are depicted as controls.  
9. Acknowledgment 
The authors will like to acknowledge Drs Gregory A. Prince, Val Hemming, Vicky Polonis, 
Christopher Broader, Tsanko Stantchev for participating in this work during the years. Part 
of this work has been supported by NIH grant R44 AI054297 to JCGB. 
10. References 
Abdool Karim, Q., Abdool Karim, S. S., Frohlich, J. A., Grobler, A. C., Baxter, C., Mansoor, L. 
E., Kharsany, A. B., Sibeko, S., Mlisana, K. P., Omar, Z., Gengiah, T. N., Maarschalk, 
S., Arulappan, N., Mlotshwa, M., Morris, L., and Taylor, D. (2010). Effectiveness 
and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV 
infection in women. Science 329(5996), 1168-74. 
Abu-Raddad, L. J., Magaret, A. S., Celum, C., Wald, A., Longini, I. M., Jr., Self, S. G., and 
Corey, L. (2008). Genital herpes has played a more important role than any other 
 
The Quest for a Small Animal Model for HIV Infection and Disease 
 
359 
sexually transmitted infection in driving HIV prevalence in Africa. PLoS ONE 3(5), 
e2230. 
Armstrong, C. (1939). The experimental transmission of poliomyelitis to the eastern cotton 
rat, Sigmodon hispidus jispidus. Public Health Reports, Wash DC 54, 1719-1721. 
Berger, E. A., Murphy, P. M., and Farber, J. M. (1999). Chemokine receptors as HIV-1 
coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 17, 657-
700. 
Bieniasz, P. D., and Cullen, B. R. (2000). Multiple blocks to human immunodeficiency virus 
type 1 replication in rodent cells. J Virol 74(21), 9868-77. 
Blanco, J. C., Pletneva, L. M., Wieczorek, L., Khetawat, D., Stantchev, T. S., Broder, C. C., 
Polonis, V. R., and Prince, G. A. (2009). Expression of Human CD4 and chemokine 
receptors in cotton rat cells confers permissiveness for productive HIV infection. 
Virol J 6(1), 57. 
Brainard, D. M., Seung, E., Frahm, N., Cariappa, A., Bailey, C. C., Hart, W. K., Shin, H. S., 
Brooks, S. F., Knight, H. L., Eichbaum, Q., Yang, Y. G., Sykes, M., Walker, B. D., 
Freeman, G. J., Pillai, S., Westmoreland, S. V., Brander, C., Luster, A. D., and Tager, 
A. M. (2009). Induction of robust cellular and humoral virus-specific adaptive 
immune responses in human immunodeficiency virus-infected humanized BLT 
mice. J Virol 83(14), 7305-21. 
Browning, J., Horner, J. W., Pettoello-Mantovani, M., Raker, C., Yurasov, S., DePinho, R. A., 
and Goldstein, H. (1997). Mice transgenic for human CD4 and CCR5 are susceptible 
to HIV infection. Proc Natl Acad Sci U S A 94(26), 14637-41. 
Brunori, M., Malerba, M., Kashiwazaki, H., and Iggo, R. (2001). Replicating adenoviruses 
that target tumors with constitutive activation of the wnt signaling pathway. J Virol 
75(6), 2857-65. 
Celum, C., Levine, R., Weaver, M., and Wald, A. (2004). Genital herpes and human 
immunodeficiency virus: double trouble. Bull World Health Organ 82(6), 447-53. 
Celum, C. L. (2004). The interaction between herpes simplex virus and human 
immunodeficiency virus. Herpes 11 Suppl 1, 36A-45A. 
Cohen, J. (2001). Building a small-animal model for AIDS, block by block. Science 293(5532), 
1034-6. 
Corey, L., Wald, A., Patel, R., Sacks, S. L., Tyring, S. K., Warren, T., Douglas, J. M., Jr., 
Paavonen, J., Morrow, R. A., Beutner, K. R., Stratchounsky, L. S., Mertz, G., Keene, 
O. N., Watson, H. A., Tait, D., and Vargas-Cortes, M. (2004). Once-daily 
valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 
350(1), 11-20. 
Deng, H., Liu, R., Ellmeier, W., Choe, S., Unutmaz, D., Burkhart, M., Di Marzio, P., Marmon, 
S., Sutton, R. E., Hill, C. M., Davis, C. B., Peiper, S. C., Schall, T. J., Littman, D. R., 
and Landau, N. R. (1996). Identification of a major co-receptor for primary isolates 
of HIV-1. Nature 381(6584), 661-6. 
Denton, P. W., Estes, J. D., Sun, Z., Othieno, F. A., Wei, B. L., Wege, A. K., Powell, D. A., 
Payne, D., Haase, A. T., and Garcia, J. V. (2008). Antiretroviral pre-exposure 
prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS 





8. Generation of transgenic cotton rats 
The original genomic constructs for human CD4, CCR5 and CycT1 that were previously 
used in the mouse and rats (Keppler et al., 2002; Sawada et al., 1998), and that expressed 
their products in a tissue-specific manner (kindly provided by Dr. Dan R. Littman, M.D., 
Ph.D., Director of the Molecular Pathogenesis at Skirball Institute of Biomolecular Medicine) 
were purified to homogeneity for pronuclear microinjections. In the first set of 
microinjections and embryo transfer experiments, a set of three founders (2 females and one 
male) were obtained. After crossing, the F1 generation was genotyped for human CD4 and 
CCR5. Several animals in the F1 generation were positive by PCR and Southern blot 
genotyping for hCD4 and CCR5, indicating the production of transgenic cotton rats (Fig. 4). 
None of the animal genotyped were found to be transgenic for both transgenes. We are 
currently in process of determining expression of these genes in the transgenic cotton rats in 
order to produce double transgenics and subsequently initiate infection experiments to 
determine the degree of susceptibility to HIV-1 infection achieved.  
 
 
Fig. 4. Genotyping the F2 generation of cotton rats harboring transgenic hCD4 (upper panel) 
and transgenic hCCR5 (lower panel) by RT-PCR followed by Southern blot. PCR 
amplifications using DNA from the original transgenic constructs (+), and from wild-type 
cotton rats (wt) are depicted as controls.  
9. Acknowledgment 
The authors will like to acknowledge Drs Gregory A. Prince, Val Hemming, Vicky Polonis, 
Christopher Broader, Tsanko Stantchev for participating in this work during the years. Part 
of this work has been supported by NIH grant R44 AI054297 to JCGB. 
10. References 
Abdool Karim, Q., Abdool Karim, S. S., Frohlich, J. A., Grobler, A. C., Baxter, C., Mansoor, L. 
E., Kharsany, A. B., Sibeko, S., Mlisana, K. P., Omar, Z., Gengiah, T. N., Maarschalk, 
S., Arulappan, N., Mlotshwa, M., Morris, L., and Taylor, D. (2010). Effectiveness 
and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV 
infection in women. Science 329(5996), 1168-74. 
Abu-Raddad, L. J., Magaret, A. S., Celum, C., Wald, A., Longini, I. M., Jr., Self, S. G., and 
Corey, L. (2008). Genital herpes has played a more important role than any other 
 
The Quest for a Small Animal Model for HIV Infection and Disease 
 
359 
sexually transmitted infection in driving HIV prevalence in Africa. PLoS ONE 3(5), 
e2230. 
Armstrong, C. (1939). The experimental transmission of poliomyelitis to the eastern cotton 
rat, Sigmodon hispidus jispidus. Public Health Reports, Wash DC 54, 1719-1721. 
Berger, E. A., Murphy, P. M., and Farber, J. M. (1999). Chemokine receptors as HIV-1 
coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 17, 657-
700. 
Bieniasz, P. D., and Cullen, B. R. (2000). Multiple blocks to human immunodeficiency virus 
type 1 replication in rodent cells. J Virol 74(21), 9868-77. 
Blanco, J. C., Pletneva, L. M., Wieczorek, L., Khetawat, D., Stantchev, T. S., Broder, C. C., 
Polonis, V. R., and Prince, G. A. (2009). Expression of Human CD4 and chemokine 
receptors in cotton rat cells confers permissiveness for productive HIV infection. 
Virol J 6(1), 57. 
Brainard, D. M., Seung, E., Frahm, N., Cariappa, A., Bailey, C. C., Hart, W. K., Shin, H. S., 
Brooks, S. F., Knight, H. L., Eichbaum, Q., Yang, Y. G., Sykes, M., Walker, B. D., 
Freeman, G. J., Pillai, S., Westmoreland, S. V., Brander, C., Luster, A. D., and Tager, 
A. M. (2009). Induction of robust cellular and humoral virus-specific adaptive 
immune responses in human immunodeficiency virus-infected humanized BLT 
mice. J Virol 83(14), 7305-21. 
Browning, J., Horner, J. W., Pettoello-Mantovani, M., Raker, C., Yurasov, S., DePinho, R. A., 
and Goldstein, H. (1997). Mice transgenic for human CD4 and CCR5 are susceptible 
to HIV infection. Proc Natl Acad Sci U S A 94(26), 14637-41. 
Brunori, M., Malerba, M., Kashiwazaki, H., and Iggo, R. (2001). Replicating adenoviruses 
that target tumors with constitutive activation of the wnt signaling pathway. J Virol 
75(6), 2857-65. 
Celum, C., Levine, R., Weaver, M., and Wald, A. (2004). Genital herpes and human 
immunodeficiency virus: double trouble. Bull World Health Organ 82(6), 447-53. 
Celum, C. L. (2004). The interaction between herpes simplex virus and human 
immunodeficiency virus. Herpes 11 Suppl 1, 36A-45A. 
Cohen, J. (2001). Building a small-animal model for AIDS, block by block. Science 293(5532), 
1034-6. 
Corey, L., Wald, A., Patel, R., Sacks, S. L., Tyring, S. K., Warren, T., Douglas, J. M., Jr., 
Paavonen, J., Morrow, R. A., Beutner, K. R., Stratchounsky, L. S., Mertz, G., Keene, 
O. N., Watson, H. A., Tait, D., and Vargas-Cortes, M. (2004). Once-daily 
valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 
350(1), 11-20. 
Deng, H., Liu, R., Ellmeier, W., Choe, S., Unutmaz, D., Burkhart, M., Di Marzio, P., Marmon, 
S., Sutton, R. E., Hill, C. M., Davis, C. B., Peiper, S. C., Schall, T. J., Littman, D. R., 
and Landau, N. R. (1996). Identification of a major co-receptor for primary isolates 
of HIV-1. Nature 381(6584), 661-6. 
Denton, P. W., Estes, J. D., Sun, Z., Othieno, F. A., Wei, B. L., Wege, A. K., Powell, D. A., 
Payne, D., Haase, A. T., and Garcia, J. V. (2008). Antiretroviral pre-exposure 
prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS 





Dunn, C. S., Mehtali, M., Houdebine, L. M., Gut, J. P., Kirn, A., and Aubertin, A. M. (1995). 
Human immunodeficiency virus type 1 infection of human CD4-transgenic rabbits. 
J Gen Virol 76 ( Pt 6), 1327-36. 
Elwood, R. L., Rajnik, M., Wilson, S., Yim, K., Blanco, J. C., Nikonenko, B., and Hemming, V. 
G. (2009). Characterization of late tuberculosis infection in Sigmodon hispidus. 
Tuberculosis (Edinb) 89(2), 183-8. 
Elwood, R. L., Wilson, S., Blanco, J. C., Yim, K., Pletneva, L., Nikonenko, B., Samala, R., 
Joshi, S., Hemming, V. G., and Trucksis, M. (2007). The American cotton rat: a novel 
model for pulmonary tuberculosis. Tuberculosis (Edinb) 87(2), 145-54. 
Filice, G., Cereda, P. M., and Varnier, O. E. (1988). Infection of rabbits with human 
immunodeficiency virus. Nature 335(6188), 366-9. 
Freeman, E. E., Weiss, H. A., Glynn, J. R., Cross, P. L., Whitworth, J. A., and Hayes, R. J. 
(2006). Herpes simplex virus 2 infection increases HIV acquisition in men and 
women: systematic review and meta-analysis of longitudinal studies. Aids 20(1), 73-
83. 
Fulhorst, C. F., Bowen, M. D., Salas, R. A., Duno, G., Utrera, A., Ksiazek, T. G., De Manzione, 
N. M., De Miller, E., Vasquez, C., Peters, C. J., and Tesh, R. B. (1999). Natural rodent 
host associations of Guanarito and pirital viruses (Family Arenaviridae) in central 
Venezuela. Am J Trop Med Hyg 61(2), 325-30. 
Fulhorst, C. F., Monroe, M. C., Salas, R. A., Duno, G., Utrera, A., Ksiazek, T. G., Nichol, S. T., 
de Manzione, N. M., Tovar, D., and Tesh, R. B. (1997). Isolation, characterization 
and geographic distribution of Caño Delgadito virus, a newly discovered South 
American hantavirus (family Bunyaviridae). Virus Res 51(2), 159-71. 
Garber, M. E., Wei, P., KewalRamani, V. N., Mayall, T. P., Herrmann, C. H., Rice, A. P., 
Littman, D. R., and Jones, K. A. (1998). The interaction between HIV-1 Tat and 
human cyclin T1 requires zinc and a critical cysteine residue that is not conserved 
in the murine CycT1 protein. Genes Dev 12(22), 3512-27. 
Ginsberg, H. S., Lundholm-Beauchamp, U., Horswood, R. L., Pernis, B., Wold, W. S., 
Chanock, R. M., and Prince, G. A. (1989). Role of early region 3 (E3) in pathogenesis 
of adenovirus disease. Proc Natl Acad Sci U S A 86(10), 3823-7. 
Ginsberg, H. S., Moldawer, L. L., and Prince, G. A. (1999). Role of the type 5 adenovirus 
gene encoding the early region 1B 55-kDa protein in pulmonary pathogenesis. Proc 
Natl Acad Sci U S A 96(18), 10409-11. 
Glass, G. E., Livingstone, W., Mills, J. N., Hlady, W. G., Fine, J. B., Biggler, W., Coke, T., 
Frazier, D., Atherley, S., Rollin, P. E., Ksiazek, T. G., Peters, C. J., and Childs, J. E. 
(1998). Black Creek Canal Virus infection in Sigmodon hispidus in southern 
Florida. Am J Trop Med Hyg 59(5), 699-703. 
Hutchinson, K. L., Rollin, P. E., and Peters, C. J. (1998). Pathogenesis of a North American 
hantavirus, Black Creek Canal virus, in experimentally infected Sigmodon 
hispidus. Am J Trop Med Hyg 59(1), 58-65. 
Keppler, O. T., Welte, F. J., Ngo, T. A., Chin, P. S., Patton, K. S., Tsou, C. L., Abbey, N. W., 
Sharkey, M. E., Grant, R. M., You, Y., Scarborough, J. D., Ellmeier, W., Littman, D. 
R., Stevenson, M., Charo, I. F., Herndier, B. G., Speck, R. F., and Goldsmith, M. A. 
(2002). Progress toward a human CD4/CCR5 transgenic rat model for de novo 
infection by human immunodeficiency virus type 1. J Exp Med 195(6), 719-36. 
 
The Quest for a Small Animal Model for HIV Infection and Disease 
 
361 
Keppler, O. T., Yonemoto, W., Welte, F. J., Patton, K. S., Iacovides, D., Atchison, R. E., Ngo, 
T., Hirschberg, D. L., Speck, R. F., and Goldsmith, M. A. (2001). Susceptibility of rat-
derived cells to replication by human immunodeficiency virus type 1. J Virol 75(17), 
8063-73. 
Langley, R. J., Prince, G. A., and Ginsberg, H. S. (1998). HIV type-1 infection of the cotton rat 
(Sigmodon fulviventer and S. hispidus). Proc Natl Acad Sci U S A 95(24), 14355-60. 
Lewandowski, G., Zimmerman, M. N., Denk, L. L., Porter, D. D., and Prince, G. A. (2002). 
Herpes simplex type 1 infects and establishes latency in the brain and trigeminal 
ganglia during primary infection of the lip in cotton rats and mice. Arch Virol 
147(1), 167-79. 
Li, X., Sambhara, S., Li, C. X., Ettorre, L., Switzer, I., Cates, G., James, O., Parrington, M., 
Oomen, R., Du, R. P., and Klein, M. (2000). Plasmid DNA encoding the respiratory 
syncytial virus G protein is a promising vaccine candidate. Virology 269(1), 54-65. 
Malley, R., DeVincenzo, J., Ramilo, O., Dennehy, P. H., Meissner, H. C., Gruber, W. C., 
Sanchez, P. J., Jafri, H., Balsley, J., Carlin, D., Buckingham, S., Vernacchio, L., and 
Ambrosino, D. M. (1998). Reduction of respiratory syncytial virus (RSV) in tracheal 
aspirates in intubated infants by use of humanized monoclonal antibody to RSV F 
protein. J Infect Dis 178(6), 1555-61. 
Mantooth, S. J., Milazzo, M. L., Bradley, R. D., Hice, C. L., Ceballos, G., Tesh, R. B., and 
Fulhorst, C. F. (2001). Geographical distribution of rodent-associated hantaviruses 
in Texas. J Vector Ecol 26(1), 7-14. 
Mariani, R., Rasala, B. A., Rutter, G., Wiegers, K., Brandt, S. M., Krausslich, H. G., and 
Landau, N. R. (2001). Mouse-human heterokaryons support efficient human 
immunodeficiency virus type 1 assembly. J Virol 75(7), 3141-51. 
Mark, K. E., Wald, A., Magaret, A. S., Selke, S., Olin, L., Huang, M. L., and Corey, L. (2008). 
Rapidly cleared episodes of herpes simplex virus reactivation in immunocompetent 
adults. J Infect Dis 198(8), 1141-9. 
Melkus, M. W., Estes, J. D., Padgett-Thomas, A., Gatlin, J., Denton, P. W., Othieno, F. A., 
Wege, A. K., Haase, A. T., and Garcia, J. V. (2006). Humanized mice mount specific 
adaptive and innate immune responses to EBV and TSST-1. Nat Med 12(11), 1316-
22. 
Nagot, N., Ouedraogo, A., Foulongne, V., Konate, I., Weiss, H. A., Vergne, L., Defer, M. C., 
Djagbare, D., Sanon, A., Andonaba, J. B., Becquart, P., Segondy, M., Vallo, R., 
Sawadogo, A., Van de Perre, P., and Mayaud, P. (2007). Reduction of HIV-1 RNA 
levels with therapy to suppress herpes simplex virus. N Engl J Med 356(8), 790-9. 
Nath, B. M., Schumann, K. E., and Boyer, J. D. (2000). The chimpanzee and other non-
human-primate models in HIV-1 vaccine research. Trends Microbiol 8(9), 426-31. 
Niewiesk, S. (2001). Studying experimental measles virus vaccines in the presence of 
maternal antibodies in the cotton rat model (Sigmodon hispidus). Vaccine 19(17-19), 
2250-3. 
Niewiesk, S., Eisenhuth, I., Fooks, A., Clegg, J. C., Schnorr, J. J., Schneider-Schaulies, S., and 
ter Meulen, V. (1997). Measles virus-induced immune suppression in the cotton rat 
(Sigmodon hispidus) model depends on viral glycoproteins. J Virol 71(10), 7214-9. 
Ottolini, M. G., Porter, D. D., Hemming, V. G., and Prince, G. A. (2000). Enhanced 
pulmonary pathology in cotton rats upon challenge after immunization with 





Dunn, C. S., Mehtali, M., Houdebine, L. M., Gut, J. P., Kirn, A., and Aubertin, A. M. (1995). 
Human immunodeficiency virus type 1 infection of human CD4-transgenic rabbits. 
J Gen Virol 76 ( Pt 6), 1327-36. 
Elwood, R. L., Rajnik, M., Wilson, S., Yim, K., Blanco, J. C., Nikonenko, B., and Hemming, V. 
G. (2009). Characterization of late tuberculosis infection in Sigmodon hispidus. 
Tuberculosis (Edinb) 89(2), 183-8. 
Elwood, R. L., Wilson, S., Blanco, J. C., Yim, K., Pletneva, L., Nikonenko, B., Samala, R., 
Joshi, S., Hemming, V. G., and Trucksis, M. (2007). The American cotton rat: a novel 
model for pulmonary tuberculosis. Tuberculosis (Edinb) 87(2), 145-54. 
Filice, G., Cereda, P. M., and Varnier, O. E. (1988). Infection of rabbits with human 
immunodeficiency virus. Nature 335(6188), 366-9. 
Freeman, E. E., Weiss, H. A., Glynn, J. R., Cross, P. L., Whitworth, J. A., and Hayes, R. J. 
(2006). Herpes simplex virus 2 infection increases HIV acquisition in men and 
women: systematic review and meta-analysis of longitudinal studies. Aids 20(1), 73-
83. 
Fulhorst, C. F., Bowen, M. D., Salas, R. A., Duno, G., Utrera, A., Ksiazek, T. G., De Manzione, 
N. M., De Miller, E., Vasquez, C., Peters, C. J., and Tesh, R. B. (1999). Natural rodent 
host associations of Guanarito and pirital viruses (Family Arenaviridae) in central 
Venezuela. Am J Trop Med Hyg 61(2), 325-30. 
Fulhorst, C. F., Monroe, M. C., Salas, R. A., Duno, G., Utrera, A., Ksiazek, T. G., Nichol, S. T., 
de Manzione, N. M., Tovar, D., and Tesh, R. B. (1997). Isolation, characterization 
and geographic distribution of Caño Delgadito virus, a newly discovered South 
American hantavirus (family Bunyaviridae). Virus Res 51(2), 159-71. 
Garber, M. E., Wei, P., KewalRamani, V. N., Mayall, T. P., Herrmann, C. H., Rice, A. P., 
Littman, D. R., and Jones, K. A. (1998). The interaction between HIV-1 Tat and 
human cyclin T1 requires zinc and a critical cysteine residue that is not conserved 
in the murine CycT1 protein. Genes Dev 12(22), 3512-27. 
Ginsberg, H. S., Lundholm-Beauchamp, U., Horswood, R. L., Pernis, B., Wold, W. S., 
Chanock, R. M., and Prince, G. A. (1989). Role of early region 3 (E3) in pathogenesis 
of adenovirus disease. Proc Natl Acad Sci U S A 86(10), 3823-7. 
Ginsberg, H. S., Moldawer, L. L., and Prince, G. A. (1999). Role of the type 5 adenovirus 
gene encoding the early region 1B 55-kDa protein in pulmonary pathogenesis. Proc 
Natl Acad Sci U S A 96(18), 10409-11. 
Glass, G. E., Livingstone, W., Mills, J. N., Hlady, W. G., Fine, J. B., Biggler, W., Coke, T., 
Frazier, D., Atherley, S., Rollin, P. E., Ksiazek, T. G., Peters, C. J., and Childs, J. E. 
(1998). Black Creek Canal Virus infection in Sigmodon hispidus in southern 
Florida. Am J Trop Med Hyg 59(5), 699-703. 
Hutchinson, K. L., Rollin, P. E., and Peters, C. J. (1998). Pathogenesis of a North American 
hantavirus, Black Creek Canal virus, in experimentally infected Sigmodon 
hispidus. Am J Trop Med Hyg 59(1), 58-65. 
Keppler, O. T., Welte, F. J., Ngo, T. A., Chin, P. S., Patton, K. S., Tsou, C. L., Abbey, N. W., 
Sharkey, M. E., Grant, R. M., You, Y., Scarborough, J. D., Ellmeier, W., Littman, D. 
R., Stevenson, M., Charo, I. F., Herndier, B. G., Speck, R. F., and Goldsmith, M. A. 
(2002). Progress toward a human CD4/CCR5 transgenic rat model for de novo 
infection by human immunodeficiency virus type 1. J Exp Med 195(6), 719-36. 
 
The Quest for a Small Animal Model for HIV Infection and Disease 
 
361 
Keppler, O. T., Yonemoto, W., Welte, F. J., Patton, K. S., Iacovides, D., Atchison, R. E., Ngo, 
T., Hirschberg, D. L., Speck, R. F., and Goldsmith, M. A. (2001). Susceptibility of rat-
derived cells to replication by human immunodeficiency virus type 1. J Virol 75(17), 
8063-73. 
Langley, R. J., Prince, G. A., and Ginsberg, H. S. (1998). HIV type-1 infection of the cotton rat 
(Sigmodon fulviventer and S. hispidus). Proc Natl Acad Sci U S A 95(24), 14355-60. 
Lewandowski, G., Zimmerman, M. N., Denk, L. L., Porter, D. D., and Prince, G. A. (2002). 
Herpes simplex type 1 infects and establishes latency in the brain and trigeminal 
ganglia during primary infection of the lip in cotton rats and mice. Arch Virol 
147(1), 167-79. 
Li, X., Sambhara, S., Li, C. X., Ettorre, L., Switzer, I., Cates, G., James, O., Parrington, M., 
Oomen, R., Du, R. P., and Klein, M. (2000). Plasmid DNA encoding the respiratory 
syncytial virus G protein is a promising vaccine candidate. Virology 269(1), 54-65. 
Malley, R., DeVincenzo, J., Ramilo, O., Dennehy, P. H., Meissner, H. C., Gruber, W. C., 
Sanchez, P. J., Jafri, H., Balsley, J., Carlin, D., Buckingham, S., Vernacchio, L., and 
Ambrosino, D. M. (1998). Reduction of respiratory syncytial virus (RSV) in tracheal 
aspirates in intubated infants by use of humanized monoclonal antibody to RSV F 
protein. J Infect Dis 178(6), 1555-61. 
Mantooth, S. J., Milazzo, M. L., Bradley, R. D., Hice, C. L., Ceballos, G., Tesh, R. B., and 
Fulhorst, C. F. (2001). Geographical distribution of rodent-associated hantaviruses 
in Texas. J Vector Ecol 26(1), 7-14. 
Mariani, R., Rasala, B. A., Rutter, G., Wiegers, K., Brandt, S. M., Krausslich, H. G., and 
Landau, N. R. (2001). Mouse-human heterokaryons support efficient human 
immunodeficiency virus type 1 assembly. J Virol 75(7), 3141-51. 
Mark, K. E., Wald, A., Magaret, A. S., Selke, S., Olin, L., Huang, M. L., and Corey, L. (2008). 
Rapidly cleared episodes of herpes simplex virus reactivation in immunocompetent 
adults. J Infect Dis 198(8), 1141-9. 
Melkus, M. W., Estes, J. D., Padgett-Thomas, A., Gatlin, J., Denton, P. W., Othieno, F. A., 
Wege, A. K., Haase, A. T., and Garcia, J. V. (2006). Humanized mice mount specific 
adaptive and innate immune responses to EBV and TSST-1. Nat Med 12(11), 1316-
22. 
Nagot, N., Ouedraogo, A., Foulongne, V., Konate, I., Weiss, H. A., Vergne, L., Defer, M. C., 
Djagbare, D., Sanon, A., Andonaba, J. B., Becquart, P., Segondy, M., Vallo, R., 
Sawadogo, A., Van de Perre, P., and Mayaud, P. (2007). Reduction of HIV-1 RNA 
levels with therapy to suppress herpes simplex virus. N Engl J Med 356(8), 790-9. 
Nath, B. M., Schumann, K. E., and Boyer, J. D. (2000). The chimpanzee and other non-
human-primate models in HIV-1 vaccine research. Trends Microbiol 8(9), 426-31. 
Niewiesk, S. (2001). Studying experimental measles virus vaccines in the presence of 
maternal antibodies in the cotton rat model (Sigmodon hispidus). Vaccine 19(17-19), 
2250-3. 
Niewiesk, S., Eisenhuth, I., Fooks, A., Clegg, J. C., Schnorr, J. J., Schneider-Schaulies, S., and 
ter Meulen, V. (1997). Measles virus-induced immune suppression in the cotton rat 
(Sigmodon hispidus) model depends on viral glycoproteins. J Virol 71(10), 7214-9. 
Ottolini, M. G., Porter, D. D., Hemming, V. G., and Prince, G. A. (2000). Enhanced 
pulmonary pathology in cotton rats upon challenge after immunization with 





Parr, M. B., Kepple, L., McDermott, M. R., Drew, M. D., Bozzola, J. J., and Parr, E. L. (1994). 
A mouse model for studies of mucosal immunity to vaginal infection by herpes 
simplex virus type 2. Lab Invest 70(3), 369-80. 
Parr, M. B., and Parr, E. L. (2003). Intravaginal administration of herpes simplex virus type 2 
to mice leads to infection of several neural and extraneural sites. J Neurovirol 9(6), 
594-602. 
Piazza, F. M., Johnson, S. A., Ottolini, M. G., Schmidt, H. J., Darnell, M. E., Hemming, V. G., 
and Prince, G. A. (1992). Immunotherapy of respiratory syncytial virus infection in 
cotton rats (Sigmodon fulviventer) using IgG in a small-particle aerosol. J Infect Dis 
166(6), 1422-4. 
Porter, D. D., Prince, G. A., Hemming, V. G., and Porter, H. G. (1991). Pathogenesis of 
human parainfluenza virus 3 infection in two species of cotton rats: Sigmodon 
hispidus develops bronchiolitis, while Sigmodon fulviventer develops interstitial 
pneumonia. J Virol 65(1), 103-11. 
Prince, G. A., Curtis, S. J., Yim, K. C., and Porter, D. D. (2001). Vaccine-enhanced respiratory 
syncytial virus disease in cotton rats following immunization with Lot 100 or a 
newly prepared reference vaccine. J Gen Virol 82(Pt 12), 2881-8. 
Prince, G. A., Jenson, A. B., Horswood, R. L., Camargo, E., and Chanock, R. M. (1978). The 
pathogenesis of respiratory syncytial virus infection in cotton rats. Am J Pathol 
93(3), 771-91. 
Prince, G. A., Prieels, J. P., Slaoui, M., and Porter, D. D. (1999). Pulmonary lesions in primary 
respiratory syncytial virus infection, reinfection, and vaccine-enhanced disease in 
the cotton rat (Sigmodon hispidus). Lab Invest 79(11), 1385-92. 
Roberts, C. (2005). Genital herpes in young adults: changing sexual behaviours, 
epidemiology and management. Herpes 12(1), 10-4. 
Roberts, C. M., Pfister, J. R., and Spear, S. J. (2003). Increasing proportion of herpes simplex 
virus type 1 as a cause of genital herpes infection in college students. Sex Transm 
Dis 30(10), 797-800. 
Rodriguez, W. J., Gruber, W. C., Groothuis, J. R., Simoes, E. A., Rosas, A. J., Lepow, M., 
Kramer, A., and Hemming, V. (1997). Respiratory syncytial virus immune globulin 
treatment of RSV lower respiratory tract infection in previously healthy children. 
Pediatrics 100(6), 937-42. 
Rojas-Martinez, A., Wyde, P. R., Montgomery, C. A., Chen, S. H., Woo, S. L., and Aguilar-
Cordova, E. (1998). Distribution, persistency, toxicity, and lack of replication of an 
E1A-deficient adenoviral vector after intracardiac delivery in the cotton rat. Cancer 
Gene Ther 5(6), 365-70. 
Rytik, P. G., Il'kevich Iu, G., Poleshchuk, N. N., Miuller, V., Kucherov, I. A., Duboiskaia, G. 
P., Podol'skaia, I. A., Novikova, I. E., and Kvacheva, Z. B. (1995). [Morphological 
characteristics of the course of HIV infection in laboratory animals]. Vestn Ross Akad 
Med Nauk(6), 37-41. 
Rytik, P. G., Kutcherov, II, Muller, W. E., Poleschuk, N. N., Duboiskaya, G. P., Kruzo, M., 
and Podolskaya, I. A. (2004). Small animal model of HIV-1 infection. J Clin Virol 31 
Suppl 1, S83-7. 
Sadowski, W., Semkow, R., Wilczynski, J., Krus, S., and Kantoch, M. (1987). [The cotton rat 
(Sigmodon hispidus) as an experimental model for studying viruses in human 
 
The Quest for a Small Animal Model for HIV Infection and Disease 
 
363 
respiratory tract infections. I. Para-influenza virus type 1, 2 and 3, adenovirus type 
5 and RS virus]. Med Dosw Mikrobiol 39(1), 33-42. 
Sawada, S., Gowrishankar, K., Kitamura, R., Suzuki, M., Suzuki, G., Tahara, S., and Koito, A. 
(1998). Disturbed CD4+ T cell homeostasis and in vitro HIV-1 susceptibility in 
transgenic mice expressing T cell line-tropic HIV-1 receptors. J Exp Med 187(9), 
1439-49. 
Speck, R. F., Penn, M. L., Wimmer, J., Esser, U., Hague, B. F., Kindt, T. J., Atchison, R. E., and 
Goldsmith, M. A. (1998). Rabbit cells expressing human CD4 and human CCR5 are 
highly permissive for human immunodeficiency virus type 1 infection. J Virol 72(7), 
5728-34. 
Stantchev, T. S., and Broder, C. C. (2001). Human immunodeficiency virus type-1 and 
chemokines: beyond competition for common cellular receptors. Cytokine Growth 
Factor Rev 12(2-3), 219-43. 
Tang, R. S., Nguyen, N., Cheng, X., and Jin, H. (2001). Requirement of cysteines and length 
of the human respiratory syncytial virus M2-1 protein for protein function and 
virus viability. J Virol 75(23), 11328-35. 
Tervo, H. M., and Keppler, O. T. High natural permissivity of primary rabbit cells for HIV-1, 
with a virion infectivity defect in macrophages as the final replication barrier. J 
Virol 84(23), 12300-14. 
Tsubota, K., Inoue, H., Ando, K., Ono, M., Yoshino, K., and Saito, I. (1998). Adenovirus-
mediated gene transfer to the ocular surface epithelium. Exp Eye Res 67(5), 531-8. 
van Maanen, M., and Sutton, R. E. (2003). Rodent models for HIV-1 infection and disease. 
Curr HIV Res 1(1), 121-30. 
Wald, A., Zeh, J., Selke, S., Warren, T., Ryncarz, A. J., Ashley, R., Krieger, J. N., and Corey, L. 
(2000). Reactivation of genital herpes simplex virus type 2 infection in 
asymptomatic seropositive persons. N Engl J Med 342(12), 844-50. 
Wang, E., Bowen, R. A., Medina, G., Powers, A. M., Kang, W., Chandler, L. M., Shope, R. E., 
and Weaver, S. C. (2001). Virulence and viremia characteristics of 1992 epizootic 
subtype IC Venezuelan equine encephalitis viruses and closely related enzootic 
subtype ID strains. Am J Trop Med Hyg 65(1), 64-9. 
Watson-Jones, D., Weiss, H. A., Rusizoka, M., Changalucha, J., Baisley, K., Mugeye, K., 
Tanton, C., Ross, D., Everett, D., Clayton, T., Balira, R., Knight, L., Hambleton, I., Le 
Goff, J., Belec, L., and Hayes, R. (2008). Effect of herpes simplex suppression on 
incidence of HIV among women in Tanzania. N Engl J Med 358(15), 1560-71. 
Wei, P., Garber, M. E., Fang, S. M., Fischer, W. H., and Jones, K. A. (1998). A novel CDK9-
associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-
affinity, loop-specific binding to TAR RNA. Cell 92(4), 451-62. 
Wildner, O., and Morris, J. C. (2002). Subcutaneous Administration of a Replication-
Competent Adenovirus Expressing HSV-tk to Cotton Rats: Dissemination, 
Persistence, Shedding, and Pathogenicity. Hum Gene Ther 13(1), 101-12. 
Wyde, P. R., Moore-Poveda, D. K., Daley, N. J., and Oshitani, H. (1999). Replication of 
clinical measles virus strains in hispid cotton rats. Proc Soc Exp Biol Med 221(1), 53-
62. 
Xu, F., Sternberg, M. R., Kottiri, B. J., McQuillan, G. M., Lee, F. K., Nahmias, A. J., Berman, S. 
M., and Markowitz, L. E. (2006). Trends in herpes simplex virus type 1 and type 2 





Parr, M. B., Kepple, L., McDermott, M. R., Drew, M. D., Bozzola, J. J., and Parr, E. L. (1994). 
A mouse model for studies of mucosal immunity to vaginal infection by herpes 
simplex virus type 2. Lab Invest 70(3), 369-80. 
Parr, M. B., and Parr, E. L. (2003). Intravaginal administration of herpes simplex virus type 2 
to mice leads to infection of several neural and extraneural sites. J Neurovirol 9(6), 
594-602. 
Piazza, F. M., Johnson, S. A., Ottolini, M. G., Schmidt, H. J., Darnell, M. E., Hemming, V. G., 
and Prince, G. A. (1992). Immunotherapy of respiratory syncytial virus infection in 
cotton rats (Sigmodon fulviventer) using IgG in a small-particle aerosol. J Infect Dis 
166(6), 1422-4. 
Porter, D. D., Prince, G. A., Hemming, V. G., and Porter, H. G. (1991). Pathogenesis of 
human parainfluenza virus 3 infection in two species of cotton rats: Sigmodon 
hispidus develops bronchiolitis, while Sigmodon fulviventer develops interstitial 
pneumonia. J Virol 65(1), 103-11. 
Prince, G. A., Curtis, S. J., Yim, K. C., and Porter, D. D. (2001). Vaccine-enhanced respiratory 
syncytial virus disease in cotton rats following immunization with Lot 100 or a 
newly prepared reference vaccine. J Gen Virol 82(Pt 12), 2881-8. 
Prince, G. A., Jenson, A. B., Horswood, R. L., Camargo, E., and Chanock, R. M. (1978). The 
pathogenesis of respiratory syncytial virus infection in cotton rats. Am J Pathol 
93(3), 771-91. 
Prince, G. A., Prieels, J. P., Slaoui, M., and Porter, D. D. (1999). Pulmonary lesions in primary 
respiratory syncytial virus infection, reinfection, and vaccine-enhanced disease in 
the cotton rat (Sigmodon hispidus). Lab Invest 79(11), 1385-92. 
Roberts, C. (2005). Genital herpes in young adults: changing sexual behaviours, 
epidemiology and management. Herpes 12(1), 10-4. 
Roberts, C. M., Pfister, J. R., and Spear, S. J. (2003). Increasing proportion of herpes simplex 
virus type 1 as a cause of genital herpes infection in college students. Sex Transm 
Dis 30(10), 797-800. 
Rodriguez, W. J., Gruber, W. C., Groothuis, J. R., Simoes, E. A., Rosas, A. J., Lepow, M., 
Kramer, A., and Hemming, V. (1997). Respiratory syncytial virus immune globulin 
treatment of RSV lower respiratory tract infection in previously healthy children. 
Pediatrics 100(6), 937-42. 
Rojas-Martinez, A., Wyde, P. R., Montgomery, C. A., Chen, S. H., Woo, S. L., and Aguilar-
Cordova, E. (1998). Distribution, persistency, toxicity, and lack of replication of an 
E1A-deficient adenoviral vector after intracardiac delivery in the cotton rat. Cancer 
Gene Ther 5(6), 365-70. 
Rytik, P. G., Il'kevich Iu, G., Poleshchuk, N. N., Miuller, V., Kucherov, I. A., Duboiskaia, G. 
P., Podol'skaia, I. A., Novikova, I. E., and Kvacheva, Z. B. (1995). [Morphological 
characteristics of the course of HIV infection in laboratory animals]. Vestn Ross Akad 
Med Nauk(6), 37-41. 
Rytik, P. G., Kutcherov, II, Muller, W. E., Poleschuk, N. N., Duboiskaya, G. P., Kruzo, M., 
and Podolskaya, I. A. (2004). Small animal model of HIV-1 infection. J Clin Virol 31 
Suppl 1, S83-7. 
Sadowski, W., Semkow, R., Wilczynski, J., Krus, S., and Kantoch, M. (1987). [The cotton rat 
(Sigmodon hispidus) as an experimental model for studying viruses in human 
 
The Quest for a Small Animal Model for HIV Infection and Disease 
 
363 
respiratory tract infections. I. Para-influenza virus type 1, 2 and 3, adenovirus type 
5 and RS virus]. Med Dosw Mikrobiol 39(1), 33-42. 
Sawada, S., Gowrishankar, K., Kitamura, R., Suzuki, M., Suzuki, G., Tahara, S., and Koito, A. 
(1998). Disturbed CD4+ T cell homeostasis and in vitro HIV-1 susceptibility in 
transgenic mice expressing T cell line-tropic HIV-1 receptors. J Exp Med 187(9), 
1439-49. 
Speck, R. F., Penn, M. L., Wimmer, J., Esser, U., Hague, B. F., Kindt, T. J., Atchison, R. E., and 
Goldsmith, M. A. (1998). Rabbit cells expressing human CD4 and human CCR5 are 
highly permissive for human immunodeficiency virus type 1 infection. J Virol 72(7), 
5728-34. 
Stantchev, T. S., and Broder, C. C. (2001). Human immunodeficiency virus type-1 and 
chemokines: beyond competition for common cellular receptors. Cytokine Growth 
Factor Rev 12(2-3), 219-43. 
Tang, R. S., Nguyen, N., Cheng, X., and Jin, H. (2001). Requirement of cysteines and length 
of the human respiratory syncytial virus M2-1 protein for protein function and 
virus viability. J Virol 75(23), 11328-35. 
Tervo, H. M., and Keppler, O. T. High natural permissivity of primary rabbit cells for HIV-1, 
with a virion infectivity defect in macrophages as the final replication barrier. J 
Virol 84(23), 12300-14. 
Tsubota, K., Inoue, H., Ando, K., Ono, M., Yoshino, K., and Saito, I. (1998). Adenovirus-
mediated gene transfer to the ocular surface epithelium. Exp Eye Res 67(5), 531-8. 
van Maanen, M., and Sutton, R. E. (2003). Rodent models for HIV-1 infection and disease. 
Curr HIV Res 1(1), 121-30. 
Wald, A., Zeh, J., Selke, S., Warren, T., Ryncarz, A. J., Ashley, R., Krieger, J. N., and Corey, L. 
(2000). Reactivation of genital herpes simplex virus type 2 infection in 
asymptomatic seropositive persons. N Engl J Med 342(12), 844-50. 
Wang, E., Bowen, R. A., Medina, G., Powers, A. M., Kang, W., Chandler, L. M., Shope, R. E., 
and Weaver, S. C. (2001). Virulence and viremia characteristics of 1992 epizootic 
subtype IC Venezuelan equine encephalitis viruses and closely related enzootic 
subtype ID strains. Am J Trop Med Hyg 65(1), 64-9. 
Watson-Jones, D., Weiss, H. A., Rusizoka, M., Changalucha, J., Baisley, K., Mugeye, K., 
Tanton, C., Ross, D., Everett, D., Clayton, T., Balira, R., Knight, L., Hambleton, I., Le 
Goff, J., Belec, L., and Hayes, R. (2008). Effect of herpes simplex suppression on 
incidence of HIV among women in Tanzania. N Engl J Med 358(15), 1560-71. 
Wei, P., Garber, M. E., Fang, S. M., Fischer, W. H., and Jones, K. A. (1998). A novel CDK9-
associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-
affinity, loop-specific binding to TAR RNA. Cell 92(4), 451-62. 
Wildner, O., and Morris, J. C. (2002). Subcutaneous Administration of a Replication-
Competent Adenovirus Expressing HSV-tk to Cotton Rats: Dissemination, 
Persistence, Shedding, and Pathogenicity. Hum Gene Ther 13(1), 101-12. 
Wyde, P. R., Moore-Poveda, D. K., Daley, N. J., and Oshitani, H. (1999). Replication of 
clinical measles virus strains in hispid cotton rats. Proc Soc Exp Biol Med 221(1), 53-
62. 
Xu, F., Sternberg, M. R., Kottiri, B. J., McQuillan, G. M., Lee, F. K., Nahmias, A. J., Berman, S. 
M., and Markowitz, L. E. (2006). Trends in herpes simplex virus type 1 and type 2 





Yim, K. C., Carroll, C. J., Tuyama, A., Cheshenko, N., Carlucci, M. J., Porter, D. D., Prince, G. 
A., and Herold, B. C. (2005). The cotton rat provides a novel model to study genital 





Yim, K. C., Carroll, C. J., Tuyama, A., Cheshenko, N., Carlucci, M. J., Porter, D. D., Prince, G. 
A., and Herold, B. C. (2005). The cotton rat provides a novel model to study genital 
herpes infection and to evaluate preventive strategies. J Virol 79(23), 14632-9. 
HIV-Host Interactions
Edited by Theresa L. Chang
Edited by Theresa L. Chang
HIV remains the major global health threat, and neither vaccine nor cure is available. 
Increasing our knowledge on HIV infection will help overcome the challenge of HIV/
AIDS. This book covers several aspects of HIV-host interactions in vitro and in vivo. 
The first section covers the interaction between cellular components and HIV proteins, 
Integrase, Tat, and Nef. It also discusses the clinical relevance of HIV superinfection. 
The next two chapters focus on the role of innate immunity including dendritic cells 
and defensins in HIV infection followed by the section on the impact of host factors 
on HIV pathogenesis. The section of co-infection includes the impact of Human 
herpesvirus 6 and Trichomonas vaginalis on HIV infection. The final section focuses 
on generation of HIV molecular clones that can be used in macaques and the potential 
use of cotton rats for HIV studies.
Photo by shutterstock
ISBN 978-953-307-442-9
H
IV-H
ost Interactions
 51-65 2
